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T
his documents the extraordinary progress achieved over the past decade in the health sector response to 
HIV. Access to evidence-informed HIV prevention, testing and counselling, treatment and care services in 
low- and middle-income countries has expanded dramatically. This progress demonstrates how countries 
can surmount seemingly intractable health and development challenges through commitment, investment 
and collective action.
The global incidence of HIV infection has stabilized and begun to decline in many countries with generalized epidemics. 
The number of people receiving antiretroviral therapy continues to increase, with 6.65 million people getting treatment 
at the end of 2010. Almost 50% of pregnant women living with HIV received effective antiretroviral regimens to 
prevent mother-to-child transmission, spurring the international community to launch the Global Plan towards the 
elimination of new HIV infections among children by 2015 and keeping their mothers alive. What would have been viewed 
as wildly unrealistic only a few years ago is now a very real possibility.
Recent published evidence from clinical trials has confi rmed the powerful impact antiretroviral drugs have on the 
epidemic as part of an effective package of options for HIV prevention. For the fi rst time, the prospect of a microbicide 
that contains antiretroviral medicine is providing additional hope to the women in sub-Saharan Africa who continue 
to bear a disproportionate burden of the HIV epidemic in this region.
Despite these advances, still too many people are acquiring HIV infection, too many people are getting sick and 
too many people are dying. Of particular concerns are trends affecting Eastern Europe and Central Asia, where the 
numbers of people acquiring HIV infection and dying from HIV-related causes continue to increase. 
New surveillance data confi rm that the epidemic disproportionately affects sex workers, men who have sex with men, 
transgender people, people who inject drugs, prisoners and migrants in both concentrated and generalized epidemics. 
Too often national AIDS plans omit these people, who face formidable legal and other structural barriers to accessing 
HIV services. Globally, more than 50% of the people eligible for treatment do not have access to antiretroviral therapy, 
including many people living with HIV who are unaware of their HIV status. Children have much poorer access to 
antiretroviral therapy than do adults, and attrition at each stage in the cascade of care has highlighted the need to 
strengthen links within HIV services and with other areas of health and community systems.
Nevertheless, several critical developments over the past year have highlighted the capacity of the global response 
to innovate and learn from scientifi c and programmatic evidence. The Political Declaration on HIV/AIDS, adopted in 
June 2011 by the United Nations General Assembly,  set ambitious targets aimed at achieving universal access and 
the health-related Millennium Development Goals by 2015. The WHO Global Health Sector Strategy on HIV/AIDS, 
2011–2015, the UNAIDS 2011–2015 Strategy: Getting to Zero, and the UNICEF’s strategic and programmatic focus 
on equity will help to guide national and global efforts to respond to the epidemic and move from an emergency 
response to a long-term, sustainable model of delivering HIV services. These strategies emphasize the need to better 
tailor national HIV responses to the local epidemics, to decentralize programmes to bring them closer to people in 
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need and to integrate with other health and community services to achieve the greatest impact. These are important 
developments aimed at consolidating gains to date and improving the quality, coverage and effi ciency of HIV services.
The past decade has seen a historically unprecedented global response to the unique threat the HIV epidemic poses 
to human development. Networks of people living with and affected by HIV, as well as civil society organizations, 
have continued to work with other partners, to demand and mobilize political leadership. This has led to increased 
funding, technical innovation and international collaboration that has saved millions of people’s lives and changed the 
trajectory of the epidemic. As capacity at all levels increases, programmes are becoming more effective and effi cient. 
Nevertheless, fi nancial pressures on both domestic and foreign assistance budgets are threatening the impressive 
progress to date. Recent data indicating that HIV funding is declining is a deeply troubling trend that must be reversed 
for the international community to meet its commitments on HIV.
HIV has proven to be a formidable challenge, but the tide is turning. The tools to achieve an AIDS-free generation 
are in our hands. Let us move forward together on the ambitious goals set for 2015 and bring us closer to realizing 
our collective vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths.
Margaret Chan Michel Sidibé Anthony Lake
Director-General Executive Director Executive Director
World Health Organization UNAIDS UNICEF
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1Introduction
T
his report reviews progress made until the end 
of 2010 in scaling up access to health sector 
interventions for HIV prevention, treatment, 
care and support in low–and middle-income 
countries. It is the fi fth in a series of annual progress 
reports published since 2006 by the World Health 
Organization (WHO), United Nations Children’s Fund 
(UNICEF) and Joint United Nations Programme on HIV/
AIDS (UNAIDS), in collaboration with national and 
international partners, to monitor key components of 
the health sector response to the HIV epidemic. The 
report reflects the commitment of United Nations 
Member States, civil society and United Nations 
agencies to ensure accountability for global progress 
in the response to HIV through regular monitoring and 
reporting. Since 2010 was the deadline established in 
2005 for achieving universal access to HIV prevention, 
treatment, care and support, this report also represents 
an important benchmark, an opportunity to take stock 
and identify both achievements and outstanding gaps 
and to take a constructive look forward in the response 
at this critical point in the response to the HIV epidemic.
The results of commitment, investment and 
collaboration over the past decade have translated 
into substantial improvements in access to evidence-
informed HIV prevention, diagnosis, treatment, care and 
support interventions in the health sector (Table 1.1).
Table 1.1 Key indicators for the HIV epidemic, 2002–2010
2002 2003 2004 2005 2006 2007 2008 2009 2010
Number of people living 
with HIV (in millions)
29.5
[27.7–31.7]
30.2
[28.4–32.1]
30.7
[28.8–32.5]
31.0
[29.2–32.7]
31.4
[29.6–33.0]
31.8
[29.9–33.3]
32.3
[30.4–33.8]
32.9
[31.0–34.4]
34.0
[31.6–35.2]
Number of people newly 
infected with HIV 
(in millions)
3.1
[3.0–3.3]
3.0
[2.8–3.1]
2.9
[2.7–3.0]
2.8
[2.6–3.0]
2.8
[2.6–2.9]
2.7
[2.5–2.9]
2.7
[2.5–2.9]
2.7
[2.5–2.9]
2.7
[2.4–2.9]
Number of people dying 
from AIDS-related causes 
(in millions)
2.0
[1.8-2.3]
2.1
[1.9-2.4]
2.2
[2.0-2.5]
2.2
[2.1-2.5]
2.2
[2.1–2.4]
2.1
[2.0–2.3]
2.0
[1.9–2.2]
1.9
[1.7–2.1]
1.8
[1.6–1.9]
% of pregnant women 
tested for HIVa
   8% 13% 15% 21% 26% 35%
Number of facilities 
providing antiretroviral 
therapya
     7 700 12 400 18 600 22 400
Number of people 
receiving antiretroviral 
therapya
300 000 400 000 700 000 1 330 000 2 034 000 2 970 000 4 053 000 5 255 000 6 650 000
Number of children 
receiving antiretroviral 
therapya
   71 500 125 700 196 700 275 400 354 600 456 000
Coverage of antiretroviral 
medicines for preventing 
mother-to-child 
transmission (%)a
9%b 14%b 23%b 33%b 43%b 48%b 48%c
a In low- and middle-income countries.
b The coverage data includes provision of single-dose nevirapine which is no longer recommended by WHO.
c This data does not include single-dose nevirapine regimen which is no longer recommended by WHO. It should not be compared with the previous years. When including single-dose 
nevirapine, the coverage in 2010 is 59%.
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• A total of 2.7 million people acquired HIV infection 
in 2010, down from 3.1 million in 2001, contributing 
to the total number of 34 million people living with 
HIV in 2010 (see Chapter 2).
• Access to HIV testing and counselling is increasing: 
coverage of HIV testing and counselling among 
pregnant women rose from 8% in 2005 to 35% in 
2010. Nevertheless, the majority of people living with 
HIV in low–and middle-income countries still do not 
know their serostatus (see Chapter 4).
• The number of health facilities providing antiretroviral 
therapy, a key indicator of expanded health system 
capacity to deliver treatment, expanded from 7700 
in 2007 to 22 400 at the end of 2010, a threefold 
increase (see Chapter 5).
• Access to antiretroviral therapy in low–and middle-
income countries increased from 400 000 in 
2003 to 6.65 million in 2010, 47% coverage of 
people eligible to treatment, resulting in substantial 
declines in the number of people dying from AIDS-
related causes during the past decade (Fig. 1.1). 
Mounting scientifi c evidence suggests that increased 
access to antiretroviral therapy is also contributing 
substantially to declines in the number of people 
acquiring HIV infection.
• The number of children receiving antiretroviral 
therapy increased from 71 500 at the end of 2005 
to 456 000 in 2010. Nevertheless, the 23% coverage 
of children is a substantial gap to the coverage of 
adults.
• Coverage of pregnant women receiving the 
most effective antiretroviral regimens to prevent 
mother-to-child transmission of HIV (excluding 
single-dose nevirapine) is estimated at 48% in 
2010(see Chapter 7).
Building foundations: political commitment, 
investment and technical innovation
At the beginning of the 21st century, the international 
community faced formidable health and development 
challenges, none more so than countries in the 
poorest region of the world: sub-Saharan Africa. 
A rapidly expanding HIV epidemic was already 
dramatically reversing decades of progress on key 
development indicators, such as infant mortality and 
life expectancy (1). Although the global incidence of 
HIV infection had peaked in the mid-1990s, more than 
3 million people were being newly infected per year, 
AIDS had become one of the leading causes of adults 
dying in sub-Saharan Africa and the full onslaught of the 
epidemic would not be felt until 2006, when more than 
2.2 million people died each year from AIDS-related 
causes (2,3). The revolution in HIV treatment brought 
about by combination antiretroviral therapy in 1996 
had forever altered the course of disease among those 
living with HIV in high-income countries but had only 
reached a fraction of people in low and middle-income 
countries, which bore 90% of the global HIV burden (1).
At the XIII International AIDS Conference in July 
2000 in Durban, South Africa, activists, community 
leaders, scientists and health care providers joined 
forces to demand access to treatment and an end to 
the enormous health inequities between the global 
North and global South. Months later, world leaders 
established the Millennium Development Goals, a 
series of ambitious, time-bound targets aimed at 
achieving progress on several health and development 
goals over the next 15 years, including Millennium 
Development Goal 6: combat HIV, malaria and other 
diseases (4). In 2001, the United Nations General 
Assembly Special Session on HIV/AIDS (UNGASS) 
approved the Declaration of Commitment on HIV/
AIDS, with common targets in specifi c technical areas, 
such as expanding access to antiretroviral therapy, 
antiretroviral prophylaxis to prevent the mother-
to-child-transmission of HIV and HIV prevention. 
The Declaration also committed Member States to 
establish a dedicated global health fund to fi nance the 
HIV response, resulting in the launch of the Global Fund 
to Fight AIDS, Tuberculosis and Malaria one year later: 
The Global Fund quickly became a cornerstone in the 
global response to HIV, funding country-led responses 
through a pioneering, performance-based grant system. 
In 2003, the United States Government announced the 
United States President’s Emergency Plan for AIDS 
Relief. At US$ 15 billion over fi ve years, it was the largest 
single funding commitment for a disease in history. The 
United States President’s Emergency Plan for AIDS 
Relief was reauthorized in 2008 for up to US$ 48 billion 
to combat AIDS, TB and malaria for 2009–2013.
Additional innovations in global health funding 
followed. By 2006, Brazil, Chile, France, Norway and 
the United Kingdom had agreed to create UNITAID, an 
international drug purchase facility fi nanced through a 
modest levy on airline tickets. UNITAID now fi nances 
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and supports strategic interventions in the drugs and 
diagnostics markets in 94 countries (5).
Increased political and fi nancial commitments to the 
HIV response developed in parallel with normative 
guidance and strategic technical innovations, including 
a ground-breaking approach to scaling up treatment 
access in low- and middle-income countries: the 
public health approach to antiretroviral therapy (6). Key 
elements of the public health approach include using 
standardized treatment protocols and drug regimens, 
simplifi ed clinical monitoring, maximizing coverage 
with limited resources, optimizing human resources for 
health and involving people living with and affected by 
HIV in designing and rolling out antiretroviral therapy 
programmes (7).
Scaling up the global HIV response
When WHO and UNAIDS launched the “3 by 5” 
Initiative on World AIDS Day in 2003, only 400 000 
people in low- and middle-income countries had access 
to antiretroviral therapy (8). The “3 by 5” Initiative, 
which set a target of obtaining access to antiretroviral 
therapy for 3 million people by the end of 2005, led a 
fundamental shift in thinking about the feasibility of 
funding and delivering antiretroviral medicines and 
other drugs for people in resource-limited settings. 
The rapid scale-up of antiretroviral therapy in low- and 
middle-income countries, especially during the past fi ve 
years, has signifi cantly reduced the number of people 
dying from AIDS-related causes (Fig. 1.1).
By the middle of the last decade, another benchmark 
was established when G8 leaders – and later all United 
Nations Member States – endorsed the goal of achieving 
universal access to a package of HIV prevention, care, 
treatment and support interventions for everyone 
who needs them (9). By the end of 2005, the number 
of people receiving antiretroviral therapy in low- and 
middle-income countries had jumped to more than 1.4 
million. Progress on Millennium Development Goal 6 
and UNGASS targets accelerated in the second half of 
the decade; guidelines on preventing mother-to-child-
transmission and on care for children, antiretroviral 
therapy, provider-initiated testing and counselling and 
medical male circumcision were released. The 2010 
WHO recommendations on antiretroviral therapy (10) 
reflect clinical evidence that early initiation of 
antiretroviral therapy (recommended at CD4 cell counts 
less than 350 per mm3) signifi cantly reduces morbidity 
and mortality and also has important preventive benefi ts.
The “3 by 5” target was met in 2007, and by the end 
of 2010 the number of people receiving treatment 
in low- and middle-income countries had reached 
6.65 million, an increase of more than 16-fold in seven 
years (see Chapter 5). The trends are similar in access 
to antiretroviral medicine for preventing mother-to-
Fig. 1.1 Number of people with access to antiretroviral 
therapy and the number of people dying from AIDS-related 
causes, low- and middle-income countries, 2000–2010  
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Fig. 1.2 Coverage of antiretroviral prophylaxis for preventing 
the mother-to-child-transmission of HIV and the number of 
new HIV infections among children, low- and middle-income 
countries, 2003–2010  
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recommended by WHO. Coverage in 2010 does not include single dose nevirapine. 
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child-transmission, enabling 350 000 infants to avoid 
HIV infection since 1995 (see Chapter 7) (Fig. 1.2).
Uptake of HIV testing and counselling, which is 
critical to ensuring appropriate referral to prevention 
and treatment services, also increased from about 
64 million tests in 2009 to 72 million in 2010 (in 87 
reporting countries). In eastern and southern Africa, the 
subregion with the highest number of pregnant women 
living with HIV, testing and counselling coverage among 
pregnant women increased from 14% to 61% between 
2005 and 2010, and the number of facilities providing 
antiretroviral therapy in low- and middle-income 
countries – a key measure of the capacity of the health 
systems to scale up to meet the demand for treatment 
– increased from less than 7700 in 2005 to 22 300 in 
2010, a three-fold increase.
Although there has been concern that investment to 
date has not adequately addressed the constraints 
of health system, a 2009 study (11) indicated that – 
on balance – HIV investment has strengthened the 
capacity of health systems, partly by introducing 
important innovations in how health services are 
funded and delivered. The grant architecture of the 
Global Fund to Fight AIDS, Tuberculosis and Malaria, 
for example, has evolved to address structural defi cits 
in health system capacity. The past few years have also 
seen evolution in thinking about how to better integrate 
HIV services with other areas of the health sector, 
including maternal, newborn and child health, sexual 
and reproductive health, drug dependence treatment 
and harm reduction (including opioid substitution 
therapy), tuberculosis and primary health care. In 
addition, approaches to task-shifting or task-sharing in 
countries are contributing to improving the productivity 
of scarce human resources for health.
Nevertheless, signifi cant challenges remain. Although 
the annual number of people newly infected with HIV 
has dropped since their peak in the late 1990s, this is 
still occurring at an unacceptably high rate: between 
2.5 and 3 million people annually for the past fi ve years, 
adding to the global number of people living with HIV 
that reached 34 million [31 600 000–35 200 000] 
by the end of 2010 (see Chapter 2). Reductions in the 
number of people acquiring HIV infection, especially 
people 15–24 years old in the countries in sub-Saharan 
Africa that have a high burden of HIV, have been offset 
by increases in new infections in Eastern Europe and 
Central Asia, where the primary mode of transmission 
is among people who inject drugs and their sexual 
networks and where the number of people dying from 
AIDS-related cause increased 1100% during the past 
decade: from an estimated 7800 in 2001 to 89 500 in 
2010 (see Chapter 2) (12).
Although HIV testing and counselling uptake has 
improved, many people living with HIV in low- and 
middle-income countries still do not know their 
HIV status, undercutting efforts to reduce onward 
transmission and refer those testing HIV-positive to 
appropriate care and treatment; an estimated 7.5 million 
people are eligible for treatment but are not accessing 
antiretroviral therapy because they are unaware of their 
HIV serostatus. Although provider-initiated testing and 
counselling has led to dramatic increases in the number 
of people living with HIV diagnosed in the symptomatic 
stages of HIV disease, testing based in health facilities 
is unlikely to identify people at earlier, asymptomatic 
stages of infection (above 200 CD4 cells per mm3). 
Novel approaches to community-based testing are 
therefore urgently needed (see Chapter 4).
For children, the situation is even graver, since less 
than one quarter of the children eligible for treatment 
are accessing antiretroviral therapy. Attrition rates of 
20% or more 12 months after people start receiving 
antiretroviral therapy in many programmes indicate 
the need for intensified efforts and strategies to 
initiate treatment earlier, retain individuals in care (see 
Chapter 5) and increase the quality of interventions.
Women, especial ly young women, remain 
disproportionately affected in sub-Saharan Africa, 
highlighting the need to address gender inequity and 
harmful gender norms as a central component of 
the global response to HIV (13). Key populations at 
higher risk of HIV infection and transmission, including 
people who inject drugs, men who have sex with men, 
transgender people, sex workers, prisoners and migrants 
continue to be underserved by current HIV services and 
often have the highest HIV prevalence in areas with 
both generalized and concentrated epidemics (see 
Chapter 2) (12). Despite the commitments made in the 
2001 and 2006 UNGASS declarations to respect the 
human rights of key populations at higher risk, these 
groups continue to face violence, social stigma and poor 
access to HIV services in many settings, a situation 
compounded by laws that criminalize homosexuality, 
drug use and sex work.
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Domestic and international HIV-specifi c funding has 
decreased from US$15.9 billion in 2009 to US$ 15 billion 
in 2010, well below the estimated US$ 22–24 billion 
needed in 2015 for a comprehensive, effective global 
response to HIV (14,15).
The past decade has witnessed fundamental changes 
in the approach to global public health challenges. 
The results have been demonstrated in both human 
and economic terms. A 2011 study (16) indicated that 
investment in antiretroviral therapy programmes to 
date is signifi cantly infl uencing increased economic 
activity and labour force productivity in low- and 
middle-income countries, reaching total gains of up 
to US$ 34 billion and 18.5 million life-years by 2020, 
more than offsetting the costs of antiretroviral therapy 
programmes. Introducing antiretroviral therapy has 
averted 2.5 million deaths in low- and middle-income 
countries globally since 1995 (Chapter 2). Nevertheless, 
at a time when mounting evidence indicates that 
political and fi nancial commitments in the fi rst decade 
of the 21st century are paying enormous dividends, 
concerns are growing about the sustainability of the 
response, the continued upward trajectory of costs and 
the millions still in need. The data in this report confi rm 
that, although important and substantial progress has 
been made, only 10 low- and middle-income countries, 
including 3 with generalized epidemics, achieved the 
universal access target for antiretroviral therapy (80% 
coverage) in 2010.
The roadmap to 2015
Budgetary constraints in the aftermath of the 2008 
recession and the ongoing volatility in the global 
economy are threatening hard-won gains and 
underscore the need to reduce commodity costs and 
maximize efficiency in how HIV programmes are 
funded and implemented.
A new investment framework seeks to ensure a 
more strategic funding approach that includes both 
the need for additional funding and a fundamentally 
different approach to designing programmes and 
delivering services, focusing on a core set of basic 
programmatic activities, critical enablers and 
developmental synergy. The investment framework 
grounds the global HIV response more firmly in 
evidence-informed interventions that should be 
universally applied for greatest impact and in local 
epidemiology (Box 1.1) (15). The Treatment 2.0 initiative, 
launched by WHO and UNAIDS in 2010, is continuing 
the drive for optimizing and innovating treatment 
in the key areas of drug regimens, point-of-care 
diagnostics, integrated and decentralized delivery of 
HIV services (17,18) and mobilizing communities (17). The 
2010 WHO recommendations on antiretroviral therapy 
refl ect clinical evidence that initiating antiretroviral 
therapy early (recommended at CD4 cell counts 
less than 350 mm3) signifi cantly reduces morbidity 
and mortality and also has significant benefits in 
preventing HIV infection and TB (10). Recent scientifi c 
breakthroughs have confi rmed the signifi cant effects 
of prevention interventions based on antiretroviral 
medicine as part of combination prevention, including 
oral pre-exposure prophylaxis, topical microbicides 
and treatment as prevention (19–21).
UNAIDS and WHO have released fi ve-year strategies 
(2011–2015), aimed at building on the progress to 
date and establishing ambitious new targets for 2015: 
zero new infections, zero discrimination and zero 
AIDS-related deaths (22,23). The Global Health Sector 
Strategy on HIV/AIDS, 2011–2015 (23), endorsed by all 
WHO Member States in May 2011, guides national HIV 
responses in the health sector and outlines the role of 
WHO and other partners in achieving the 2015 targets. 
The strategy focuses on four strategic directions: 
optimizing HIV prevention, diagnosis treatment and 
care; leveraging broader health outcomes through HIV 
responses; building strong and sustainable health and 
community systems; and reducing vulnerability and 
removing structural barriers to accessing services. 
Success in scaling up access to antiretroviral therapy 
and antiretroviral prophylaxis to prevent mother-
to-child-transmission of HIV has driven the recent 
commitment among United Nations Member States, 
civil society and United Nations Agencies, co-convened 
by UNICEF and WHO, to establish a global plan aimed 
at eliminating new HIV infections among children and 
improving maternal health through intensifi ed, country-
led action and resource mobilization (24).
The 2011 Political Declaration on HIV/AIDS builds on 
the enormous progress made during the past decade, 
establishing bold and ambitious targets for 2015 (26). 
The Declaration acknowledges the challenges faced 
by countries in achieving universal access by the 
original 2010 deadline and commits to intensified 
efforts to reach universal access and Millennium 
Development Goal targets. For the fi rst time in the 
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more than 30 years since the epidemic emerged, 
the international community can see success on the 
horizon. Scientifi c advances, committed leadership and 
strategic investment will yield a long-term, sustainable 
response to HIV that also strengthens synergy with 
other health and development goals. The hard-won 
progress during the past decade has proven what can 
be achieved through collective action on common goals.
In an era dominated by economic crises and fi scal 
constraints, the HIV response continues to provide 
examples of how focused and smart investment can 
reap enormous human, economic and social benefi ts. 
Countries and communities enter the fourth decade 
with HIV at a crossroads. Although the challenges are 
daunting, the road to success is clear.
This report is structured as follows.
Chapter 1 outlines the purpose of the report and 
reviews and analyses global progress towards universal 
access during the past decade.
Chapter 2 provides updated epidemiological 
information on the HIV epidemic, including global and 
regional trends in incidence, prevalence and mortality 
from AIDS-related causes.
Chapter 3 reviews progress in scaling up health 
sector interventions for HIV prevention in the general 
population.
Box 1.1
Towards an improved investment approach for an effective global HIV response
At the end of 2010, about US$ 15 billion was available to scale up HIV services worldwide, split almost evenly between international and 
domestic sources (Fig. 1.3). But international assitance has declined from US$ 8.7 billion  in 2009 to US$ 7.6 billion in 2010. More than 70% 
of international donor government disbursements for HIV programmes were channelled bilaterally, and the remainder was allocated primarily 
through UNITAID and the Global Fund to Fight AIDS, Tuberculosis and Malaria. After years of considerable increases, international funding 
for HIV programmes actually fell in 2010.
The investment framework promotes setting priorities for the efforts based on a nuanced understanding of country epidemiology and context 
and calls for evidence-informed activities that directly reduce HIV transmission, morbidity and mortality to be scaled up according to the 
size of the relevant affected populations.
Annual resource needs to deliver on this optimized approach should peak at US$ 22–24 billion in 2015, when universal access is achieved, and 
should subsequently decline, along with HIV transmission, morbidity and mortality rates. By 2020, the return on this comprehensive investment 
framework would be 12 million fewer people newly infected with HIV than would be possible with current funding levels and 7.4 million fewer 
people dying from AIDS-related causes (Fig. 1.4).
Fig. 1.4 Annual number of people newly infected with 
HIV, 2011–2020 baseline scenario and optimized 
investment framework
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Fig. 1.3 Global resources available for HIV programmes in 
low- and middle-income countries, billions of US dollars, 
2002–2010
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Chapter 4 presents global progress in expanding the 
availability and uptake of HIV testing and counselling.
Chapter 5 presents global progress in scaling up access 
to treatment and care for people living with HIV and 
highlights recent efforts to optimize treatment through 
the Treatment 2.0 initiative.
Chapter 6 presents global progress towards scaling up 
HIV services for key populations at higher risk of HIV 
infection and transmission.
Chapter 7 reviews progress in scaling up HIV services 
for women and children, including eliminating mother-
to-child transmission and improving maternal and 
child health.
Chapter 8 identifi es the main challenges and the way 
forward towards achieving universal access to HIV 
prevention, treatment, care and support.
The statistical annexes and explanatory notes at the 
end of this report provide supplementary information 
on data sources and methods.
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KEY FINDINGS
At the end of 2010, an estimated 34 million people (31 600 000–35 200 000) were living with HIV globally, including 
3.4 million [3 000 000–3 800 000] children less than 15 years. There was 2.7 million [2 400 000–2 900 000] new 
HIV infections in 2010, including 390 000 [340 000–450 000] among children less than 15 years.
Globally, the annual number of people newly infected with HIV continues to decline, although there is stark regional 
variation. In sub-Saharan Africa, where most of the people newly infected with HIV live, an estimated 1.9 million 
[1 700 000–2 100 000] people became infected in 2010. This was 16% fewer than the estimated 2.2 million 
[2 100 000–2 400 000] people newly infected with HIV in 2001 and 27% fewer than the annual number of people 
newly infected between 1996 and 1998, when the incidence of HIV in sub-Saharan Africa peaked overall.
The annual number of people dying from AIDS-related causes worldwide is steadily decreasing from a peak of 
2.2 million [2 100 000–2 500 000] in 2005 to an estimated 1.8 million [1 600 000–1 900 000] in 2010. The number 
of people dying from AIDS-related causes began to decline in 2005–2006 in sub-Saharan Africa, South and South-
East Asia and the Caribbean and has continued subsequently.
 
In 2010, an estimated 250 000 [220 000–290 000] children less than 15 died from AIDS-related causes, 20% 
fewer than in 2005.
Not all regions and countries fi t the overall trends, however. The annual number of people newly infected with HIV 
has risen in the Middle East and North Africa from 43 000 [31 000–57 000] in 2001 to 59 000 [40 000–73 000] 
in 2010. After slowing drastically in the early 2000s, the incidence of HIV infection in Eastern Europe and Central 
Asia has been accelerating again since 2008. 
The trends in AIDS-related deaths also differ. In Eastern Europe and Central Asia, the number of people dying from 
AIDS-related causes increased more than 10-fold between 2001 and 2010 (from about 7800 [6000–11 000] to 
90 000 [74 000–110 000]). In the same period, the number of people dying from AIDS-related caused increased 
by 60% in the Middle East and North Africa (from 22 000 [9700–38 000] to 35 000 [25 000–42 000]) and more 
than doubled in East Asia (from 24 000 [16 000–45 000] to 56 000 [40 000 76 000]).
 
Introducing antiretroviral therapy has averted 2.5 million deaths in low- and middle-income countries globally since 
1995. Sub-Saharan Africa accounts for the vast majority of the averted deaths: about 1.8 million.
Providing antiretroviral prophylaxis to pregnant women living with HIV has prevented more than 350 000 children 
from acquiring HIV infection since 1995. Eighty-six per cent of the children who avoided infection live in sub-Saharan 
Africa, the region with the highest prevalence of HIV infection among women of reproductive age.
2Update on the HIV epidemic
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2.1 Global overview
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2.1.1 HIV incidence continues to decline
Globally, the annual number of people newly infected 
with HIV continues to decline, although this varies 
strongly between regions.
In 2010, an estimated 2.7 million [2 400 000–
2 900 000] people were newly infected with HIV, 
15% fewer than the 3.1 million [3 000 000–3 300 000] 
people newly infected in 2001 and more than one 
fifth (21%) fewer than the estimated 3.4 million 
[3 100 000–3 600 000] in 1997, the year when the 
number of people newly infected with HIV peaked 
(Fig. 2.1–2.4).
Between 2001 and 2009, the incidence of HIV infection 
has declined in 33 countries, 22 of them in sub-Saharan 
Africa. In that region, which continues to have the 
majority of the people newly infected with HIV, an 
estimated 1.9 million [1 700 000–2 100 000] people 
became infected in 2010. This was 16% fewer than the 
estimated 2.2 million [2 100 000 2 400 000] people 
newly infected with HIV in 2001 and 26% fewer than 
the annual number of people newly infected in 1997 
(when the overall HIV incidence in sub-Saharan Africa 
peaked).
In South and South-East Asia, the estimated 270 000 
[230 000–340 000] people newly infected with HIV 
in 2010 were 40% fewer than the 470 000 [410 000–
530 000] people estimated to have acquired HIV 
infection in 1996, when the epidemic in that subregion 
peaked.
These trends reflect a combination of factors: the 
natural course of HIV epidemics, behavioural changes 
associated with greater awareness about the effects of 
the epidemics and with intensifi ed prevention efforts 
and increasing coverage of antiretroviral therapy.
HIV prevalence is declining among young people
Encouraging trends are evident among young people 
in several countries with a great burden of HIV. HIV 
prevalence trends among young people can indicate 
recent trends in people acquiring HIV infection, since 
most young people living with HIV have been infected 
in the previous few years.
A regression model was applied to antenatal clinic 
data from 2000 to 2010 to estimate HIV prevalence 
trends among young people. It showed that the HIV 
prevalence declined among women 15–24 years old in 
22 of the 24 countries with a national HIV prevalence 
of 1% or higher and with data available.1 The decline 
in HIV prevalence was statistically signifi cant among 
pregnant women attending antenatal clinics in 12 of 
these countries: Burkina Faso, Botswana, Democratic 
Republic of the Congo, Ethiopia, Ghana, Kenya, Malawi, 
Nigeria, Namibia, Togo, United Republic of Tanzania 
and Zimbabwe. Four of these countries (Botswana, 
Malawi, United Republic of Tanzania and Zimbabwe) 
also had statistically signifi cant declines in the general 
population based on the results from population-based 
surveys (among women in Botswana, Malawi and 
Zimbabwe and among men in the United Republic 
of Tanzania). Three other countries had statistically 
signifi cant declines within the general population but no 
signifi cant declines among antenatal clinic attendees 
(among women in Zambia and among men in Lesotho 
and South Africa).
Among the 24 countries, the average decline in 
prevalence was 31% among pregnant women attending 
antenatal clinics (Fig. 2.5). The range, however, was 
wide: from an increase exceeding 50% in Angola to a 
decline exceeding 70% in Ethiopia and Kenya. Seven 
of the 24 countries achieved the 50% reduction in HIV 
prevalence, but there was no apparent decline in fi ve 
others, including in South Africa, which has the largest 
HIV epidemic in the world.2
1 Angola, Bahamas, Burkina Faso, Botswana, Democratic Republic of the 
Congo, Chad, Ethiopia, Gabon, Ghana, Haiti, Kenya, Lesotho, Malawi, 
Mali, Mozambique, Nigeria, Namibia, South Africa, Swaziland, Togo, 
Uganda, United Republic of Tanzania, Zambia and Zimbabwe.
2 In the 2001 UNGASS Declaration, countries committed themselves to 
achieving a 50% decline in HIV prevalence by 2010.
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Fig. 2.5 Prevalence of HIV infection among various population samples in the 24 countries with prevalence exceeding 1% and 
data available, 2000–2010
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Namibia
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The declines in HIV prevalence have occurred amid 
signs of encouraging changes in sexual behaviour 
among people 15–24 years old in several countries with 
generalized epidemics. Survey data from 20 countries 
in sub-Saharan Africa and the Caribbean provides 
evidence of these changes (Fig. 2.5).1 
Analysis shows that the percentage of young men 
with multiple partners in the 12 months before the 
most recent survey decreased signifi cantly in 11 of the 
19 countries with data available (including in 4 countries 
with national adult HIV prevalence exceeding 10% in 
2009), and among women it decreased in 6 countries 
(half of them with HIV prevalence exceeding 10%). 
In Rwanda and Zimbabwe, however, the share of 
young women with multiple partners appears to have 
increased, and Guyana and Lesotho have a similar trend 
among young men.
The proportion of young people who said they used a 
condom the last time they had high-risk sex increased 
signifi cantly in 7 (for men) and 5 (for women) of the 
17 countries with data available. More than half these 
countries had a national adult HIV prevalence of at 
least 10% in 2009. However, condom use during high-
risk sex appears to have decreased among young men 
in Uganda and Zimbabwe and among young women 
in Mali.
The percentage of young men and women who have 
had sex before age 15 years decreased signifi cantly in 
8 of the 18 countries with data available. In 4 of these 
1 The analysis is based on survey data in countries in which more than 
one survey was conducted between 2000 and 2010. If more than two 
surveys were conducted, only the fi rst and last surveys were analysed. 
On average, the surveys were fi ve years apart. UNGASS indicators were 
used: the percentage of men and women aged 15–24 years who had 
sex before age 15 years; the percentage of men and women aged 15–24 
years who had more than one partner in the past 12 months; and the 
percentage of men and women aged 15–24 years who had more than 
one partner in the past 12 months and who used a condom at last sex.
8 countries, the national adult HIV prevalence exceeded 
10% in 2009. In contrast, the proportion of young 
people who had sex before age 15 years increased 
among men in Guyana, Lesotho and Rwanda, among 
women in Lesotho and among both men and women 
in Haiti.
2.1.2 Fewer people are dying from AIDS-related 
causes …
The annual number of people dying from AIDS-related 
causes worldwide is steadily decreasing from a peak 
of 2.2 million [2 100 000–2 500 000] in 2005 to an 
estimated 1.8 million [1 600 000–1 900 000] in 2010 
(Fig. 2.6). AIDS-related mortality began to decline in 
2005–2006 in sub-Saharan Africa, South and South-East 
Asia and the Caribbean and has continued subsequently. 
Two signal developments have caused this decline: 
fi rst, the increased availability of antiretroviral therapy, 
as well as care and support, to people living with HIV, 
especially in sub-Saharan Africa; and second, fewer 
people newly infected with HIV since the late 1990s. 
The effects of antiretroviral therapy are especially 
evident in sub-Saharan Africa, where an estimated 
460 000 (or 30%) fewer people died from AIDS-
related causes in 2010 than in 2004, when access 
to antiretroviral therapy began to be dramatically 
expanded (Fig. 2.6).
2.1.3 … but the trends vary by region
Not all regions and countries fi t the overall trends, 
however. The annual number of people newly infected 
with HIV has risen in the Middle East and North Africa 
from 43 000 [31 000–57 000] in 2001 to 59 000 
[40 000–73 000] in 2010. After slowing drastically 
in the early 2000s, the HIV incidence in Eastern 
Europe and Central Asia has been accelerating again 
since 2008.
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The trends in AIDS-related deaths also differ. For 
example, in Eastern Europe and Central Asia, the 
number of people dying from AIDS-related causes 
increased from 7800 [6000–11 000] in 2001 to 
90 000 [74 000–110 000] in 2010. In the same period, 
AIDS mortality increased by 60% in the Middle East 
and North Africa (from 22 000 [9700–38 000] to 
35 000 [25 000–42 000]) and more than doubled in 
East Asia (from 24 000 [16 000–45 000] to 56 000 
[40 000–76 000]).
In North America and in Western and Central Europe, 
the number of people dying from AIDS-related causes 
began to decline soon after antiretroviral therapy was 
introduced in 1996. The number of deaths attributed 
to AIDS in Latin America has declined since its peak 
in 2001–2003 but appears to have levelled off since 
2008.1
2.1.4 As treatment expands, the number of 
people living with HIV is rising
UNAIDS estimates that 34 million [31 600 000–
35 200 000] people were living with HIV globally 
at the end of 2010 versus 28.6 million [26 700 000–
30 900 000] in 2001 – a 17% increase (Fig. 2.7). This 
refl ects the high numbers of people newly infected 
with HIV along with signifi cantly expanded access to 
antiretroviral therapy, which has helped to reduce the 
number of people dying from AIDS-related causes, 
especially since 2004–2005 (Table 2.1).
2.1.5 Half the people living with HIV are women
Globally, women constituted half (50% [48–53%]) 
the adults (15 years and older) living with HIV in 
2010, according to UNAIDS estimates (Fig. 2.8). That 
proportion has shifted very little in the past 15 years. The 
burden of HIV on women, however, varies considerably 
by region and is heaviest in sub-Saharan Africa. In 
that region, 1.4 times more adult women than men 
were living with HIV in 2010. Women comprised 59% 
[56–63%] of the adults living with HIV in sub-Saharan 
Africa in 2010, as they have for most of the past decade.
1 Mexico is now included in the HIV estimates for Latin America. These 
latest estimates therefore supersede those published in the past by 
UNAIDS (including estimates for previous years).
The Caribbean is the only other region where women 
outnumber men among adults living with HIV; they 
comprised 53% [47–61%] of the adults living with 
HIV in 2010 (this pattern largely results from the 
fact that women outnumber men in Haiti, which has 
the greatest epidemic in the Caribbean). Two regions 
have experienced slight increases in the proportion 
of women among people living with HIV in the past 
decade or more: Latin America (35% [29–41%] in 2010 
versus 32% [26–41%] in 2001) and North America 
and Western and Central Europe (26% [23–33%] in 
2010 versus 25% in 2001 [22–28%]). Elsewhere the 
proportion has hardly shifted, including in Asia (34% 
[30–37%] to 35% [30–38%]), Eastern Europe and 
Central Asia (34% [28–40%] to 35% [30–40%]), 
the Middle East and North Africa (45% [24–57%] to 
45% [31–50%]) and Oceania (44% [37–55%] to 44% 
[39–51%]).
2.1.6 Positive developments among children
As access to services for preventing the mother-to-
child transmission of HIV increased, the annual number 
of children acquiring HIV infection stabilized in the early 
2000s before decreasing steeply in the past few years 
(Fig. 2.9). An estimated 390 000 [340 000–450 000] 
children were newly infected with HIV in 2010, 30% 
fewer than the peak of 560 000 [500 000–630 000] 
children newly infected annually in 2002 and 2003. The 
number of children (younger than 15 years) living with 
HIV globally has levelled off in the past few years and 
totaled 3.4 million [3 000 000–3 800 000] in 2010; 
more than 90% were living in sub-Saharan Africa.2 
Deaths among children younger than 15 years are 
declining. The estimated 250 000 [220 000–290 000] 
children who died from AIDS-related illnesses in 
2010 were 20% fewer than the estimated 320 000 
[280 000–360 000] who died in 2005. This trend 
refl ects the steady expansion of services to prevent 
HIV from being transmitted to infants and, to a lesser 
degree, the slow expansion of access to treatment for 
children.
2 This is higher than previous estimates because of improvements made 
to the estimation models, including improved assumptions about the 
survival of children living with HIV and the effects on their survival of the 
timing of their infection (see Box 2.4).
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Box 2.1
Antiretroviral therapy has averted 2.5 million deaths in low- and middle-income countries
Introducing antiretroviral therapy has averted 2.5 million 
deaths in low- and middle-income countries globally since 
1995, according to new calculations by UNAIDS1. Sub-Saharan 
Africa accounts for the vast majority – about 1.8 million – of 
the averted deaths, 300 000 each for Asia and the Pacifi c 
and Latin America, 41 000 for Eastern Europe and Central 
Asia, 26 000 for the Caribbean and 6000 for the Middle 
East and North Africa.
The number of deaths averted has doubled in the past 
two years. In 2010 alone, antiretroviral therapy averted 
an estimated 700 000 deaths in low- and middle-income 
countries. Nevertheless, only 100 000 (4%) of the 2.5 million 
averted deaths have been among children younger than 
15 years.
The 2.5 million total is lower than previous estimates, which 
included high-income countries in Western Europe and North 
America, with high impact of antiretroviral therapy.
1 To gauge the effect of antiretroviral therapy on AIDS-related mortality rates, two scenarios were created using Spectrum 2010 country fi les. In one scenario, the number of adults 
and children receiving antiretroviral therapy in low- and middle-income countries was reduced to zero. The second scenario refl ects UNAIDS’ best current estimate of the number of 
people dying from AIDS-related causes from 1995 to 2010. The difference in the numbers of deaths in the two scenarios constitutes an estimate of the number of deaths averted by 
antiretroviral therapy.
Fig. 2.10 Total number of people dying from AIDS-related 
causes in low- and middle-income countries, 1995–2010  
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Box 2.2
More than 350 000 children avoided acquiring HIV infection because of antiretroviral prophylaxis
UNAIDS recently calculated that more than 350 000 children 
have avoided becoming newly infected with HIV since 1995 
because of the antiretroviral prophylaxis provided to pregnant 
women living with HIV (Fig. 2.11).1
Eighty-six per cent of the children who avoided HIV infection 
live in sub-Saharan Africa, the region with the highest HIV 
prevalence among women of reproductive age. Eastern Europe 
and Central Asia has the second highest number of children who 
avoided acquiring HIV infection (virtually all women in these 
countries are tested for HIV during antenatal care) at 23 000. 
In the remaining regions, the numbers of children avoiding HIV 
infection were 14 000 in Asia and the Pacifi c, 9000 in Latin 
America, 3000 in the Caribbean and less than 1000 in the Middle 
East and North Africa.
The cumulative number of children who avoided infection from 
programmes to prevent mother-to-child transmission doubled 
between 2008 and 2010, as coverage of these services grew 
dramatically.
The analysis only considers the children who avoided infection because of antiretroviral prophylaxis and does not include children who 
avoided infection because of other services to prevent the mother-to-child transmission of HIV (such as counselling on infant feeding, 
reducing unwanted pregnancies among women living with HIV or reducing the number of women of reproductive age who become newly 
infected with HIV).
1 These calculations are based on two scenarios that were created using Spectrum 2010 country fi les. In one scenario, no pregnant women received antiretroviral prophylaxis to 
prevent the mother-to-child transmission of HIV. The second scenario describes the UNAIDS estimate of the number of children newly infected with HIV since 1995 within the 
context of existing coverage levels of programmes to prevent mother-to-child transmission. The difference between the numbers of children newly infected with HIV in each of the 
two scenarios constitutes an estimate of the number of children who avoided acquiring infection because of antiretroviral prophylaxis.
Fig. 2.11 Number of new HIV infections among children in 
low- and middle-income countries 1995–2010
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Box 2.3
Using strategic information to optimize the allocation of resources
During the past few years, several countries in eastern and southern Africa (1), western and central Africa (2), Asia (3,4) and Latin America (4) 
have analysed the distribution of the people newly infected with HIV according to the mode of transmission. In Morocco, this type of analysis 
has been combined with information on recent spending patterns to focus future prevention planning.
In Morocco in 2009, estimates of HIV incidence were calculated for different key affected populations, using the modes of transmission 
model (5). The calculations were based on a review of the available epidemiological, biological, behavioural and contextual HIV data for 
Morocco.
The modes of transmission analysis indicated that the main factors in the HIV epidemic in Morocco are unprotected paid sex, sex between 
men and the sharing of contaminated drug-injecting equipment. Together this higher-risk behaviour accounts about two thirds of the total 
number of people acquiring HIV infection and should therefore be given priority for HIV programming. In more detail, the analysis showed 
the following.
• HIV infection acquired in paid sex networks contributed an 
estimated 43% [26–64%] of the number of people newly infected 
with HIV in 2009. HIV transmission among female sex workers 
occurs across most of the country but is most intense in the south 
(especially in Agadir), where the prevalence of HIV infection 
exceeds 5%.
• Together, networks of men who have sex with men and people who 
inject drugs are estimated to have contributed just over 20% of the 
people newly infected with HIV in 2009. The analysis indicated the 
potential for a substantial HIV epidemic among people who inject 
drugs. Data about risk behaviour among men who have sex with men 
were limited but will be improved in 2011 using the results from an 
integrated biological and behavioural surveillance survey.
• Although the HIV incidence in the general heterosexual population 
is low, the actual number of people acquiring HIV infection in this 
population group is considerable because this group comprises 
most of the sexually active population.
The comparison showed that HIV prevention spending in 2008 did not 
match the distribution of people newly infected with HIV in Morocco. 
As a result, the resource needs for future prevention interventions 
were revised. The 2012–2016 National Strategic Plan for Morocco 
now proposes to allocate 63% of AIDS resources towards prevention 
among key populations at higher risk – including 13% for people who 
inject drugs, 13% for men who have sex with men and 23% for sex 
workers and their clients.
The mode of transmission modelling, however, is limited by several 
factors.
There are gaps in the available scientific evidence on which it 
draws. More representative multicentre integrated biobehavioural 
surveillance that reaches hidden and hard-to-reach key populations at 
higher risk would further strengthen iterations of this type of analysis, 
as would mapping and more scientifi c estimations of the numbers 
of people who inject drugs, men who have sex with men and female 
sex workers and their clients. Morocco is planning several integrated 
biobehavioural surveillance surveys among key populations at higher 
risk in the next two years.
The model does not incorporate overlapping risk factors; it calculates 
the number of people newly infected with HIV only over the short 
term of one year, and it is generally applied at the national level rather 
than at the local or regional level.
Nevertheless, the comparison of the distribution of the people newly 
infected against current programme spending has helped Morocco 
recognize the mismatch in resource allocation and has led to new 
priority-setting for future programming.
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Fig. 2.12 Morocco: number of people newly infected 
with HIV (by mode of transmission) in 2009 compared 
with the percentage distribution of HIV prevention 
spending in 2008 and the proposed percentage 
distribution of HIV prevention budgets for 2012–2016  
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2.2 Sub-Saharan Africa
2.2.1 Sub-Saharan Africa remains disproportionately affected …
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Fig. 2.13 Number of people living with HIV, sub-Saharan Africa, 1990–2010
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Fig. 2.15 Number of people dying from AIDS-related causes, sub-Saharan Africa, 1990–2010
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Fig. 2.16 Number of children 0–14 years old living with HIV, sub-Saharan Africa, 1990–2010
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Sub-Saharan Africa continues to bear a disproportionate 
share of the global HIV burden. In mid-2010, about 68% 
of all people living with HIV resided in sub-Saharan 
Africa, a region with only 12% of the global population 
(Fig. 2.13–2.16).
The 1.9 million [1 700 000–2 100 000] people who 
became newly infected with HIV in 2010 in sub-
Saharan Africa represented 70% of all the people who 
acquired HIV infection globally. However, the number 
of people newly infected in this region is decreasing. 
About 16% fewer people acquired HIV infection in 
2010 than in 2001 (when an estimated 2.2 million 
[2 100 000–2 400 000] people were newly infected).
Because people accessing antiretroviral therapy and 
care tend to survive longer, the total number of people 
living with HIV in sub-Saharan Africa is increasing; it 
reached 22.9 million [21 600 000–24 100 000] in 2010 
(12% more than in 2001).
More women than men in sub-Saharan Africa are living 
with HIV; in 2010, women comprised 59% [56–63%] 
of the people living with HIV in that region (very close 
to the same proportion as a decade ago).
The epidemics in sub-Saharan Africa vary considerably, 
however, with southern Africa most severely affected 
(Table 2.1). An estimated 11.1 million [10 600 000–
11 600 000] people were living with HIV in southern 
Africa in 2009, 31% more than the 8.6 million 
[8 100 000–9 100 000] people living with HIV in the 
region a decade earlier.
2.2.2 … but the incidence of HIV infection is 
declining in almost half the countries
Modelling indicates that the incidence of HIV infection 
(the number of people newly infected with HIV) peaked 
in the mid-1990s in sub-Saharan Africa, and evidence 
indicates that the incidence is declining in almost half 
the countries in the region.
In 22 countries, national models of HIV prevalence 
showed that the incidence of HIV infection declined 
by more than 25% between 2001 and 2009 – including 
in some of the countries with the largest epidemics in 
the region: Ethiopia, Nigeria, Zambia and Zimbabwe.
Zimbabwe is the fi rst country in southern Africa to 
record a signifi cant, sustained decline in the national 
prevalence of HIV infection among adults, which fell 
from 29% in 1997 to 16% in 2007 (6). In the capital, 
Harare, for example, the annual HIV incidence is 
estimated to have peaked in 1991 (at 5.5%) and slowed 
to 1% in 2010 (7). These trends reflect the natural 
evolution of the HIV epidemic along with changes in 
sexual behaviour (6). Increased awareness of AIDS 
deaths and the country’s economic decay appeared to 
have been the primary factors driving these changes 
in behaviour (8).
South Africa’s HIV epidemic remains the largest in 
the world, with an estimated 5.6 million [5 400 000–
5 800 000] people living with HIV in 2009 (9).1 This 
fi gure equals the total number of people living with 
HIV in all of Asia. The annual HIV incidence in South 
Africa was still a high 1.5% [1.3–1.8%] in 2009, down 
from 2.4% [2.1–2.6%] in 2001, although it varied 
considerably – from 0.5% in Western Cape province 
to 2.3% in KwaZulu-Natal, the most severely affected 
province in the country (9). These trends have occurred 
alongside apparent shifts to safer sex among young 
people (mainly increased condom use) (10).
The epidemics in Botswana, Namibia and Zambia 
(where the HIV incidence declined, especially among 
women, between 2004 and 2008 (11)) also appear to 
be declining, while those in Lesotho, Mozambique and 
Swaziland seem to be levelling off. However, in all these 
countries, the proportion of the population living with 
HIV remains exceedingly high. Angola’s comparatively 
younger epidemic still appears to be growing.
2.2.3 The epidemics vary between the 
subregions
The southern Africa subregion continues to experience 
the most severe HIV epidemics in the world. One third 
(34%) of all people living with HIV globally in 2009 
resided in the 10 countries in southern Africa,2 as did 
about 40% of all women living with HIV. Fully 31% of 
the people newly infected with HIV and 34% of all the 
people dying from AIDS-related causes in the same 
year lived in these 10 countries.
The epidemics in eastern Africa began declining about a 
decade ago and have since stabilized in many countries. 
The HIV incidence slowed in the United Republic of 
Tanzania to about 3.4 per 1000 person-years between 
1 UNAIDS publishes HIV estimates for individual countries every two 
years; the most recent set of estimates (for 2009) was published in 
2010.
2 Angola, Botswana, Lesotho, Malawi, Mozambique, Namibia, South 
Africa, Swaziland, Zambia and Zimbabwe.
Chapter 2 – Update on the HIV epidemic     25
2004 and 2008 (11). The national HIV prevalence in 
Kenya fell from about 14% in the mid-1990s to 6% in 
2006 (12) and has stayed there since 2006, while in 
Uganda it has been stable at between 6% and 7% since 
2001, and in Rwanda it stayed at about 3% between 
2005 and 2009.
Much smaller proportions of the population are living 
with HIV in western and central Africa, where the 
adult HIV prevalence was estimated to be 2% or 
less in 12 countries in 2009 (Benin, Burkina Faso, 
Democratic Republic of the Congo, Gambia, Ghana, 
Guinea, Liberia, Mali, Mauritania, Niger, Senegal and 
Sierra Leone). The national HIV prevalence in 2009 
was highest in Cameroon at 5.3% [4.9–5.8%], Central 
African Republic 4.7% [4.2–5.2%], Côte d’Ivoire 3.4% 
[3.1–3.9%], Gabon 5.2% [4.2–6.2%] and Nigeria 
3.6% [3.3–4.0%]. Nigeria continues to have the 
second largest number of people living with HIV in 
sub-Saharan Africa.
2.2.4 Fewer children acquire HIV infection and 
die from AIDS
There has been strong progress in reducing the HIV 
incidence among children younger than 15 years in sub-
Saharan Africa. The estimated 350 000 [300 000–
410 000] children who were newly infected with HIV 
in 2010 in sub-Saharan Africa were 30% fewer than 
the 500 000 [450 000–570 000] who acquired 
HIV infection in 2001. Fewer children are dying from 
AIDS-related causes, from an estimated 320 000 
[280 000–360 000] in 2005 to 230 000 [200 000–
260 000] in 2010.
South Africa is one of the few countries in the world 
in which child and maternal mortality increased in the 
2000s, a trend that largely resulted from AIDS (13). 
However, the country’s national programme for 
preventing mother-to-child transmission of HIV is 
showing highly encouraging results and could help 
reverse that child mortality trend. New data show that, 
after nine years of implementing the programme, the 
transmission rate at 4-8 weeks (early transmission 
which excludes transmission caused by breastfeeding) 
was less than 4% (ranging from 2.3% to 6.2%, 
depending on the province) (14). Based on a set of 
assumptions on breastfeeding duration and related 
transmission probabilities1, adding the postnatal 
transmission from breastfeeding (late transmission) 
1 Assuming median duration of breastfeeding among women living with 
HIV is 12 months and transmission is 1.57 per month among those with 
CD4 counts less than 350 and 0.51 per month among women with CD4 
counts more than 350.
results in an estimated fi nal overall mother to child 
transmission rate between 12% and 18%. 
2.2.5 Fewer people are dying from AIDS-related 
causes
AIDS has claimed at least 1 million lives annually in 
sub-Saharan Africa since 1998, with that death toll 
having peaked at 1.7 million [1 600 000–1 900 000] 
in 2005. Since then, however, the number of people 
dying from AIDS-related causes has steadily decreased, 
as antiretroviral therapy free of charge became more 
widely available in the region. The estimated 1.2 million 
[1 100 000–1 400 000] people dying from AIDS-
related illnesses in 2010 were 29% fewer than in 2005. 
Almost half the deaths occurred in southern Africa.
Local studies are confi rming that expanded access to 
antiretroviral therapy is reducing AIDS mortality rates 
in sub-Saharan Africa.
A recent study based on mortality records from 
the cities of Bulawayo and Harare in Zimbabwe has 
shown a 19% decline in crude mortality rates after 
antiretroviral therapy access expanded (15). In a rural 
district in Malawi, where antiretroviral therapy became 
available free of charge in 2005, the death rate among 
adults declined by 10% and AIDS-related mortality 
fell by 19% between 2002 and 2006 (16). Among 
women participating in an infant-feeding trial in Lusaka, 
Zambia, mortality more than halved after treatment 
became available in 2004–2005 (17). A similar decrease 
was observed in the capital of Ethiopia, Addis Ababa, 
where the number of people dying from AIDS-related 
causes declined by more than half fi ve years into the 
antiretroviral therapy programme. The decline in AIDS-
related deaths was steepest after antiretroviral therapy 
became available free of charge and fell 38% for men 
and 43% for women between 2005 and 2007 (18). In a 
rural district in South Africa’s KwaZulu-Natal province, 
overall population mortality and AIDS-related mortality 
declined signifi cantly after antiretroviral therapy was 
provided in the community. Between 2002–2003 
(before treatment was available) and 2004–2006 
(after it was introduced), AIDS-related mortality 
decreased from 26.5 to 18.7 per 1000 person-years 
for men aged 25–49 years and from 22.5 to 17.6 per 
1000 person-years for women in the same age group.
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Such has been the intensity of the AIDS epidemic, 
however, that it has dramatically increased the risk 
of dying in many sub-Saharan African countries, 
especially in southern Africa. Since 1990, the estimated 
probability of people dying between the ages of 15 and 
60 years has risen considerably in that subregion: in 
2010, it exceeded 600 per 1000 for men in Botswana, 
Lesotho, Malawi, Mozambique, Namibia, Swaziland, 
Zambia and Zimbabwe and was at least 500 for women 
in Lesotho, Malawi, Namibia, Swaziland, Zambia and 
Zimbabwe (19).
2.2.6  HIV transmission in long-standing 
relationships and concurrent 
partnerships …
The vast majority of people newly infected with 
HIV in sub-Saharan Africa acquire the virus during 
unprotected heterosexual intercourse (including paid 
sex) or as newborns and breastfed babies (via mother-
to-child transmission). Having unprotected sex with 
multiple partners and having other sexually transmitted 
infections (especially genital ulcers caused by herpes 
simplex virus type 2) are the greatest risk factors for 
HIV infection in this region.
Overlapping sexual networks can drastically speed up 
the rate of HIV transmission and boost the scale of HIV 
epidemics such as those in sub-Saharan Africa (20–22). 
Nevertheless, the empirical evidence supporting the 
importance of concurrency remains weak (23,24). Recent 
studies have found a very strong relationship between 
people having had more than one sexual partner and 
living with HIV but found no association between 
concurrence in men and HIV incidence in women (24) 
or between concurrency and HIV prevalence among 
men (25).
Meanwhile, increasing evidence shows that, as mainly 
heterosexual epidemics evolve, increasing proportions 
of the people who are newly infected with HIV are in 
HIV-discordant cohabiting couples (in which only one 
person is living with HIV) (26,27), and HIV transmission 
within long-term relationships is increasing (28).
Many of these serodiscordant couples are unaware of 
one another’s HIV status. In Kenya, Malawi and Uganda, 
more than 80% of all unprotected sex acts involving 
people living with HIV are estimated to occur with 
spouses or cohabiting partners (29,30). Consequently, 
large proportions of the people newly infected with HIV 
are within married or cohabiting heterosexual couples.
Moreover, it was assumed that, in such serodiscordant 
couples, the partner living with HIV is most likely to 
be male. But a recent review of Demographic and 
Health Survey data from 14 countries in sub-Saharan 
Africa found that women were as likely to be the index 
partner: the proportion of women living with HIV in 
stable serodiscordant couples was 47% (31). Additional 
research suggests that large proportions of cases in 
which the woman is the partner living with HIV are 
widowed or divorced women remarrying (32).
Prevention strategies need to be tailored to these trends 
and patterns of HIV transmission, with behavioural 
change programmes that aim to reduce the number 
of partners and expanded HIV testing and counselling 
for couples, especially for preventing mother-to-
child transmission. Among serodiscordant couples in 
northern Malawi, for example, HIV transmission was 
drastically reduced after the person living with HIV 
discovered his or her serostatus and began antiretroviral 
therapy; in those couples, zero HIV transmission 
occurred during a three-year follow-up period (33).
2.2.7 … and unprotected paid sex and sex 
between men remain signifi cant factors
Continuing evidence indicates that unprotected paid 
sex and sex between men are signifi cant factors in the 
HIV epidemics in several sub-Saharan African countries.
It has been postulated that unprotected paid sex was a 
more signifi cant factor in early HIV epidemics in sub-
Saharan Africa. However, a review of 68 studies from 18 
countries suggests that paid sex can remain an equally 
important factor in mature epidemics (34).
An estimated 14% of the people acquiring HIV infection 
in Kenya are linked to sex work (HIV infection among 
sex workers, their clients or their other sex partners) 
(35). An earlier study concluded that about four fi fths 
of prevalent cases of HIV among adult men in Accra, 
Ghana, might have been acquired during unprotected 
paid sex (36). Female sex workers continue to have very 
high HIV incidence and prevalence in several other 
countries: 12% annual HIV incidence in north-central 
Nigeria (37) and 30% prevalence in Dar es Salaam, 
United Republic of Tanzania (38), for example. This 
indicates that condoms are not being routinely used 
routinely in sex work.
The results from recent studies indicate that cities 
in sub-Saharan Africa have many men who have sex 
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with men and high rates of HIV infection among those 
surveyed (39). Fully half (50%) of men who have sex with 
men who participated in a 2008 study in Johannesburg, 
South Africa, were living with HIV, as were 28% of 
those in surveyed in the port city of Durban (40). In 
Unguja, Zanzibar, United Republic of Tanzania, the HIV 
prevalence among men who have sex with men was 
12% (41), 17% in Lagos and 9% in Kano (Nigeria) in a 
2007 study (42), 14% in a 2008–2009 study in Kampala 
(Uganda) (43), and an average 17% in Botswana, Malawi 
and Namibia (44). In most of these instances, the HIV 
prevalence among men who have sex with men was 
even higher than in the general population.
In sub-Saharan Africa, as in other regions where sex 
between men is highly stigmatized, large proportions 
of men who have sex with men also have sex with 
women. In Senegal, 82% of surveyed men who have 
sex with men said that they also had sex with women 
(45), while 50% of those participating in the Lagos 
study cited above said they had sex with girlfriends 
(46) and one third of those surveyed in Malawi were 
married or cohabiting with a woman. Enforcement of 
criminal penalties on sex between men compromises 
the health of men who have sex with men and their 
various partners by limiting access to essential HIV and 
other essential public health services (47).
2.2.8 Injecting drug use is a growing problem in 
some countries
Injecting drug use is a relatively recently reported 
phenomenon in sub-Saharan Africa. It is the main risk 
factor for HIV infection only in Mauritius (48), where 
47% of people who inject drugs tested HIV-positive 
in a recent study (49). However, studies elsewhere have 
also revealed high HIV prevalence among people who 
inject drugs: 42% among those tested in Dar es Salaam 
(United Republic of Tanzania) (50), 16% in Unguja, 
Zanzibar (51) (United Republic of Tanzania) and 36% 
in Nairobi (Kenya) (52). In the latter instances, however, 
injecting drug use remains a minor factor in these 
countries’ HIV epidemics, since few people inject drugs.
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2.3 Asia
2.3.1 There are signs that the epidemic is slowing down …
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In Asia, the rate of HIV transmission appears to be 
slowing down: the estimated 360 000 [300 000–
450 000] people who were newly infected with HIV in 
Asia in 2010 were considerably fewer than the 450 000 
[410 000–500 000] estimated for 2001.
The incidence of HIV infection in the older epidemics 
in South and South-East Asia appears to have peaked 
in the mid-1990s (at 440 000–465 000 people newly 
infected annually) and decreased markedly since 
then to about 270 000 [230 000–340 000] people 
acquiring HIV infection in 2010. In East Asia, however, 
the HIV incidence did not reach its highest levels until 
the mid-2000s (about 94 000 people newly infected 
annually in 2004–2005) but decreased subsequently 
to about 88 000 [48 000–160 000] in 2010.
About 4.8 million [4 300 000–5 300 000] people 
were living with HIV in Asia in 2010, 11% more than 
the 4.2 million [3 800 000–4 600 000] in 2001 
(Table 2.1, Fig. 2.17–2.20). HIV transmission rates have 
slowed in the larger epidemics, but expanded access 
to antiretroviral therapy has increased the survival 
rates of people living with HIV. An estimated 310 000 
[260 000–340 000] people died from AIDS-related 
causes in 2010 – the largest death toll outside sub-
Saharan Africa. That death toll has stayed relatively 
stable during the past decade in Asia overall, but in East 
Asia it doubled from 24 000 [16 000–45 000] in 2001 
to 56 000 [40 000–76 000] in 2010.
Seven countries report an estimated 100 000 or more 
people living with HIV in 2009: India, China, Thailand 
(the only country in this region in which the prevalence 
is close to 1%), Indonesia, Viet Nam, Myanmar and 
Malaysia (ranked by the number of people living with 
HIV in each). More than 90% of the people with HIV in 
Asia live in these countries, with India alone accounting 
for 49% of the people living with HIV in the entire region.
The proportion of women living with HIV has stabilized 
at about 35% [30–38%]. Many of these women 
acquired HIV during unprotected sex with their regular 
male partners.
The estimated number of children younger than 
15 years living with HIV increased from 110 000 
[75 000–140 000] in 2001 to 180 000 [130 000–
230 000] in 2010. The annual number of children 
dying from AIDS-related causes has ranged between 
15 000 [9400–21 000] (in 2010) and 17 000 [12 000–
24 000] (in 2004) for the past decade but appears to 
be decreasing slowly.
The number of children newly infected with HIV 
declined by 23% in Asia overall between 2001 and 
2010, from an estimated 28 000 [19 000–39 000] to 
22 000 [16 000–30 000]. This probably refl ects the 
slowing rate of HIV incidence in this region overall as 
well as the (uneven) expansion of services to prevent 
mother-to-child transmission of HIV. However, an 
opposite trend is evident in East Asia, where the 
incidence of HIV infection among children rose by 
31% (from 1600 [1100–2200] to 2200 [1100–3600] 
people newly infected) in that same period.
The overall trends in this region hide important 
variation in the epidemics, both between and within 
countries. In many Asian countries, national epidemics 
are concentrated in relatively few provinces. In China, 
for example, fi ve provinces account for just over half 
(53%) the people living with HIV (53), and much of 
Indonesia’s burden of HIV is in its Papua and West 
Papua provinces (54).
Various combinations of injecting drug use, unprotected 
sex between men and unprotected paid sex fuel the 
epidemics in this region, with paid sex especially 
prominent in the more mature epidemics.
Most epidemics in Asia follow a similar path, although 
the intensity and pace of the progress of the epidemics 
vary greatly, depending on the levels of drug injecting 
and sexual risk-taking in a country.
In most countries in this region, outbreaks of HIV were 
fi rst detected among men who have sex with men or 
people who inject drugs. However, the links between 
injecting drug use and sex work (both people who inject 
drugs and who also buy sex, and sex workers who also 
inject drugs) eventually generate a more extensive 
epidemic among sex workers and their clients. Since 
large numbers of men buy sex, sex work becomes a 
major component of overall national epidemics in most 
countries. The male clients then transmit HIV more 
slowly but steadily to their wives and girlfriends. In 
recent years, an existing lower-intensity epidemic among 
men who have sex with men has surged throughout 
the region. Mobility, social changes and other factors 
(including Internet dating and soft drug use) appear 
to be providing further opportunities for HIV to spread 
extensively among men who have sex with men.
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2.3.2 … but HIV infection trends among sex 
workers vary …
Infection levels reported in various surveys conducted 
among female sex workers vary considerably: in China, 
from well under 1% in Nanning (55) and Shanghai (56) 
to 10% in Kaiyuan City (57) in 2008–2009; in India, 
from 4.6% in Mumbai and Thane (58) to 24% among 
street-based sex workers and 29% among their brothel-
based counterparts in some districts in Maharashtra 
in 2009 (59).
Although still low (under 1%), the percentages of 
female sex workers living with HIV have increased in 
Afghanistan (60), Indonesia and Pakistan (61), as HIV 
transmission in these countries expands among and 
beyond people who inject drugs. Many people who 
inject drugs also buy or sell sex, thus compounding 
the risk of HIV transmission. In some locations, such 
as Cebu (Philippines), Ho Chi Minh City (Viet Nam) 
and parts of southern China, the prevalence among sex 
workers who inject drugs is much higher than among 
sex workers who do not inject drugs. In a review of 
studies in China, for example, 12–49% of female sex 
workers who also inject drugs were living with HIV, 
depending on the place (62).
But there is also increasing evidence that intensive HIV 
prevention programmes among female sex workers 
can be highly effective. A prevention programme in 
Karnataka (India) was associated with a drop in HIV 
prevalence from 25% to 13% among female sex workers 
in three selected districts between 2004 and 2009 (63) 
and from 1.4% to 0.8% among young antenatal clinic 
attendees between 2004 and 2008 in 18 districts (64). 
In Mumbai and Thane, a similar programme was 
accompanied by a decline in HIV prevalence from 
45% in 2004 to 13% in 2010 among brothel-based 
sex workers (58).
Clients of sex workers make up the largest key 
population at higher risk in Asia: depending on the 
country, between 0.5% and 15% of adult men in the 
region are believed to buy sex (65–70). Recent studies 
are revealing the extent to which clients are infected 
with HIV: the HIV prevalence in three cities in China’s 
Sichuan province was 1.5% in 2008 (71) and 5.6% 
among their peers in six districts in India’s Karnataka 
state in 2010 (72). In a study among men frequenting 
bars, beer gardens and massage parlours (places were 
sex is commonly sold) in eight cities in Cambodia, 
the HIV prevalence among the men who said they 
had sexual partners other than their spouses or 
girlfriends was 1.6% (three times the national adult 
HIV prevalence) (73).
2.3.3 … large proportions of people who inject 
drugs are becoming infected …
The prevalence among people who inject drugs is still 
very high in several countries and is increasing in others.
An estimated 4.5 million people in Asia inject drugs; 
more than half live in China (74).
Overall, an estimated one in six people who inject 
drugs (16%) in Asia is living with HIV (74), but the HIV 
prevalence is much higher in some places.
In recent local studies, between 11% and 24% of people 
who inject drugs in Thailand (75) tested HIV-positive, 
as did between 23% and 58% of those in various 
provinces in Viet Nam (76–78), more than 50% in parts 
of Indonesia (54) and 23% in Rawalpindi and 52% in 
Mandi Bahauddin, cities in Punjab (Pakistan) (79). (In 
earlier sentinel surveillance studies in Thailand, the 
HIV prevalence ranged between 30% and 50% among 
people who inject drugs (80).) The prevalence of HIV 
infection among people who use drugs varies widely 
in China – from less than 1% in the cities of Haikon, 
Hangzhou, Qingdao and Shanghai, to 2.6% in Beijing, 
7.5% in Chongqing and 16% in Kunming (81).
Most countries in the region have been slow to 
introduce and expand harm reduction programmes. 
In such a context, the HIV prevalence tends to rise 
drastically, as it has in Pakistan (from 11% in 2005 to 
21% in 2008 (82)) and in Cebu, Philippines (from 0.6% 
to 53% in 2009–2011 (83)). Many people who inject 
drugs are sexually active, but the rates of consistent 
condom use among them tend to be low (84–87). 
Consequently, many of their sexual partners may be 
living with HIV. In Hanoi (Viet Nam), for example, 14% 
of the sexual partners of people who inject drugs tested 
HIV-positive in a 2008 study (88).
However, evidence also indicates that harm reduction 
efforts are working in Asia. In Bangladesh’s capital, 
Dhaka, harm reduction programmes have been credited 
with slowing the spread of HIV among people who 
inject drugs (89). Prevalence in that key population at 
higher risk rose from 1.4% in 2000 to 7% in 2007 
(90), but modelling suggests it could have exceeded 
40% in the absence of those programmes. A peer 
Chapter 2 – Update on the HIV epidemic     31
education and needle and syringe programme in Viet 
Nam’s Lang Son province resulted in a decline in HIV 
prevalence from 46% to 23% among people who inject 
drugs between 2002 and 2010. In Ning Ming county 
(in China’s Guangxi province), a similar programme 
was associated with a decline in HIV prevalence from 
17% to 11% in the same period (91). In Malaysia, the 
HIV prevalence was much lower among participants 
in a methadone maintenance treatment programme 
(4%) than among those in the wider drug-injecting 
community (22%) (92).
2.3.4 … and the epidemic among men who have 
sex with men is growing
Epidemics among men who have sex with men are 
growing across the region. In Thailand, that facet of 
the epidemic had been largely ignored until a study 
uncovered 17% prevalence among men who have sex 
with men in Bangkok in 2003 (93). The HIV prevalence 
found in subsequent studies was 31% in 2007 and 
25% in 2009 (93). A recent three-year study found a 
6% HIV incidence among men who have sex with men 
in Bangkok (94).
High prevalence – between 8% and 32% – has been 
found among surveyed men who have sex with men 
in cities in Indonesia (8% in Jakarta) (95), India (up to 
18% in the south) (96), Myanmar (29%) (97) and Viet 
Nam. A recent review of studies in China has estimated 
a national HIV prevalence among men who have sex 
with men of 5.3% (98), considerably higher than the 
1.8% national prevalence estimated for 2004–2005 
in another study (99). The prevalence appears to be 
highest in south-western China (100). In the Philippines, 
outbreaks of HIV in this population group have been 
reported in Metro Manila (2% prevalence in 2010), 
Cebu (5% in 2010) and other cities (101).
Data for male sex workers and transgender people are 
scarce but show very high HIV prevalence: between 
9% and 25% of surveyed male sex workers have tested 
HIV-positive in China (102), Indonesia and Thailand, 
for example, as have 34% of transgender (hijra) sex 
workers in Jakarta (Indonesia), 16% of their peers in 
Mumbai (India) and 14% of transgender people in 
Bangkok (Thailand) (103).
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2.4 Eastern Europe and Central Asia
2.4.1 An epidemic that continues to grow
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Fig. 2.21 Number of people living with HIV, Eastern Europe and Central Asia, 1990–2010
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Fig. 2.22 Number of people newly infected with HIV, Eastern Europe and Central Asia, 1990–2010
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Eastern Europe and Central Asia has had a steep 
increase since 2001 in the number of people living 
with HIV, increasing 250% from an estimated 410 000 
[340 000–490 000] to 1.5 million [1 300 000–
1 700 000] in 2010 (Table 2.1, Fig. 2.21–2.24). This 
refl ects the rapid increase in the number of people newly 
infected with HIV around the turn of the century. The 
annual incidence of HIV infection slowed dramatically 
after 2002 but has begun accelerating again in the past 
few years. An estimated 160 000 [110 000–200 000] 
people acquired HIV infection in 2010 – 23% fewer 
than the 210 000 [170 000–240 000] estimated for 
2001 but more than the estimated 130 000 [110 000–
160 000] people newly infected annually in 2007 and 
2008.
The prevalence of HIV infection among adults in 2009 
was 1% [0.9–1.2%] in the Russian Federation and 
1.1% [1.0–1.3%] in Ukraine. Together, those countries 
account for almost 90% of the people newly reported 
to be diagnosed with HIV infection in this region (104) 
and are home to twice as many people living with HIV 
as all of Western and Central Europe combined (105).
Overall, women comprised about 35% [30–40%] of 
adults living with HIV in Eastern Europe and Central 
Asia in 2010 (104). Although that proportion has stayed 
relatively steady since the turn of the century, about 
one fi fth more children were newly infected with HIV 
in 2010 than in 2001: 2200 [1700–2900] versus 1800 
[1500–2300]. The total estimated number of children 
living with HIV rose fi ve-fold from 3400 [2800–4700] 
to 17 000 [14 000–23 000] in the same period, and 
the number of children dying from AIDS-related causes 
more than doubled from fewer than 500 [<500–
<1000] to almost 1200 [<1000–1800].
Unlike most other regions, the number of people dying 
from AIDS-related causes continues to rise in Eastern 
Europe and Central Asia. The HIV epidemic claimed 
an estimated 83 000 [69 000–100 000] lives from 
AIDS-related causes in 2010 – 11 times more than the 
estimated 7800 [6000–11 000] in 2001.
The epidemic in this region began spreading rapidly in 
the late 1990s among people who inject drugs and later 
also among their sexual partners. In Ukraine, between 
39% and 50% of the estimated 230 000–369 000 
people who inject drugs are believed to be living with 
HIV (106), as are more than one third (37%) of the 
1.5 million to 2 million people who inject drugs in the 
Russian Federation (104).
2.4.2 Very high HIV prevalence among people 
who inject drugs
There is no sign yet that the epidemic in this region 
has peaked (104). The incidence of HIV infection among 
people who inject drugs in St Petersburg (Russian 
Federation), for example, was 8.1 per 100 person-years1 
in 2009 – almost twice the rate fi ve years earlier (107). 
Newly reported diagnoses of people living with HIV 
have increased in Kyrgyzstan, Tajikistan, Turkmenistan 
and Uzbekistan (104). Localized studies continue to 
reveal very high HIV prevalence among people who 
inject drugs: up to 59% in St Petersburg and 64% in 
Yekaterinburg (Russian Federation) (108), an average 
of 32% in 16 cities in Ukraine (109) and 42% in Balti, 
Republic of Moldova (110).
Large shares of these people living with HIV are 
undiagnosed: 53% of the people who inject drugs 
who tested HIV-positive in a study in St Petersburg 
did not know they were infected, versus 73% of those 
in Yekaterinburg and 80% of those in Omsk (all in the 
Russian Federation) (108).
Up to one third of sex workers in the Russian Federation 
are believed to inject drugs (111). The combination of 
unprotected sex and injecting drug use compounds 
the risk of acquiring and transmitting HIV infection. 
In Ukraine, an HIV prevalence of 43% has been found 
among sex workers who inject drugs versus 8.5% 
among those who did not inject (112). An estimated 
35% of women living with HIV probably acquired HIV 
through injecting drug use, and an additional 50% were 
probably infected by partners who inject drugs (113). The 
use of non-sterile injecting equipment, in other words, 
remains the core driver of the epidemic in this region.
In the Russian Federation, an estimated 72% of the 
people living with HIV are younger than 30 years (114). 
However, the HIV prevalence in Ukraine among 
people who recently started injecting drugs appears 
to be declining (115). Overall in the region, most people 
diagnosed as living with HIV are 30–39 years old (116).
Signifi cant proportions of women engaging in sex work 
in some countries are still in their teens. About 20% of 
1 This implies that if 100 people were followed for one year, 8.1 of those 
people would become newly infected during that year.
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females selling sex in Ukraine (117) are believed to be 
younger than 19 years, and an HIV prevalence of 19% 
has been found among those aged 15–19 years (118). 
Street children in some countries are also at special 
risk: in a recent study in Donetsk, Kyiv and Odessa 
(Ukraine), HIV prevalence ranged as high as 28% 
among street children who were both orphaned and 
homeless (119).
The available data indicate that unprotected sex 
between men is a minor contributor to the epidemics 
in this region, accounting for less than 1% of the people 
newly diagnosed with HIV (for which the route of 
transmission was identifi ed) (116). However, offi cial 
data probably underplay the actual state of affairs. 
Small surveys among men who have sex with men have 
shown an HIV prevalence of up to 5% in Georgia, 6% 
in the Russian Federation (120) (and 16% among male 
sex workers in Moscow (121)) and between 4% (in Kyiv) 
and 23% (in Odessa) in Ukraine (106).
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2.5 Caribbean
2.5.1 Fewer people newly infected and fewer people dying from AIDS-related causes
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Fig. 2.25 Number of people living with HIV, Caribbean, 1990–2010
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Fig. 2.26 Number of people newly infected with HIV, Caribbean, 1990–2010
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Fig. 2.27 Number of people dying from AIDS-related causes, Caribbean, 1990–2010
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The epidemic in the Caribbean has slowed signifi cantly 
since the mid-1990s. The 12 000 [9400–17 000] 
people newly infected with HIV estimated for 2010 
were more than one third fewer than the 19 000 
[16 000–22 000] people who acquired HIV infection in 
2001. The HIV incidence has declined by an estimated 
25% in the Dominican Republic and Jamaica since 2001 
and by about 12% in Haiti.
The number of people living with HIV has also declined 
slightly since the early 2000s – from about 210 000 
[170 000–240 000] to 200 000 [170 000–220 000] 
in 2010, or about 1% [0.9–1.1%] of adults (Table 2.1, 
Fig. 2.25–2.28). The HIV prevalence among adults 
exceeds 1% in fi ve of the seven larger countries in the 
region (122).
Increased access to antiretroviral therapy has led to a 
considerable drop in the number of people dying from 
AIDS-related causes. The 9000 [6900–12 000] people 
dying attributable to AIDS in 2010 were about half as 
many as the 18 000 [14 000–22 000] estimated to 
have died in 2001.
The Caribbean is the only region besides sub-Saharan 
Africa in which more adult women than men are living 
with HIV. In 2010, an estimated 53% [47–61%] of 
adults living with HIV were women (a proportion that 
has remained steady since the late 1990s). This mainly 
refl ects the pattern of infection in Haiti (which has the 
largest epidemic in the region), the Bahamas, Belize and 
the Dominican Republic (123). In the most of the other 
countries in the region, men outnumber women among 
people living with HIV.
Slowing HIV incidence and increased access to services 
that can prevent the mother-to-child transmission of 
HIV has led to a 60% decline in the number of children 
newly infected with HIV (from 2900 [2200–3600] to 
1200 [<1000–1700]) and a 47% decline in the number 
of children dying from AIDS-related causes (from 1900 
[1400–2400] to 1000 [<1000–1300]) between 2001 
and 2010. However, the progress is not uniform across 
the region. Coverage of programmes to prevent mother-
to-child transmission is still low in countries such as the 
Bahamas, Belize and Haiti but is comparatively high in 
Barbados, the Dominican Republic and Guyana.
The island of Hispaniola, which contains the Dominican 
Republic and Haiti, is home to about 70% (182 000) 
of the people living with HIV in this region. Evidence 
indicates that the epidemics in both these countries 
have declined in the past decade (124,125). The burden 
of HIV varies considerably between countries, 
however. Cuba’s very low adult HIV prevalence of 0.1% 
[0.08–0.13%] in 2009 contrasts, for example, with a 
prevalence of 3.1% [1.2–5.4%] in the Bahamas.
There is also variation inside countries. In Jamaica, for 
example, the HIV prevalence is highest in the parishes 
of St James, Kingston and St Andrew (126), and in Haiti 
the departments of Nord and Les Nippes have the 
highest prevalence (127). In the Dominican Republic, 
the HIV prevalence in communities of sugar plantation 
workers (the bateyes) is nearly four times the national 
average (128).
2.5.2 Unprotected sex is the main route for HIV 
transmission …
Unprotected sex between men and women and 
between men – including paid sex – are the main modes 
of HIV transmission in this region (129). The prevalence 
of HIV infection among female sex workers varies 
considerably – from 2% in the Dominican Republic (130) 
and 5% in Jamaica (123) to 17% in parts of Guyana and 
24% in parts of Suriname (123).
Unprotected sex between men features in all the 
region’s epidemics, but it is rarely acknowledged as a 
factor. Various studies since 2005 have found that the 
HIV prevalence among men who have sex with men 
ranges from more than 5% in four of the Dominican 
Republic’s largest cities in 2008 (131) to almost 7% 
in Suriname, 8% in the Bahamas and 19% in Guyana. 
Preliminary results show that 33% of men who have 
sex with men participating in a 2011 study in Jamaica 
tested HIV-positive (as did 32% in a 2007 study) (132).
Many Caribbean countries still criminalize sexual 
relations between men (133). Many men who have sex 
with men also have sex with women. One third of the 
men participating in the Jamaica study cited earlier, 
for example, also had sex with women in the previous 
year (132).
In Bermuda and Puerto Rico, unsafe injecting drug use 
contributes signifi cantly to the spread of HIV. In Puerto 
Rico, contaminated injecting equipment accounted for 
an estimated 40% of men becoming newly infected in 
2006 and for 27% among women (134). Crack cocaine 
users appear to be another key affected group. The HIV 
prevalence is 5% in Jamaica and 7% in St Lucia. Studies 
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show that crack cocaine users often sell sex to support 
their drug habit and seem less likely to sustain safe sex 
behaviour (135,136).
The criminalization of drug use and sex between men, 
along with unprotected forced sex, probably accounts 
for the high HIV prevalence being found in detention 
facilities in some countries – 3% in Jamaica’s largest 
correctional facility (137) and close to 5% in Belize (123) 
and Guyana (138), for example.
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2.6 Latin America
2.6.1 A stable epidemic overall
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Fig. 2.29 Number of people living with HIV, Latin America, 1990–2010
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Fig. 2.30 Number of people newly infected with HIV, Latin America, 1990–2010
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Fig. 2.31 Number of people dying from AIDS-related causes, Latin America, 1990–2010
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The HIV epidemics in Latin America are generally 
stable (Table 2.1, Fig. 2.29–2.32). A steady decrease 
in the annual number of people newly infected with 
HIV since 1996 levelled off in the early 2000s.1 Since 
then, the estimated annual number of people acquiring 
HIV infection has varied between 99 000 [75 000–
130 000] and 100 000 [73 000–140 000] (the latter 
fi gure for 2010).
The total number of people living with HIV in this region 
continues to grow and reached 1.5 million [1 200 000–
1 700 000] in 2010, up from 1.3 million [1 000 000–
1 700 000] in 2001. This increase is partly attributable 
to the increase in the number of people living with 
HIV receiving antiretroviral therapy, which has helped 
reduce the annual number of people dying from AIDS-
related causes to 67 000 [45 000–92 000] in 2010, 
down from a peak of 83 000 [50 000–130 000] in 
2001–2003. More than one third (36%) of the adults 
living with HIV in this region in 2010 were women.
The number of children younger than 15 years living 
with HIV in this region has declined from about 47 000 
[23 000–94 000] in 2001 to 42 000 [30 000–54 000] 
in 2010. The same period also saw a considerable 
decrease in the number of children newly infected 
(from 6300 to 3900, or 38%) and the number of 
children dying from AIDS-related causes (4400 to 
2700, or 39%) between 2001 and 2010.
Brazil, the most populous country in the region, is 
home to about one third of the people living with HIV 
in Central and South America. However, the adult 
HIV prevalence in Brazil has never reached 1%. An 
early well-coordinated response, protection of human 
rights and a focus on preventing HIV infection among 
men who have sex with men, people who inject drugs 
and female sex workers with large, evidence-informed 
programmes helped Brazil to avoid a potentially much 
larger HIV epidemic (139).
2.6.2 Unprotected sex between men is fuelling 
the epidemic
In most of the HIV epidemics in this region, HIV is 
spreading predominately in and around networks of 
men who have sex with men. During the past decade, 
surveys have found HIV prevalence of at least 10% 
1 Previously published UNAIDS estimates for Latin America did not 
include Mexico, which is now included in this region. These new 
HIV estimates (including the estimates for previous years) therefore 
supersede those published previously for Latin America.
among men who have sex with men in 9 of 14 countries 
in the region, with infection levels as high as 19% in 
parts of Colombia and Uruguay, 21% in Bolivia (140) 
and more than 12% on average in the 10 cities in 
Brazil (141) and three cities in Honduras that conducted 
studies (142). An earlier review (143) concluded that 
men who have sex with men in 15 countries in South 
and Central America were 33 times more likely to be 
living with HIV compared with other men in the general 
population.
A 2010 longitudinal cohort study in Nicaragua’s two 
largest provinces (Managua and Chinandega) found 
an incidence of 3% among men who have sex with 
men, only about one third of who said they used 
condoms consistently (144). In 2009, a study reported 
an incidence of 3.5% in men who have sex with men 
who attended public health clinics in Lima, Peru (145). 
In San Pedro Sula, Honduras, 9% of 18- to 24-year-old 
men who have sex with men were living with HIV, 
indicating high rates of HIV transmission (146).
Very little data exist on HIV trends among male 
and transgender sex workers. A study in 13 cities 
in Argentina uncovered alarming incidence rates in 
10.7 per 100 person-years among transgender sex 
workers and 2.3 per 100 person-years among male sex 
workers (147). One third (34%) of the transgender sex 
workers were living with HIV (148). In Campinas, Brazil, 
a 2008 study found an HIV prevalence of 14% among 
male sex workers (versus 6% among other men who 
have sex with men) (149).
Many men who have sex with men also have sex with 
women. For example, in the 2010 Nicaragua study 
cited above (144), 40% of men who have sex with men 
in Managua and 57% of those in Chinandega said they 
had had sex with women in the previous year.
Few national HIV programmes focus suffi ciently on 
preventing and treating HIV infection among men 
who have sex with men. Of the 12 countries reporting 
spending on prevention activities, only Peru directed 
more than 5% of its HIV prevention spending toward 
prevention programmes for men who have sex with 
men (150). This misallocation of resources is especially 
evident in Central America and in the Andean 
region (151).
Generally, countries have been more inclined to address 
HIV transmission during paid sex – and with apparent 
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success in some places. High condom use rates and 
zero HIV prevalence have been reported among female 
sex workers in Santiago, Chile (152), while in Guatemala 
high rates of condom use accompanied a drop in HIV 
incidence among female sex workers (from 1.85 per 
100 person-years in 2005 to 0.4 in 2008) (153). On the 
other hand, HIV prevalence was 3% among the 317 
female sex workers tested in a recent study in Buenos 
Aires, Argentina (154), and the annual HIV incidence 
was 0.8% among female sex workers in Managua and 
Chinandega, Nicaragua, in 2009 (155).
Studies are also revealing a high prevalence of 
sexually transmitted infections (especially herpes 
simplex virus 2, which is believed to increase the risk 
of acquiring HIV) among female sex workers, which 
indicates that unprotected paid sex is far from unusual. 
The prevalence of herpes simplex virus 2 was 77% in 
Panama City in a 2009–2010 study (156) and 76% and 
84% in the Nicaragua study (155), for example.
Injecting drug use is another signifi cant route of HIV 
transmission in this region, especially in the southern 
cone of South America, and in Mexico (which has a 
sizeable HIV epidemic, with about 220 000 adults and 
children living with HIV in 2009). The interplay of the 
drug and sex trades appears to be an important factor 
in Mexico’s epidemic, especially along the border with 
the United States (157). The HIV prevalence was 12% 
in 2007 among female sex workers in Tijuana and 
Ciudad Juarez who injected drugs (158). Recent data 
on HIV trends among people who inject drugs in other 
countries in this region are scarce.
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2.7 North America and Western and Central Europe
2.7.1 A largely stable epidemic
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Fig. 2.33 Number of people living with HIV, North America and Western and Central Europe, 1990–2010
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Fig. 2.34 Number of people newly infected with HIV, North America and Western and Central Europe, 1990–2010
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Fig. 2.35 Number of people dying from AIDS-related causes, North America and Western and Central Europe, 1990–2010
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The HIV epidemic in North America and Western 
and Central Europe remains stable overall, with the 
incidence of HIV infection having changed little since 
2004. An estimated 88 000 [56 000–150 000] people 
were newly infected with HIV in 2010, most of them in 
the United States of America. According to the United 
States Centers for Disease Control and Prevention, the 
HIV incidence in the United States has been relatively 
stable in the past few years, with between 48 600 
and 56 000 people acquiring HIV infection annually 
between 2006 and 2009 (159).
The total number of people living with HIV in North 
America and Western and Central Europe reached 
an estimated 2.2 million [1 900 000–2 700 000] in 
2010, about one third (34%) more than the 1.6 million 
[1 400 000–1 800 000] in 2001 (Table 2.1, Fig. 2.33–
2.35). More than half (about 1.2 million) of the people 
with HIV in this region live in the United States.
The rising number of people living with HIV refl ects 
the wide-scale availability of antiretroviral therapy, 
especially in the countries with the largest epidemics, 
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which has signifi cantly reduced AIDS-related mortality. 
The number of people dying from AIDS-related causes 
has varied little since 2000 (despite the 34% increase 
in the number of people living with HIV) and totalled 
about 30 000 [26 000–37 000] in 2010.
The epidemic’s recent trends vary across this region. 
The rates of diagnosed HIV cases doubled between 
2000 and 2009 in Bulgaria, Czech Republic, Hungary, 
Lithuania, Slovakia and Slovenia and increased by more 
than 50% in the United Kingdom (116). In contrast, the 
number of people newly diagnosed with HIV decreased 
by more than 20% in Latvia, Portugal and Romania (116).1 
2.7.2 Unprotected sex between men is fuelling 
HIV transmission
Unprotected sex between men continues to be the 
main driver of HIV transmission in this region (116), 
with injecting drug use and unprotected paid sex being 
minor factors. In the United States, for example, men 
who have sex with men represent about 2% of the 
total population but account for 57% of the people 
newly infected (160,161). The HIV incidence in the United 
States increased during 2006–2009 among young men 
who have sex with men and especially among African-
American men who have sex with men (159).
This epidemic pattern means that, across this region, 
men outnumber women among people living with 
HIV. In 2010, 26% of the people living with HIV in 
North America and Western and Central Europe were 
women, a proportion that has changed little since the 
late 1990s.
The HIV epidemics among men who have sex with 
men appear to be resurgent in North America and 
much of western Europe (162). In Western and Central 
Europe, the number of men who have sex with men 
newly diagnosed with HIV infection increased from 
7601 in 2004 to 9541 in 2009 (116). The 3080 men 
who have sex with men newly diagnosed in the United 
Kingdom in 2010 was the highest annual number 
yet  (163). Trends of increasing numbers of people living 
with HIV in this key population at higher risk are also 
evident in Belgium (164), France (165), Germany (166), 
the Netherlands (166), Slovenia (167) and Spain (168,169).
1 People who are newly diagnosed with HIV infection did not necessarily 
acquire HIV infection recently, nor does this refl ect the actual number 
of people newly infected. But where HIV testing coverage remains 
relatively consistent, trends in the numbers of people newly diagnosed 
with HIV can provide a useful picture of recent trends in the epidemic.
The HIV incidence among men who have sex with men 
in the United Kingdom is estimated to have increased 
from 0.5% [0.1–0.8%] in 2002 to 0.9% [0.5–1.3%] in 
2007 (170). In France, about 50% of the men who have sex 
with men newly diagnosed with HIV infection between 
2003 and 2008 had acquired infection recently (165). 
In the United Kingdom, one quarter of the men newly 
diagnosed with HIV in 2010 had become infected 4–5 
months before diagnosis (171). In the United States of 
America, the estimated number of men who have sex 
with men newly infected with HIV increased by 17% 
from 2005 to 2008 in the 37 states with suffi cient 
data (172,173). In New York City, the HIV incidence in 
2005–2008 more than doubled among men who have 
sex with men, and syphilis rates increased six-fold among 
those aged 18–29 years (174) – an indication of increased 
sexual risk-taking (175). Similar trends have been reported 
in Canada (176). This underscores the need for ongoing 
prevention efforts, especially ones tailored for young 
men who have sex with men.
2.7.3 HIV infection trends are showing 
signifi cant racial, ethnic and 
socioeconomic disparities
In the United States of America, the increase in HIV 
diagnoses has been especially marked among black 
men who have sex with men, especially those who 
are young (177,178). National behavioural surveillance 
data for 2008 showed a 28% HIV prevalence among 
African-American men who have sex with men versus 
18% among Hispanics and 16% among whites (179).
Those racial and ethnic disparities are mirrored also 
in the overall HIV epidemic in the United States (180), 
with blacks disproportionately affected. Despite 
representing less than 14% of the country’s total 
population, African-Americans accounted for half the 
people diagnosed with HIV infection in 37 states in 
2005–2008 (181,182). Blacks have an estimated 1 in 22 
lifetime risk of receiving an HIV diagnosis versus 1 in 
170 for whites and 1 in 52 for Hispanics (181).2 
Socioeconomic divides appear to be equally important 
in the epidemic in the United States. A study in 23 
cities found an average HIV prevalence of 2.1% among 
heterosexual residents of high-poverty areas (183). 
The HIV prevalence was inversely related to annual 
household income – the lower the income, the higher 
2 Lifetime risk refers to the probability, at the day of birth, that an 
individual will be diagnosed with HIV infection at some point during his 
or her lifetime.
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the HIV prevalence. HIV prevalence did not differ by 
race or ethnicity in that population. The researchers 
concluded that poverty may account for some of the 
racial and ethnic disparities found in HIV prevalence 
rates for the overall population in the United States – 
46% of African-Americans and 40% of Hispanics live 
in high-poverty areas versus just 10% of whites (184).
In Canada, meanwhile, Aboriginal people continue to 
be overrepresented in the HIV epidemic. Although they 
comprise less than 4% of Canada’s population, they 
accounted for 8% of the total number of people living 
with HIV and almost 13% of the people newly infected 
in 2008 (185). Injecting drug use was the probable cause 
for most of the Aboriginal Canadians newly infected 
(66% versus 17% for all Canadians) (185).
Immigrants living with HIV have become a growing 
feature of the epidemics in several countries in Europe. 
In Western and Central Europe, 49% of the people 
newly diagnosed with HIV infection acquired through 
heterosexual transmission originated from countries 
with generalized epidemics (in sub-Saharan Africa, 
the Caribbean and Asia) (116). In the United Kingdom, 
for example, two thirds of the heterosexuals newly 
diagnosed with HIV infection in 2009 had probably 
acquired HIV infection, mainly in sub-Saharan 
Africa (186). However, the number of diagnoses among 
people infected heterosexually outside the country has 
decreased in the United Kingdom since 2003 (186), and 
diagnoses among people who most likely were infected 
inside the United Kingdom have risen (from 210 in 1999 
to 1150 in 2010) (171).
The decline in the rates of new infections among 
people who inject drugs in western Europe and parts 
of central Europe appears to be continuing and has been 
attributed to harm-reduction services (187). Injecting 
drug use continues to drive the epidemic in Estonia, 
which has the highest national HIV prevalence among 
adults in all of Europe (1.2%). The HIV incidence among 
new injectors has declined signifi cantly since 2005, 
however. The estimated HIV incidence among people 
who inject drugs in Tallinn (Estonia), for example, 
slowed from 18 to 8 per 100 person-years between 
2005 and 2009, a period when the needle and syringe 
programme expanded signifi cantly (188).
Injecting drug use also appears to be fuelling the more 
recent epidemic in Poland, where 18% of people who 
inject drugs tested in 2009 in eight regions were living 
with HIV (189). However, the absolute numbers of 
people who inject drugs newly diagnosed with HIV 
infection have decreased (from 201 in 2004 to 39 in 
2009) (116). In Greece, the 113 people who inject drugs 
newly diagnosed with HIV in the fi rst seven months of 
2011 was almost nine times higher than the average 
annual number of people who inject drugs diagnosed 
in the previous decade (190).
Considering the overall scale of the epidemic in this 
region, the estimated number of children living with 
HIV is very small: slightly more than 6000 [3500–
8000] in 2010. This refl ects both the centrality of 
sex between men in the epidemic and the extensive 
provision of services that can prevent the mother-to-
child transmission of HIV. Remarkably few children 
younger than 15 years have been newly infected with 
HIV (<500) or died from AIDS-related illnesses (<500) 
in this region in 2010.
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2.8 Middle East and North Africa
2.8.1 Another growing epidemic
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Fig. 2.36 Number of people living with HIV, Middle East and North Africa, 1990–2010
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Fig. 2.37 Number of people newly infected with HIV, Middle East and North Africa, 1990–2010
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Fig. 2.38 Number of people dying from AIDS-related causes, Middle East and North Africa, 1990–2010
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The available evidence on the HIV epidemics in the 
Middle East and North Africa indicates ongoing 
increases in the number of people newly infected with 
HIV, the number of people living with HIV and the 
number of people dying from AIDS-related causes. 
The estimated 59 000 [40 000–73 000] people newly 
infected with HIV in 2010 was the highest annual 
number yet, 36% more than the 43 000 [31 000–
57 000] people estimated to have been newly infected 
in 2001. In the same period, the estimated number of 
people living with HIV rose steeply, from 320 000 
[190 000–450 000] to 470 000 [350 000–570 000] 
(Fig. 2.38–2.39), as did the number of people dying 
from AIDS-related causes, which increased from 
22 000 [9700–38 000] in 2001 to 35 000 [25 000–
42 000] in 2010.
The national HIV prevalence among adults in the Middle 
East and North Africa is low – except for Djibouti and 
South Sudan, where HIV is spreading in the general 
population, and where at least 1% of pregnant women 
using antenatal services have tested HIV-positive.
Overall, the number of children younger than 15 years 
living with HIV almost doubled from 24 000 [9400–
45 000] to 40 000 [27 000–52 000] between 2001 
and 2010. The number of children newly infected rose 
from 5400 [2700–7600] to 6800 [4800–8800], 
and the number of children dying from AIDS-related 
causes increased from 2600 [1100–4300] to 3900 
[2700–5000] in the same period. This refl ects an 
accelerating epidemic and the comparatively high 
proportions of women among the people living with 
HIV (44–45% in 2001–2010) along with the generally 
inadequate provision of services to prevent the mother-
to-child transmission of HIV.
2.8.2 The major factors are injecting drug use 
and unprotected sex …
HIV data in the region have improved but remain 
limited. Current research indicates that unprotected sex 
(including between men) and the sharing of non-sterile 
drug-injecting equipment remain the primary drivers of 
HIV infection in the Middle East and North Africa (191). 
Most people newly infected with HIV are men and 
live in urban settings (except in Sudan, where more 
women and people living in rural areas are acquiring 
HIV infection). Some evidence indicates that many 
returning migrants are living with HIV and transmit 
HIV to their spouses (191). Indeed, many women living 
with HIV are believed to have acquired infection from 
their spouses, who practice high-risk behaviour (191). 
Women comprised an estimated 41% of adults living 
with HIV in the Middle East and North Africa in 2010.
The Islamic Republic of Iran is believed to have the 
largest number of people who inject drugs in the 
region, and its HIV epidemic is concentrated mainly 
within this population group. An estimated 14% of the 
people who inject drugs countrywide were living with 
HIV in 2007 (192). Exposure to contaminated drug-
injecting equipment also features in the epidemics 
of Algeria, Egypt (where 7% of men who inject drugs 
in Alexandria and 8% of those in Cairo tested HIV-
positive in 2010 (193)), Lebanon, Libya, Morocco (up to 
6% prevalence (194)), Oman, the Syrian Arab Republic 
and Tunisia.
2.8.3 … including unprotected sex between men
Sex between men is heavily stigmatized in this region 
and is deemed a criminal offence in many countries. 
High-risk sexual practices, low levels of condom use 
and generally low levels of HIV knowledge have been 
observed in several countries among men who have 
sex with men (139). In surveys in Sudan, 8–9% of men 
who have sex with men tested HIV-positive (120), as 
have 5% of their peers in Cairo and 7% of those in 
Alexandria (Egypt) (193), 5% in Tunisia (195) and 4% in 
Morocco (196). There are signs of expanding investment 
in HIV prevention programmes for this key population 
at higher risk in some countries, but service coverage 
remains limited (139).
In most countries, the prevalence of HIV among 
female sex workers remains relatively low. However, 
up to 2–4% of female sex workers in parts of Algeria, 
Morocco and Yemen are believed to be living with HIV 
(197), and the HIV prevalence is between 0% (198) and 
7% (199) among female sex workers in Morocco (with 
the highest level in Sous Massa Draa) (200).
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2.9 Oceania
2.9.1 A small, stable epidemic
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Fig. 2.40 Number of people living with HIV, Oceania, 1990–2010
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Fig. 2.41 Number of people newly infected with HIV, Oceania, 1990–2010
5
4
1
Th
ou
sa
nd
s
4
3
2
1
0
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Fig. 2.42 Number of people dying from AIDS-related causes, Oceania, 1990–2010
Th
ou
sa
nd
s
6
5
4
2
0
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Fig. 2.43 Number of children 0–14 years old living with HIV, Oceania, 1990–2010
3
1
Chapter 2 – Update on the HIV epidemic     47
The HIV epidemic in Oceania remains small and 
appears to be stable. The annual number of people 
newly infected with HIV increased slowly until the 
early 2000s and then declined to 3300 [2400–4200] 
in 2010 (down from about 4000 [3300–4600] in 
2001). The number of people living with HIV in this 
region reached an estimated 54 000 [48 000–
62 000] at the end of 2010, about 34% more than 
the estimate of 40 000 [34 000–50 000] for 2001 
(Table 2.1, Fig. 2.40–2.43). The number of people dying 
from AIDS-related causes has decreased considerably, 
falling to 1600 [1200–2000] in 2010 (compared 
with the annual fi gure of about 2400 [1900–3300] 
in 2005–2007).
Scattered over one third of the world’s surface, almost 
all the 22 Pacifi c island countries and territories are 
experiencing very small HIV epidemics. In each of them, 
fewer than 500 HIV cases have been reported since 
1985. The one exception is Papua New Guinea, which 
has the largest and the only generalized HIV epidemic 
in Oceania (201).
The national HIV prevalence among adults in Papua 
New Guinea in 2009 was an estimated 0.9% 
[0.8–1.0%], with about 34 000 [30 000–39 000] 
people living with HIV. An increase in the number of 
sites providing HIV tests has led to an improvement in 
the volume and quality of HIV data, which now indicate 
that the country’s epidemic might have stabilized.
A lack of high-quality survey data creates diffi culty in 
determining the role of sex work in Papua New Guinea’s 
epidemic. A 2010 study among people who sold or 
exchanged sex in Port Moresby found an (unadjusted) 
HIV prevalence of 19% among women, 9% among men 
and 24% among transgender people (202). Paying for 
sex appears to be common among mobile populations, 
including migrant workers, transport workers and 
military personnel (203). Sex between men is also 
common, with up to 13% of surveyed truckers, sugar 
workers, port workers and military personnel reporting 
sex with other men (204).
The next largest epidemic in the region is in Australia, 
where the annual number of people newly diagnosed 
with HIV infection has stayed relatively stable at 
about 1000 since 2005 (following an earlier increase 
up to the late 1990s) (205). In New Zealand’s smaller 
epidemic, the annual number of people newly 
diagnosed peaked at about 180 in 2005–2006 before 
decreasing to about 160 (206).
2.9.2 Unprotected sex is the main driver of HIV 
transmission
Most people diagnosed with HIV infection in Oceania 
have acquired HIV through sexual transmission (207). 
Unprotected heterosexual intercourse is the main 
mode of transmission in Papua New Guinea (208) (and 
in the rest of Melanesia), whereas unprotected sex 
between men plays a larger role in the epidemics in 
Micronesia and Polynesia and in those of Australia and 
New Zealand. In Australia, men who have sex with men 
accounted for 85% of the people newly diagnosed with 
HIV infection in 2009 (205). An increase in the number 
of men who have sex with men newly diagnosed in 
Australia abated after 2005, and the number newly 
diagnosed has stayed relatively steady since then (205). 
New Zealand has a similar trend (206).
Although the HIV prevalence is low in most of Oceania, 
the high prevalence of other sexually transmitted 
infections is a concern, since people who have another 
sexually transmitted infection have a higher risk of HIV 
transmission (207). In Papua New Guinea, for example, 
the prevalence of sexually transmitted infections has 
increased, especially among young women and rural 
dwellers as well as in the Southern and Highlands 
regions (209).
Injecting drug use plays a minor role in the epidemics 
in this region. In French Polynesia, about 12% of the 
cumulative reported HIV cases have been attributed 
to injecting drug use (207). Nevertheless, in Australia 
in 2009, injecting drug use was the probable cause 
of transmission for about 20% of the Aboriginal and 
Torres Strait Islander people newly infected with 
HIV (205).
The proportion of women among the people newly 
diagnosed with HIV in the Pacifi c region has increased 
steadily, although this might partly result from 
increased antenatal testing. By the end of 2009, women 
comprised 60% of the people newly diagnosed in 
Papua New Guinea and about 30% elsewhere (207). 
Overall, women comprised about 44% of the adults 
living with HIV in Oceania in 2010. However, mother-
to-child transmission of HIV is a signifi cant factor only 
in Papua New Guinea’s epidemic, where nearly 10% of 
all people newly diagnosed with HIV to date acquired 
it during perinatal exposure (210). Overall, about 4600 
[3600–5800] children were living with HIV in Oceania 
in 2010, 500 [<500–<1000] of whom were newly 
infected in 2010.
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Box 2.4
The latest improvements in estimates on HIV and AIDS
Estimates for countries and regions are generated with the Spectrum software package (211), using all pertinent, available data – including 
surveys of pregnant women attending antenatal clinics, population-based surveys (conducted at the household level), sentinel surveillance 
among key populations at higher risk of HIV infection, case reporting, information on antiretroviral therapy and on programmes for preventing 
mother-to-child infection and demographic data (Fig. 2.44). The current models use the 2010 revision of demographic estimates and 
projections produced by the United Nations Population Division (212).
Projection assumptions are updated regularly using the latest available research. For this reason, the latest estimates (for the current year 
and for past years) tend to be more accurate and reliable than those produced in previous years.1
The latest version of the software merges the Spectrum and Estimates and Projection Program (EPP) models into one package. This has made 
it easier for countries to produce their own HIV estimates. The combined model has been updated to be more fl exible in fi tting the prevalence 
curves to available surveillance and survey data. This is especially important for capturing changes in the prevalence of HIV infection that 
occur because of the expanding coverage of antiretroviral therapy, and to fi t epidemics in which the HIV prevalence has declined sharply 
and then stabilized or risen again.
In the latest version of the software, the speed of progression from people being newly infected with HIV to dying depends on age. People 
infected at younger ages progress more slowly than those infected at older ages. As a result, the estimated number of young people living 
with HIV is higher than in previous estimates. This also raises the estimated number of women needing services for preventing mother-to-
child transmission and the number of children newly infected.
1 For a technical description of the processes used to arrive at the estimates and a detailed description of the methods, software, quality of data and development of ranges, please 
see a series of articles published in a supplement in the journal Sexually Transmitted Infections in December 2010 (213). The articles are open access and can be downloaded for 
free.
Fig. 2.44 Process of producing HIV and AIDS estimates
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Table 2.1 HIV and AIDS statistics by geographical region, 2001 and 2010
Adults and children living 
with HIV
Adults and children newly 
infected with HIV
Prevalence of HIV 
infection among adults 
(%)
Adults and children dying 
from AIDS-related causes
Prevalence of HIV infection 
among people 15–24 years old (%)
Men Women
Sub-Saharan Africa 
2010
22 900 000 1 900 000 5.0 1 200 000 1.4 3.3
[21 600 000–24 100 000] [1 700 000–2 100 000] [4.7–5.2] [1 100 000–1 400 000] [1.1–1.8] [2.7–4.2]
2001
20 500 000 2 200 000 5.9 1 400 000 2.0 5.2
[19 100 000–22 200 000] [2 100 000–2 400 000] [5.6–6.4] [1 300 000–1 600 000] [1.6–2.7] [4.3–6.8]
Middle East and North Africa 
2010
470 000 59 000 0.2 35 000 0.1 0.2
[350 000–570 000] [40 000–73 000] [0.2–0.3] [25 000–42 000] [0.1–0.2] [0.1–0.2]
2001
320 000 43 000 0.2 22 000 0.1 0.1
[190 000–450 000] [31 000–57 000] [0.1–0.3] [9700–38 000] [0.1–0.2] [0.1–0.2]
South and South-East Asia 
2010
4 000 000 270 000 0.3 250 000 0.1 0.1
[3 600 000–4 500 000] [230 000–340 000] [0.3–0.3] [210 000–280 000] [0.1–0.2] [0.1–0.1]
2001
3 800 000 380 000 0.3 230 000 0.2 0.2
[3 400 000–4 200 000] [340 000–420 000] [0.3–0.4] [200 000–280 000] [0.2–0.2] [0.2–0.2]
East Asia 
2010
790 000 88 000 0.1 56 000 <0.1 <0.1
580 000–1 100 000] [48 000–160 000] [0.1–0.1] [40 000–76 000] [<0.1–<0.1] [<0.1–<0.1]
2001
380 000 74 000 <0.1 24 000 <0.1 <0.1
[280 000–530 000] [54 000–100 000] [<0.1–0.1] [16 000–45 000] [<0.1–<0.1] [<0.1–<0.1]
Oceania 
2010
54 000 3300 0.3 1600 0.1 0.2
[48 000–62 000] [2400–4200] [0.2–0.3] [1200–2000] [0.1–0.1] [0.1–0.2]
2001
41 000 4000 0.2 1800 0.1 0.2
[34 000–50 000] [3300–4600] [0.2–0.3] [1300–2900] [0.1–0.2] [0.2–0.3]
Latin America 
2010
1 500 000 100 000 0.4 67 000 0.2 0.2
[1 200 000–1 700 000] [73 000– 140 000] [0.3–0.5] [45 000– 92 000] [0.1–0.4] [0.1–0.2]
2001
1 300 000 99 000 0.4 83 000 0.2 0.1
[1 000 000–1 700 000] [75 000– 130 000] [0.3–0.5] [50 000– 130 000] [0.1–0.6] [0.1–0.2]
Caribbean 
2010
200 000 12 000 0.9 9000 0.2 0.5
[170 000–220 000] [9400–17 000] [0.8–1.0] [6900–12 000] [0.2–0.5] [0.3–0.7]
2001
210 000 19 000 1.0 18 000 0.4 0.8
[170 000–240 000] [16 000–22 000] [0.9–1.2] [14 000–22 000] [0.2–0.8] [0.6–1.1]
Eastern Europe and Central Asia 
2010
1 500 000 160 000 0.9 90 000 0.6 0.5
[1 300 000–1 700 000] [110 000–200 000] [0.8–1.1] [74 000–110 000] [0.5–0.8] [0.4–0.7]
2001
410 000 210 000 0.3 7800 0.3 0.2
[340 000–490 000] [170 000–240 000] [0.2–0.3] [6000–11 000] [0.2–0.3] [0.1–0.2]
Western and Central Europe 
2010
840 000 30 000 0.2 9 900 0.1 0.1
[770 000–930 000] [22 000–39 000] [0.2–0.2] [8 900–11 000] [0.1–0.1] [<0.1–0.1]
2001
630 000 30 000 0.2 10 000 0.1 0.1
[580 000–690 000] [26 000–34 000] [0.2–0.2] [9 500–1 100] [0.1–0.1] [0.1–0.1]
North America 
2010
1 300 000 58 000 0.6 20 000 0.3 0.2
[1 000 000–1 900 000] [24 000–130 000] [0.5–0.9] [16 000–27 000] [0.2–0.6] [0.1–0.4]
2001
980 000 49 000 0.5 19 000 0.3 0.2
[780 000–1 200 000] [34 000–70 000] [0.4–0.7] [15 000–24 000] [0.2–0.4] [0.1–0.3]
Total 
2010
34 000 000 2 700 000 0.8 1 800 000 0.3 0.6
[31 600 000–35 200 000] [2 400 000–2 900 000] [0.8–0.8] [1 600 000–1 900 000] [0.3–0.3] [0.5–0.6]
2001
28 600 000 3 100 000 0.8 1 900 000 0.4 0.8
[26 700 000–30 900 000] [3 000 000–3 300 000] [0.7–0.8] [1 700 000–2 200 000] [0.4–0.4] [0.7–0.8]
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KEY FINDINGS
More than 550,000 males were circumcised for HIV prevention in the priority countries of sub-Saharan Africa by 
the end of 2010. However, progress towards the target of expanding coverage of male circumcision to 80% of men 
15 -49 years old is still very limited in most countries.
The availability and safety of blood and blood products for transfusion remain a concern. In 40 countries, less than 
25% of the blood supplies comes from voluntary unpaid blood donors; in low-income countries with available data, 
only 53% of blood donations were screened in a quality-assured manner in 2008.
The global burden of sexually transmitted infections remains high in most regions of the world. Early identifi cation 
and treatment of sexually transmitted infections are important elements in a comprehensive and effective HIV 
response. New rapid syphilis tests provide an opportunity to scale up syphilis screening in many settings in which 
traditional tests were unavailable.
In 2010 and 2011, landmark studies were published strengthening the evidence base on the preventive effects of 
antiretroviral drugs. People living with HIV receiving antiretroviral therapy are less likely to transmit HIV, and HIV-
negative people who take antiretroviral pre-exposure prophylaxis orally in tablet form or topically in a vaginal gel 
reduce their risk of acquiring HIV.
3Selected health sector interventions for HIV prevention
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3.1 Overview and challenges
Thirty years after AIDS was first reported, HIV 
continues to spread. Although 2010 estimates suggest 
that the annual number of people newly infected with 
HIV has declined 20% from the global epidemic peak 
in 1998, an estimated 2.7 million people acquired the 
virus in 2010 alone (see Chapter 2). Existing prevention 
efforts, although improving, are often insuffi ciently 
comprehensive or inadequately tailored to local 
epidemics. This requires stronger country surveillance 
systems, especially among key populations at higher 
risk of HIV infection, greater political commitment to 
implementing evidence-informed programmes and 
the development of new prevention approaches and 
improved tools to strengthen national responses and 
accelerate progress towards achieving the Millennium 
Development Goals.
3.1.1 Understanding the characteristics of the 
epidemic to inform prevention programmes
The selection of which HIV prevention programme 
components to deploy for which priority populations 
must be based on a clear understanding and mapping 
of the national epidemiology of HIV – who is acquiring 
HIV, where, how and why – to design the appropriate 
mix of prevention programmes. To successfully limit 
transmission, effective prevention services must reach 
the areas and populations where HIV is spreading most 
rapidly. Achieving population-level impact requires that 
programmes be implemented at the necessary scale 
and intensity (1).
Moreover, many countries have in fact mixed epidemics, 
with important in-country variation in HIV incidence 
and subpopulations at higher risk for HIV infection. 
Effective prevention policies must adequately account 
for local differences in HIV transmission dynamics.
3.1.2 Promoting combination HIV prevention
Experience from successful programmes suggests that 
a mix of components tailored for different populations 
and implemented in different settings is the most 
effective approach to reduce HIV transmission (2). 
Certain elements of a comprehensive prevention 
strategy are often implemented while ignoring others, 
diminishing their overall impact on HIV incidence. 
Countries need to determine their prevention priorities, 
combining biomedical with behavioural and structural 
interventions relevant to their epidemic.1 
Critical enablers must be assessed and strengthened 
to remove social and programmatic barriers that hinder 
the implementation or effectiveness of prevention 
programmes. This entails incorporating complementary 
strategies to make environments more conducive to 
the uptake of HIV prevention programmes and to help 
improve the overall performance of service delivery.2 
New data from biomedical HIV prevention studies 
published in 2010 and 2011 have expanded the set of 
available prevention interventions, shedding light on the 
effectiveness and potential impact of new strategies 
(4–6). It is now necessary to develop approaches that 
can successfully integrate these novel biomedical 
interventions into prevention packages and existing 
services and systems.
This chapter describes progress made in 2010 in scaling 
up select interventions for HIV prevention related to 
the health sector (male circumcision, blood safety 
and preventing sexually transmitted infections). It 
also discusses the role of antiretroviral therapy and 
key emerging approaches for HIV prevention, such as 
pre-exposure prophylaxis and the use of antiretroviral 
therapy for HIV prevention. Chapter 6 discusses 
prevention programmes for key populations at higher 
risk of HIV infection, particularly sex workers, men 
1 HIV prevention includes:
• HIV testing and counselling, including testing and counselling of 
couples;
• preventing sexual transmission, including promoting male and female 
condoms, screening and managing sexually transmitted infections, 
voluntary medical male circumcision focusing on adult men in 
settings with a high prevalence of HIV infection, non-occupational 
antiretroviral post-exposure prophylaxis, antiretroviral pre-exposure 
prophylaxis (taken by HIV-negative people to prevent them from 
acquiring HIV infection) and antiretroviral therapy for prevention 
(taken by people living with HIV);
• preventing transmission among people who inject drugs, including 
the comprehensive set of nine harm reduction strategies; and
• preventing HIV in health care settings, including blood and injection 
safety and occupational antiretroviral post-exposure prophylaxis.
 These components differ in their direct individual- and population-level 
effect and effects on reducing the number of people newly infected with 
HIV.
2 Social enablers consist of outreach for HIV testing and HIV treatment 
literacy, stigma reduction, advocacy to protect human rights, monitoring 
the equity and quality of programme access and results and mass 
communication designed to raise awareness and support change in 
social norms. Programme enablers include incentives for programme 
participation, methods to improve the retention of people receiving 
antiretroviral therapy, building capacity for developing community-
based organizations, strategic planning, communication infrastructure, 
disseminating information and efforts to improve service integration and 
links from testing to care (3).
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who have sex with men and injecting drug users. 
Chapter 7 considers the prevention of mother-to-child 
transmission of HIV, including primary prevention 
of HIV infection among women of childbearing age, 
family planning to prevent unplanned pregnancies, 
antiretroviral prophylaxis and antiretroviral therapy to 
keep mothers alive.
3.2 Selected HIV prevention interventions 
in the health sector
3.2.1 Male circumcision in countries in sub-
Saharan Africa with a high burden of HIV
Three randomized clinical trials conducted in sub-
Saharan Africa to study the efficacy of voluntary 
medical male circumcision for preventing HIV 
acquisition among heterosexual HIV-negative men 
showed a strong protective effect, with an approximate 
60% reduction in the risk of acquiring HIV (7–9). A 
Box 3.1 
Preventing HIV among young people
People aged 15–24 years are at the forefront of the epidemic. 
Five (5.0) million [4.3–6.5 million] of these young women and 
men were living with HIV as of December 2010. Young women 
are especially vulnerable to HIV, and they disproportionately 
account for 64% [60–83%] of the young people living with 
HIV worldwide. In most epidemic contexts, but especially in 
those in which HIV is concentrated in certain subpopulations, 
prevention efforts must also focus on young people who inject 
drugs, young sex workers and young men who have sex with 
men, since they have a higher risk of HIV exposure and infection.
A comprehensive and yet tailored package of programme 
components is needed to engage young people and address 
their specifi c circumstances and needs. These include increasing 
the availability of condoms and effectively promoting their 
correct and consistent use; implementing evidence-informed, 
skills-based comprehensive sexuality education; scaling up 
mass media programmes to infl uence and change harmful social 
and cultural norms; providing youth-friendly health services; 
and mobilizing and engaging young people in designing, 
implementing, monitoring and evaluating HIV programmes.
Despite improved surveillance systems, data collected by 
UNAIDS and WHO indicate that most countries are still unable 
to provide epidemiological or programmatic data specifi c to 
young people. Few countries report national indicators by age 
and sex, and although some countries report on programmes for 
key populations at higher risk, there is often little information 
on young people within these populations. Greater investment 
is needed both nationally and internationally to identify 
programmatic gaps and design and implement adequate 
policies.
Box 3.2
Community-level impact of male circumcision in 
Orange Farm, South Africa
Despite the strong protective effects of male circumcision, 
replicated in three large randomized controlled trials, limited 
evidence exists on how scaling up voluntary medical male 
circumcision services affects the population-level incidence and 
prevalence of HIV infection. However, a recently published study 
conducted in Orange Farm, a community comprising 110 000 
adults in South Africa, has shown that the preventive benefi ts 
of male circumcision among men can also be observed at the 
community level.
The cross sectional study was conducted in 2007–2008 among 
1198 men 15–49 years. Circumcision status was self reported and 
clinically assessed.  Men without foreskins had a 65% lower HIV 
incidence (adjusted incidence rate ratio = 0.35) and 55% lower 
prevalence than men with foreskins (adjusted prevalence rate 
ratio = 0.45). There were no differences between men in terms 
of sexual behaviour, and most, although not all, were aware that 
circumcised men could become HIV infected. 
Source: Lissouba et al. (10).
population-based study in a South African township has 
also shown reduced HIV prevalence and incidence at 
the community level three years after male circumcision 
services began to be rolled out (Box 3.2) (10).
In 2007, WHO and UNAIDS recommended including 
male circumcision as an additional HIV prevention 
programme component in settings with high HIV 
prevalence and low levels of male circumcision. 
Thirteen countries were identifi ed as priority areas for 
scaling up voluntary medical male circumcision based 
on their epidemiological profi les and prevalence of male 
circumcision (11).
It has been estimated that expanding the coverage 
of voluntary medical male circumcision to 80% of 
15 to 49 year old men within fi ve years could avoid 
around 3.5 million people becoming newly infected 
with HIV in eastern and southern Africa, representing 
cost savings of about US$ 16.6 billion between 2011 
and 2025 (12). Recent studies have also noted indirect 
or potential benefi ts of male circumcision for women, 
who may be less exposed to HIV infection because 
the HIV prevalence among men is reduced. One 
modelling study suggested that male circumcision has 
the potential to reduce, in the long term, the rate of 
heterosexual transmission from males to females by 
46% (13). Further, the female partners of circumcised 
HIV-negative men had a lower prevalence of high-risk 
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human papillomavirus than did the female partners 
of uncircumcised men, a pattern that may lead to a 
reduction in cervical cancer among women whose 
partners are circumcised in addition to a lower 
incidence of penile cancer (14).
By the end of 2010, most of the priority countries in 
Eastern and Southern Africa had put in place the key 
programmatic elements to support the roll-out of male 
circumcision programmes. More than 550 000 males 
Countries
Number of male circumcisions done by calendar year Estimated number of male circumcisions needed 
to reach 80% coverage among males 
15–49 years old2008 2009 2010 Total
Botswana 0 5424 5773 11 197 345 244
Ethiopia (province of Gambella) 0 769 2689 3458 40 000
Kenya 11 663 80 719 139 905a 232 287a 860 000*
Lesothob 0 0 Unknownb Unknownb 376 795
Malawi 589c 1234c 1296c 3119c 2 101 566
Mozambique 0 100 7633 7733 1  059 104
Namibia 0 224 1763 1987 330 218
Rwanda 0 0 1694 1694 1 746 052
South Africa 5190d 9168d 131 117d 145 475d 4 333 134
Swaziland 1110 4336 18 869 24 315 183 450
United Republic of Tanzania 0 1033 18 026e 19 059e 1 373 271
Uganda 0 0 9052 9052 4 245 184
Zambia 2758 17 180 61 911 81 849 1 949 292
Zimbabwe 0 2801 11 176 13 977 1 912 595
Total 21 310 122 988 410 904 555 202 20 855 905
* Kenya’s goal is: to increase the proportion of men aged 15–49 years who are circumcised in Kenya from 84 to 94% by 2013; the number of male circumcisions needed to achieve this 
national goal are in the table. Source: Kenya National Strategy for Voluntary medical Male Circumcision, October 2009, Republic of Kenya Ministry of Public health and Sanitation. 
Data sources: PEPFAR Male Circumcision Technical Working Group (unpublished data) unless otherwise indicated.
a National AIDS & STI Control Programme of Kenya. 
b Ministry of Health of Lesotho.
c Ministry of Health of Malawi.
d National Department of Health of South Africa.
e Ministry of Health of the United Republic of Tanzania.
Table 3.1 Number of males circumcised for HIV prevention during 2008–2010 and estimated number of male circumcisions 
needed to reach 80% coverage among 15–49 year old men in priority countries of eastern and southern Africa
Fig. 3.1 Numbers of males circumcised, United Republic of 
Tanzania, September 2009 to May 2010
1500
1200
900
600
300
Nu
m
be
r o
f M
Cs
Sep
2009
0
Oct
2009
Nov
2009
Dec
2009
Jan
2010
Feb
2010
Mar
2010
Apr
2010
May
2010
Switch to MOVE in 
public facilities
were reported to be circumcised for HIV prevention 
between 2008 and 2010 in the 13 priority countries 
of Eastern and Southern Africa and in the Ethiopian 
province of Gambella, and 77% were performed in 2010 
(Table 3.1).1  Kenya, South Africa and Zambia performed 
the largest absolute numbers of male circumcisions 
in 2010.
Countries have relied on various modes of service 
delivery to accelerate the scaling up of male 
circumcision. These include stand-alone clinics, routine 
facility-based services into which the male circumcision 
package of interventions is integrated and outreach and 
mobile services. Implementing effi ciency measures 
that allow for more procedures to be performed in 
a safe but less time-consuming manner, such as the 
MOVE2 (models for optimizing volume and effi ciency) 
framework, has also contributed to expanding male 
circumcision services (15). In the United Republic of 
Tanzania, the number of males circumcised increased 
three-fold after the MOVE approach was adopted 
(Fig. 3.1).
1 UNAIDS and WHO identifi ed 13 priority countries in 2007, based on 
the prevalence of HIV infection and male circumcision. The United 
States President’s Emergency Plan for AIDS Relief in addition to these 13 
countries is supporting Gambella province of Ethiopia.
2 MOVE includes three categories of approaches such as simplifi ed safe 
circumcision techniques, task-sharing and task-shifting.Source: Ministry of Health, United Republic of Tanzania, 2010.
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However, progress towards the target of expanding 
coverage of male circumcision to 80% of men 15–49 
years old is still very limited in most. Greater efforts 
are thus needed to overcome challenges, accelerate 
programme implementation, and ultimately affect 
population-level prevention (Box 3.3) (16). Research is 
underway on innovative technologies including non-
surgical devices that may address some challenges.
All priority countries have adopted the minimum 
package of male circumcision services recommended 
by WHO and UNAIDS, including management of 
sexually transmitted infections, HIV testing and 
counselling, condom promotion and safer sex 
education. In 2010, the reported uptake of HIV testing 
and counselling ranged between 56% and 98% among 
men receiving male circumcision across all priority 
countries, demonstrating how male circumcision 
services can be leveraged as an important entry point 
to provide men with an opportunity to learn their HIV 
serostatus (17). 
Box 3.3
Expanding and integrating male circumcision for HIV 
prevention in Zambia
In 2007, Zambia’s HIV prevalence was 14.3% and the male 
circumcision rate was 12.8% (18). Zambia’s target for male 
circumcision for 2010 was 100 000, of which about 62 000 
were performed, bringing the cumulative number of males 
circumcised in the country to 81 849 as of December 2010. 
High-level commitment has been sustained, and the Ministry 
of Health has established mechanisms to coordinate the 
programme for scaling up male circumcision with the various 
partners involved. Tasks have been shifted to nurses, midwives 
and clinical offi cers to expand services.
Zambia uses a multisectoral approach involving the defence 
forces, police and prison services as well as the private sector. 
Service delivery options include static, outreach and mobile 
sites in public and private facilities. Safe male circumcision 
interventions are integrated into sexually transmitted infection 
and HIV programming to optimize the available resources. These 
services are further linked to other appropriate interventions, 
including antiretroviral therapy. In parallel to the catch-up 
phase with adolescents and adult men, Zambia has commenced 
neonatal circumcision in three sites.
Important progress has been made in expanding access 
to and uptake of voluntary medical male circumcision for 
HIV prevention, but the gap to reach 80% coverage is still 
considerable. Cultural influences and beliefs, including 
those linked with traditional male circumcision, as well as 
insuffi ciently robust commodity management systems, have 
been identifi ed as challenges for accelerating scale-up.
3.2.2 Preventing and managing sexually 
transmitted infections
Rapidly identifying and treating sexually transmitted 
infections are important elements in controlling HIV, 
since sexually transmitted infections synergistically 
increase the risk of HIV transmission (19). Substantial 
evidence suggests that sexually transmitted infections 
increase HIV shedding in the genital tract of people 
living with HIV, thereby boosting infectiousness, 
and disrupt mucosal barriers, leading to increased 
susceptibility to acquiring HIV infection among HIV-
negative individuals.
Various interventions for controlling sexually 
transmitted infections have proven effective, including 
syndromic management of genital ulcer disease 
and urethral discharge, syphilis testing of pregnant 
women and individuals diagnosed with other sexually 
transmitted infections, treating the male partners of 
people with trichomoniasis, counselling about risk 
reduction related to HIV and sexually transmitted 
infections, human papillomavirus vaccination and 
treating the partners of people with gonococcal, 
chlamydial and syphilis infections.
New rapid syphilis tests have provided an opportunity 
to scale up syphilis screening in many settings in which 
traditional tests were unavailable (20). Recent evidence 
suggests that tenofovir gel, a vaginal microbicide, 
shows promise as an intervention to prevent not only 
HIV infection but also herpes simplex virus-2 infection 
among women (21).
Where implemented widely, these interventions have 
resulted in a decline in the prevalence of sexually 
transmitted infections such as chancroid, syphilis, 
gonorrhoea and genital warts as well as long-term 
consequences such as infertility, congenital syphilis and 
cervical cancer in many parts of the world. Controlling 
sexually transmitted infections may have also 
contributed to the gradual decline in HIV prevalence 
in several low- and middle-income countries (22). 
Unfortunately, however, the global burden of sexually 
transmitted infections remains high in most regions of 
the world (Box 3.4) (23).
Services for sexually transmitted infections are a 
critical component of comprehensive HIV prevention 
and reproductive health programmes. In addition to 
addressing issues specific to sexually transmitted 
infections, they provide an opportunity to offer 
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provider-initiated testing and counselling for HIV and 
can serve as entry points for HIV care and treatment 
interventions. Data on sexually transmitted infections 
can also assist in interpreting HIV epidemiological risk 
factors. For example, changes in syphilis prevalence 
among antenatal care attendees can provide an early 
warning of changes in risk behaviour associated 
with HIV transmission in the general population or 
assist in interpreting HIV epidemiological risk factors 
(Box 3.5). Acute sexually transmitted infections such 
as gonorrhoea and primary and secondary syphilis 
also serve as biomarkers of HIV and the effectiveness 
of programmes to prevent sexually transmitted 
infections. Although broad-based services are well 
Box 3.4
Global estimates of incidence and prevalence of selected sexually transmitted infections: Chlamydia trachomatis, 
Neisseria gonorrhoeae, Treponema pallidum (syphilis) and Trichomonas vaginalis
In 2008, there were 498 million new cases of sexually transmitted infection globally: 106 million new cases of Chlamydia trachomatis, 
106 million new cases of Neisseria gonorrhoeae, 10 million new cases of syphilis and 276 million new cases of Trichomonas vaginalis. These 
estimates are similar to the values seen in 2005, when the total number of new cases of these four sexually transmitted infections was 
estimated to be 448 million using comparable methods (Table 3.2).
These infections, however, are only 4 of the more than 30 infections that can be transmitted sexually. Although these estimates are based on 
limited data from surveillance and special studies, they indicate that the global burden of sexually transmitted infections remains high. Improved 
and more accurate estimates require collecting higher-quality data on sexually transmitted infections at the country and regional levels.
WHO region
Chlamydia 
trachomatis
Neisseria 
gonorrhoeae
Treponema pallidum 
(syphilis)
Trichomonas 
vaginalis Total
African Region 8.3 21.1 3.4 59.7 92.6
Region of the Americas 26.4 11.0 2.8 85.4 125.7
Eastern Mediterranean Region 3.2 3.1 0.0 20.2 26.4
European Region 20.6 3.4 0.2 22.6 46.8
South-East Asia Region 7.2 25.4 3.0 42.9 78.5
Western Pacifi c Region 40.0 42.0 0.5 45.7 128.2
Total 106 106 10 276 498
a See Annex 10 for a complete list of countries by WHO regions.
Table 3.2 Number of new cases of infection in millions among adult men and women 15–49 years old, 2008a
Box 3.5
Differences in the prevalence of HIV and syphilis among pregnant women in urban and rural areas in Ethiopia
In 2009, Ethiopia conducted an unlinked anonymous antenatal care 
sentinel HIV survey in which HIV testing was performed on leftover 
blood collected for routine syphilis rapid plasma reagin testing. The 
survey was conducted in 114 sentinel sites: 73 rural and 41 urban.
Among 43 036 specimens, the national prevalence of syphilis was 
2.3%: 2.6% in rural sites and 1.7% in urban sites. People living with 
HIV were twice as likely to be positive for syphilis (3.9%) than HIV-
negative people (2.1%). People living with HIV in rural areas had 
a higher prevalence of syphilis (6.9%) than those in urban areas 
(1.8%) (Fig. 3.2).
Ethiopia’s Federal Ministry of Health concluded that the prevalence 
of syphilis observed requires strengthening services for sexually 
transmitted infections throughout the country, especially in rural 
areas. In addition, routine syphilis screening and treatment should 
also be available at all antenatal care clinics throughout the year.
Source: Report on the 2009 round antenatal care sentinel HIV surveillance in 
Ethiopia (24).
Fig. 3.2 Prevalence of syphilis (%) in a sentinel survey in 
Ethiopia by HIV serostatus and site setting, 2009
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suited to address general population needs, in areas 
with high levels of stigma or legal barriers, dedicated 
services for populations at higher risk of HIV infection, 
such as sex workers and men who have sex with men, 
may be necessary to engage these populations and 
ensure adequate access to tailored health programmes. 
Chapter 6 reviews the prevalence of sexually 
transmitted infections among sex workers and men 
who have sex with men. Similarly, Chapter 7 discusses 
the prevalence of sexually transmitted infections and 
access to interventions for pregnant women.
3.2.3 Safety of blood supplies
An estimated 92 million units of blood are donated 
globally each year.1 About half are collected in high-
income countries and half in low- and middle-income 
countries. Although important progress has been made 
in the past decade in improving safe blood supply 
worldwide, the availability and safety of blood supplies 
for transfusion remain issues of concern in multiple 
settings, especially in low-income countries. A shortage 
of safe blood may lead to the collection of blood from 
unsafe replacement or paid donors or to blood being 
transfused without testing, thus contributing to an 
increased risk of transfusion-transmitted HIV and 
hepatitis. Reducing the incidence of HIV infection 
caused by unsafe blood transfusion requires 
implementing an integrated strategy led by a nationally 
1 Based on 2008 data from the Global Database on Blood Safety (25) as 
reported by 164 Member States directly to WHO.
coordinated blood transfusion service, collecting blood 
from voluntary, unpaid donors; screening all donated 
blood for transfusion-transmissible infections such as 
HIV; and ensuring adequate training of clinicians on 
rational blood use.
The generally accepted minimum rate of blood 
donation required to meet a country’s most basic 
requirements for blood is estimated to be 10 units 
per 1000 population per year. Blood donation rates 
are 13 times higher in high-income countries than in 
low-income countries. The median blood donation 
rate in high-income countries is 36.4 units per 1000 
population (range 13.3–64.6), 11.6 (range 1.6–36.2) in 
middle-income countries, and 2.8 (range 0.4–8.2) in 
low-income countries (26).
In 2008, 70 countries (including 21 low-income and 
41 middle-income countries) reported an increase 
in voluntary unpaid blood donations exceeding 10% 
compared with 2007. Conversely, 23 low- and middle-
income countries reported a year-on-year decline 
in voluntary unpaid blood donation exceeding 10%. 
Among the 164 countries reporting data in 2008, 40 
collected less than 25% of their blood supplies from 
voluntary unpaid blood donors, and much of the blood 
supply in these countries still depended on family or 
replacement and paid blood donors (Fig. 3.3).
Percentage (%)
<25.0
25.0–49.9
50.0–89.9
90.0–98.9
99.0–100
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Not applicable
Fig. 3.3 Percentage of blood donated that is voluntary and unpaid, 2008
Source: WHO Global Database on Blood Safety [online database] (25).
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To protect the safety of blood supplies, blood donations 
should be screened in a quality-assured manner1, which 
includes using standard operating procedures and 
participating in an external quality assessment scheme. 
Data provided by 105 countries2 on the percentage of 
blood supplies screened in a quality-assured manner 
in 2008 continue to show an important gap among 
1 For the purposes of data collection, screening in a quality-assured 
manner is defi ned as screening performed in blood centres or blood 
screening laboratories that (1) follow documented standard operating 
procedures and (2) participate in an external quality assurance scheme 
(27).
2 Including 2008 data from WHO’s Global Database on Blood Safety (25) 
for 97 countries and data collected through the UNAIDS 2009 UNGASS 
reporting process for Algeria, Bulgaria, Cyprus, Japan, Monaco, Saudi 
Arabia, Spain and Tunisia.
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Fig. 3.4 Prevalence of HIV in donated blood by country (% positive or reactive for HIV), 2008
Source: WHO Global Database on Blood Safety [online database] (25).
Income group (number 
of countries reporting)
Total number of 
units donated
% of units 
screened 
for HIV in a 
quality-assured 
manner
Number of 
units not 
screened in a 
quality-assured 
manner
High-income (n = 34) 27 541 000 99.7% 74 000
Middle-income (n = 47) 13 041 000 83.6% 2 133 000
Lower-income (n = 24) 1 642 000 53.4% 765 000
Total (n = 105) 42 224 000 92.9% 2 972 000
Source: WHO Global Database on Blood Safety [online database] (25). 
Table 3.3 Global situation of donated blood screened in a quality-
assured manner
countries: 99.7% of donations in high-income countries 
and 83.6% in middle-income countries were screened 
following these quality procedures, but in low-income 
countries the comparable fi gure was markedly lower, 
at 53.4%. It is estimated that at least 2.97 million 
donations – 2.90 million of which are in low- and middle-
income countries – are not screened in accordance with 
quality assurance procedures (Table 3.3).
In addition, of 164 countries that provided data on 
screening for transfusion-transmissible infections – 
including HIV, hepatitis B, hepatitis C and syphilis – 
5 high-income, 21 middle-income and 13 low-income 
countries reported being unable to screen all donated 
blood for one or more of these infections. Irregular 
supply of test kits is one of the most commonly 
reported barriers that prevent many low- and middle-
income countries from screening all the blood they 
collect. One third of the 98 low- and middle-income 
countries reporting indicated that test kits for screening 
transfusion-transmissible infections were out of stock 
at some point during the 12-month reporting period. 
This is particularly concerning, since the prevalence 
rate of HIV in blood donations remains elevated in 
many low- and middle-income countries (Fig. 3.4). 
The difference refl ects the variable prevalence among 
members of the population who are eligible to donate 
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blood, the type of donors (such as voluntary unpaid 
blood donors from populations at lower risk) and the 
effectiveness of the system of educating and selecting 
blood donors.
WHO recommends that all activities related to blood 
collection, testing, processing, storage and distribution 
be coordinated at the national level through effective 
organization and a national blood policy supported 
by appropriate legislation to promote uniform 
implementation of standards and consistency in the 
quality and safety of blood and blood products (28). 
Since 2004, more countries have been able to develop 
and adopt key elements of nationally coordinated blood 
transfusion services (Fig. 3.5).
Although trends have generally been positive in the 
past 10 years, blood transfusion safety is still a concern, 
especially in low- and middle-income countries, 
where the prevalence of transfusion-transmissible 
infections among blood donors is high, blood shortages 
are common, dependence on family or replacement 
and paid donations is commonplace and the quality 
and coverage of blood screening is inadequate. It is 
important to scale up ongoing efforts to strengthen 
national blood systems and ensure suffi cient and safe 
blood supplies worldwide, especially in the low- and 
middle-income countries.
Fig. 3.5 Percentage of countries reporting selected policy or mechanisms for developing nationally coordinated blood 
transfusion services, 2004 and 2008
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Source: WHO Global Database on Blood Safety [online database] (25).
3.2.4 New HIV prevention technologies
3.2.4.1 Topical and oral antiretroviral pre-
exposure prophylaxis to prevent HIV-
negative individuals from acquiring HIV 
infection
The scientifi c base underpinning the use of antiretroviral 
drugs to prevent HIV acquisition in uninfected 
individuals has considerably evolved in 2010 and 2011 
with the publication of groundbreaking results from 
several clinical trials.
In July 2010, the fi rst trial to report on the use of a topical 
tenofovir-containing gel to prevent HIV acquisition in 
women reported an overall 39% effectiveness, with 
substantially better results among those who used the 
gel with greater consistency (21). In November 2010, the 
iPrex trial (29), a multinational trial of daily oral tenofovir/
emtricitabine tablets among men who have sex with 
men, showed that pre-exposure prophylaxis (PrEP) 
was 44% effective in preventing HIV transmission, 
with even stronger results among those who took the 
drug as prescribed. Importantly, this trial established 
the proof of concept of oral pre-exposure prophylaxis 
among men who have sex with men.
In April 2011 the FEM-PrEP trial, which assessed the 
effectiveness of oral tenofovir plus emtricitabine 
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tablets among women in Kenya, South Africa and the 
United Republic of Tanzania, was discontinued when 
an interim analysis revealed that the trial would not 
be able to find a difference in risk reduction, if one 
existed, between the treatment and the placebo arms 
(30). Subsequently, two trials among heterosexual men 
and women reported encouraging results. Partners 
PrEP, a trial among serodiscordant couples (couples in 
which only one partner is living with HIV) in Kenya and 
Uganda, compared two oral pre-exposure prophylaxis 
formulations, tenofovir alone and tenofovir plus 
emtricitabine, with a placebo control. In this trial, a 
62% reduction in the risk of HIV acquisition was found 
among those taking tenofovir tablets and a 73% decline 
in the group taking the combination tablets (31). The 
trial was stopped early on interim review because of the 
evident effectiveness of pre-exposure prophylaxis. TDF2, 
a smaller study among heterosexual men and women in 
Botswana, reported similar results, with the combination 
tenofovir plus emtricitabine tablet reducing the risk of 
acquiring HIV infection by 63% overall (32).
WHO and the UNAIDS Secretariat, with support 
from the Bill & Melinda Gates Foundation, have been 
working during the past two years to plan for eventually 
implementing and scaling up pre-exposure prophylaxis 
once the evidence base is suffi ciently strong. In that 
effort, consultations have been held in eight countries 
where pre-exposure prophylaxis research has been 
planned or conducted (Brazil, Ecuador, Kenya, Peru, 
Thailand, United Republic of Tanzania, Zambia, and 
Zimbabwe). In addition, fi ve regional consultations, 
held in Dakar, Nairobi, Brasilia, Johannesburg and 
Bangkok, have brought together countries with fi rst-
hand experience of pre-exposure prophylaxis trials and 
those for which it is a new topic. As a result, dialogue 
about and planning for implementing pre-exposure 
prophylaxis has begun in some countries. Initial 
efforts remain largely exploratory, as the appropriate 
populations, the best delivery points and the safest 
and most effective delivery methods still need to be 
identifi ed through implementation research. Informed 
by further scientific developments and outcomes 
from implementation research, guidelines for oral pre-
exposure prophylaxis will be developed (Table 3.4).
3.2.4.2 Antiretroviral therapy for prevention 
among people living with HIV
A strong scientifi c evidence base has also emerged 
in recent years showing that antiretroviral therapy, by 
lowering a person’s viral load and restoring the immune 
system, signifi cantly reduces HIV transmission and the 
incidence of TB.
The almost complete elimination of HIV infection 
among children in high-income countries by the 
appropriate administration of antiretroviral prophylaxis 
to pregnant women had long provided evidence of the 
substantial effect of antiretroviral therapy in preventing 
mother-to-child HIV transmission. Theoretical models 
also suggested that antiretroviral therapy could 
decrease HIV incidence and mortality, and a 2009 
meta-analysis including 11 cohorts (5021 heterosexual 
couples) found a nearly zero risk of sexual transmission 
among people receiving antiretroviral therapy and with 
viral load below 400 copies per ml (33–37).
Study name
Type and antiretroviral 
agents used Study population Date results release Study results
CAPRISA 004 (21) Pre-exposure prophylaxis – 
vaginal tenofovir gel 1%
Women July 2010 39% overall decrease in HIV 
acquisition
iPrex (29) Pre-exposure prophylaxis – 
oral tenofovir plus emtricitabine
Men who have sex with men November 2010 44% overall decrease in HIV 
acquisition and 79% decrease in 
high- adherence group
FEM-PrEP (30) Pre-exposure prophylaxis – 
emtricitabine and tenofovir
Women April 2011 Discontinued because of a 
lack of statistically signifi cant 
difference
Partners PrEP (31) Pre-exposure prophylaxis – 
oral tenofovir
Serodiscordant couples July 2011 62% decrease in HIV acquisition
Pre-exposure prophylaxis – 
oral tenofovir plus emtricitabine
Serodiscordant couples July 2011 73% decrease in HIV acquisition
TDF2 (32) Pre-exposure prophylaxis – 
oral tenofovir plus emtricitabine
HIV-negative heterosexual men 
and women
July 2011 63% decrease in HIV acquisition 
Table 3.4 Summary of recently published studies on topical and oral pre-exposure prophylaxis
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However, the publication of results from the landmark 
HPTN 052 study in 2011 considerably strengthened 
the available evidence base, since it was the 
first multinational randomized controlled trial to 
demonstrate a signifi cant reduction in HIV transmission 
in serodiscordant couples from antiretroviral therapy 
(Box 3.6). A recent systematic review further confi rmed 
the role of antiretroviral therapy in HIV prevention in 
serodiscordant couples in which the partner living with 
HIV had CD4 cell counts below 550 cells/mm3 (38).
Moreover, the impact of antiretroviral therapy on 
community-level HIV transmission is being increasingly 
documented. In British Columbia, a decrease in 
community plasma HIV RNA concentrations and 
HIV incidence among people who inject drugs was 
associated with the use of antiretroviral therapy (40). 
Between 2004 and 2008, the number of people newly 
diagnosed with HIV infection in San Francisco fell by 
45%, the average viral load among the people living 
with HIV fell by 40% and the actual incidence of 
people becoming newly infected with HIV fell by one 
third between 2006 and 2008. In the Chinese province 
of Taiwan, a 53% reduction in new HIV cases was 
associated with free access to antiretroviral therapy (41).
WHO, UNAIDS and partners are currently engaged in 
further research to better understand how antiretroviral 
therapy affects TB, the relative importance of drug 
resistance and other assumptions on overall therapy 
outcomes, the effects of combining pre-exposure 
Box 3.6
The HPTN 052 study
Started in 2005, the HPTN 052 trial followed serodiscordant 
couples in Botswana, Brazil, India, Malawi, South Africa, 
Thailand and Zimbabwe (39). The study had two arms – one 
in which the partner living with HIV in a serodiscordant couple 
received antiretroviral therapy immediately if his or her CD4 
cell count fell below 550 cells/mm3 and the other, the delayed 
arm, in which partners did not receive antiretroviral therapy 
until they met the prevailing eligibility criteria of having CD4 
cell counts at or below 250 cells/mm3. All participants received 
ongoing couples counselling and condoms.
The study found that providing immediate antiretroviral 
therapy to the partner living with HIV was associated with a 
96% reduction in the likelihood of HIV transmission among 
serodiscordant couples. As of 21 February 2011, HIV-1 had been 
transmitted to 39 partners. Of these, 28 were virologically 
linked to the partner living with HIV, and only one occurred 
in the group getting early antiretroviral therapy. Although the 
probability of death did not differ signifi cantly between the 
two arms, HIV-related clinical events declined by 41% in the 
subgroup that received immediate antiretroviral therapy.
prophylaxis and antiretroviral therapy, the economic 
costs and benefi ts of the various strategies and the 
effectiveness of various models of providing testing 
and counselling. As more scientifi c evidence becomes 
available, WHO will assess its implications for the 
strategic use of antiretroviral drugs in HIV prevention 
and its repercussions for the development of technical 
guidelines for countries.
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KEY FINDINGS
The number of facilities providing HIV testing and counselling continued to increase. The reported number of health 
facilities providing HIV testing and counselling services reached 131 000 in 2010 (119 countries), from 107 000 in 
2009 (118 countries), 78 000 in 2008 (111 countries) and 30 300 in 2007 (78 countries). In a subset of 104 countries 
reporting data in both 2009 and in 2010, the median number of facilities per 100 000 population increased from 
5.7 to 8.2 (44%).
The number of HIV tests increased globally. In a subset of 87 countries providing data in both 2009 and 2010, about 
72 million HIV tests were performed, an increase from the 64 million tests performed in 2009; the median number 
of tests per 1000 adult population rose from 47 to 55, a 17% gain.
Population-based surveys conducted in selected low-income countries in sub-Saharan Africa show that 1) the 
proportion of people who report having ever had an HIV test is higher among women than men and 2) knowledge 
of HIV status, although increasing, remains broadly inadequate. In six countries with results from population-based 
surveys conducted in 2007–2009, a large proportion of respondents was not aware of their HIV seropositivity before 
the survey, from about 30% in Kenya to close to 70% in the Congo.
Available data indicate that extensive attrition exists between HIV testing and counselling and treatment, care and 
support services. Greater attention is needed to implement service delivery models that refl ect local needs and can 
strengthen links between HIV testing and counselling and other services, including prevention, treatment, care and 
support interventions.
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76     GLOBAL HIV/AIDS RESPONSE – Epidemic update and health sector progress towards Universal Access – Progress Report 2011
4.1  Overview of progress and key 
challenges
As a critical gateway to services, HIV testing and 
counselling are essential in expanding access to HIV 
prevention and treatment and ultimately achieving 
universal access. Facility-level data and population-
based surveys show that both the availability and 
uptake of HIV testing have increased considerably 
across low- and middle-income countries in recent 
years. Most countries have now adopted client- and 
provider-initiated testing and counselling policies, 
which have decisively contributed to raising awareness 
of HIV status in the general population and among 
key populations at higher risk of HIV infection and 
transmission (1).
Nevertheless, the widespread increase in HIV testing 
and counselling availability and uptake across diverse 
settings has highlighted several key programmatic gaps 
that must be tackled to maximize the population-level 
benefi ts of testing and counselling services for scaling 
up HIV prevention and treatment. First, available data 
show that, in generalized epidemics, a large proportion 
of  people with HIV are still unaware of their HIV 
status and that, in low and concentrated epidemics, 
despite high levels of testing in some contexts, such 
as antenatal care clinics, key populations at higher risk 
of HIV infection are often not reached. Greater efforts 
are needed to ensure that HIV testing and counselling 
adequately reach the population groups at higher risk of 
HIV infection, for whom timely knowledge of HIV status 
is essential to implement prevention interventions and 
avoid late initiation of antiretroviral therapy.
Moreover, recent evidence indicates that extensive 
attrition takes place between HIV testing and 
counselling and treatment, care and support services. 
In many circumstances, people informed of their 
HIV-positive status are not adequately linked with 
the appropriate services, thus preventing immediate 
enrolment in care and hindering follow-up for eventually 
initiating antiretroviral therapy. Links between HIV 
testing and counselling and other services, including 
prevention interventions, must therefore be greatly 
expanded and strengthened to ensure that testing and 
counselling services adequately fulfi l their role as the 
main gateway to a comprehensive HIV response.
Lastly, client age and structural, operational, logistical 
and social barriers, including stigma and discrimination, 
continue to limit access to existing HIV testing and 
counselling services and must be addressed. As 
national programmes search for ways to improve the 
performance of programmes, priority should be given to 
HIV testing and counselling approaches that are cost-
effective and achieve maximum impact in increasing 
knowledge of serostatus.
To this end, WHO and UNAIDS support the adoption 
of a combination of innovative and cost-effective HIV 
testing and counselling models that protect the human 
Box 4.1 
Note on methods
The data discussed in this chapter are based on two sources. The fi rst consists of reports sent by countries to WHO, UNAIDS and UNICEF 
regarding policies, programmes and indicators based on information collected from health facilities. These data were compiled and verifi ed 
where feasible, in collaboration with countries. However, given the lack of adequate strategic information systems in many countries, they 
are often not formally validated. Data aggregation across countries may also be methodologically challenging, as defi nitions may not be 
standardized. Data on service availability and uptake may not cover all public, private and nongovernmental health facilities in a country or 
may not include all service delivery points where HIV testing and counselling services are provided. In addition, calculations of aggregate 
measures, especially regional medians, are based on subsets of countries with available comparable data that may not be fully representative 
of their respective regions. Specifi c numbers should hence be interpreted with caution.
The second source of data comprises national population surveys conducted in some low- and middle-income countries. These surveys are 
generally based on nationally representative samples and typically follow standardized methods that provide comparable data on respondents’ 
reports of their use of specifi c HIV services, thus enabling coverage to be estimated for various population groups. Some surveys also draw 
blood from respondents who agree to be tested and can thus provide information on the HIV status among specifi c groups. The extent to 
which such surveys can provide estimates of knowledge of HIV status depends on the specifi c information that is asked of respondents, in 
particular, regarding their HIV status. The estimates provided by these two sources of data may differ, especially if country reports do not 
include information from all nongovernmental facilities. Population surveys would generally provide more accurate estimates of uptake.
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rights of all individuals, respect principles of informed 
consent and confi dentiality and are suitable to local 
epidemiology and context (2). An updated HIV testing 
and counselling framework is currently being developed 
to assist countries in developing an appropriate and 
effective combination of HIV testing and counselling 
approaches to maximize coverage and impact.
This chapter discusses national-level data on the 
availability and coverage of HIV testing and counselling 
among adults in the general population. Chapter 6 
discusses testing among key populations at higher risk 
of HIV infection, and Chapter 7 reviews data on testing 
among pregnant women and among infants.
4.2 Policies and programmes for HIV 
testing and counselling
In 2010, 113 of 126 low- and middle-income countries 
providing data indicated having national guidelines on 
the implementation of provider-initiated testing and 
counselling in health facilities: 20 (77%) in East, South 
and South-East Asia, 23 (96%) in Latin America and 
the Caribbean, 15 (79%) in Europe and Central Asia, 
37 (82%) in sub-Saharan Africa, and 8 (67%) in the 
Middle East and North Africa.
Among 38 reporting countries with generalized HIV 
epidemics, 32 stated that their policy guidelines advise 
health care providers to initiate testing and counselling 
in all encounters patients, a substantial progress from 
the 19 countries reporting it in 2008. Among countries 
with low-level or concentrated epidemics, 86 of 93 
providing data indicated having policies or guidelines 
to implement focused testing and counselling for 
populations at higher risk of HIV infection.
4.3 Availability and uptake of HIV testing 
and counselling
A total of 119 low- and middle-income countries 
submitted data on the availability of HIV testing and 
counselling services in health facilities through this 
year’s reporting process (Table 4.1). HIV testing and 
counselling services were provided by 131 000 health 
facilities in 2010 versus 107 000 health facilities in 
2009 (118 countries), 78 000 in 2008 (111 countries) 
and 30 300 in 2007 (78 countries).
With respect to the uptake of testing and counselling, 
108 countries reported that more than 79 million people 
received HIV testing and counselling in 2010, whereas 
67.4 million tests were reported in 100 countries in 
2009 (Table 4.2).1 Country reports provide the total 
number of people tested, but these figures do not 
correct for the fraction of people tested more than 
once during the course of the year, which may vary 
considerably among countries.
1 Annex 2 provides country data.
Region
Number of facilities 
with HIV testing and 
counselling
Number of countries 
reporting
Number of people 
15–49 years old who 
received HIV testing and 
counsellinga in the past 
12 months and know the 
results
Number of countries 
reporting
Sub-Saharan Africa 36 000 42 45 000 000 44
Latin America and the Caribbean 44 000 23 21 000 000 16
East, South and South-East Asia 29 000 24 19 000 000 23
Europe and Central Asia 20 000 18 8 900 000 16
North Africa and the Middle East 2 000 12 1 100 000 13
Total 131 000 119 95 000 000 112
a Based on the numbers of people tested as reported by countries but without correcting for the fraction of people who are tested more than once.
Table 4.1 Number of facilities with HIV testing and counselling and number of people aged 15–49 years who received HIV 
testing and counsellinga by region (low- and middle-income countries), 2010
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Table 4.2 presents a ratio of facilities per 100 000 
population and a ratio of tests per 1000 population 
to more adequately monitor changes in availability 
and uptake over time. To analyse trends and ensure 
methodological accuracy, these ratios have been 
calculated only for countries that provided comparable 
data in both 2009 and 2010. It is important to consider, 
however, that the sub-selection of countries included 
in the analysis may not be fully representative of their 
regions, and fi gures should be interpreted as such.
A total of 104 countries reported information on the 
number of facilities providing testing and counselling 
services in both 2009 and in 2010. In this group, 
the median number of facilities per 100 000 adult 
population increased by 44% year-on-year, from 5.7 to 
8.2. However, there is considerable regional variation: 
fewer than 2 facilities per 100 000 were reported in 
North Africa and the Middle East and in East, South 
and South-East Asia versus 12 in sub-Saharan Africa 
and 24 in Latin America and the Caribbean.
In a subset of 87 countries who provided data in both 
2009 and 2010,the number of tests increased from 
64 to about 72 million. Globally, the median number 
of tests per 1000 adult population rose from 47 to 55, 
a 17% increase. All regions recorded higher median 
numbers of tests per 1000 adult population, except for 
Region
Median number of 
facilities per 100 000 
adult population 
(number of countries 
reporting)
Median number of 
tests per 1000 adult 
population (number of 
countries reporting)
2009 2010 2009 2010
Sub-Saharan Africa 8.6 12 70 82
(n = 41) (n = 43)
Latin America and the Caribbean 18 24 52 56
(n = 22) (n = 12)
East, South and South-East Asia 1.2 1.6 15 22
(n = 20) (n = 17)
Europe and Central Asia 3.0 3.4 35 36
(n = 15) (n = 10)
North Africa and the Middle East 0.9 1.1 3.7 3.6
(n = 6) (n = 6)
Median (all countries) 5.7 8.2 47 55
a Based on the numbers of people tested as reported by countries but without correcting for the fraction 
of people who are tested more than once.
b Country data can differ from those published in the 2010 universal access report (3) due to updates and 
corrections subsequently submitted by countries.
Table 4.2 Number of facilities that provide HIV testing per 100 000 
population and number of testsa per 1000 population for countries 
reporting data for 2009b and 2010, by region
North Africa and the Middle East, where this remained 
broadly stable. Variation is also great within region: 
from 3.6 tests per 1000 in North Africa and the Middle 
East to 82 in sub-Saharan Africa.
4.4 Coverage of HIV testing and 
counselling
A growing number of countries are conducting 
national surveys, including Demographic and Health 
Surveys, which contain an HIV module. These provide 
information on the proportion of respondents who have 
been tested for HIV in the 12 months preceding the 
survey and on the proportion of those who have ever 
been tested for HIV. Such surveys, when repeated, can 
also help identify trends in testing uptake and monitor 
the extent to which individuals use HIV testing and 
counselling services.
An analysis of data from countries that have conducted 
repeat population surveys between 2003 and 2010 
reveals substantial increases in HIV testing rates 
among both women and men (Fig. 4.1). In Lesotho, 
for instance, the percentage of women tested in the 
12 months preceding the survey increased almost 
seven-fold between 2004 and 2009, from 6.3% to 
42%, and almost fi ve-fold among men, from 4.8% to 
24%. In the United Republic of Tanzania, testing rates 
in the last 12 months grew from a baseline of 4.9% in 
2003–2004 to 29.5% in 2010 among women and from 
7.3% to 25.0% among men.
In addition, HIV testing rates were generally higher 
among women than among men in five of the six 
countries conducting repeat surveys in 2009–2010. In 
the Congo, the proportions of men and women tested 
in the last 12 months were similar: 7.2% and 6.5%, 
respectively. Earlier surveys showed higher percentages 
of testing among men, as observed in Kenya, 
Mozambique and the United Republic of Tanzania in 
2003–2004, whereas results from surveys carried out 
in 2009–2010 showed the opposite sex distribution. 
This suggests that recent efforts to increase HIV testing 
and counselling, including through national campaigns, 
implementing provider-initiated testing and counselling 
policies and improving integration between HIV and 
maternal and child health services have provided 
greater benefi ts to women than men.
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HIV testing uptake differs between men and women in 
East, South and South-East Asia and may refl ect local 
epidemiological patterns. Among countries submitting 
data in 2010, the proportion of men receiving an HIV 
test was higher in countries with larger numbers of 
people who inject drugs (such as Bangladesh, Indonesia 
and Myanmar). Relatively more women were tested for 
HIV in countries with epidemics with unprotected sex 
as the primary mode of HIV transmission (such as India, 
Nepal, Sri Lanka and Thailand), where many pregnant 
women receiving HIV testing through maternal and 
child health care services.
Lack of knowledge of serostatus by people living with 
HIV is a major obstacle to realizing the goal of universal 
access to treatment and prevention. A significant 
proportion of people living with HIV continue to present 
late for treatment because they are unaware that they 
are seropositive, including in high-income countries (4),1 
thus reducing the effectiveness of antiretroviral therapy 
on morbidity, survival and preventing HIV infection. 
Surveys that ask people about testing uptake and 
include a seroprevalence component provide an 
1 In the European Union, an estimated one third of people living with HIV 
are unaware of their HIV status (4). In the United States, the percentage 
of people with late HIV diagnoses was 32% in 2007, suggesting that at 
least a similar proportion remained unaware of their serostatus (5).
Country
Year of 
survey Women Men Both
Congo 2009 35.2 21.1 30.9
Kenya 2008–2009 73.5 58.6 68.9
Lesotho 2009 70.8 51.8 64.4
Mozambique 2009 43.2 30.1 38.7
Sao Tome and Principe 2008–2009 a a 41.0
United Republic of Tanzania 2007–2008 43.7 30.8 39.0
Sources: Demographic and Health Surveys [web site] (6).
a When denominators are based on less 50 cases, the corresponding indicator is not reported.
Table 4.3 Percentage of people living with HIV who have ever 
received an HIV test and their test results before the survey: national 
population surveys, 2007–2009
approximate indication of knowledge of HIV status 
among people living with HIV (5). Table 4.3 reports 
data on knowledge of HIV status before the survey 
among people living with HIV for a subset of six African 
countries with surveys conducted between 2007 and 
2009. The percentage of respondents living with HIV 
who report that they have been tested for HIV provides 
an upper limit of the estimated number of people living 
with HIV who know their status.2 The results show 
2 The accuracy of serostatus knowledge is lower than suggested by 
this percentage, because some people who have tested may not have 
received their results or may have seroconverted after an earlier negative 
test. For example, this is well documented in the 2007 Kenya AIDS 
Indicator Survey (5).
Fig. 4.1 Percentage of women and men receiving an HIV test and test results in the past 12 months preceding the survey in selected countries 
with repeat population surveys, 2003–2010
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Box 4.3 
HIV testing and counselling for adolescents and young people
An estimated 2 million adolescents (aged 10–19 years) are living with HIV; most of them are unaware of their HIV status. Age and sex-
disaggregated data on the uptake of HIV testing and counselling among young people are not available for many countries, thus preventing 
the generation of regional estimates. However, recent survey data from sub-Saharan Africa showed that only 15% of young women aged 15–24 
years and 10% of young men have been tested and know their HIV status (13). As such, many adolescents and young adults are diagnosed 
late and do not access treatment until they are severely immunocompromised. A study in Zimbabwe found that 50% of adolescents admitted 
for acute care in primary health facilities were living with HIV, and HIV accounted for about 75% of the hospitalized adolescents who died 
(14). Improving the application of the guidelines for provider-initiated testing and counselling among adolescent clients receiving chronic 
care could help improve early diagnosis of HIV in adolescents and minimize late initiation on antiretroviral therapy.
Age-specifi c prevalence data show a clear sex disparity in HIV prevalence by age 15 years, indicating how non-vertical transmission affects 
adolescents. In Botswana, the HIV prevalence among men 15–19 years old was 2.4% in 2008 but reached 5% among young women in the 
same age group (15). A similar pattern was observed in South Africa, where men aged 15–19 years had an HIV prevalence of 2.5% in 2008 
versus 6.7% among young women (16). This underscores the need to increase testing uptake among adolescents, including through provider-
initiated testing and counselling. WHO is currently developing global guidance on HIV testing and counselling for adolescents to help address 
the gap in diagnosis and uptake of HIV testing and counselling among adolescents. UNICEF, WHO and the United Nations Population Fund 
are also working to strengthen the capacity of service providers and advocacy by developing a network of trainers and developing guidance 
on key areas for adolescents living with HIV.
Sources: Botswana AIDS Impact Survey III (BAIS III), 2008: preliminary results (15) and Shisana O et al. (16).
Fig. 4.2 Percentage of people living with HIV who have ever 
been tested and received their results before the survey, repeat 
population surveys, 2003–2008
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Box 4.2 
HIV testing and counselling for couples
HIV testing and counselling approaches have almost exclusively focused on providing services for individuals. However, in most countries in 
sub-Saharan Africa with generalized HIV epidemics, three quarters of adults aged 20–49 years are in cohabiting unions (6). Among people 
with HIV from high-prevalence, generalized epidemics in sub-Saharan Africa who are in stable relationships, up to half have an HIV-negative 
partner. This proportion has been reported in both the general population (7–9) and specifi cally among women and their partners attending 
antenatal clinics (10).
There are many potential advantages in supporting couples to test together and mutually disclose their HIV status so that they make informed 
decisions about HIV prevention and conception. Findings from many published studies suggest that people living with HIV and people in 
serodiscordant couples are more likely to adopt preventive behaviour after learning their HIV status. In addition, providing antiretroviral 
therapy to the partner living with HIV can signifi cantly decrease transmission to the HIV-negative partner in serodiscordant couples (11,12). 
Additional potential advantages of having couples test together and share their results include mutual support to access and adhere to 
antiretroviral therapy and to interventions for preventing the mother-to-child transmission of HIV. WHO is developing normative guidance 
on interventions targeting serodiscordant couples, including testing and counselling.
that many respondents were not aware of being HIV 
seropositive before the survey, with sizable variation 
between countries: from about 30% in Kenya to close 
to 70% in the Congo. In countries with available data, 
women were also more knowledgeable than men about 
their status.
Successive surveys conducted between 2003 and 
2008 in Kenya, Lesotho and the United Republic of 
Tanzania show an important improvement in serostatus 
awareness among people living with HIV (Fig. 4.2). The 
proportion of men living with HIV who were informed of 
their HIV status increased by more than 50% between 
2003–2004 and 2007–2008 in the United Republic 
of Tanzania and tripled in Lesotho between 2004 and 
2009. Progress was also noteworthy among women: in 
Lesotho, the proportion of women living with HIV who 
were aware of their status rose by more than 400% 
in the same period. Despite these accomplishments, 
available data indicate that many people who test HIV 
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positive are not immediately or adequately linked to the 
relevant care and treatment services, thus preventing 
HIV testing and counselling from reaching its ultimate 
objective, which is to increase the uptake of other 
essential health interventions.
4.5 Achieving universal access to 
HIV testing and counselling – the 
effectiveness of different models
Alternative models of HIV testing and counselling 
urgently need to be rapidly scaled up to achieve universal 
knowledge of HIV status and more equitable coverage 
(Fig. 4.3). Initially, HIV testing and counselling was 
predominantly delivered through the voluntary testing 
and counselling model and, more recently, through 
provider-initiated testing and counselling, which 
has been shown to increase testing uptake in many 
settings, including antenatal services (17). Nevertheless, 
it is increasingly recognized that voluntary testing and 
counselling and provider-initiated testing and counselling 
must be complemented by alternative approaches to 
more rapidly expand the availability and uptake of HIV 
testing and counselling. Several country programmes 
have already introduced many of these approaches, 
which include public campaigns, mobile testing, 
workplace testing and home- and school-based testing.
Home-based HIV testing and counselling, whereby 
services may be provided to everyone in a community 
or to households with a person known to have TB or 
be living with HIV (an index patient), aims to increase 
access to HIV testing while reducing the stigma 
associated with HIV testing in facility settings (18,19). 
Evidence suggests that the strategy is cost effective, 
increases testing uptake (20–22) and reduces the 
inequities in access of existing testing services 
(Box 4.2) (23). Nevertheless, data are limited on its 
impact in diverse epidemiological settings and its effect 
on access to prevention, treatment, care and support 
services following a positive result. Mobile HIV testing 
and counselling aims to improve access to and coverage 
of HIV testing by using vans, trucks or other mobile sites 
in addition to existing facilities, such as schools (24). 
Evidence from Thailand, the United Republic of Tanzania 
and Zimbabwe suggests that mobile testing can achieve 
higher testing uptake, including among younger clients, 
compared with the uptake of clinic-based voluntary 
testing and counselling (25), and that mobile approaches 
to HIV testing and counselling are also cost-effective, 
reaching a high proportion of individuals who are not 
aware of their HIV status. Critically, door-to-door and 
mobile HIV testing and counselling may facilitate 
access to testing and counselling by populations that 
are more diffi cult to reach, including those living in 
rural communities and areas underserved by formal 
health facilities. 
Workplace HIV testing and counselling entails 
providing employees with HIV testing and counselling 
at the workplace and making results available promptly, 
often on the day of testing (26). By providing services at 
a convenient time and location, while ensuring their 
confi dentiality and voluntary uptake, workplace testing 
has been shown to increase HIV testing, especially 
among men, compared with when employees were 
referred to off-site voluntary testing and counselling (27).
Fig. 4.3 Models of HIV testing and counsellinga
Health facility
Provider-initiated 
testing and 
counselling in 
antenatal care
Provider-initiated 
testing and 
counselling
Integrated 
voluntary HIV 
testing and 
counselling Stand-alone 
voluntary HIV 
testing and 
counselling
HIV testing and 
counselling
Workplace 
Mobile School basedHome based 
Door-to-door Index 
Community
a In the index model, HIV testing and counselling is offered to the household members of an individual with HIV or TB, also known as the index patient. 
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National HIV testing and counselling campaigns are 
nationwide efforts to improve the demand for and 
access to testing services and to normalize HIV testing 
at the community level. Campaigns may be of variable 
duration, running from days to years. Various countries 
have implemented national campaigns, and some have 
integrated HIV testing and counselling with other 
disease prevention campaigns in a bid to jointly improve 
the coverage of multiple preventive services. In South 
Africa, where an ambitious national campaign was 
launched in April 2010 to encourage 15 million sexually 
active individuals aged 12 years and older to test for HIV 
over a 12-month period, more than 10 million people 
have been tested, and 1.7 million of these were found to 
be living with HIV (28). The campaign, the world’s largest 
to date, has engaged health facilities, stand-alone HIV 
testing sites, mobile testing services, pharmacies and 
universities, and planning is currently underway to 
implement it into secondary schools to target children 
aged 12 years and over. In Kenya, a targeted, one-
week community-based campaign against HIV, malaria 
and diarrhoeal disease was able to reach more than 
47 000 people, or 87% of the targeted population aged 
15–49 years, with health education counselling, durable 
insecticide-treated bed-nets, household water fi lters 
and condoms. Nearly all (99.7%) participants tested 
for HIV, and 4.2% tested HIV positive. Importantly, 
this was the fi rst HIV test for more than 80% of the 
people reached (29).
It is important for countries to give priority to HIV 
testing and counselling approaches that are appropriate 
to their epidemic and context. Table 4.4 highlights the 
key fi ndings of a literature review on the populations 
reached and the estimated costs by model of HIV 
testing and counselling. Available evidence suggests 
that home-based testing may be an adequate way to 
support couples to test together, and workplace testing 
and campaigns may be especially suitable approaches 
for men. The limited published data on the costs of 
the various models indicate that traditional voluntary 
testing and counselling may be a more expensive model 
than other community-based approaches and provider-
initiated testing and counselling.
Limited evidence is available on the extent to which 
people are effectively linked to prevention and care 
services following HIV testing and counselling. 
Most available data on links between HIV testing 
and counselling and care services are from studies 
conducted in health facility settings, such as antenatal 
care services (30) or TB clinics, and show that people 
who test positive are often inadequately linked to 
antiretroviral therapy services for their own clinical 
benefit (31). This may be a particular challenge for 
community-based HIV testing and counselling sites 
without direct connections to care services. In Uganda, 
for instance, only 10.5% of individuals identifi ed as 
living with HIV through home-based HIV testing and 
counselling were linked to antiretroviral therapy (32). 
Additional research is required to understand how 
alternative models of testing can best connect 
individuals identifi ed as HIV positive with prevention 
and care services (Table 4.4, Box 4.4).
Model of testing
% of people 
being tested 
who are male 
(range)
% of people 
being tested 
who are 
female (range)
% of people 
being tested 
who are 
younger than 
25 years
% of people 
being tested 
who are tested 
as a couple
% of people 
being tested 
who were 
tested for the 
fi rst time HIV positivity
% of 
individuals 
identifi ed as 
HIV positive 
with CD4 
counts <200 
cells/mm3
Cost per 
individual 
tested (in US 
dollars)
Voluntary testing and 
counselling (24,33,34) 34–59% 41–66% 28–42% 4–54%
b 58–73% 3–22%c 48% 19–27
Home-based testing 
(32,33,35–39) 24–49% 51–76% 7–60% 42–64% 23–95% 4–8% 31–45% 6–14
Community or mobile 
testing (24,40–42) 38–58% 42–100%
d 34e–51% 1–28% 69–91% 2–29% 11% 9–20
Workplace testing 
(26,43,44) 50–59% 40–50% — 3% — 4% 30% —
Provider-initiated 
testing and counselling 
(31,33,45,46)
40% 60% 27–51%e 6% — 6–42% 16–47% 12
a Not all studies are included in each cell.
b Individuals in Thailand in standard voluntary testing and counselling programmes.
c People being tested for the fi rst time.
d 100% uptake reported in a study conducted in Thailand among female sex workers.
e  Individuals younger than 26 years of age.
Table 4.4 Summarizing testing uptake, positivity rates, CD4 counts and costa
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Box 4.4 
Promoting community-based HIV testing and counselling and timely entry to care: The Academic Model Providing 
Access to Healthcare (AMPATH) Partnership of the United States Agency for International Development in Kenya
An important proportion of people living with HIV in Kenya, as elsewhere in sub-Saharan Africa, continue to access HIV care relatively late 
in their stage of disease, thus compromising the potential benefi ts of combination antiretroviral therapy. To address this issue, AMPATH 
developed a community-based door-to-door HIV testing and counselling service that offers testing and counselling to everyone 13 years and 
older and to children younger than 13 years of age whose mothers are dead, have unknown vital status, are living with HIV or have unknown 
HIV status. Since 2008, more than 350 000 people have received testing and counselling through AMPATH. Importantly, 83% of the adults 
and 86% of the children found to be living with HIV were newly identifi ed cases.
A comparison of HIV testing and counselling approaches in Kenya found that people who were diagnosed as HIV-positive through home-
based HIV testing and counselling had signifi cantly higher median CD4 cell counts when entering HIV care than those who tested positive 
through other points of entry. This implies that antiretroviral therapy can be initiated in a timely manner; in this context, strengthening links 
between testing and care services is essential to facilitate access and effective follow-up. Moreover, a higher proportion of people entering 
care treatment from home-based HIV testing and counselling were members of HIV-serodiscordant couples, or were pregnant and could 
benefi t from treatment and prevention interventions tailored to their specifi c needs.
Variables
Home-based 
counselling and 
testing 
(n = 946)
Voluntary testing 
and counselling 
(n = 10 261)
Provider-initiated 
testing and 
counselling 
(n = 8073)
TB 
(n = 272) P
Median (interquartile range) 
age in years 37 (30–46) 36 (29–44) 36 (29–44) 36 (30–44) 0.022
Male 268 (28%) 3 537 (34%) 3 050 (38%) 136 (50%) <0.001
Female 678 (72%) 6 726 (66%) 5 023 (62%) 136 (50%)
Pregnant 75 (11%) 360 (5%) 321 (6%) 7 (5%) <0.001
Member of a discordant couple 214 (24%) 649 (7%) 466 (6%) 13 (5%) 0.05
Median (interquartile range) 
CD4 count per mm3
323 (194–491) 217 (87–404) 190 (70–371) 136 (59–266) <0.001
Table 4.5 Client characteristics by entry point for HIV testing and counselling
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Box 4.6 
Understanding retention in HIV care between testing and treatment
Although retention on long-term antiretroviral therapy is being increasingly researched and documented (section 5.3.4), evidence on and 
knowledge about the retention of people living with HIV before they initiate antiretroviral therapy are considerably more limited. It is known, 
however, that late presentation for antiretroviral therapy remains a major driver of morbidity and mortality, and improving the outcomes of 
HIV treatment programmes requires strongly linking the various services a person must navigate once being diagnosed with HIV.
A systematic review of the literature on pre–antiretroviral therapy retention in care in Africa has shed important light on this issue. 
Schematically, the cascade of interventions between testing and counselling and initiating antiretroviral therapy can be divided into three 
main stages: stage 1, from HIV diagnosis to assessment (receipt of CD4 count or clinical staging); stage 2, from assessment to eligibility for 
antiretroviral therapy; and stage 3, from eligibility to actual initiation of antiretroviral therapy (Fig. 4.4). For each stage, data were aggregated 
from relevant articles and subsequently compiled for analysis.
Two main fi ndings emerged from this review. First, it demonstrates that pre–antiretroviral therapy retention is relatively poorly documented: 
only 28 publications matched the criteria to be included in the analysis, 10 documenting stage 1 and 14 reporting on stages 2 and 3 each. 
Some studies covered more than one stage, but none followed a cohort through all three stages.
Second, available data suggest that a very high percentage of people are lost at each stage of the cascade: the median proportion of people 
retained was 59% in stage 1, 46% in stage 2 and 68% in stage 3. Combining these three fi gures implies that only about 18% of all the people 
diagnosed as living with HIV but not immediately eligible for antiretroviral therapy remained continuously in care until they became eligible. 
This fi gure probably underestimates the actual retention levels because of the low quality of the data and diffi culty associated with tracking 
people who transfer between facilities or who are lost in one stage but later return to care. The most complete study included in the review, 
a cohort in South Africa followed between 2004 and 2009, estimated an overall retention rate of 33% between the provision of a fi rst CD4 
count and the initiation of antiretroviral therapy. This higher fi gure nevertheless confi rms the high proportion of people who are lost to 
follow-up in the pre–antiretroviral therapy cascade.
These fi ndings therefore underscore the need to urgently strengthen patient tracking systems to improve knowledge of the retention cascade 
and to implement timely corrective interventions. The rates of attrition must be monitored at all stages, and the underlying causes of poor 
performance of pre–antiretroviral therapy care systems in retaining people must be adequately identifi ed, including those related to health 
care behaviour among people who do not feel sick, accessibility of the health care system, cost, stigma and discrimination.
In September 2011, WHO hosted an international consultation on pre–antiretroviral therapy and antiretroviral therapy retention to share 
country experiences and shed light on the key constraints, at the health system and individual levels, that cause attrition in resource-limited 
settings. Efforts are ongoing to develop comprehensive strategies and recommendations to improve monitoring and optimize retention in care.
Source: Rosen and  Fox (47)
Fig. 4.4 Stages before antiretroviral therapy is initiated 
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KEY FINDINGS
At the end of 2010, 6 650 000 people were receiving 
antiretroviral therapy in low- and middle-income 
countries, an increase of over 1.4 million people, or 
27%, from December 2009. Sub-Saharan Africa had 
the greatest increase in the absolute number of people 
receiving antiretroviral therapy in 2010, from 3 911 000 
in December 2009 to about 5 064 000 a year later.
Overall, the estimated coverage of antiretroviral therapy 
among adults and children in low- and middle-income 
countries continued to increase and was 47% [44–50%] 
of the 14.2 million [13 400 000–15 000 000] people 
eligible for treatment at the end of 2010, up from 39% 
[37–42%] observed in December 2009.
As of December 2010, ten low- and middle-income 
countries, including three countries with generalized 
epidemics (Botswana, Namibia and Rwanda), had 
already achieved universal access to antiretroviral 
therapy, defi ned as providing antiretroviral therapy 
to at least 80% of the people eligible for treatment. 
Seven additional countries, including two countries 
with generalized epidemics (Swaziland and Zambia), 
had estimated coverage levels between 70% and 79%.
The number of children younger than 15 years of age 
receiving antiretroviral therapy in low- and middle-
income countries increased by 29% between 2009 and 
2010. About 456 000 children younger than 15 years 
were receiving antiretroviral therapy at the end of 
2010, up from 354 600 in December 2009. However, 
the estimated coverage is much lower among children 
(23%) than among adults (51%).
Among 109 reporting countries, the estimated 
antiretroviral therapy coverage was higher among 
women, estimated at 53%, than among men (40%).
Moderate levels of transmitted drug resistance have 
been observed in some countries. Among 11 surveys 
conducted in 2009 to monitor transmitted HIV drug 
resistance, fi ve showed moderate (between 5% and 
15%) transmitted HIV drug resistance.
Data on the proportion of people who remain on 
antiretroviral therapy over time in low- and middle-
income countries continue to show that most attrition 
(discontinuation of antiretroviral therapy) occurs within 
the fi rst year of starting therapy. The average retention 
rate at 12 months after initiating antiretroviral therapy 
was 81% (92 reporting countries), 75% at 24 months 
(73 countries) and 67% at 60 months (46 countries).
In low- and middle-income countries outside the 
Americas (45 reporting countries), most (97%) adults 
were receiving fi rst-line regimens and 3% second-
line regimens as of December 2010. In the Region of 
the Americas (21 reporting countries), a substantially 
higher proportion (28%) of adults received second-line 
regimens, and 3% received third-line regimens.
Among 93 reporting countries, 88 already recommend 
initiating antiretroviral therapy for everyone with CD4 
counts less than 350 cells per mm3 as of late 2010. 
Among 87 reporting countries, 84 have also adopted 
international guidelines that recommend shifting away 
from stavudine-based to zidovudine- or tenofovir-
based regimens.
Progress continues to be made in expanding access to 
and uptake of HIV testing and counselling for people 
with tuberculosis (TB). A total of 2.1 million people with 
TB were tested for HIV in 2010, equivalent to 34% of 
all notifi ed cases, versus 28% in 2009 and 3% in 2004.
As of December 2010, 58% of reporting low- and 
middle-income countries (69 of 119) indicated that 
isoniazid preventive therapy was a part of their package 
of interventions for people living with HIV; 90% (113 of 
125) indicated having policies to promote intensifi ed 
case–fi nding, and 78% (98 of 126) had a policy for 
TB infection control. Coverage of isoniazid preventive 
therapy remained low, as only 12% of the reported 
number of people living with HIV newly enrolled into 
care received isoniazid preventive therapy in 2010.
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5.1 Overview and key challenges
At the end of 2010, 6 650 000 people were receiving 
antiretroviral therapy in low- and middle-income 
countries. This represents an increase of 27%, or 
1.4 million people, from December 2009, and a 
17-fold increase from the approximately 400 000 
people recorded in December 2003. Ten low- and 
middle-income countries, including three countries 
with generalized epidemics (Botswana, Namibia and 
Rwanda) and seven countries with concentrated 
or low-level epidemics (Cambodia, Chile, Croatia, 
Cuba, Guyana, Nicaragua and Slovakia) have achieved 
universal access to antiretroviral therapy, commonly 
understood as providing antiretroviral therapy to at 
least 80% of the people who need it (Table 5.5). 
Seven additional countries, including two countries 
with generalized epidemics (Swaziland and Zambia) 
and five countries with concentrated epidemics 
(Argentina, Brazil, Dominican Republic, Mexico and 
Uruguay) have estimated coverage levels between 
70% and 79%.
Despite this exceptional progress, the estimated 
global coverage in low- and middle-income countries 
is still less than 50% (based on the 2010 WHO 
guidelines on initiating treatment (1) at a CD4 
count <350 cells per mm3). People living with HIV 
have extensive attrition between HIV testing and 
counselling and treatment, care and support services. 
Late presentation for treatment is still common in 
many settings, including in high-income countries (2), 
and a considerable proportion of people are lost to 
follow-up after initiating antiretroviral therapy (see 
Box 4.6). Moreover, the current rate of enrolment on 
antiretroviral therapy is insuffi cient to reach the goal, 
agreed at the United Nations High-Level Meeting on 
AIDS held in June 2011, of working towards providing 
antiretroviral therapy to 15 million people by 2015 (3). 
Between 2008 and 2010, about 1.3 million new people 
were enrolled and retained on antiretroviral therapy per 
year and, at this rate, less than 14 million people will 
be receiving antiretroviral therapy at the end of 2015.
This has several important operational and strategic 
implications. Under current initiation and attrition 
rates, expanding antiretroviral coverage to 15 million 
people by 2015 would entail further increasing the 
number of people initiating antiretroviral therapy every 
year. However, in the current economic and fi nancial 
context, doing so would be particularly challenging, 
and increasing the effi ciency and effectiveness of the 
global HIV response becomes ever more relevant and 
necessary.
One area in which considerable effi ciency gains can 
be realized is in improving retention throughout the 
cascade of interventions, from testing and counselling 
to initiating and maintaining lifelong antiretroviral 
therapy. Reducing the currently high proportion of 
people living with HIV who initiate antiretroviral 
therapy but are eventually lost to follow-up is key to 
achieving universal access by 2015 (Box 4.3).
Current service delivery models must be adapted to 
expand service coverage and to cope with large and 
growing cohorts of people living with HIV. In 15 years, 
most of the 34 million [31 600 000–35 200 000] 
people currently living with HIV, as well as many 
of those who will become HIV positive, will require 
antiretroviral therapy.
Although much has been accomplished, services are 
often too distant from the users of the services, and 
systems can be too difficult to navigate. Affected 
communities and people living with HIV are still 
insufficiently engaged and mobilized. The current 
model for HIV treatment must evolve if universal access 
is to be achieved and sustained.
This chapter is divided into two parts. The first 
introduces a set of fi ve key strategies – collectively 
known as the Treatment 2.0 initiative – to accelerate 
progress towards universal access, describes its main 
components and shows how focused action on each 
of its fi ve key areas can improve effi ciency, coverage 
and impact. The second part provides detailed data 
on progress made in 2010 in scaling up access to 
antiretroviral therapy and care interventions, including 
combined TB and HIV interventions, in low- and 
middle-income countries.
5.2 Catalysing the next phase of scaling up 
treatment: the Treatment 2.0 initiative
In June 2010, the UNAIDS Secretariat and WHO 
launched Treatment 2.0, an initiative designed to 
improve the effi ciency and impact of HIV care and 
treatment programmes in resource-limited countries 
and ultimately ensure their long-term sustainability. 
Treatment 2.0 builds on the programmatic and clinical 
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evidence and experience of the past 10 years of 
scaling up global antiretroviral therapy and seeks to 
simplify and optimize HIV diagnosis, treatment and 
care through a series of innovations and effi ciency 
gains in fi ve priority areas (Box 5.1) (4). Leveraging the 
positive impact that antiretroviral therapy has on HIV 
prevention is also an important cross-cutting aspect of 
Treatment 2.0 (sections 3.2.3.2 and 5.4.2).
5.2.1 Optimize drug regimens
Drug regimen optimization entails establishing optimal 
dosages of antiretroviral medicines, reducing the 
pill burden by developing fi xed-dose combinations 
and designing improved formulations for children. 
Potential areas for optimization include simplifying 
the production of active pharmaceutical ingredients, 
increasing drug bioavailability, reducing doses and 
using current and new drugs in novel combinations 
with the aim of improving the effi cacy, convenience, 
durability, stability, cost and tolerability of regimens.
Fully optimal regimens that meet the target product 
profi le may not be available commercially in the near 
future. However, current drugs and formulations can 
Box 5.2
Scaling up fi xed-dose combination antiretroviral 
drugs for children in Uganda
Fixed-dose combination antiretroviral drugs for children offer 
many advantages over syrups, especially greater convenience 
and lower costs. In Uganda, a carefully coordinated approach 
to training and procurement among all stakeholders, under 
the leadership of the Ministry of Health, streamlined the 
country’s fragmented supply chain and created the conditions 
for the rapid uptake of fi xed-dose combinations for children 
and a smooth transition away from syrups and single-drug 
formulations.
The Ministry of Health, in partnership with UNITAID and 
the Clinton Health Access Initiative, implemented a multi-
prong strategy that involved training-of-trainers with 
clinicians representing both government facilities and major 
implementing partners for children to educate them on the 
benefi ts of fi xed-dose combinations for dosing, adherence and 
ease of drug supply. Further, it provided additional support to 
the forecasting unit to help in procuring the new fi xed-dose 
combinations and developed a logistics plan to track existing 
stocks of syrups and single-drug formulations to ensure that 
drugs were not wasted during the transition period.
In response to these actions, the use of fixed-dose 
combinations among eligible children living with HIV rose 
from 17% in January 2009 to 82% in June 2010. Because of the 
nature of the country’s forecasting system – which based new 
orders on formulations consumed during the previous quarter 
– and the existence of remote, hard-to-reach facilities located 
well outside city centres, uptake of fi xed-dose combinations 
subsequently stabilized. To close this gap, in early 2011 the 
Ministry of Health undertook a detailed analysis and identifi ed 
each facility still using syrups, single-drug formulations and 
other suboptimal formulations and agreed with all partners to 
completely phase out the procurement of these formulations.
With the cessation of orders for 14 suboptimal formulations 
for children and the consumption of the remaining limited 
supply of suboptimal stock in early 2011, 100% of the 22 798 
eligible children living with HIV receiving treatment were 
accessing fi xed-dose combinations as of March 2011. This 
transition has saved Uganda more than US$ 2 million since 
2009. In addition, the use of fi xed-dose combinations has 
considerably eased the management of the country’s drug 
supplies and reduced the burden on all children receiving 
antiretroviral therapy.
Box 5.1
Treatment 2.0 priority areas and goals for 2020
1. Optimize drug regimens
Effective, affordable, one-pill, once-daily antiretroviral regimens 
with minimal toxicity or drug interactions and high barriers to 
resistance are available in low- and middle-income countries.
2. Provide access to point-of-care and other simplifi ed 
diagnostics and monitoring tools
A package of simple, affordable, reliable, quality-assured 
point-of-care and other simplifi ed diagnostics is available and 
accessible in low- and middle-income countries.
3. Reduce costs
High-quality HIV care and treatment programmes are available 
at the lowest possible cost with optimal effi ciency to everyone 
who needs them in low- and middle-income countries.
4. Adapt delivery systems
HIV care and treatment programmes are decentralized and 
appropriately integrated with other HIV and non-HIV health 
services, with increased community engagement in service 
delivery and improved retention in care.
5. Mobilize communities
People living with HIV and key populations at higher risk of HIV 
infection are fully involved in demanding, creating, planning, 
delivering and evaluating quality-assured, human rights–based 
HIV care and treatment programmes in all low- and middle-
income countries.
be improved in the interim by providing clear targets 
for innovator and generic drug manufacturers to invest 
in enhancing current antiretroviral therapy regimens. 
WHO and partners have taken steps to support this 
process. A list of short-term priority actions was 
published in July 2011 to guide the development of 
optimized fi rst- and second-line antiretroviral regimens 
for adults and adolescents and for children in the 
following three years (5).
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5.2.2 Provide access to point-of-care and other 
simplifi ed diagnostics and monitoring 
tools
A package of affordable diagnostics tests, performed 
at the point of service delivery, is a prerequisite to 
further expanding HIV testing, reducing late initiation 
of antiretroviral therapy and ensuring adequate 
monitoring of lifelong HIV therapy, in particular at 
the level of primary health care settings and within 
the community.
Recent fi eld-testing of point-of-care CD4 testing and 
of dried blood spots for quantifying viral load and 
early infant diagnosis has demonstrated promising 
results (6,7). Recent research has confirmed the 
accuracy of point-of-care tests for CD4 count, 
clinical chemistry and haemoglobin conducted in a 
primary health setting. The study showed that, for all 
three assays, haemoglobin, CD4 count and alanine 
aminotranferase, point-of-care and laboratory test 
results were comparable. Importantly, nurses were 
able to operate the point-of-care devices reliably and 
reproducibly, thus making such devices key tools to 
support decentralized service delivery (Box 5.3) (8). 
Likewise, GeneXpert, which uses a self-contained 
polymerase chain reaction (PCR) platform for rapid 
Box 5.3
Implementing point-of-care CD4 testing in 
Mozambique
Recent research has shown that the loss to follow-up after 
HIV infection is diagnosed but before antiretroviral therapy is 
initiated may be as high as 50% (10). A large part of this loss 
occurs between HIV diagnosis and CD4 staging, since primary 
health clinics, which often do not have on-site laboratory 
facilities, must rely on central laboratories, thus delaying the 
delivery of results and preventing immediate enrolment for 
those who need it.
In Mozambique, the Alere PIMA point-of-care CD4 device was 
implemented at selected primary health clinics in the southern 
Maputo and central Sofala provinces. The test was used for 
immunological staging of everyone diagnosed as HIV-positive 
and enrolling in HIV care. After the point-of-care CD4 testing 
was introduced, the total loss to follow-up of the enrolled 
people living with HIV declined by half, from 64% to 33%, 
and the proportion of people initiating antiretroviral therapy 
with CD4 staging increased from 11% to 18%. The time taken 
to complete CD4 staging was reduced from a median of 27.5 
days to just one day. Faster CD4 results also reduced the time 
between enrolment in care after HIV diagnosis and initiating 
antiretroviral therapy from a median of 48 to 20 days (11).
diagnosis of TB and resistance to rifampicin, can 
substantially facilitate the diagnosis and management 
of TB among people living with HIV. More than 
30 countries are currently in the process of rolling 
out the GeneXpert technology, and plans are currently 
being developed to leverage the GeneXpert platform 
to eventually perform HIV viral load testing as well (9).
WHO, UNAIDS and partners are currently working 
to determine the ideal package of point-of-care 
diagnostics and other simplified monitoring tools, 
identify the bottlenecks to developing and delivering 
new technologies and accelerate the critical path 
towards making them available.
5.2.3 Reduce costs
There are signifi cant opportunities for reducing costs 
and improving efficiency in HIV programmes. The 
new UNAIDS investment framework estimates that, 
if countries target HIV spending effi ciently, annual 
resource needs should peak at US$ 22 billion in 2015 
and subsequently decline, along with HIV transmission, 
morbidity and mortality rates (Box 1.1) (12).
Commodity costs can be reduced by pooling the 
procurement of drugs (Box 5.4) and diagnostics 
and through simplified manufacturing processes, 
potentially reducing the doses of drugs, using fi xed-
dose combinations and negotiating for additional 
reductions in the prices of active pharmaceutical 
ingredients and fi nished formulations. Low- and middle-
income countries can also take greater advantage of 
fl exibilities under the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) to 
ensure that life-saving health commodities are available 
to all in need (13).
Efficiency can be improved in service delivery as 
well, especially by shifting tasks, expanding the role 
of communities and developing feasible strategies 
to improve retention in care. In South Africa, the 
costs associated with providing antiretroviral therapy 
to people living with HIV managed by nurses at 
decentralized facilities were 11% lower than for doctor-
managed people in central hospitals – with lower rates 
of death and loss to follow-up among the people at 
the decentralized facilities (Box 5.4) (14). Such results 
suggest that this strategy can expand treatment 
capacity and conserve resources without compromising 
outcomes and the quality of care.
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Alternative models of service delivery, including 
home-based HIV treatment, can also cut the costs 
people incur to access services, which often function 
as an important barrier to successfully scaling up 
treatment in various settings (15,16). In Jinja, Uganda, 
by decentralizing services and bringing them closer 
to end-users, a home-based treatment programme 
was able to cut the costs incurred to access care by 
more than 50% in the fi rst year and by 66% thereafter, 
while achieving rates of viral suppression and mortality 
similar to those of a facility-based HIV care model (17). 
Given the lifelong nature of antiretroviral therapy, the 
impact of such a large difference in costs to access care 
may become even more crucial as people accumulate 
years of treatment.
5.2.4 Adapt delivery systems
Although the number of health facilities providing 
antiretroviral therapy has increased dramatically since 
antiretroviral therapy began to be rapidly scaled up in 
2003 (section 5.3.3), service coverage is still limited, as 
only 47% of the people currently eligible for treatment 
have access in low- and middle-income countries. 
Further expanding and maintaining antiretroviral 
therapy coverage in high-prevalence settings requires 
bringing services closer to end-users, especially to 
poorer, rural and other underserved areas, which often 
cater to significantly marginalized populations (20). 
Systems must also be integrated and streamlined 
so that users can more easily navigate the often-
complex chain of interventions from testing to care, 
treatment and support. Coverage of interventions to 
address comorbidity, including TB, viral hepatitis and 
other needs, such as family planning for women of 
childbearing age, also needs to dramatically increase. 
This requires establishing and improving links with 
other health programmes whenever appropriate.
This shift away from the current highly specialized 
service delivery model implies further decentralizing 
services to the primary health care level, with 
concomitant task-shifting to various types of health 
professionals, including nurses, health assistants and 
others, while expanding and strengthening links to 
community systems. This combination strategy has 
shown encouraging results in multiple settings, with 
treatment outcomes, including survival and retention 
rates, similar to or sometimes significantly better 
than those observed among people receiving doctor-
managed, hospital-based care (Boxes 5.5 and 5.6) 
(14,17,20–23). Recent evidence from country programmes 
has also shown that integrating HIV treatment into 
Box 5.4
Reducing treatment costs in South Africa by improving the procurement of antiretroviral medicines
As of December 2010, almost 1.4 million people were 
receiving antiretroviral therapy in South Africa. However, 
this represents only 55% of the people who were eligible 
to receive treatment. To expand coverage while controlling 
costs and ensuring the sustainability of its national 
antiretroviral therapy programme, in December 2010 the 
Government of South Africa introduced a new tender 
procedure for purchasing antiretroviral drugs. By combining 
strategies to increase competition among suppliers and 
improve price transparency, it substantially reduced the 
prices paid for the antiretroviral drugs used in the national 
HIV programme (Table 5.1).
To increase competition among drug manufacturers, efforts were made to ensure the registration of an adequate number of products with 
the country’s Medicines Control Council, and all potential suppliers – including international providers – were encouraged to participate. In 
addition, the government published a reference price list based on international transactional prices, and suppliers were required to provide 
a breakdown of their cost components so that price changes could be monitored through the life cycle of the tender.
The percentage decrease in the cost of individual antiretroviral drugs ranged from 4% to 81%. For instance, whereas in 2008 a month’s supply 
of a 300-mg tenofovir tablet cost the government R155 (about US$ 23), its price fell to less than R55 (US$ 8) in the new tender process. In 
total, antiretroviral drug costs fell by 53%, generating estimated savings of about R4.7 billion (US$ 685 million) during the next two years (18). 
This should allow the national antiretroviral therapy programme to treat twice as many treatment-eligible people as before. Because of delays 
in the registration process with the country’s Medicines Control Council, the new tender included few fi xed-dose combinations, but their 
participation is expected to increase in future rounds (19).
Antiretroviral drug
2008 price 
(in rands)
2010 price 
(in rands)
Price 
reduction (%)
Efavirenz (600-mg tablet) R107.07 R39.22 63%
Lamivudine (150-mg tablet) R29.77 R18.22 39%
Nevirapine (200-mg tablet) R31.53 R22.99 27%
Tenofovir (300-mg tablet) R155.60 R54.82 65%
Source: Government of South Africa, 2010.
Table 5.1 Price reductions of some key antiretroviral drugs used 
in South Africa after the new tender strategy
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other areas of health care, such as antenatal care, 
maternal, newborn and child health, TB or drug 
dependence services, is feasible and effective and 
leverages scarce resources (Boxes 5.7 and 5.8) (24–26).
Programme managers are using and developing various 
strategies to enhance service delivery by adapting it to 
local circumstances and people’s needs. One of these is 
“down-referral”, in which the management of clinically 
stable people is delegated from a higher-level facility 
to a lower-level facility within the health system, often 
geographically closer to the people’s residence. Down-
referral to primary health care facilities can increase 
the capacity of initiation sites to enrol new people who 
are eligible for antiretroviral therapy and provide care 
for people with complicated conditions who require 
referral. In addition, by reducing travel distances for 
people living with HIV, lowering costs to access care 
and facilitating community involvement, down-referral 
can improve adherence and retention rates (20,29,30). 
Nevertheless, introducing or strengthening systems 
to educate, support and track people not attending 
appointments at the primary health care level is 
essential to ensure that down-referral strategies are 
successfully implemented (31,32).
Although decentralizing service delivery to primary 
health care facilities is key to expanding coverage, it is 
often hindered by the severe lack of human resources in 
many resource-limited settings, especially in rural areas 
and slums. In such circumstances, task-shifting, which 
involves redistributing selected tasks from physicians 
to adequately trained nurses and from nurses to 
adequately trained lower-level health workers or lay 
providers, often at the district level, becomes necessary 
to expand services and increase coverage (22,33–35). 
Indeed, programmes that have successfully scaled up 
HIV treatment and care have often done so through a 
combination of these strategies to optimize outcomes 
(Box 5.6).
In addition to enhancing coverage and treatment 
outcomes, decentralizing HIV services may also 
positively affect the health-related quality of life and 
perceived quality of care among people receiving 
antiretroviral therapy (38,39). To accelerate progress, 
WHO has begun to develop normative and operational 
Box 5.5
Integrated service delivery
Various defi nitions of service integration exist and are used in the 
public health literature (27). WHO (28) has described integrated 
service delivery as “the organization and management of health 
services so that people get the care they need, when they need 
it, in ways that are user-friendly, achieve the desired results and 
provide value for money”. As such, integration may be seen 
as a continuum, rather than two extremes. Some services can 
be delivered and managed separately by different teams at 
different locations, but in other cases service delivery can be 
improved if structures and functions are more closely linked 
(such as links between HIV and maternal, newborn and child 
health services through strengthened referrals) or even fully 
integrated (such as one-stop shops) (28).
Box 5.6
Scaling up HIV treatment in Thyolo, Malawi through 
decentralization and task-shifting
In Thyolo, Malawi, the district hospital initiated the fi rst people 
on antiretroviral therapy in April 2003, mainly by clinical 
offi cers. Antiretroviral therapy care tasks were shifted from 
clinical offi cers to medical assistants in 2005, resulting in 
the possibility to decentralize the initiation of antiretroviral 
therapy to health centres. In 2007, the policy was further 
revised to allow nurses to start people on antiretroviral therapy. 
Another important adaptation was the shifting of HIV testing 
and counselling from nurses to trained health surveillance 
assistants, a type of community health worker initially created 
to be responsible for preventive activities and organizing 
disease outbreak responses. Decentralizing and shifting tasks 
related to accessing antiretroviral therapy in hospitals and 
health centres had considerable impact (Fig. 5.1) (36).
Improved coverage allowed people to start treatment earlier at 
a higher CD4 count, and the time to initiation decreased from 
nearly 100 days in 2003 to less than three weeks in 2009. Based 
on the 2006 guidelines on antiretroviral therapy for adults and 
adolescents, universal access (coverage of at least 80% of 
estimated needs) was achieved in 2007 in Thyolo (37).
Fig. 5.1 Access to antiretroviral therapy in Thyolo 
district (2004–2009)
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Source: Bemelmans et al. (21). 
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guidance for improving the delivery of services, 
including key issues of equity, community consultation, 
community-based service delivery, task-shifting 
and integrating HIV care into TB and antenatal and 
primary health care clinics in resource-limited settings. 
Decentralization processes must consider the need 
to strengthen drug procurement and supply chain 
management, improve referral and communication 
systems and implement targeted approaches to tackle 
HIV-related stigma and discrimination at the local level.
Box 5.7
Improving treatment outcomes and impact by decentralizing service delivery in South Africa
In Johannesburg, South Africa, down-
referring stable people receiving 
antiretroviral therapy from a doctor-
managed, hospital-based specialized 
antiretroviral therapy clinic to a 
nurse-managed primary health care 
facility has been found to be cost-
effective   (14). Compared with a 
matched sample of people eligible for 
down-referral but not down-referred, 
after 12 months, the combined rate 
of death and loss to follow-up among 
people managed at the primary care 
level was 1.7% versus 6.2% at the 
treatment-initiation site (Table 5.2).
The average cost per person-year for those in care and responding at 12 months was US$ 492 for down-referred people and US$ 551 for 
people remaining at the treatment-initiation site, a statistically signifi cant difference of 11%.
A comparative study among antiretroviral therapy–naive adults enrolled at primary, district and regional hospitals in four South African 
provinces (Western Cape, Eastern Cape, KwaZulu-Natal and Mpumalanga) also found superior treatment outcomes among people managed 
at the primary care level (40). Although the people at the primary care facilities had more advanced HIV illness when starting antiretroviral 
therapy, the differences in retention in care and mortality rates between the people attending different facilities were large and statistically 
signifi cant. Viral suppression at primary health care facilities was also similar to and often considerably better than the rates observed at 
higher-level facilities.
Fig. 5.2 Four provinces in South Africa, December 2004–December 2007. A) Cumulative probability of being in care. 
B) Cumulative probability of mortality.
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Outcome
Treatment-initiation 
group (n = 1623) Down-referral group
Relative risk
(95% CI)
Total 2136 (100%) 712 (100%)
In care and responding 1912 (89.5%) 680 (95.5%) 1.07 (1.04–1.09)
In care but not responding 91 (4.3%) 20 (2.8%) 0.66 (0.39–1.06)
No longer in care 133 (6.2%) 12 (1.7%) 0.27 (0.15–0.49)
Died 25 (1.2%) 0 (0%)
Lost to follow up 108 (5.1%) 12 (1.7%)
Source: Long et al. (14).
Table 5.2 HIV treatment outcomes of people 12 months after they become eligible 
for down-referral
Source: Fatti et al. (40).
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5.2.5 Mobilize communities
Fully engaged, mobilized communities are essential 
to catalyse the demand for antiretroviral therapy and 
other HIV services, to promote fair prices for medicines 
and other health commodities, to design, improve and 
deliver services – particularly for underserved key 
populations at higher risk for HIV infection – and to 
ensure that care and treatment programmes promote 
and protect human rights. As coverage expands, non 
governmental organizations and community-based 
service providers will require increased funding and 
technical support to mobilize communities and expand 
the range and quality of community-based services 
required to achieve universal access goals.
In Rwanda, which reached antiretroviral therapy 
coverage of 88% in 2010, the national HIV programme 
has engaged networks of people living with HIV in 
treatment and care for many years. Other countries 
are also strengthening links between communities 
and health systems to support programme design 
and implementation. In Viet Nam, peer educators, 
including people living with HIV and members of key 
populations at higher risk for HIV infection, are engaged 
to take active roles in HIV prevention, treatment, care 
and support (41,42) (see Box 5.12). Swaziland recently 
launched a national Treatment 2.0 campaign centred 
on a community approach to rapidly achieve universal 
access to testing and treatment.
UNAIDS and the International Treatment Preparedness 
Coalition have led a series of regional community 
consultations to mobilize support and identify 
community needs so that they can take on expanded 
roles in stimulating demand for HIV services, 
participating in national, regional and global planning 
bodies and in delivering and managing HIV testing, 
counselling, care and treatment programmes.
5.3 Antiretroviral therapy
5.3.1 Global, regional and country progress in 
access to antiretroviral therapy
At the end of 2010, 6 650 000 people were receiving 
antiretroviral therapy in low- and middle-income 
countries, an increase of 27% from December 2009 
(Table 5.3 and Fig. 5.3). In total, 1 675 000 people 
initiated treatment in 2010.1 
1 A total of 121 countries provided data on eligible adults and children who 
newly initiated antiretroviral therapy during 2010, representing 95% of 
all people on antiretroviral therapy in 2010.
Box 5.8
Mobilizing communities to enhance antiretroviral therapy delivery and retention in Mozambique
To address constraints on capacity and human resources and to improve retention over time, Médecins Sans Frontières and the authorities 
of Tete Province in Mozambique launched in 2008 an innovative out-of-clinic model of antiretroviral therapy distribution and adherence 
monitoring by community antiretroviral therapy groups.
In this model, people receiving antiretroviral therapy who were stable for six months were invited to form groups. Each month a group meeting 
was held in the community before each clinic visit and the designated group leader counted each member’s pills (adherence check). Any new 
signs or symptoms, adherence problems or intention to relocate to another area or interrupt treatment were discussed and documented for 
each person on the group-held group monitoring form. Individual appointment cards were given to the group representative so that they 
could be taken to the health facility to be completed. At the facility level, the group monitoring form was jointly reviewed and the group 
representative discussed each group member with a counsellor or clinician. Antiretroviral therapy and prophylactic drugs for each group 
member were then given to the group representative, to be eventually distributed upon return to the community.
Between February 2008 and May 2010, 1384 people living with HIV were enrolled in 291 groups, with an average of 4.75 people per group. 
The median follow-up time within a group was 12.9 months. Early outcomes have been satisfactory in terms of mortality and retention in 
care, showing the feasibility of out-of-clinic approaches. During this time, 83 (6%) people were transferred out, and of the 1301 people still 
in community groups, 1269 (97.5%) remained in care, 30 (2.3%) died, and 2 (0.2%) were lost to follow-up. Moreover, in terms of workload 
reduction, staff members at health facilities reported that community antiretroviral therapy groups resulted in an approximately four-fold 
reduction in consultations among the people receiving care based on a community antiretroviral therapy group.
Beyond considerably reducing the transport and opportunity costs associated with antiretroviral therapy uptake, the community antiretroviral 
therapy group model encourages people to take greater responsibility for their own health by engaging them as active partners in health care 
delivery and promotes the development and reinforcement of social networks and peer support, which have been identifi ed as important 
ways to support treatment adherence.
Source: Decroo et al. (43).
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Table 5.3 Number of adults and children (combined) receiving and eligible for antiretroviral therapy, and estimated percentage 
coverage in low- and middle-income countries by region, December 2009 to December 2010a,b,c
Geographical region
December 2010 December 2009
Number of 
people receiving 
antiretroviral 
therapy
Estimated number of people 
eligible for antiretroviral 
therapy [range]a
Antiretroviral 
therapy 
coverage 
[range]d
Number of 
people receiving 
antiretroviral 
therapy
Estimated number of people 
eligible for antiretroviral 
therapy [range]a
Antiretroviral 
therapy 
coverage 
[range]d
Sub-Saharan Africa 5 064 000 10 400 000[9 700 000–11 000 000]
49%
[46–52%] 3 911 000
9 600 000
[9 000 000–10 200 000]
41%
[38–43%]
Eastern and southern 
Africa 4 221 000
7 600 000
[7 100 000–8 000 000]
56%
[53–59%] 3 203 000
7 000 000
[6 600 000–7 400 000]
46%
[43–48%]
Western and central 
Africa 842 000
2 800 000
[2 600 000–3 100 000]
30%
[28–33%] 709 000
2 600 000
[2 400 000–2 800 000]
27%
[25–30%]
Latin America and the 
Caribbean 521 000
820 000
[710 000–920 000]
63%
[57–73%] 469 000
780 000
[670 000–870 000]
60%
[54–70%]
Latin America 461 000 720 000[620 000–810 000]
64%
[57–74%] 416 000
690 000
[590 000–780 000]
60%
[53–70%]
Caribbean 60 300 100 000[91 000–110 000]
60%
[53–67%] 52 400
93 000
[84 000–110 000]
56%
[50–63%]
East, South and South-
East Asia 922 000
2 300 000
[2 100 000–2 500 000]
39%
[36–44%] 748 000
2 300 000
[2 000 000–2 400 000]
33%
[31–37%]
Europe and Central Asia 129 000 570 000[500 000–650 000]
23%
[20–26%] 114 500
520 000
[450 000–600 000]
22%
[19–25%]
North Africa and the 
Middle East 14 900
150 000
[120 000–190 000]
10%
[8–13%] 12 400
140 000
[110 000–180 000]
9%
[7–12%]
Total 6 650 000 14 200 000[13 400 000–15 000 000]
47%
[44–50%] 5 255 000
13 300 000
[12 400 000–14 100 000] 39% [37–42%]
Note: some numbers do not add up because of rounding.
a See Box 5.9 for further information on the methods for estimating the need for and coverage of antiretroviral therapy in 2010.
b The 2009 fi gures may differ from those previously published because countries have submitted newly available data.
c All estimated needs have been developed according to 2010 WHO guidelines and criteria for initiating treatment.
d The coverage estimate is based on the unrounded estimated numbers of people receiving and needing antiretroviral therapy.
As the region most affected by the epidemic, sub-
Saharan Africa recorded the greatest increase in the 
absolute number of people receiving treatment in 2010, 
from 3 911 000 in December 2009 to about 5 064 000 
a year later – a 30% increase. In all other regions, 
growth rates were lower than 25% from 2009 to 2010.
Latin America is the region with the smallest percentage 
increase in the number of people receiving antiretroviral 
therapy in 2010 versus 2009: 11%. Although this may 
be partly explained by the fact that most large countries 
in the region have already achieved relatively high 
levels of coverage, it may also be related to diffi culty in 
scaling up HIV testing and counselling and effectively 
diagnosing HIV infection in early stages (44).
Twenty countries accounted for 84% of the people 
receiving antiretroviral therapy in low- and middle-
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income countries in 2010, most in sub-Saharan Africa 
(Table 5.4). Home to the greatest absolute number 
of people living with HIV, South Africa now provides 
antiretroviral therapy to a fifth of all the people 
receiving antiretroviral therapy in low- and middle-
income countries. Zimbabwe recorded the highest 
rise in enrolment, with an increase of almost 50% in 
the number of people receiving treatment between 
December 2009 and December 2010. Despite continued 
progress, however, treatment in many of these countries 
remained well below the estimated needs.
At least 745 000 people are receiving antiretroviral 
therapy in high-income countries, including about 
430 000 in Europe, 300 000 in North America and 
the Caribbean, and 16 700 in Asia, Oceania and the 
Middle East. At the end of 2010, the total number of 
people accessing antiretroviral therapy worldwide, 
including in high-income countries, was estimated to 
be about 7.4 million.
The Global Fund to Fight AIDS, Tuberculosis and Malaria 
and the United States President’s Emergency Plan 
for AIDS Relief remained the two major international 
sources of funding for antiretroviral therapy 
programmes in low- and middle-income countries in 
2010. As of December 2010, Global Fund–supported 
programmes provided treatment to 3.0 million 
people, and programmes funded by the United States 
President’s Emergency Plan for AIDS Relief supported 
antiretroviral therapy for 3.2 million people. About 
1.5 million people were receiving treatment through 
programmes jointly funded by the two initiatives; hence, 
together they supported programmes that provided 
treatment to about 4.7 million people at the end of 
2010 (45,46).
Coverage of antiretroviral therapy in low-and middle-
income countries continued to increase in 2010 
and reached 47% [44–50%] of the 14.2 million 
[13 400 000–15 000 000] people estimated to need 
it at the end of 2010 (Table 5.3).
As in previous years, Latin America and the Caribbean 
had the highest regional coverage level in 2010, at 63% 
[57–73%], because of the relatively longer duration 
Table 5.4 Twenty low- and middle-income countries with the highest number of people receiving antiretroviral therapy and 
their respective share of the total number of people receiving antiretroviral therapy in low- and middle-income countries as 
of December 2010
Country
Reported number 
of people receiving 
antiretroviral therapy, 
2009
Reported number 
of people receiving 
antiretroviral therapy, 
2010
Estimated 
antiretroviral therapy 
coverage, 
2010
Percentage increase 
between 2009 and 
2010
Percentage of total 
people receiving 
antiretroviral therapy 
in low- and middle-
income countries, 
2010
South Africa 971 556 1 389 865 55% [52–58%] 43% 21%
Kenya 336 980 432 621 61% [56–66%] 28% 7%
India 330 300 424 802 ... [30–38%]a 29% 6%
Nigeria 302 973 359 181 26% [24–28%] 19% 5%
Zambia 283 863 344 407 72% [67–77%] 21% 5%
Zimbabwe 218 589 326 241 59% [54–62%] 49% 5%
United Republic of Tanzania 199 413 258 069 42% [39–46%] 29% 4%
Malawi 198 846 250 987 ... [49–57%]a 26% 4%
Uganda 200 413 248 222 47% [43–51%] 24% 4%
Thailand 216 118 236 808 67% [55–85%] 10% 4%
Ethiopia 176 632 222 723 ...a 26% 3%
Mozambique 170 198 218 991 40% [36–46%] 29% 3%
Brazil 185 982 201 279 70% [65–75%] 8% 3%
Botswana 145 190 161 219 93% [89–>95%] 11% 2%
Rwanda 76 726 91 984 88% [76–>95%] 20% 1%
Cameroon 76 228 89 455 38% [34–43%] 17% 1%
Namibia 70 498 88 717 90% [78–>95%] 26% 1%
China 65 481 86 122 32% [26–37%] 32% 1%
Russian Federation 75 900 79 430 ... [21–29%]a 5% 1%
Lesotho 61 736 76 487 57% [53–60%] 24% 1%
a Estimates of the number of people needing antiretroviral therapy are currently being revised and will be adjusted, as appropriate, based on ongoing data collection and analysis. Therefore, 
coverage cannot be presented or only as a range.
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of antiretroviral therapy programmes in some of the 
region’s largest countries.
In sub-Saharan Africa, antiretroviral therapy coverage 
reached 49% [46–52%] in 2010. The region accounted 
for 73% of the estimated treatment need in low- 
and middle-income countries and 76% of the total 
number of people receiving treatment at the end of 
2010. However, important intraregional differences 
in coverage were observed: whereas 56% [53–59%] 
of the people who needed antiretroviral therapy in 
eastern and southern Africa had access, in western 
and central Africa antiretroviral therapy coverage was 
only 30% [28–33%].
Coverage in 2010 improved across all other regions as 
well, but was lowest in East, South and South-East Asia, 
with 39% [36–44%], Europe and Central Asia, with 
23% [20–26%] and North Africa and the Middle East, 
where only 10% [8–13%] of the regional antiretroviral 
therapy needs were met. In these regions, many 
countries face HIV epidemics that are concentrated 
among key populations at higher risk for HIV infection, 
who often have relatively greater diffi culty in accessing 
treatment and care services (section 6.4).
At the end of 2010, ten low- and middle-income 
countries, including three countries with generalized 
epidemics (Botswana, Namibia and Rwanda), four 
countries with concentrated epidemics (Cambodia, 
Chile, Guyana and Nicaragua) and three countries 
with low level epidemics (Croatia, Cuba and Slovakia), 
had already achieved universal access to antiretroviral 
therapy, commonly understood as providing 
antiretroviral therapy to at least 80% of the people who 
need it (Table 5.6). Seven countries (Argentina, Brazil, 
Dominican Republic, Mexico, Swaziland, Uruguay and 
Zambia) had near-universal coverage levels, between 
70% and 79%, and 31 additional countries had coverage 
rates higher than 50%.
Box 5.9
Methods for estimating the need for and coverage of antiretroviral therapy among adults
Antiretroviral therapy coverage measures the proportion of people receiving it, as reported by national programmes, in relation to the 
estimated number of people who need it. National HIV prevalence curves are used as a basis for calculating the numbers of people eligible 
for antiretroviral therapy. Several factors infl uence the number of adults eligible, including the CD4 count threshold at which antiretroviral 
therapy is deemed necessary. In 2010, WHO recommended that the threshold be changed from 200 cells per mm3 to 350 cells per mm3 (1) 
– substantially increasing the number of people eligible for antiretroviral therapy in low- and middle-income countries (47).
To capture these changes, Spectrum now tracks the number of adults living with HIV according to their CD4 count. This enables more precise 
estimates of the numbers of adults who are eligible for antiretroviral therapy and of the number of people dying from AIDS-related causes. 
With available new data on the distribution of the people living with HIV by CD4 count and annual declines in CD4 counts, it appears that 
progression from the time a person acquires HIV infection until he or she is eligible for treatment is slower than previously estimated. As a 
result, the estimates of the numbers adults eligible for antiretroviral therapy published in this report are lower than the estimates published 
in the 2010 universal access report (47).
Finally, the latest demographic dataset from the United Nations Population Division (48), incorporated in the 2011 model, has population 
estimates that are about 2% lower than previous estimates. Collectively, these changes have resulted in lower estimates for the number of 
adults eligible for antiretroviral therapy in 2009: 13.4 million [12 600 000–13 800 000] according to the 2009 model, versus 11.7 million 
[11 000 000–12 200 000] in the 2011 model.
Meanwhile, the estimated number of children who need antiretroviral therapy in 2009 was revised upwards, from 1 270 000 [830 000–
1 700 000] to 1 670 000 [1 500 000–1 800 000] (see Box 7.19). Hence, the coverage rates published here should not be compared with 
coverage fi gures published in previous editions of this universal access report.
In 2010, according to the revised model, an estimated 2.02 million [1 800 000–2 300 000] children needed antiretroviral therapy.
2009 model 2011 model
2009 2009 2010
Estimated number of adults who need antiretroviral therapy
13 400 000 
[12 600 000–13 800 000]
11 700 000 
[11 000 000–12 200 000]
12 300 000 
[11 600 000–12 800 000]
Estimated number of children who need antiretroviral therapy
1 270 000 
[830 000–1 700 000]
1 670 000 
[1 500 000–1 800 000]
2 020 000 
[1 800 000–2 300 000]
Table 5.5 Estimated number of adults and children who need antiretroviral therapy in 2009 and 2010, per model year
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Box 5.10
Scaling up services in Rwanda
Rwanda has a generalized HIV epidemic, with an estimated prevalence of HIV infection of 3% in the general population and 4% among 
pregnant women (49). With a gross national income per person of US$ 520 in 2010, it is considered a low-income country according to the 
World Bank (50). Despite the political and economic upheaval that destroyed most of the country’s health infrastructure in the 1990s, Rwanda 
has made great strides in expanding access to the continuum of HIV interventions, including testing and counselling, treating adults and 
children and preventing the mother-to-child transmission of HIV.
The national response, coordinated at the central level by the National AIDS Control Commission, is characterized by a multisectoral, 
multidisciplinary, decentralized and community-based approach. Each of the country’s 30 districts has a District AIDS Control Committee, 
and all implementing agencies have a clear division of labour to ensure accountability and avoid duplication of work. People living with HIV 
are also involved in several HIV-related activities, especially through peer educator programmes in which people living with HIV help to 
sensitize their family members for HIV testing and adherence to treatment. Peer educators also serve as liaisons between health centres and 
antiretroviral therapy sites and people living with HIV, thus facilitating the follow-up of those defaulting treatment. Associations of people 
living with HIV have also received fi nancial support from the government and development partners to start income-generating activities.
Considerable progress has been made in increasing the uptake of HIV testing and counselling among the general population. By 2010, 434 
sites offered voluntary counselling and testing versus only 44 in 2003. The number of HIV tests performed has also steadily increased 
through information, education and behavioural change campaigns, reaching 1 863 000 in 2010, a four-fold increase from the 472 000 
recorded in 2006 (49).
Coverage of antiretroviral therapy has signifi cantly increased as well. The number of people receiving antiretroviral therapy was only 870 
in 2002, grew to 34 000 in 2006 and reached 92 000 in 2010. Between 2008 and 2010, at least 1000 new adults started antiretroviral 
therapy every month. As of December 2010, 96% [85–>95%] of adults and 45% [36–53%] of children eligible for antiretroviral therapy 
were receiving it.1 The percentage of health facilities offering antiretroviral therapy reached 64% (328 of 512) in 2010, up from 38% (133 of 
354) in 2006. According to the National Strategic Plan 2009–2012, all health facilities should be able to offer antiretroviral therapy services 
by 2012, and 90% of eligible adults and children should have access to antiretroviral therapy.
Considerable investment has been made in scaling up services for preventing the mother-to-child transmission of HIV. The national programme 
was established in 2001, and its services have been gradually integrated into existing maternal and child services. In 2010, 68% of all 
expected pregnant women were tested for HIV. Sixty-seven per cent of the estimated number of pregnant women living with HIV received 
antiretroviral drugs to prevent mother-to-child transmission in 2010.2 In November 2010, Rwanda recommended that all pregnant women 
living with HIV receive triple-antiretroviral prophylaxis starting as soon as possible during pregnancy based on standard eligibility criteria 
and continuing during the entire breastfeeding period up to 18 months of age. The introduction and scale up of early infant diagnosis of HIV 
using PCR is effective in all sites with services for preventing mother-to-child transmission, and links between preventing mother-to-child 
transmission, antiretroviral therapy and family planning services are being strengthened. The programme aims to reduce vertical transmission 
rates below 2% by 2012.
1 These coverage estimates were developed using standardized Spectrum estimates (see Box 5.9 for estimates for adults and Box 7.19 for estimates for children).
2 In 2010, 10% of pregnant women received single-dose nevirapine.
Antiretroviral therapy coverage
50–69% 
(31 countries)
70–79% 
(7 countries)
80% or higher 
(10 countries)
Belarus
Belize
Benin
Costa Rica
Ecuador
El Salvador
Ethiopia
Gabon
Georgia
Guatemala
Guinea
Haiti
Honduras
Jamaica
Kenya
Lao People’s Democratic Republic
Lesotho
Malawi
Papua New Guinea
Paraguay
Peru
Philippines
Romania
Senegal
South Africa
Thailand
Togo
Turkey
Venezuela (Bolivarian Republic of)
Viet Nam
Zimbabwe
Argentina
Brazil
Dominican Republic
Mexico
Swaziland
Uruguay
Zambia
Botswana
Cambodia
Chile
Croatiab
Cuba
Guyana
Namibia
Nicaragua
Rwanda
Slovakiab
a Countries with less than 100 people who need antiretroviral therapy are not included in the table.
b Countries with an estimated antiretroviral therapy need of less than 1000 people. The data for these countries should be interpreted cautiously because of how ranges of uncertainty affect 
the estimates.
Table 5.6 Low- and middle-income countries with estimated antiretroviral therapy coverage levels of 50–69%, 70–79% and 
80% or higher as of December 2010a 
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Box 5.11
Achieving universal access to antiretroviral therapy in Cambodia
Cambodia has an estimated population of 13.8 million (2010), and epidemiological data show that the country’s HIV epidemic is concentrated 
and has particularly affected sex workers, people who inject drugs and men who have sex with men. According to the most recent estimates, 
about 63 000 people were living with HIV in the country in 2009.
Despite a fragile health care system debilitated by decades of civil war and despite being a low-income country (annual gross national income 
per person of US$ 710 (51)), Cambodia has been able to implement a comprehensive and effective national HIV response. The prevalence of 
HIV infection has declined from an estimated 2.0% among people 15–49 years old in 1998 to a projected 0.7% in 2010, and it has been able 
to achieve universal access targets for antiretroviral therapy, with close to 43 000 people receiving antiretroviral therapy, or 92% of adults 
and children who need it (Table 5.7). Cambodia has achieved this by leveraging high-level political support to develop an evidence-informed, 
integrated and decentralized national response.
Antiretroviral therapy was introduced on a small scale in 2001, but rapid scale-up was hampered by the uncoordinated efforts of multiple 
actors, limited capacity and poor infrastructure of local health facilities and a high level of stigma and discrimination against people living with 
HIV. To address these constraints and create a comprehensive and sustainable national antiretroviral therapy programme, the National Center 
for HIV/AIDS, Dermatology and STD (NCHADS) led the establishment of the Continuum of Care Framework in 2003, based on district-level 
services that emphasized teamwork, community links, including through home-based care, and a public health approach to service delivery.
HIV health services were progressively expanded in a coordinated way to cover most of the country’s operational districts. In 2008, NCHADS 
and the National Maternal and Child Health Center introduced a collaborative strategy called the “Linked Response”, which provided a 
comprehensive approach to preventing mother-to-child transmission, including HIV testing and counselling at the health centre level. 
Similarly, NCHADS and the National Center for Tuberculosis and Leprosy Control accelerated TB and HIV collaborative activities, including HIV 
testing and counselling for people with TB in health centers and the three I’s for HIV and TB (section 5.4.2) at the operational district level.
National policies have also been put in place to provide a continuum of prevention to care and treatment services for key populations at 
higher risk of HIV infection, including sex workers, men who have sex with men and people who inject drugs. Access to health services has 
been improved by enhancing links and referral mechanisms between community outreach programmes and HIV testing and counselling, HIV 
care and treatment and sexual and reproductive health services.
Attention is also given to measuring and improving the quality of the HIV care and treatment programme. Coordination meetings are held 
regularly, mentoring is provided to district and health centre staff and national and regional network meetings for clinicians and counsellors 
facilitate the exchange of experiences and best practices. A strategy for tackling HIV drug resistance has been adopted, including monitoring 
for early-warning indicators, and a strategy for continuous quality improvement is currently being rolled out. Each operational district is 
supported in collecting indicators that measure the quality of management of health service users across the continuum of care and to 
implement appropriate corrective measures.
Table 5.7 Selected national indicators of HIV care and treatment, Cambodia, 2010 
Number of people receiving antiretroviral therapy 43 000 (39 000 adults and 4 000 children)
% of people on antiretroviral therapy among those who need it 92% [68%–>95%]
Adults alive and receiving antiretroviral therapy at 12, 24 and 60 months 86% (12 months), 84% (24 months) and 78% (60 months)
Median CD4 county at pre-antiretroviral therapy enrolment 197 per mm3
% newly registered in pre-antiretroviral therapy care screened for TB 64%
% of pregnant women who were tested for HIV and received the test result 57%
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5.3.2 Access to antiretroviral therapy among 
women and children
A total of 136 low- and middle-income countries 
reported data disaggregated for adults and children. 
About 456 000 children 0–14 years old were receiving 
antiretroviral therapy at the end of 2010, up from 
354 600 at the end of 2010, a 29% increase from 2009 
(Chapter 7 provides an in-depth analysis of treatment 
of and policy on children living with HIV).
Overall antiretroviral therapy coverage among children 
was lower than among adults in low- and middle-
income countries. Children represented 7% of the 
people receiving antiretroviral therapy and 14% of the 
people who needed it. Of the 2 020 000 [1 800 000–
2 300 000] children estimated to need antiretroviral 
therapy, only 23% [20–25%] had access to treatment 
versus 51% of adults [48–54%].1 One of the main 
reasons is that sub-Saharan Africa accounts for 91% of 
the children who need treatment but has an estimated 
coverage rate of about 21% (Table 
5.8). Indeed, only in Europe and 
1 The coverage rates observed in 2010 decreased compared with 2009 
because the estimated number of children who need antiretroviral 
therapy increased (see box 7.19).
Central Asia is the coverage among children higher 
than among adults, a fact that may be partly explained 
by the scale up of services for preventing mother-to-
child HIV transmission in the region and robust links 
with treatment and care services.
Data disaggregated by sex on the number of people 
receiving and needing antiretroviral therapy are 
available from 109 low- and middle-income countries, 
representing 95% of the 6.65 million people receiving 
treatment in 2010.2 Women represented 58% of the 
people receiving antiretroviral therapy and 51% of those 
who need it. Overall, antiretroviral therapy coverage was 
higher among women, estimated at 53%, versus 40% 
among men. However, this pattern does not apply to all 
regions (Table 5.9). Women are especially advantaged 
compared with men in East, South and South-East Asia 
and in sub-Saharan Africa. In contrast, in Latin America 
and Caribbean, coverage of antiretroviral therapy is 
higher among men than women.
2 Some countries provided disaggregated data only for a proportion of the 
people receiving antiretroviral therapy in the country. For the countries 
with incomplete data sets, treatment data by sex were obtained by 
applying male–female ratios from existing data to the total numbers 
of people receiving treatment. Similarly, for seven countries that could 
supply data by sex in 2008 or 2009 but not in 2010, the available male–
female ratios from 2008 or 2009 were applied to the 2010 data.
Table 5.8 Number of children 0–14 years old receiving and estimated to need antiretroviral therapy and percentage coverage 
among children and adults in low- and middle-income countries, by region, December 2010a
Geographical region
Number of children receiving 
antiretroviral therapy, 
December 2010
Estimated number of children 
needing antiretroviral 
therapy, 2010 [range]
Antiretroviral therapy 
coverage among children, 
December 2010 [range]b
Antiretroviral therapy 
coverage among adults, 
December 2010 [range]b
Sub-Saharan Africa 387 500 1 840 000 [1 600 000–2 100 000]
21%
[19–24%]
55%
[52–58%]
Eastern and southern 
Africa 337 200
1 290 000 
[1 100 000–1 400 000]
26%
[23–29%]
62%
[59–65%]
Western and central 
Africa 50 200
550 000 
[480 000–630 000]
9%
[8–11%]
35%
[33–38%]
Latin America and the 
Caribbean 16 300
41 400 
[34 000–50 000]
39%
[32–48%]
64%
[58–74%]
Latin America 13 600 30 600 [25 000–38 000]
44%
[36–55%]
65%
[58–75%]
Caribbean 2 700 10 800 [8 700–13 000]
25%
[21–31%]
64%
[57–70%]
East, South and South-
East Asia 43 800
113 000 
[84 000–140 000]
39%
[30–52%]
39%
[37–43%]
Europe and Central Asia 7 500 11 400 [10 000–13 000]
65%
[55–71%]
22%
[19–25%]
North Africa and the 
Middle East 840
18 500 
[12 000–25 000]
5%
[3–7%]
10%
[8–14%]
All low- and middle-
income countries 456 000
2 020 000 
[1 800 000–2 300 000]
23%
[20–25%]
51%
[48–54%]
Note: some numbers do not add up because of rounding.
a For an explanation of the methods used, see the explanatory notes for Annex 4 and 5, and Box 5.9.
b The coverage estimate is based on the unrounded numbers of people receiving and needing antiretroviral therapy.
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5.3.3. Availability of antiretroviral therapy
The number and distribution of health facilities 
providing antiretroviral therapy are important indicators 
of the scaling up of and access to treatment services. 
In 2010, 128 low- and middle-income countries 
reported a total of 22 369 health facilities providing 
antiretroviral therapy. Of these facilities, 78% were in 
the public sector and 8% in the private sector (14% 
were unspecifi ed).
A total of 109 countries provided data for both 2009 
and 2010. In these countries, the reported number 
of health facilities providing antiretroviral therapy 
increased from 18 386 to 21 641, or an 18% increase 
in one year. It increased by 22% in sub-Saharan Africa 
(from 8462 to 10 359 in 39 countries); 10% in Latin 
America and the Caribbean (from 2759 to 3048 in 
24 countries); 12% in East, South and South-East Asia 
(from 6015 to 6741 in 21 countries) and 33% in Europe 
and Central Asia (from 1033 to 1369 in 17 countries). 
In North Africa and the Middle East, the number of 
facilities providing antiretroviral therapy increased from 
117 in 2009 to 124 in 2010 across 8 reporting countries, 
an increase of 6%.
The average number of people receiving antiretroviral 
therapy per health facility in the subset of 109 countries 
Table 5.9 Comparison of estimated antiretroviral therapy coverage levels among men and women, in low- and middle-income 
countries by region, December 2010
Geographical region
(number of countries 
reporting/total countries 
in region)
Men Women
Coveragea
Number receiving 
antiretroviral 
therapy
Estimated number 
who need it Coveragea
Number receiving 
antiretroviral 
therapy
Estimated number 
who need it
Sub-Saharan Africa 
(44/46) 41% 1 751 900 4 300 000 55% 3 060 100 5 600 000
Eastern and southern 
Africa (20/22) 48% 1 467 400 3 100 000 62% 2 503 300 4 000 000
Western and central 
Africa (24/24) 23%  284 500 1 200 000 35%  556 800 1 600 000
Latin America and the 
Caribbean (20/29) 64%  322 900  500 000 62%  177 600  280 000
Latin America (16/20) 64%  292 800 455 000 64%  147 800  230 000
Caribbean (4/9) 64%  30 100  47 000 56%  29 800  53 000
East, South and South-
East Asia (20/34) 34%  521 800 1 600 000 48%  399 700  830 000
Europe and Central Asia 
(18/26) 20%  27 100  140 000 20%  20 600  100 000
North Africa and the 
Middle East (7/14) 9%  7 600  86 000 9%  5 600 61 000
Total (109/149) 40% 2 631 300 6 600 000 53% 3 663 500 6 900 000
a The coverage estimate is based on the unrounded numbers of people receiving and needing antiretroviral therapy.
Table 5.10 Number of facilities providing antiretroviral therapy in 2009 and 2010, countries reporting in both years
Geographical region
Number of countries 
reporting in both 2009 
and 2010
Number of 
antiretroviral therapy 
facilities in 2010
Number of 
antiretroviral therapy 
facilities in 2009
Increase from 
2009 to 2010 (%)
Average number of 
people receiving 
antiretroviral therapy 
per health facility
Sub-Saharan Africa 39 10 359 8 462 22% 484
Latin America and the 
Caribbean 24 3 048 2 759 10% 153
East, South and South-
East Asia 20 6 741 6 015 12% 132
Europe and Central Asia 17 1 369 1 033 33% 34
North Africa and the 
Middle East 8  124  117 6% 66
Total 109 21 641 18 386 18% 297
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reporting data in both years increased from 277 in 2009 
to 297 in 2010. The average fi gure in sub-Saharan Africa 
is substantially higher than in the rest of the world, with 
484 people receiving antiretroviral therapy per health 
facility versus 457 in 2009. Although sites cannot be 
directly compared across regions because of their 
different structures, it is necessary to ensure facilities 
are adequately distributed, staffed and equipped to 
cope with growing cohorts, as the workload of health 
care providers can signifi cantly infl uence the quality of 
service delivery.
5.3.4 Outcomes at the programme level: 
retention on antiretroviral therapy
Adequately measuring retention on antiretroviral 
therapy (the proportion of people started on lifelong 
antiretroviral therapy who survive and continue it 
over time) is paramount to monitor the quality of 
service delivery and ensure the long-term success of 
antiretroviral therapy programmes. However, gaining a 
broader perspective of the effectiveness of national care 
programmes also requires reinforcing the monitoring of 
the people living with HIV throughout the continuum 
of care, especially those enrolled in care but not yet 
receiving antiretroviral therapy.
Although limited country data are available on retention 
rates throughout the cascade of interventions, a 
recent analysis has shown very low rates of retention 
between testing and treatment initiation for people 
living with HIV (Box 4.3). In Viet Nam, the comparison 
of cumulative cases reported for HIV case-reporting 
and enrolment in HIV care and antiretroviral therapy 
identifi ed major gaps between services, leading to the 
implementation of changes in programme management 
(Box 5.12).
In December 2010, 92 low- and middle-income 
countries provided data on retention at 12 months, a 
decrease from the 115 that reported retention data as 
Box 5.12
Strengthening the continuum of prevention and care to promote retention in HIV services in Viet Nam
Viet Nam has made considerable progress in rapidly scaling up access to prevention, treatment and care services. As of December 2010, 
49 492 people were receiving antiretroviral therapy, an 18-fold increase since December 2005. Nevertheless, an analysis of HIV case reporting 
and care and treatment data showed that many people who tested HIV-positive were not enrolled in care and did not initiate antiretroviral 
therapy (Fig. 5.4). To address these gaps, the Viet Nam Authority of HIV/AIDS Control has been working to strengthen the continuum of 
services across diagnosis, care and treatment retention and bolster links between HIV care sites and other health and community services.
Greater community involvement has been actively 
encouraged to expand coverage of HIV prevention and to 
promote early HIV testing. In many sites, people living with 
HIV also work as peers assisting other people in navigating 
the various steps from HIV diagnosis to enrolment in 
HIV care outpatient clinics. With the development of 
national guidelines on home-based care in 2010, community 
teams have been trained to support retention in care and 
adherence to antiretroviral therapy.
In some districts, results can already be observed. Tu 
Liem and Dong Anh District Health Centers (Hanoi) have 
promoted collaborative activities with peer educators and 
integrated services (e.g. with TB services, methadone 
maintenance therapy), and the rate of retention on 
antiretroviral therapy at 12 months now exceeds 90%. 
In Tan Chau District Health Center (An Giang), where 
substantial investment has been made to strengthen the 
follow-up of people living with HIV through home-based 
care teams, the antiretroviral therapy retention rate 
improved from 66% to 85% between 2009 and 2010, and 
the percentage keeping appointments increased from 76% 
to 86% in the same period.
Fig. 5.4 Cascade of HIV diagnosis, care and treatment in Viet Nam 
in 2010
250 000
200 000
150 000
100 000
50 000
Sources: The number of people living with HIV was estimated by using EPP and Spectrum. The 
number of people diagnosed and reported as living with HIV is from the national case reporting 
system. The data on people in care and receiving antiretroviral therapy are from national routine 
reporting systems of the Viet Nam Authority of HIV/AIDS Control, Ministry of Health. Case-reporting 
data may include instances of double-counting.
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of December 2009. However, the number of people 
assessed at each 12-month interval slightly increased. 
The number of countries reporting data on retention at 
24 months also increased from 2009 to 2010, as did 
the number of people assessed (Table 5.11).
The data reported for each time-point were aggregated 
to produce regional and global estimates. Data on the 
proportion of people retained on antiretroviral therapy 
over time continue to show that most attrition occurs 
within the fi rst year. Attrition continues with longer 
follow-up but not at the level observed during the 
fi rst year of treatment. In 2010, the average global 
retention rate at 12 months was 81% (interquartile 
range: 75–90%), dropping to 75% (interquartile range: 
69–88%) at 24 months and to 67% (interquartile range: 
59–83%) at 60 months. Importantly, the reported 
retention trends in 2010 were in the range of those 
observed in 2008 (52) and 2009 (53). Nevertheless, 
the reported retention rates varied importantly across 
2008 2009 2010
Number of 
countries reporting
Number of people 
assessed
Number of 
countries reporting
Number of people 
assessed
Number of 
countries reporting
Number of people 
assessed
Retention at 12 months 61 297 408 115 519 890 92 630 535
Retention at 24 months 42 132 427 66 284 017 73 297 239
Retention at 60 months NA NA NA NA 46 92 477
NA: not asked.
Table 5.11 Number of countries reporting on retention on antiretroviral therapy at 12, 24 and 60 months among 149 low- 
and middle- income countries, 2008, 2009 and 2010
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The selected countries represent 91% of the people for whom retention data at 60 months is available. The results may not be linear over time, since outcomes at 12, 24 and 60 months are 
measured based on different cohorts according to the year antiretroviral therapy is initiated.
Box 5.13
Monitoring the continuum of care and improving 
data quality
With the scaling up of antiretroviral therapy, considerable 
investment has been made to improve the monitoring of cohorts 
of people initiating antiretroviral therapy, including retention 
rates (Table 5.11). However, reported programme data are still 
incomplete, and associated outcomes may be subject to biases 
(52,54) Importantly, few countries are able to produce consistent 
data on the full national cohort of people initiating antiretroviral 
therapy and for the most recent calendar period. For 2010, only 
Ethiopia and Malawi, among countries with a high prevalence 
of HIV, were able to produce estimates of antiretroviral therapy 
retention at 12 months based on data for over 90% of the people 
who started during 2009. Thus, the reported data may not be 
representative of national programmes.
countries, especially at fi ve years (Fig. 5.5). Although 
the actual underlying attrition may explain some of 
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this variation, some may be related to defi ciencies in 
information and systems tracking follow-up (Box 5.13).
A total of 50 countries reported disaggregated 
retention data at 12 months by sex, and 47 countries 
provided similarly disaggregated data by age (children 
0–14 years old and people 15 years and older). Globally, 
retention at 12 months is similar among women and 
men, averaging 84% in both cases in the 50 reporting 
countries. The average retention rate at 12 months is 
80% among children and 82% among adolescents and 
adults. The retention rate among children improved 
compared with the data reported in 2009, when it 
was 73%.
Few countries are able to provide detailed information 
on the reasons for discontinuing antiretroviral therapy 
(such as death, stopping treatment or loss to follow-up). 
Only 41 (45% of those reporting) and 32 (70% of those 
reporting) countries, respectively, provided detailed 
data on retention at 12 and 60 months. Countries that 
are able to report at 60 months may have better cohort 
monitoring and outcome tracking systems. For both 
periods, loss to follow-up accounted for more than half 
of the people discontinuing treatment. Nevertheless, 
the people lost to follow-up may be in a variety of 
different circumstances; some have died and others 
have been transferred to another site to continue 
treatment but have not been properly registered and 
tracked. The causes of such high rates of loss to follow-
up therefore cannot be precisely ascertained.
High retention rates are essential to maximize the long-
term health benefi ts of treatment and to ensure the 
sustainability of programmes, and greater investment 
is needed to continually support them. Timely 
presentation for initiating treatment is fundamental to 
reduce the number of people dying soon after starting 
antiretroviral therapy (55). Programmatic factors such 
as site capacity and increasing workload because 
of growing loads of people receiving treatment may 
become more prominent in time if systems are not 
adapted to cope with increased demand. Indeed, recent 
studies from South Africa have found higher risks of 
loss to follow-up among people initiating antiretroviral 
therapy in more recent calendar years compared with 
previous years (56,57), a fi nding in part related to the 
considerable strain on health services because of rapid 
scale-up.
Effective and simplifi ed cohort monitoring systems 
are critical to support the adequate scale-up of other 
essential interventions as well, such as prevention 
of and care for opportunistic infections (including 
TB), nutritional support, pharmacovigilance, drug 
resistance and adherence. Given the growing workload 
associated with gathering and processing information 
on more indicators for a greater number of people, 
novel approaches for generating data may need to be 
developed to protect the robustness and sustainability 
of national health information systems (58).
5.3.5 Preventing and assessing HIV drug 
resistance
As access to antiretroviral therapy expands, HIV 
drug resistance inevitably emerges because of HIV’s 
high mutation rate, viral recombination and the need 
for sustained, lifelong treatment. To improve the 
surveillance of HIV drug resistance with standardized 
approaches, WHO, in collaboration with the WHO 
HIVResNet, the Global HIV Drug Resistance Network, 
has developed a global strategy for preventing and 
assessing HIV drug resistance based on three key 
elements: (1) routine monitoring of early-warning 
indicators of HIV drug resistance, (2) surveys to 
assess acquired HIV drug resistance and associated 
programmatic factors among populations receiving 
antiretroviral therapy and (3) surveys to classify 
transmitted HIV drug resistance in populations recently 
infected with HIV (59). As of mid-2011, more than 60 
countries had implemented one or more elements 
of the strategy for preventing and assessing HIV 
drug resistance (60). To facilitate the implementation 
of country plans, WHO supports the accreditation 
of national, regional and specialized laboratories 
for testing HIV drug resistance. As of mid-2011, 27 
testing laboratories for HIV drug resistance had been 
accredited.
5.3.5.1 HIV drug resistance – early-warning 
indicators
Research shows that various programme and site 
factors are closely associated with the emergence of 
HIV drug resistance, and proper monitoring can serve 
as early-warning indicators to support appropriate 
management of programmes. WHO has identified 
eight early-warning indicators for HIV drug resistance, 
each with an associated recommended target, and 
recommends monitoring them annually in all or many 
representative sites (Box 5.14) (61,62). WHO suggests 
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Box 5.14 
List of early-warning indicators and associated 
recommended targets
Early-warning indicator Target (%)
1. % of initial antiretroviral therapy 
prescriptions congruent with national or 
WHO guidelines
100
2. % of people receiving antiretroviral therapy 
lost to follow-up at 12 months
≤20
3. % of people receiving antiretroviral therapy 
retained on fi rst-line antiretroviral therapy 
at 12 months
≥70
4. % of people receiving antiretroviral therapy 
with 100% on-time drug pick-ups during 
the fi rst 12 months of antiretroviral therapy 
or during a specifi ed time period
≥90
5. % of people receiving antiretroviral therapy 
who attended all appointments on time 
during the fi rst 12 months of antiretroviral 
therapy or during a specifi ed time period
≥80
6. % continuity of antiretroviral drug supply 
during a 12-month period
100
7. % of people receiving antiretroviral therapy 
adhering to antiretroviral therapy by pill 
count or other standardized measure
≥90
8. % of people receiving antiretroviral therapy 
with a viral load <1000 copies/ml at 12 
months
≥70
Box 5.15
Proportion of monitored clinics achieving WHO-
recommended early-warning indicator targets, by 
indicator and region, 2004–2009
The percentage of adult clinics meeting WHO-recommended 
targets varies considerably by early-warning indicator and 
region. Whereas most participating clinics in Africa and Asia 
met the target for early-warning indicator 1 (appropriate fi rst-
line prescribing practices), only 46% of monitored clinics in 
Latin America and the Caribbean achieved recommended levels. 
Globally, 69% clinics monitored met the targets for the second 
early-warning indicator (loss to follow-up) and 67% for the third 
early-warning indicator (retention on fi rst-line antiretroviral 
therapy). Only 17% of clinics monitored achieved early-warning 
indicator 4 target of providing at least 90% of people receiving 
antiretroviral therapy with 100% on-time drug pick-up. Fifty-
eight per cent of clinics achieved WHO’s recommended level 
for early-warning indicator 5 (keeping appointments on time), 
and 65% provided a continuous supply of antiretroviral drugs 
during a 12-month period (early-warning indicator 6). Limited 
data are available on early-warning indicators 7 and 8. Overall, 
early-warning indicators results raise important concerns, since 
the targets were not achieved in many countries. These data 
support the urgent need for strengthening the monitoring of 
antiretroviral therapy programmes and support for improving 
adherence and retention in antiretroviral therapy, robust tracing 
of defaulters and preventing drug stock-outs.
that national antiretroviral therapy programmes monitor 
early-warning indicators for HIV drug resistance that 
are feasible based on routinely available data.
As of mid-2011, 50 countries monitored one or more 
early-warning indicators based on available routinely 
collected data, covering 132 000 people initiating 
antiretroviral therapy during 2004–2009 at 2107 
antiretroviral therapy clinics.
Many countries have used the results from monitoring 
early-warning indicators to improve manage-
ment (63–65). Based on high rates of loss to follow-up, 
missed appointments or failure to pick up antiretroviral 
drugs on time, countries have worked to improve the 
mechanisms for tracing people receiving treatment. 
In Namibia, for instance, the Ministry of Health and 
Social Services, which identifi ed migrant workers as 
being at risk of interrupting treatment, has planned to 
intensify existing systems for tracing discontinuation 
by improving its electronic record-keeping system, 
establishing a national patient database with unique 
identifiers and increasing the mobilization and 
redistribution of human resources (66).
5.3.5.2 Surveys to assess acquired HIV drug 
resistance and associated programmatic 
factors
Standardized surveys performed at sentinel clinics 
providing antiretroviral therapy to adults or children 
are important instruments for assessing the emergence 
and prevention of HIV drug resistance in populations 
receiving fi rst-line antiretroviral therapy (67). Surveys 
to monitor HIV drug resistance identify factors that 
can be addressed by making adjustments at the site 
or programme level to minimize the emergence of 
preventable drug resistance. The results of surveys 
performed regularly at representative sites can 
strengthen the available evidence base for optimizing 
the selection of national antiretroviral therapy regimens. 
As of mid-2011, 51 surveys of acquired HIV drug 
resistance had been implemented in 13 countries (in 
Africa and South and South-East Asia). In an aggregate 
analysis of 15 surveys from 5 countries, 6% of 2150 
people initiating fi rst-line antiretroviral therapy had 
any baseline HIV drug resistance. After 12 months of 
antiretroviral therapy, 10% had viral failure (viral load 
greater than 1000 copies per ml). Among these, 69% 
had detectable HIV drug resistance. Among people 
living with HIV for which fi rst-line treatment failed, 
with drug-resistant virus at 12 months, 96% were 
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predicted to achieve viral suppression with currently 
recommended second-line regimens (68).
5.3.5.3 Surveys to classify transmitted HIV drug 
resistance
A survey method has been developed to classify 
transmitted HIV drug resistance in populations likely 
to have been recently infected with HIV. The method’s 
eligibility criteria for selecting sites and individuals were 
designed to minimize the inclusion of antiretroviral 
therapy–experienced individuals and/or chronically 
infected individuals and defi nes three categories of 
transmitted HIV drug resistance: low (under 5%), 
moderate (5–15%) and high (>15%) (69). The results of 
these surveys, combined with results from other key 
assessments, provide critical information relevant to 
preventing drug resistance.
As of mid-2011, 53 surveys to assess transmitted HIV 
drug resistance had been completed in 22 countries: 
83% of surveys showed low transmitted drug 
resistance and 17% moderate resistance. The overall 
prevalence of transmitted HIV drug resistance was 
3.7% [95% confi dence interval (3.0–4.4%)]. Notably, 
5 of the 11 surveys of transmitted HIV drug resistance 
conducted in 2009 showed moderate transmitted 
HIV drug resistance (11). Although additional studies 
are necessary to reliably perform trend analysis, 
other groups (70–73) have observed increasing rates 
of transmitted HIV drug resistance. Surveys should be 
repeated to confi rm fi ndings and investigations into 
antiretroviral therapy programme factors favouring the 
emergence and transmission of drug-resistant virus. 
Nevertheless, moderate levels of transmitted HIV drug 
resistance in specifi c populations merit attention, and 
strategies must be designed and implemented with 
urgency to mitigate them.
As antiretroviral therapy continues to be scaled up 
rapidly, programmatic assessments, informed by 
surveillance of transmitted and acquired HIV drug 
resistance, must be regularly performed to timely and 
adequately adapt policy and implementation practices. 
Increased funding and adequate infrastructure are 
needed to support ongoing surveillance of HIV drug 
resistance as well as increased efforts to further 
optimize care and treatment of people living with HIV, 
an essential element to minimize the emergence of HIV 
drug resistance (74).
5.3.6 Supplies of drugs for antiretroviral 
therapy
Drug stock-outs remain an issue of concern in low- and 
middle-income countries. The number of countries 
providing data on the occurrence of stock-outs increased 
from 98 in 2009 to 118 in 2010. The proportion of 
countries experiencing stock-outs of drugs for 
antiretroviral drugs remained stable in 2010 compared 
with previous years. Of the 118 countries reporting 
information for 2010, 45 (38%) reported at least one 
episode of stock-out of antiretroviral drugs in health 
facilities in 2010 versus 37 of 98 countries (38%) in 
2009 and 36 of 97 countries (37%) in 2008. The most 
severely affected regions were the African Region and 
the Region of the Americas, where 50% and 52%, 
respectively, of responding countries reported having 
experienced stock-outs of one or more antiretroviral 
drugs in 2011. The least severely affected regions 
were the South-East Asia Region and Western Pacifi c 
Region, where 25% and 23%, respectively, of responding 
countries reported having experienced stock-out 
episodes in 2011. In a subset of 87 countries providing 
comparable data in both 2009 and 2010, the number of 
countries experiencing stock-outs of antiretroviral drugs 
decreased from 34 (39%) to 32 (37%).
Ensuring an uninterrupted supply of antiretroviral drugs 
is critical to protect the health and well-being of people 
living with HIV, minimize the emergence of HIV drug 
resistance, support retention and ultimately reach 
universal access goals. As such, greater coordinated 
efforts must be made to identify and address 
bottlenecks in drug procurement and management. 
Several strategies have been deployed at the country 
and global levels to minimize the risk of treatment 
interruptions. For instance, procurement and supply 
managers in Thailand reported that they borrowed 
missing medicines from nearby health facilities; in Mali 
and Serbia, missing formulations were replaced by 
suitable alternatives. These experiences suggest that 
robust and affordable triple fi xed-dose formulations 
could improve the reliability of supply systems, in 
particular in settings where single formulations are 
primarily responsible for stock-outs and potential 
treatment interruption.
Globally, the Coordinated Procurement Planning 
Initiative is fostering the coordination and sharing 
of information on stock levels among national and 
international partners. Through a coordinated alert 
and response mechanism, Coordinated Procurement 
Planning partners can indicate alternative sources 
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of emergency supplies when the risk of a stock-out 
arises. The Emergency Commodity Fund of the United 
States President’s Emergency Plan for AIDS Relief 
has also been able to provide assistance to avert 
antiretroviral therapy disruptions. Through August 2011, 
the Emergency Commodity Fund has responded to 
requests from programmes in near stock-out situations 
of critical antiretroviral medicines and rapid test kits in 
11 countries (Angola, Benin, Central African Republic, 
Côte d’Ivoire, Ethiopia, Ghana, Liberia, Mozambique, 
South Sudan, Swaziland and Zimbabwe).
5.3.7 Antiretroviral drug regimens
In 2011, WHO’s AIDS medicines and diagnostics service 
(AMDS) conducted the fifth annual survey on the 
distribution and composition of fi rst- and second-line 
antiretroviral therapy regimens used and on the status 
of implementation of WHO’s antiretroviral therapy 
recommendations in low- and middle-income countries. 
The complete questionnaire was sent to the health 
ministries of the 97 countries, covering all six WHO 
regions, with the highest number of people receiving 
antiretroviral therapy as of December 2010 (76).
5.3.7.1 Antiretroviral regimens used in 
antiretroviral therapy 
A total of 66 countries provided detailed data on the 
antiretroviral regimens used by 5 811 000 people, or 
87% of the 6.65 million people receiving antiretroviral 
Box 5.16
Using early-warning indicators to prevent stock-outs in Zimbabwe
After extensive consultations at the country, regional and global levels, WHO published in 2011 a set of harmonized monitoring and evaluation 
indicators for procurement and supply management systems (75). It contains 12 key indicators to monitor the performance of supply chain 
management systems, six of which are considered as early-warning indicators to prevent stock-outs and overstocking of antiretroviral, 
antituberculosis and antimalarial medicines. In order to identify best practices to support the implementation of monitoring and evaluation 
systems for procurement and supply management, pilot tests were conducted in Burkina Faso, Burundi, Cameroon, Côte d’Ivoire, Guinea, 
Mozambique, Uganda, United Republic of Tanzania and Zimbabwe.
In the Ministry of Health and Child Welfare (MOHCW) in Zimbabwe, after a period of fi eld-testing, a monitoring plan was adopted and relevant 
data sources were identifi ed. To leverage and strengthen existing systems, procurement and supply management indicators were integrated 
into the routine mechanisms for collecting and analysing data on the country’s antiretroviral management programme.
From the beginning of January 2010, indicator results were reviewed at monthly stakeholder meetings which guided the design of strategies 
to address identifi ed shortcomings, including:
• implementing specifi c training workshops to address data quality issues and to ensure that at least two managers at every facility had been 
trained in procurement and supply management;
• pre-emptively adjusting buffer stock levels and placing orders before reaching critically low levels, which exposed them to higher stock-outs 
risks;
• piloting mobile phone solutions to minimize delays in transferring data from peripheral levels in the Ministry of Health and Child Welfare 
to central-level for aggregation;
• putting plans in place to introduce computerized dispensing software in high-volume facilities to ensure adequate logistic infrastructure; 
and
• restructuring central warehouses through decentralisation of warehousing of antiretrovirals to ensure timely order processing and reduce 
lead time.
As a result of corrective actions, the rate of stock-outs for adult fi rst-line antiretroviral medicines fell consistently, resulting in no facilities 
reporting any stock-out of fi rst-line regimens between February and December 2010.
The roll-out of procurement and supply management indicators highlighted areas with high system performance (such as 100% of products 
ordered by all partners meeting national standard treatment guidelines and 100% of product batches meeting quality control tests), areas in 
which even lower targets could be pursued (such as lowering the target for the rate of product loss from 2% to 1%), and areas were continued 
effort was necessary (such as antiretroviral drugs for children, antiretroviral drug use, etc.). Coordination of all stakeholders and leadership by 
the Ministry of Health and Child Welfare in the procurement and supply management system also contributed to this success in Zimbabwe.
The experience in Zimbabwe demonstrates that procurement and supply management indicators can be implemented and can help 
governments to increase the performance of national supply systems and ultimately result in insignifi cant stockouts and losses of critical 
medicines in the public health system. However, although indicators are useful to aggregate logistic information and identify emerging 
bottlenecks, they will not per se improve national supply management systems unless corrective action is implemented with the full 
involvement of all relevant stakeholders and partners.
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Participating countries Group A Group A
Number of countries 45 21
% of the total number of people receiving antiretroviral therapy by December 2010 83% (n = 5 467 000) 5% (n = 344 100)
Regional distribution:
Sub-Saharan Africa 22
Latin America and the Caribbean 24
East, South and South-East Asia 8
Europe and Central Asia 3
North Africa and the Middle East 8
Western Pacifi c 4
People and regimens Adults 93% (n = 4 974 000) Adults 97% (n = 332 000)
First-line regimens 97.1% (n = 4 830 000) 69.1% (n = 230 000)
Second-line regimens 2.9% (n = 142 000) 27.8% (n = 92 000)
Third-line regimens 0.05% (n = 2000) 3.1% (n = 10 000)
Compliance with 2010 WHO recommendations (preferred and alternative) (1) First line: 99.9%
Second line: 95.7%
First line: 98.1%
Second line: 60.3%
Children 7% (n = 383 020) Children 3% (n = 11 100)
First-line regimens 96.8% (n = 371 000) 72.1% (n = 8000)
Second-line regimens 3.2% (n = 12 000) 24.9% (n = 2800)
Third-line regimens 0.01% (n = 20) 3.0% (n = 300)
Compliance with 2010 WHO recommendations (preferred and alternative) First line: 99.9%
Second line: 88.8%
First line: 84.2%
Second line: 80.9% 
Table 5.12 Characteristics of responding countries, people and regimens in groups A (45 low- and middle-income countries 
excluding the Region of the Americas) and B (21 low- and middle-income countries from the Region of the Americas)
Fig. 5.6 Composition and frequency of fi rst-line 
antiretroviral therapy regimens used among adults 
in group A (45 low- and middle-income countries, 
excluding countries from the Region of the Americas), 
December 2010 
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d4T: stavudine; 3TC: lamivudine; AZT: zidovudine; NVP: nevirapine; EFV: efavirenz; 
TDF: tenofovir; FTC: emtricitabine.
Fig. 5.7 Composition and frequency of second-line 
antiretroviral therapy regimens used among adults 
in group A (45 low- and middle-income countries, 
excluding countries from the Region of the Americas), 
December 2010 
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therapy in low- and middle-income countries as of 
December 2010.1 
Similar to previous surveys, an initial analysis revealed 
that the 21 reporting countries from the Region of the 
Americas (comprising 344 100 people, with 332 000 
adults and 11 100 children) presented a pattern of 
use of antiretroviral drugs notably different from the 
one observed in the remaining 45 low- and middle-
income countries (comprising 5 467 020 people, with 
4 974 000 adults and 383 020 children) that responded 
to the survey. To account for such differences, the 
results are presented separately between the two 
groups: group A includes 45 low- and middle-income 
countries but excludes countries from the Region of the 
Americas, and group B includes the 21 countries from 
the Region of the Americas (Table 5.12).
Adults
In group A, a large majority of the adults (97%) were 
receiving fi rst-line regimens as of December 2010. Of 
these, 58% received either zidovudine- or tenofovir-
based regimens (39% and 19%, respectively), and 
the remaining (42%) received a stavudine-containing 
combination (Fig. 5.6).
Only 3% of adults (n = 142 000) were receiving a 
second-line regimen in group A, with most using a 
zidovudine-based (48%) or tenofovir-based (47%) 
regimen. Ritonavir-boosted lopinavir remained the 
predominant protease inhibitor, used by 95% of the 
people receiving a second-line regimen (Fig. 5.7).
In group B, comprising 21 reporting countries from the 
Region of the Americas, 69% of adults were receiving 
fi rst-line regimens as well, although this proportion 
was considerably lower than in group A. Of these, 82% 
received a zidovudine-containing regimen. Similar to 
previous surveys, an important proportion of the adults 
receiving fi rst-line treatment reported the use of a 
protease inhibitor (27%), and only a small proportion 
(4%) received stavudine. Countries in the Americas 
reported a higher rate of second-line (28%) regimens 
among adults.
Children
In group A, most children (97%) were on fi rst-line 
regimens as of December 2010 (Fig. 5.8). Of the 
1 Five more countries responded with information on distribution among 
fi rst- second- and third-line regimens and information on national 
guidelines (but no data on the composition of the regimens).
children receiving a first-line regimen, 56% used 
stavudine, 29% zidovudine and 15% abacavir. Uptake 
of ritonavir-boosted lopinavir in fi rst-line regimens 
was low (12%).2 As in adults, stavudine-containing 
regimens are no longer considered as preferred 
treatment options for children in accordance with 
WHO’s 2010 antiretroviral therapy guidelines (1) but 
remain in use in many countries. The development 
and uptake of user-friendly, affordable and less toxic 
fixed-dose combinations for children need to be 
promoted to increase the use of WHO-recommended 
preferred combinations. In group B, a large majority of 
children receiving fi rst-line regimens were receiving a 
zidovudine-containing combination (88%).
Trends
Fifteen countries from group A participated in all fi ve 
consecutive surveys on the use of antiretroviral drugs 
between 2006 and 2010.3 They provided detailed 
information on the regimens used by 3 100 000 people, 
representing 47% of the 6 650 000 people receiving 
antiretroviral therapy in low- and middle-income 
2 WHO’s 2010 guidelines on antiretroviral therapy (1) recommend 
ritronavir-boosted lopinavir in fi rst-line regimens for infants and children 
younger than 24 months of age who have been exposed to nevirapine or 
other non-nucleoside reverse-transcriptase inhibitors.
3 Burkina Faso, Burundi, Cambodia, Cameroon, Ethiopia, India, Kenya, 
Lesotho, Namibia, Nigeria, Swaziland, Uganda, United Republic of 
Tanzania, Zambia and Zimbabwe.
Fig. 5.8 First-line regimens used for children in 
antiretroviral therapy programmes in group A (45 low- 
and middle-income countries, excluding countries from 
the  Region of the Americas), December 2010
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d4T: stavudine; 3TC: lamivudine; AZT: zidovudine; NVP: nevirapine; EFV: efavirenz; 
LPV/r: lopinavir with a ritonavir boost; ABC: abacavir.
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countries by December 2010. In this subset of countries, 
the use of stavudine in fi rst-line regimens decreased 
from 67% in 2006 to 43% in 2010, whereas the use of 
zidovudine and tenofovir increased concomitantly from 
29% and less than 0.1%, respectively, in 2006, to, 42% 
and 15% of fi rst-line combinations in 2010 (Fig. 5.9).
Data from 2009 and 2010 surveys show that a 
large majority of low- and middle-income countries 
have already incorporated or are in the process of 
adopting into their national treatment guidelines 
WHO’s revised recommendations on eligibility criteria 
and regimen choice for adults and adolescents (1). 
Most (88 of 93) reporting countries now recommend 
initiating antiretroviral therapy for everyone with CD4 
counts of or below 350 cells per mm3. Two countries 
apply the same initiation criteria for pregnant women 
only. Moreover, almost all (84 of 87) reporting countries 
also recommend shifting away from stavudine-based 
to zidovudine- or tenofovir-containing regimens as of 
late 2010 (Fig. 5.10).
5.3.7.2 Progress in phasing out the use of 
stavudine in low- and middle-income 
countries
In 2010, WHO published revised guidelines on 
antiretroviral therapy for adults and adolescents 
recommending that countries phase out the use 
of stavudine due to its long-term toxicity and side 
effects. As actual implementation practices often lag 
behind changes in normative guidelines, a qualitative 
survey of 24 low- and lower-middle-income countries 
representing all regions was undertaken in March 2011 
to gather data on actual programmatic practices and 
Fig. 5.9 Proportions of people receiving stavudine, 
zidovudine or tenofovir in fi rst-line regimens in 15 
reporting countries, 2006–2010 
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Fig. 5.10 Adoption of the 2010 WHO recommendation on the preferred medicine in fi rst-line antiretroviral regimens into 
national antiretroviral therapy guidelines, in reporting low- and middle-income countries, 2010–2011
a Not a preferred medicine in fi rst-line line antiretroviral regimens according to 2010 WHO recommendations.
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Box 5.17
Phasing out stavudine in India, Kenya, Malawi and Mozambique
Implementation of stavudine phase-out plans is currently under way in India, Kenya, Malawi and Mozambique, and their experiences illustrate 
some of the key issues and challenges facing programme managers.
In India, while previous guidelines already recommended zidovudine-based regimens as the preferred fi rst-line therapy for non-anaemic 
patients (nearly 55% patients are already on Zidovudine based regimen), national expert opinion was initially divided on the full phase-out 
of stavudine. On the one hand, there was little local evidence of stavudine-related toxicities, and lipodystrophy was not yet a major patient 
concern. On the other hand, some experts considered that stavudine should be phased out from treatment guidelines in view of its potential 
long-term toxicities. Overall, the consensus among a group of experts convened in 2010 to assess the matter was to reduce the use of stavudine 
by (a) substituting it with tenofovir in patients with evidence of long-term stavudine-related toxicities and, (b) recommending that new patients 
eligible for ART with baseline anaemia be started on a stavudine based regimen and then revaluated for anaemia after six months on ART. 
They shall be then shifted to Zidovudine based regimen if anaemia improves or to a tenofovir based regimen if they continue to be anaemic.
In Kenya, stavudine phase-out has proceeded more slowly than originally envisaged. Following the publication of WHO’s 2010 antiretroviral 
treatment recommendations for adults and adolescents, national ART guidelines were promptly revised and a recommendation was issued 
to substitute patients from stavudine- to tenofovir-based regimens following confi rmed or suspected toxicities. This substitution from 
stavudine did not happen as anticipated in July 2011. An assessment by the National AIDS and STD Control Program (NASCOP) of the main 
ART sites, found that only 9% of patients had their stavudine-based regimens substituted, as opposed to the annual 20% to 30% initially 
planned. According to national reports, the slower transition of stable adult patients on stavudine to other regimens has been associated 
with the absence of stavudine-specifi c toxicities. In response, NASCOP has decided to revise national protocols to better assist ART clinics 
in evaluating patients on stavudine regimens and will organize mentorship support. All paediatric patients on stavudine based ART have 
been transitioned to either AZT or ABC based ART except older children who are on adult formulations
In Malawi, insuffi cient fi nancial resources have delayed or slowed the pace of stavudine phase-out. The failure to secure additional grant 
funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria has led to the prioritization of a sub-group of patients to shift to 
preferred regimen. Initially, only pregnant women, co-infected patients with tuberculosis, and patients with lipodystrophy will receive 
preferred regimens until future Global Fund grants and partner support can be secured. 
In Mozambique, implementation of stavudine phase-out was initiated in June 2010, and six months later, 90% of adults and 65% of children 
were already receiving a zidovudine-based fi rst-line regimen. The choice of zidovudine as the preferred molecule was supported by fi nancial 
and logistic considerations, including its lower price as compared to tenofovir, the existence of large AZT stocks and the fact that health 
workers were already familiar with it. In order to improve monitoring and diagnosis of anaemia, one of AZT’s major side effects, national 
authorities will strengthen linkages with PMTCT sites, where investments are being made to improve laboratory capacity.
Table 5.13 Progress in implementing plans for phasing out stavudine in 13 low- and middle-income countries, 2009–2011
Countrya
Preferred nucleoside 
reverse-transcriptase 
inhibitor for substitution
Percentage 
using stavudine 
(2009)b
Percentage 
using stavudine 
(2010)c
Estimated 
percentage of 
reduction
Start date of 
implementation Timeline for completion
South Africa Tenofovir 82%d 40%e Æ51% February 2010 Not available
Kenya Tenofovir 68% 54% Æ21% February 2010 2013–2015
India Tenofovir 46% 47% "1% Under discussion Under discussion
Zimbabwe Tenofovir 95% 93% Æ2% April 2011 2013
United Republic of Tanzania Tenofovir and zidovudine 72% 63% Æ3% 2011 2015
Malawi Tenofovir 95% 93% Æ2% July 2011 Under discussion
Uganda Tenofovir 18% 2% Æ89% 2009 2010
Mozambique Zidovudine 78% 7% Æ91% March 2010 December 2010
Ethiopia Zidovudine and tenofovir 63% 59% Æ6% January 2009 2014
Cameroon Zidovudine and tenofovir 63% 57% Æ10% 2010 2015
China Zidovudine 48% 43% Æ10% 2011 2013
Swaziland Zidovudine 40% 27% Æ33% January 2011 July 2011 – being extended
Ukraine Tenofovir 8% 6% Æ25% August 2010 2012
a In descending order of number of people receiving antiretroviral therapy as of December 2010.
b Proportion of people receiving antiretroviral therapy who got a fi rst-line regimen in the country as of December 2009.
c Proportion of people receiving antiretroviral therapy who got a fi rst-line regimen in the country as of December 2010.
d Personal communication, G. Meyer-Rath, Health Economics and Epidemiology Research Offi ce, Boston University and University of the Witwatersrand, Johannesburg, South Africa, 2010.
e Personal communication, Clinton Health Access Initiative – South Africa Team, September 2011.
114     GLOBAL HIV/AIDS RESPONSE – Epidemic update and health sector progress towards Universal Access – Progress Report 2011
to identify emerging operational bottlenecks in the 
phase-out of stavudine. Responses were received from 
14 countries (Table 5.13).1 
Although substantial progress has been made in 
phasing out the use of stavudine, this process has been 
uneven. Stavudine has already been almost completely 
replaced by appropriate WHO-recommended preferred 
regimens in a few countries, but new fi rst-line regimens 
are still being rolled out or have only recently started 
in others. Implementation of phase-out plans has 
proceeded more swiftly where national treatment 
guidelines were quickly revised to refl ect updated WHO 
guidance, service delivery providers were adequately 
trained, phase-out strategies were clearly defi ned and 
active support of funding partners was secured.
5.3.7.3  Use of laboratory services for 
monitoring antiretroviral therapy
Sixty-six low- and middle-income countries, with 
3 700 000 people receiving antiretroviral therapy as 
of December 2010, provided data on the availability of 
selected laboratory services. Laboratory capacity for 
CD4 count tests was considerably greater than that 
for quantifying viral load. Among reporting countries, 
2155 facilities were equipped to perform CD4 count 
tests, whereas only 394 facilities had the necessary 
infrastructure for measuring viral load. Twelve 
countries reported having no viral load capacity. A 
1 Among responding countries, one (Cambodia) postponed the phase-out 
of stavudine because of fi nancial constraints.
total of 3 935 000 CD4 tests and 1 175 000 viral load 
measurements were performed in 2010.
Cross-country comparative analyses are method-
ologically challenging because of the absence of a 
standardized package of laboratory services and the 
consequent existence of a varying number of machines 
per structure and tests per machine. Nevertheless, 
available data suggest important disparities in the 
availability of CD4 and viral load tests across countries 
and regions (Table 5.14). Moreover, the capacity to 
perform viral load tests is still considerably limited in 
most low- and middle-income countries, a fact that may 
be partly explained by the relatively higher equipment 
and maintenance costs associated with viral load 
measurements.
5.3.8 Antiretroviral drug prices in low- and 
middle-income countries
The WHO Global Price Reporting Mechanism collects 
information on the transaction prices of HIV, TB 
and malaria drugs and diagnostics from a variety of 
procurement partners and funding agencies, including 
the Global Fund to Fight AIDS, Tuberculosis and Malaria 
and the United States President’s Emergency Plan 
for AIDS Relief. Its broadly representative database 
currently contains data on the procurement of 
antiretroviral drugs from 128 countries, including 35 
low-income, 51 lower-middle-income and 42 upper-
middle-income countries (77). This section reports on 
price trends based on data accrued up to 1 July 2011.
In low-income countries, the prices of the six most 
frequently used fi rst-line regimens recommended by 
WHO declined between 2% and 53% between 2009 
and 2010 (Fig. 5.11). Lower-middle-income and upper-
middle-income countries had the same downward 
trend. Regionally, prices tended to be lower in sub-
Saharan Africa than in other regions. However, the 
average prices paid for second-line regimens remain 
relatively high in all regions. Procurement data show 
that the number of prequalifi ed generic alternatives 
available is strongly correlated with the declines in the 
prices of antiretroviral drugs.
5.3.8.1 Prices of fi rst-line regimens in low-
income countries
Table 5.14 Number of people receiving antiretroviral 
therapy per laboratory with CD4 cell count or viral load 
measurement capacity, by geographical region, as of 
December 2010
CD4 Viral load
Geographical 
region
(number of countries 
surveyed = 97)
Number of 
responding 
countries
Average number 
of people 
receiving 
antiretroviral 
therapy per 
laboratory 
[range] 
Average number 
of people 
receiving 
antiretroviral 
therapy per 
laboratory 
[range]
Sub-Saharan Africa 20 2 287[10–10 745]
39 539
[5257–326 241]
Middle East and 
North Africa 8
150 
[15–439]
183 
[15–531]
East, South and 
South-East Asia 
and Oceania
12 897 [23–5350]
5 125 
[256–55 686]
Europe and Central 
Asia 4
1 025
[309–1419]
1 025
[523–1419]
Latin America and 
the Caribbean 22
1 913 
[61–5843]
2 773 
[156–20 042]
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The median price paid for fi rst-line regimens in low-
income countries in 2010 ranged from US$ 64 per 
person per year for the fixed-dose combination of 
stavudine + lamivudine + nevirapine1 (the most widely 
used combination) to US$ 242 for the most expensive 
fi xed-dose combination of tenofovir + emtricitabine + 
efavirenz (Fig. 5.11). The weighted median price2 of the 
10 most widely used fi rst-line regimens (representing 
99% of those prescribed in low-income countries) was 
US$ 121 per person per year in 2010, 12% lower than the 
average weighted median price of the six most widely 
1 WHO does not recommend stavudine + lamivudine + nevirapine, but it 
remains the most frequently used fi xed-dose combination based on the 
2010 survey of the use of antiretroviral drugs (see section 5.3.7).
2 The weighted median price is the sum of the median prices of the 
individual regimens multiplied by the percentage of people using that 
specifi c regimen.
used fi rst-line regimens in 2009 (representing 96% of 
those prescribed in low-income countries). This decline 
in prices occurred despite the wider adoption of more 
expensive tenofovir-based regimens.
These observations are consistent with the price 
trends observed since 2006: in 2010, the weighted 
median price of antiretroviral drugs in low-income 
countries was 60% lower than in 2006. This can be 
attributed to the sustained scaling up of treatment 
programmes, leading to growing transaction volumes, 
greater predictability of demand and more vigorous 
competition among the various manufacturers.
Fig. 5.11 Median annual cost (in US dollars) of fi rst-line antiretroviral drug regimens for adults in low-income countries, 
2008–2010
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Fig. 5.12 Median annual cost (in US dollars) of fi rst-line antiretroviral drug regimens for children (weighing 10 kg or more) in 
low-, lower-middle- and upper-middle-income countries, 2008–2010 
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In 2010, the combination of stavudine + lamivudine + 
nevirapine remained the most commonly prescribed 
formulation for children, representing 35% of total fi rst-
line regimens prescribed for children weighing 10 kg or 
more. Its average price declined from US$ 57 per person 
per year in 2006 to US$ 52 in 2009 and early 2010. 
The average prices of other combinations continued 
to fall as well (Fig. 5.12). Such price decreases can be 
attributed to the economies of scale associated with a 
larger market for formulations for children, especially 
resulting from UNITAID’s focused programme for 
children, successful negotiations with major generic 
manufacturers and the development of fixed-dose 
combination formulations for children.
5.3.8.2 Prices of fi rst-line regimens in lower-
middle-income countries
The median prices in 2010 ranged from US$ 70 per 
person per year for the least expensive regimen of 
stavudine + lamivudine + nevirapine to US$ 241 per 
person per year for the most expensive regimen of 
tenofovir + emtricitabine + efavirenz. In 2010, the 
weighted median price of the 10 most widely used 
combinations in first-line regimens was US$ 124 
per person per year, a decrease of 12% from the 
previous year.
The most commonly used combination among children 
(weighing 10 kg or more) was stavudine + lamivudine 
+ nevirapine, and the price fell from US$ 70 per person 
per year in 2006 to US$ 52 in 2010.
5.3.8.3 Prices of fi rst-line regimens in upper-
middle income countries
In 2010, the median reported prices in upper-middle-
income countries ranged from US$ 66 per person per 
year for the least expensive regimen of stavudine + 
lamivudine + nevirapine to US$ 242 per person per 
year for tenofovir + emtricitabine + efavirenz. In the 
same year, the weighted average median price of the 
10 most widely used fi rst-line regimens reported in the 
Global Price Reporting Mechanism was US$ 121 per 
person per year – a 40% decrease from the median 
price recorded in 2009.
The growing use of generic medicines (especially 
tenofovir- and nevirapine-containing formulations) in 
upper-middle-income countries is partly responsible for 
this rapid decline in median prices: in early 2010, about 
70% of the transactions recorded in the Global Price 
Reporting Mechanism involved generic antiretroviral 
drugs versus about 30% in previous years. In addition, 
a few lower-middle-income countries became upper-
middle-income countries but retained their previous 
price levels. However, the fall in median prices observed 
between 2009 and 2010 may not be representative of 
all upper-middle-income countries, as data captured 
through the Global Price Reporting Mechanism may 
not comprehensively include all relevant transactions. 
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Fig. 5.14 Median annual cost (in US dollars) of second-line antiretroviral drug regimens for adults in low-income countries 
(LIC), 2008–2010  
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Indeed, some price increases have been noted 
elsewhere (78).
5.3.8.4 Prices of second-line regimens in low- 
and middle-income countries
The reported prices of second-line regimens also 
declined in 2010 but remained higher than the prices 
of fi rst-line regimens across low-income (Fig. 5.13), 
lower-middle-income and upper-middle-income 
countries. In 2010, the median reported cost of the 
most commonly used second-line regimen, lamivudine 
+ tenofovir + ritonavir-boosted lopinavir, was US$ 554 
per person per year in low-income-countries, US$ 692 
per person per year in lower-middle-income countries 
and US$ 601 in upper-middle-income countries. The 
median reported cost of zidovudine + didanosine + 
ritonavir-boosted lopinavir, the second most commonly 
used second-line regimen, was US$ 701 per person per 
year in low-income-countries, US$ 908 per person per 
year in lower-middle-income countries and US$ 970 
in upper-middle-income countries, with important 
variation across countries (78).
The decline in the prices of second-line drugs between 
2006 and 2010 can be attributed to falls in the prices of 
abacavir, ritonavir-boosted lopinavir and tenofovir, the 
prequalifi cation of generic versions of ritonavir-boosted 
lopinavir and tenofovir, the expiry of the patent for 
didanosine, the scaling up of treatment programmes, 
new pricing policies by research-based pharmaceutical 
companies and the efforts of key partners to expand 
the market for second-line regimens. Although 
these developments are encouraging, addressing the 
relative higher cost of second-line regimens remains 
an important objective as antiretroviral therapy 
programmes mature and the number of people who 
need second-line regimens continues to grow.
5.4 Collaborative TB and HIV activities
HIV-related TB remains a serious challenge for the 
health-sector response and for people living with HIV. 
Of the estimated 34 million people living with HIV, 
about one third are estimated to have concomitant 
latent infection with Mycobacterium tuberculosis. 
In 2010, of 8.8 million incident TB cases worldwide, 
1.1 million were among people living with HIV, with 
an estimated 350 000 deaths [320 000–390 000]. 
Sub-Saharan Africa continues to account for the global 
majority of the people living with HIV and TB, with an 
estimated 82% in 2010. HIV is the strongest risk factor 
for developing active TB disease, and in some countries 
up to 82% of people with TB have HIV (79).
Collaborative activities between national TB and 
HIV programmes are essential to prevent, diagnose 
and treat TB among people living with HIV and HIV 
among people with TB. These include establishing 
mechanisms for collaboration, such as coordinating 
bodies, joint planning, surveillance and monitoring 
and evaluation; decreasing the burden of HIV among 
people with TB (with HIV testing and counselling for 
individuals and couples, co-trimoxazole preventive 
therapy, antiretroviral therapy and HIV prevention, 
care and support); and decreasing the burden of TB 
among people living with HIV (with the three I’s for 
HIV and TB: intensifi ed case-fi nding; TB prevention 
with isoniazid preventive therapy and early access to 
antiretroviral therapy; and infection control for TB). 
Initiating antiretroviral therapy for all people living with 
HIV with CD4 cell counts less than 350 cells per mm3 
or with active TB irrespective of CD4 count is important 
to prevent TB- and HIV-related transmission, morbidity 
and mortality. Integrating HIV and TB services, when 
feasible, may be an important approach to improve 
access to services for people living with HIV, their 
partners, families and the community.
5.4.1 Reducing the burden of HIV among people 
with TB and their communities
Provide HIV testing and counselling
Provider-initiated HIV testing should be offered to 
everyone with TB and people presenting with signs 
and symptoms suggesting TB in settings with a high 
prevalence of HIV infection (80). TB often represents 
an early entry point for detecting and treating HIV. A 
total of 2.1 million people with TB were tested for HIV in 
2010, equivalent to 34% of all notifi ed TB cases, versus 
28% in 2009 and 3% in 2004. Of the people tested in 
2010, 488 000 (23%) were HIV-positive. In the WHO 
African Region, 880 000 people with TB (59%) were 
tested for HIV, and 405 000 (46%) were HIV-positive.
Scale up co-trimoxazole preventive therapy
All people with both HIV and TB should be given 
co-trimoxazole preventive therapy during their TB 
treatment and for life thereafter unless contraindicated 
or unless they receive antiretroviral therapy and their 
CD4 cell count rises above 500 cells per mm3. To gain 
maximum benefi t, people with TB should start co-
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trimoxazole preventive therapy as soon as possible after 
HIV infection is diagnosed, as mortality is highest early 
in the course of TB treatment. Although there has been 
some progress, slightly more than 300 000 people 
with both TB and HIV were receiving co-trimoxazole 
preventive therapy at the end of 2010, representing 
77% of the people with TB known to be living with HIV. 
In sub-Saharan Africa, 76% of the people identifi ed with 
HIV and TB were receiving co-trimoxazole.
Scale up antiretroviral therapy and ensure HIV 
care, treatment and support
WHO recommends that antiretroviral therapy be 
considered for all people living with HIV who have 
TB as soon as possible and no later than eight weeks 
after TB treatment begins, regardless of immune stage. 
Among people with profound immune suppression 
(CD4 count less than 50 cells per mm3), antiretroviral 
therapy should be started as a matter of emergency 
within the fi rst two weeks after TB treatment starts.
However, expanding access to antiretroviral therapy for 
people with both TB and HIV continues to be a major 
challenge. Globally, access to antiretroviral therapy 
for people diagnosed with TB increased modestly 
from 173 000 people in December 2009 to more than 
200 000 at the end of 2010 (47) among 101 reporting 
countries. In 2005, 69 countries had reported 67 000 
people diagnosed with TB receiving antiretroviral 
therapy.
In 2010, 20% of the total estimated number of people 
with TB and HIV – or 46% of people with TB who 
tested positive for HIV – were receiving antiretroviral 
therapy. In Africa, 42% (158 000) of the estimated 
number of people with both TB and HIV were reported 
to be receiving antiretroviral therapy. These fi gures are 
lower than the estimated coverage of antiretroviral 
therapy of 47% for all eligible people living with HIV 
in low- and middle-income countries. Given evidence 
of growing access to HIV testing by people with TB, 
and better links between TB and HIV services, this 
gap may refl ect the weaknesses of reporting access to 
care among people with both TB and HIV by settings 
providing HIV services. However, this may also refl ect 
poorer access to life-saving antiretroviral therapy by 
people with TB.
In addition to considerably improving the quality of life, 
reducing morbidity and enhancing the survival of people 
with advanced HIV infection, antiretroviral therapy 
reduces HIV transmission and the incidence of TB (81,82). 
Evidence has also emerged on how antiretroviral therapy 
coverage affects TB incidence at the community or 
population level (83). In Malawi, for instance, increased 
antiretroviral therapy coverage in a rural community has 
been associated with a 33% decline in TB incidence (84). 
Early access to antiretroviral therapy should be part of 
the TB prevention package together with the three I’s for 
HIV and TB (see section 5.4.2).
5.4.2 Decreasing the burden of TB among 
people with HIV
WHO recommends the three I’s for HIV and TB – 
intensified TB case-finding, isoniazid preventive 
treatment and TB infection control – to decrease the 
burden of TB among people with HIV. In 2010, progress 
continued in expanding the availability of these 
interventions in low- and middle-income countries. 
As of December 2010, among 119 countries providing 
data, 69 (58%) indicated that isoniazid preventive 
therapy was part of their package of interventions for 
people living with HIV, versus 48 (or 43%) among 112 
countries reporting in 2009. Ninety per cent (113 of 
125) of countries reported having policies to promote 
intensifi ed case fi nding, versus 60% in 2009, and 78% 
(98 of 126 countries) had a policy for TB infection 
control, versus 51% in 2009.
5.4.2.1 Implement intensifi ed TB case-fi nding
Intensifi ed case-fi nding and treatment of TB among 
people living with HIV interrupts disease transmission, 
reduces mortality, decreases the risk of nosocomial 
(hospital-acquired) TB transmission and offers the 
opportunity to provide isoniazid preventive therapy 
to people living with HIV unlikely to have active TB 
disease. In 2010, 72 low- and middle-income countries 
provided data on TB screening at the last visit for HIV 
care. The reported number of adults and children 
screened for TB at their last visit was 2.3 million.1 
In the subset of 69 countries also reporting on the 
number of adults and children enrolled in HIV care, 
coverage was estimated at 58% among people in HIV 
care in 2010.
5.4.2.2 Provide access to isoniazid preventive 
therapy
WHO recommends that national HIV programmes 
provide isoniazid preventive therapy as part of the 
package of care for people living with HIV when 
active TB is excluded (85,86). In 2010, despite increased 
1 This fi gure does not correct for potential double testing.
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adoption at the policy level, only about 180 000 
adults and children were receiving isoniazid preventive 
therapy in 54 countries. In a subset of 50 countries also 
providing the total number of adults and children newly 
enrolled in HIV care in 2010, coverage of isoniazid 
preventive therapy was 12%.
5.4.2.3 Ensure TB infection control in health 
care and congregate settings
HIV is the strongest risk factor for the development of 
TB, and people living with HIV are very vulnerable to 
the risk of nosocomial TB transmission. With the roll-
out of HIV care and treatment, people living with HIV, 
their partners and families are increasingly accessing 
care in health care settings. Multidrug-resistant and 
extensively drug-resistant TB have especially been 
recognized as emergent risks in these contexts. It is 
essential that health care and congregate settings have 
a plan and implement administrative, environmental 
and personal infection control and protection measures 
to reduce the transmission of TB. Although this is 
diffi cult to measure accurately, 77 low- and middle-
income countries reported a cumulative number of 
15 232 health facilities providing antiretroviral therapy 
services with demonstrable TB infection control 
practices, representing 76% of the number of facilities 
providing antiretroviral therapy in these countries.
5.5  Co-trimoxazole prophylaxis
Co-trimoxazole preventive therapy is a simple, 
inexpensive and highly effective intervention that has 
been shown to reduce mortality among people receiving 
antiretroviral therapy by about 50% and to improve the 
retention of people living with HIV throughout the 
continuum of HIV care. According to current WHO 
recommendations, all adults and adolescents with 
symptomatic HIV disease and asymptomatic people 
living with HIV with CD4 cell count less than 350 
cells/mm3 should initiate co-trimoxazole preventive 
therapy (87). Further, all HIV-exposed infants born 
to mothers living with HIV should also receive co-
trimoxazole preventive therapy, beginning at 4–6 
weeks of age and continuing until HIV infection can be 
excluded (88). Expanding the availability and uptake of 
co-trimoxazole preventive therapy is thus a key element 
in further improving treatment outcomes and the 
survival of people living with HIV. Among 126 reporting 
low- and middle-income countries, 86% indicated 
having in place national guidelines on providing co-
trimoxazole for people living with HIV.
Ninety-two low- and middle-income countries provided 
data on access to co-trimoxazole preventive therapy in 
2010 (39 from sub-Saharan Africa, 21 from East, South 
and South-East Asia, 12 from Europe and Central Asia, 
11 from Latin America and the Caribbean and 9 from 
North Africa and the Middle East). In these countries, 
3.3 million people received co-trimoxazole preventive 
therapy in 2010.
Among these countries providing data on access to co-
trimoxazole preventive therapy, a subset of 82 countries 
also provided data on estimated co-trimoxazole needs, 
defi ned as the number of people in HIV care and eligible 
for co-trimoxazole preventive therapy. In this subgroup 
of countries, 71% of eligible people actually received 
co-trimoxazole preventive therapy (2.93 million).1 
1 The samples from which these fi gures are derived may not be 
representative of the full cohort of people enrolled in HIV care, 
thereby limiting the interpretation of the resulting coverage rates. 
Valid monitoring systems need to be established to track progress and 
obstacles in providing the full range of HIV care services and to develop 
improved estimates of coverage and attrition, especially during the 
period preceding enrolment in antiretroviral therapy.
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KEY FINDINGS
Prevention
Coverage of harm reduction programmes for people 
who inject drugs remained limited in 2010. Among 
107 reporting countries, 42 had needle and syringe 
programmes and 37 offered opioid substitution therapy.
In the subset of 30 countries that provided data on 
needle and syringe programmes, the median number 
of syringes distributed per year per person who 
injects drugs was 50.7, still below the internationally 
recommended level of 200 syringes per person who 
injects drugs per year. Three low- and middle-income 
countries – Bangladesh, India and Slovakia – provided 
200 or more syringes per person who inject drugs per 
year, and an additional three – Kazakhstan, Tajikistan 
and Viet Nam – distributed between 100 and 200 
syringes per person who inject drugs per year.
Less than 2.5% of people who inject drugs received 
opioid substitution therapy among 32 reporting 
countries.
A total of 113 low- and middle-income countries 
reported information on the availability of programmes 
engaging men who have sex with men. The most 
commonly reported interventions were HIV testing and 
counselling, followed by antiretroviral therapy and care. 
Regionally, the availability of targeted interventions 
for men who have sex with men was higher in Latin 
America and the Caribbean, in Europe and Central Asia 
and in East, South and South-East Asia.
A total of 113 low- and middle-income countries 
reported information on the existence of programmes 
and policies engaging sex workers. The most commonly 
available intervention was HIV testing and counselling, 
followed by antiretroviral therapy and care. On a 
6Scaling up services for key populations at higher risk of HIV infection
regional basis, availability was generally highest in East, 
South and South-East Asia and was substantially more 
limited in North Africa and the Middle East. Although 
sexually transmitted infection management is available 
in many countries for people who inject drugs, men who 
have sex with men, and sex workers, the prevalence of 
active syphilis in these key populations is still over 15% 
in several countries.
Testing and counselling
The reported proportions of selected key populations 
at higher risk of HIV infection receiving testing and 
counselling in the past 12 months remain limited: 
the median percentage receiving HIV testing and 
counselling was 49% among sex workers, 32% among 
men who have sex with men and 23% among people 
who inject drugs.
In the subset of countries reporting multiple surveys, 
the median uptake of HIV testing and counselling 
increased from 39% in 2006–2008 to 52% in 2009–
2010 among sex workers, increased from 30% to 35% 
among men who have sex with men and from 23% to 
25% among people who inject drugs.
Treatment and care
In Europe and Central Asia, available data reveal 
continued inequity in the access of people who inject 
drugs to antiretroviral therapy. In 2010, people who 
inject drugs represented 62% of the cumulative 
number of reported HIV cases with a known route 
of transmission but only 22% of those receiving 
antiretroviral therapy.
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6.1 Overview
This chapter describes progress made in expanding 
access to and coverage of selected health-sector 
interventions for HIV prevention among people who 
inject drugs, men who have sex with men and sex 
workers. HIV continues to disproportionately affect 
these specifi c populations, not only in countries with 
low and concentrated epidemics but also in generalized 
epidemic settings. High HIV prevalence rates have 
been reported in all three populations across all regions 
(see Chapter 1). Realizing the vision of zero new HIV 
infections and zero AIDS-related deaths thus depends 
on accelerating progress in controlling the epidemic 
among these key populations at higher risk of HIV 
infection and transmission.
Robust epidemiological surveillance among people 
who inject drugs, men who have sex with men and 
sex workers, including estimating population sizes, is 
Box 6.1 
Methodological notes on the quality and 
interpretation of data
Member States directly reported the data collated and 
discussed in this section on key populations at higher risk of 
HIV infection to WHO, UNAIDS and UNICEF in 2011. Many of the 
data points provided by countries on the coverage and impact of 
interventions for key populations at higher risk of HIV infection 
come either from surveys with relatively small sample sizes or 
from sentinel sites whose methods and sample sizes can be 
highly heterogeneous. In addition, offi cial government data may 
underestimate actual service availability if they do not consider 
data from programmes run by nongovernmental organizations, 
which in many contexts are major service providers to key 
populations at higher risk of HIV infection. The fact that a 
particular policy may be in place does not indicate the level, 
scope or quality of services available or actually delivered. 
Considerable effort is currently underway to improve data 
collection methods and processes (2).
Interpretations of coverage data must consider the fact that 
many surveys were conducted in a few large urban areas and 
the fact that the results may not necessarily refl ect prevailing 
conditions at the national level. As a result, coverage estimates 
may not be based on nationally representative estimates and 
may not be comparable across countries. Moreover, estimates 
of the sizes of these populations are still insuffi ciently available 
across regions, thus preventing the development of global 
estimates of coverage.
The analyses of HIV data presented in this section do not include 
surveys conducted before 2008 and those based on sample 
sizes with less than 100 participants. In addition, regional 
medians are only provided when the number of observations is 
equal to or greater than fi ve.
key to assessing the effectiveness and impact of HIV 
prevention programmes (see Chapter 1). Important 
progress has been made in recent years in improving 
HIV surveillance among these communities (Box 6.2). 
However, people who inject drugs, men who have sex 
with men and sex workers continue to face high levels 
of stigma and discrimination and laws that criminalize 
their behaviour, thus preventing access to health care, 
including preventive commodities, and hindering the 
very collection of data on which the design of more 
effective and effi cient programmes depends (1). Poverty, 
exclusion and other structural factors, including gender 
inequity, interact as additional barriers to expand 
access to essential services.
Enhancing the effectiveness of prevention efforts 
requires rapidly scaling up proven interventions and 
assuring the quality of programming. Moreover, the 
development of new and creative approaches must 
be intensifi ed. Upcoming guidelines on indicators and 
target setting for universal access to HIV prevention, 
treatment, care and support for sex workers and men 
who have sex with men should facilitate the assessment 
of uptake of available interventions, in addition to their 
standard availability.
6.2 Health sector interventions to prevent 
HIV infection among key populations at 
higher risk
6.2.1 People who inject drugs
WHO, UNODC and UNAIDS recommend a 
comprehensive package of nine interventions for 
HIV prevention, treatment and care among people 
who inject drugs. These are: 1 needle and syringe 
programmes, 2  opioid substitution therapy (for 
people dependent on opioid drugs) and other drug 
dependence treatments; 3 HIV testing and counselling, 
4 antiretroviral therapy, 5 prevention and treatment of 
sexually transmitted infections, 6 condom promotion 
for people who inject drugs and their sexual partners, 
7 targeted information, education and communication, 
8 diagnosis and treatment of and vaccination for viral 
hepatitis and 9  prevention, diagnosis and treatment 
of TB (3).
A total of 109 low- and middle-income countries 
reported information on the existence of programmes 
and policies engaging people who inject drugs in 2010 
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(Table 6.1), an increase of 18% compared with the 
92 countries providing data in 2009.
Regionally, most countries in Europe and Central 
Asia and in East, South and South-East Asia reported 
offering the most interventions of the comprehensive 
package of interventions for people who inject drugs, 
although these data do not assess their scope or quality 
(Table 6.2).
Availability of needle and syringe programmes and 
opioid substitution therapy, key interventions in the 
recommended package for people who inject drugs, 
remained limited, being reported by only 43 and 
37 countries, respectively. In contrast, 58 countries 
reported the availability of other types of drug 
dependence treatment, although they may not be as 
effective as opioid substitution therapy. More than 
two thirds of all reporting countries indicated having 
services that provide HIV testing and counselling as 
well as antiretroviral therapy to people who inject drugs. 
Other interventions were less frequently available.
Although the combination of suitable interventions and 
their specifi c content depend on the context in which 
they are applied, access to sterile injecting equipment 
and opioid substitution therapy are key elements of 
any successful programme to reduce HIV transmission 
associated with injecting drug use (3). Nevertheless, 
despite ongoing global efforts and advocacy, needle and 
syringe programmes and opioid substitution therapy 
remain relatively unavailable in many regions, notably 
in Latin America and the Caribbean, in the Middle 
East and North Africa. In sub-Saharan Africa, only 
one country – Mauritius – reported making available 
scaled-up needle and syringe programmes and opioid 
substitution therapy for people who inject drugs (4). 
Although responses must be context-specifi c, this is 
a critical gap in national responses, as recent research 
has clearly documented the occurrence of injecting 
drug use in the region and its contribution to the spread 
of HIV (4,5).
Figures published through other reporting systems, such 
as those undertaken by the United Nations Reference 
Needle and 
syringe 
programmes
Drug 
dependence 
treatment: 
opioid 
substitution 
therapy
Drug 
dependence 
treatment: 
others
HIV 
testing and 
counselling
Antiretroviral 
therapy
Preventing 
and treating 
sexually 
transmitted 
infections
Condom 
programming 
for people 
who inject 
drugs and 
their sexual 
partnersa 
Targeted 
information, 
education and 
communication
Viral hepatitis 
diagnosis, 
treatment and 
vaccination
Prevention, 
diagnosis and 
treatment 
of TB
Number of 
countries reporting 107 107 108 109 109 108 108 108 105 106
Number of 
countries reporting 
this intervention 
42 37 58 70 71 66 50 63 41 46
East, South and South-East Asia 
Yes 15 12 18 22 22 21 20 21 10 15
No 11 13 8 4 4 5 6 5 15 11
Europe and Central Asia  
Yes 20 20 20 19 20 17 15 18 14 11
No 0 0 0 1 0 2 5 1 4 7
Latin America and the Caribbean
Yes 4 2 9 11 11 11 6 8 5 8
No 13 15 8 6 6 6 10 9 11 9
North Africa and the Middle East
Yes 2 2 7 9 9 8 6 8 7 6
No 8 8 3 2 2 3 5 3 4 4
Sub-Saharan Africa
Yes 1 1 4 9 9 9 3 8 5 6
No 33 34 31 26 26 26 32 27 30 29
a This indicator may underestimate the availability of condom programmes, since it may not include non-targeted programming from non-public providers. 
Table 6.1 Number of low- and middle-income countries (of 149 countries surveyed) reporting the availability of interventions for HIV prevention, 
treatment and care among people who inject drugs
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Country
Number of interventions 
adopted as policy
Needle and syringe 
programmes
Opioid substitution 
therapy
HIV prevalence among 
people who inject drugs 
(%)
East, South and South-East Asia (11 countries) 
Afghanistan 9 Yes Yes 7
Cambodia 7 Yes Yes 24
China 10 Yes Yes 7
Indonesia 9 Yes Yes 27
Lao People's Democratic republic 7 No No 17
Malaysia 10 Yes Yes 22
Myanmar 10 Yes Yes 28
Nepal 8 Yes Yes 19
Pakistan 9 Yes No 21
Thailand 9 Yes Yes 31
Viet Nam 8 Yes Yes 18
Europe and Central Asia (13 countries) 
Albania 10 Yes Yes 0
Armenia 8 Yes Yes 9
Bosnia and Herzegovina 8 Yes Yes < 1
Croatia 10 Yes Yes 1
Hungary 8 Yes Yes 0
Kazakhstan 10 Yes Yes 3
Latvia 5 Yes Yes 6
Republic of Moldova 8 Yes Yes 16
Romania 8 Yes Yes 1
Serbia 8 Yes Yes 2
Tajikistan 10 Yes Yes 17
The Former Yugoslav Republic of Macedonia 10 Yes Yes 0
Ukraine 9 Yes Yes 23
Latin America and the Caribbean (4 countries) 
Brazil 9 Yes No 6
Colombia 7 No Yes 2
Mexico 9 Yes Yes 5
Paraguay 7 Yes No 9
North Africa and the Middle East (8 countries) 
Egypt NR - - 7
Jordan 8 No No 0
Lebanon 10 Yes Yes 0
Morocco 9 Yes Yes 14
Oman 7 No No 2
Iran (Islamic Republic of) 10 Yes Yes 13
Syrian Arab Republic 4 No No 6
Tunisia 6 No No 3
Sub-Saharan Africa (4 countries)
Ghana 0 No No 11
Kenya 7 No No 21
Mauritius 9 Yes Yes 47
Nigeria 5 No No 4
Total yes 30 28
Total no 9 11
a Opioid substitution therapy and other drug dependence treatments are counted as two interventions in this table, bringing the total number of WHO recommended interventions to 10.
Table 6.2 Availability of selected policies or interventions for people who inject drugs and HIV prevalence among them in 
39 countries, 2010a
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Group on HIV and Injecting Drug Use and Harm 
Reduction International (formerly the International 
Harm Reduction Association), may differ from those 
submitted by countries to WHO, UNAIDS and UNICEF 
because scope of the respective surveys differs and 
because WHO, UNAIDS and UNICEF focus on low- 
and middle-income countries only. The United Nations 
Reference Group on HIV and Injecting Drug Use found 
that, in 2009, among 158 countries with reports of 
injecting drug use and 120 countries with reports of 
HIV among people who inject drugs, needle and syringe 
programmes and opioid substitution therapy had been 
implemented in 82 and 70 countries, respectively (6). 
A survey conducted in 2010 by Harm Reduction 
International found similar fi gures, with 82 countries 
providing needle and syringe programmes and 73 
offering opioid substitution therapy (7,8).
WHO and UNODC recommend that psychosocially 
assisted pharmaceutical treatment should not be 
compulsory (9). Nevertheless, recent analysis of 
compulsory treatment suggests that up to several 
hundred thousand people who inject drugs are 
administratively or legally detained to undergo 
treatment and that opioid substitution therapy is 
made available only to a fraction of opioid-dependent 
detainees (10). Drug detention centres have poor records 
in preventing drug use and high rates of recidivism. In 
addition, drug detention centres can enhance HIV and 
related risks, violate human rights and undermine the 
potential success of proven interventions (11).
Thirty-nine countries provided data on the prevalence 
of HIV infection among people who inject drugs (Table 
6.3), ranging from close to 0% in Albania, Lebanon and 
elsewhere to 31% in Thailand and 47% in Mauritius.
Seven countries, including Myanmar and Tajikistan, 
reported having adopted all policies included in the 
package of recommended interventions. Among 
countries reporting HIV prevalence rates greater than 
0% among people who inject drugs, 25 indicated 
having available needle and syringe programmes and 
23 opioid substitution therapy. However, the adoption 
of these two interventions is still inadequate in many 
contexts. In sub-Saharan Africa, only four countries 
provided data on their availability, and three reported 
providing neither needle and syringe programmes nor 
opioid substitution therapy, including Ghana and Kenya, 
where the HIV prevalence among people who inject 
drugs exceeds 10%.
In 2010, 33 countries provided data for assessing 
the number of needle and syringe programme sites 
per 1000 people who inject drugs. As observed in 
previous years, most reporting countries are in Europe 
and Central Asia and in East, South and South-East 
Asia. Available data show that accessibility remained 
limited in 2010, with a median of 1.4 needle and syringe 
programme sites per 1000 people who inject drugs, the 
same fi gure observed among 28 reporting countries in 
2009. The highest levels were observed in Viet Nam 
and Slovakia, with 17.1 and 8.6 needle and syringe 
programme sites respectively per 1000 people who 
inject drugs.
Thirty countries reported a median of 50.7 syringes and 
needles distributed per person who injects drugs per 
year, an increase from the 44.4 reported by 27 countries 
in 2009. These levels are nevertheless substantially 
below the minimum of 200 syringes per person who 
injects drugs per year recommended by WHO, UNODC 
and UNAIDS as a key HIV prevention policy for this 
population (3). Among countries providing data in 2010, 
uptake reached the internationally recommended target 
in only three – Bangladesh, India and Slovakia. In three 
others – Kazakhstan, Tajikistan and Viet Nam – the 
number of syringes distributed per person who inject 
drugs per year was between 100 and 200.
Coverage of opioid substitution therapy remained 
limited as well in most of the 32 countries providing 
data, with a median of 2.4% of people who inject drugs 
receiving this intervention. Coverage was highest in 
the Islamic Republic of Iran and Mauritius, where 84% 
and 32%, respectively, of people who inject drugs had 
access to opioid substitution therapy.
Greater investment is needed to expand coverage of 
harm reduction interventions, including needle and 
syringe programmes and opioid substitution therapy. In 
this context, the participation of civil society and local 
communities is key to ensure that policies are tailored 
to the local context and to respond to the needs of 
people who inject drugs (Box 6.2).
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Country
Estimated number of 
people who inject drugs
Number of needle and 
syringe programmes sites 
per 1000 people who 
inject drugs
Number of syringes per 
person who injects drugs 
distributed by needle and 
syringe programmes
Percentage of people 
who inject drugs 
receiving opioid 
substitution therapy
Number of countries reporting 34 33 30 32
Median for all reporting countries 1.4 50.7 2.4
East, South and South-East Asia 
Afghanistan  20 000 1.1 34.7 0.4
Bangladesh  40 000 3 214.4 0.3
Cambodia  2 100 0.5 43.8 2.9
China  642 800 1.6 18.9 28.4
India  177 000 1.4 228.2 3
Indonesia  105 800 1.8 10.2 2.4
Iran (Islamic Republic of)  250 000 2.7 35.9 84.0 
Malaysia  170 000 1.7 17 21.8
Myanmar  75 000 0.6 91.7 1.5
Nepal  28 500 1.6 56.5 1.2
Sri Lanka 700 0 … 0
Thailanda 40 000–97 000 0.5–1.2 2.4–5.8 2.3–5.5
Viet Nam  193 300 17.1 140.6 1.3
Median  1.6 44 2
Europe and Central Asia 
Albania  7 000 0.7 … 7.5
Armenia  5 000 0.6 15.7 2.2
Belarus  50 000 0.7 46.5 0.9
Bosnia and Herzegovina  7 500 1.1 50.7 9.8
Croatia  6 300 1.3 98.4 22.4
Georgia  40 000 0.3 26.6 7
Hungary  5 700 3 65.8 17.4
Kazakhstan  119 100 1.4 176.4 0.1
Latvia  18 000 1 17.3 1.1
Republic of Moldova  25 000 1.2 65.8 1.4
Romania  17 700 0.6 54.6 9.1
Serbia  18 000 0.2 25.5 6.9
Slovakia 800 8.6 209.1 75
Tajikistan  25 000 1.9 104.4 0.1
The former Yugoslav Republic of Macedonia  10 200 1.5 49 11.2
Ukraine  290 000 5.3 62.4 2.1
Median  1.1 55 7
Latin America and the Caribbean 
Brazil  472 200 … … …
Mexico  64 300 0.4 2.7 …
North Africa and the Middle East 
Morocco  18 000 0.2 2.8 0.4
Sub-Saharan Africa
Madagascar 600 1.7 … 0
Mauritius  10 000 5.2 51.9 32.8
a Thailand is not included in the median for East, South and South-East Asia.
Table 6.3 Estimated percentage of people who inject drugs receiving opioid substitution therapy and estimated number of 
syringes and needles distributed by needle and syringe programmes per person who injects drugs during the past 12 months, 
2010
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Box 6.2 
MENAHRA: strengthening civil society to support and expand harm reduction activities in the Middle East and North Africa
In 2007, WHO and the International Harm Reduction Association partnered to establish the Middle East and North Africa Harm Reduction 
Association (MENAHRA) with fi nancial support from the DROSOS Foundation. MENAHRA consists of a multi-stakeholder regional network 
on harm reduction involving civil society organizations, governments, experts and academe. It is represented by a Secretariat and three 
subregional knowledge hubs located in the Islamic Republic of Iran, Lebanon and Morocco, and it seeks to support civil society across the 
region to lead the change towards evidence-informed policies and accelerate the roll-out of harm reduction strategies.
Through its work to date, MENAHRA has delivered over 30 training workshops with more than 12 training resource modules and 6 advocacy 
workshops. Advocacy materials have also been disseminated to harm reduction stakeholders in 18 countries from the Middle East, North 
Africa and beyond through its online resources and conferences. It also organized and hosted the fi rst regional conference on harm reduction 
in 2009 and hosted Harm Reduction International’s annual conference in 2011. Ten civil society organizations in seven countries in the Middle 
East and North Africa have benefi ted from direct MENAHRA technical and fi nancial support. More than 1000 people are now continually 
receiving information related to harm reduction in the region through the MENAHRA web site and newsletters.
Stakeholders have also indicated that MENAHRA has been able to positively infl uence the policy environment towards greater acceptance 
of harm reduction as a core strategy for HIV prevention for people who inject drugs. In 2009, Morocco revised its national strategy on drug 
use to incorporate harm reduction activities. In 2010, Tunisia developed a harm reduction strategy and the Syrian Arab Republic secured 
funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria to implement harm reduction interventions through a successful Round 
10 proposal. Pakistan approved piloting opioid substitution therapy in 2010, and funding from the Global Fund has now been obtained to 
scale up coverage to 1000 people who inject drugs. Partner civil society organizations have also highlighted that their cooperation with 
MENAHRA has allowed them to expand their needle and syringe programmes and outreach to people who inject drugs and to improve 
collaboration with national stakeholders.
MENAHRA has been able to mobilize additional resources from the Global Fund to Fight AIDS, Tuberculosis and Malaria through a fi ve-year, 
US$ 8.3 million grant approved in funding Round 10 in 2010. This is the fi rst regional Global Fund grant exclusively dedicated to support 
harm reduction and civil society activities. Through this grant, MENAHRA and the Global Fund expect to provide additional support for civil 
society organizations to catalyse an environment conducive to the implementation of harm reduction strategies, build the capacity of service 
providers and supply technical resources to assist and accelerate programme implementation.
6.2.2 Men who have sex with men
Men who have sex with men continue to be at 
considerably higher risk for HIV infection worldwide 
compared with general populations surveyed. A meta-
analysis of surveillance data in low- and middle-income 
countries found that men who have sex with men are 
19.3 times more likely to be living with HIV than the 
general population (12). The reported prevalence of 
HIV infection among men who have sex with men 
ranges from 0% to 33%, with rates surpassing 20% 
in countries as diverse as Bolivia, Jamaica, Mexico, 
Myanmar, Thailand, Trinidad and Zambia (13). Syphilis 
infection, which is recognized as facilitating HIV 
infection, is highly prevalent among MSM, particularly 
among MSM living with HIV (Box 6.4) (13). The reported 
prevalence of active syphilis infection among men who 
have sex with men was over 15% in countries such 
as Afghanistan, Argentina, Fiji, Guatemala, Jamaica, 
Morocco, Nicaragua, and Paraguay (Annex 2).
WHO and partners have made recommendations for a 
public health approach to preventing and treating HIV 
and other sexually transmitted infections among men 
who have sex with men and transgender people (13,14). 
This package of interventions1 covers the key areas in 
which action is needed to develop comprehensive and 
effective responses, including recommendations on 
human rights and non-discrimination in health care 
settings, on HIV prevention, treatment and care and 
on prevention and care for other sexually transmitted 
infections. Studies have shown positive effects of these 
interventions among men who have sex with men, and 
recent modelling suggests that these interventions 
may also positively affect the number of people newly 
infected among the general population (15).
Improving access to and uptake of prevention, 
treatment and care services among men who have 
sex with men requires supplementing health sector 
interventions with structural interventions to address 
stigma and discrimination (Box 6.3). Legal and policy 
barriers play a key role in the vulnerability of men who 
have sex with men and transgender people to HIV. Laws 
and policies that promote universal access and gender 
1 Guidelines provide evidence and technical recommendations on: 1) 
preventing sexual transmission, 2) HIV testing and counselling, 3) 
behavioural interventions and information, education, communication, 
4) substance use and prevention of bloodborne infections, 5) HIV care 
and treatment and 6) prevention and care for other sexually transmitted 
infections (15).
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equality in principle may fail for men who have sex with 
men in practice, where homophobic cultural, religious 
or political forces are active and where criminalization 
of same-sex behaviour exists (15). It is thus essential 
to address legal constraints and cultural norms that 
prevent access to services and discourage health-
seeking behaviour.
A total of 113 low- and middle-income countries 
reported information on the existence of programmes 
engaging men who have sex with men (Table 6.4). 
The most commonly reported interventions were HIV 
testing and counselling, available in 84 countries, 
followed by antiretroviral therapy and care, available 
in 80 countries. Internet-based interventions, hepatitis 
B screening and vaccination and harm reduction 
programmes were reported less frequently and were 
available in only 33, 23 and 15 countries, respectively.
Regionally, the availability of interventions engaging 
men who have sex with men is higher in Latin America 
and the Caribbean, in Europe and Central Asia and in 
East, South and South-East Asia. Despite evidence 
indicating high HIV prevalence among men who have 
sex with men in sub-Saharan Africa, the availability 
of targeted interventions was generally lowest in this 
region (see Chapter 1).
Box 6.3 
Scaling-up a comprehensive HIV response among men who have sex with men in Mexico
Mexico has a concentrated HIV epidemic affecting predominantly key populations at higher risk of HIV infection (Fig. 6.1). At the end of 2010, 
an estimated total of 225 000 people were living with HIV, with 143 281 people with AIDS and about 102 000 total deaths. Sex among men 
has been estimated as the main mode of transmission in the country, accounting for about 59% of all the cumulative people infected with HIV.
Since 2007, the National Center for AIDS Prevention and Control in Mexico (CENSIDA) has invested more than US$ 15 million through 
nongovernmental organizations to fi nance prevention activities and strategies focusing on men who have sex with men. The federal government 
currently distributes around 25–30 million male condoms per year, mostly for men who have sex with men and other key populations at higher 
risk for HIV infection, along with an additional 60–80 million condoms through state-level programs for specifi c population groups. In 2011, 
Mexico started to implement a fi ve-year, US$ 64 million project supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria in 44 
cities with the highest cumulative HIV incidence among men who have sex with men. It will promote HIV testing and counselling, distribute 
condoms and lubricants and implement peer workshops for behaviour change.
Before 2003, immediate access to antiretroviral therapy depended on insurance provided by health social welfare institutions linked to formal 
employment, and waiting lines were frequent for uninsured people. In addition, antiretroviral therapy was restricted to women, children 
and “family men”, thus excluding men who have sex with men, transgender people, sex workers and people who inject drugs. However, 
universal access to antiretroviral therapy was introduced in 2003, and implementation was completed in 2008–2009. Now all people with a 
medical indication for antiretroviral therapy in accordance with national treatment guidelines (CD4 cell count at or below 350 cells/mm3) are 
immediately enrolled in care and antiretroviral therapy, although late diagnosis remains an important issue among men who have sex with men.
Stigma and homophobia are still prevalent in many sectors of Mexican society and have been identifi ed as major obstacles to accessing 
health care, prevention and early diagnosis of HIV. The National AIDS Programme has introduced a full-fl edged training process to raise 
awareness and sensitize health personnel working at centres that provide direct HIV services to prevent discrimination, stigma, homophobia 
and transphobia. CENSIDA has also launched mass media and face-to-face seasonal campaigns, called “Homophobia is OUT”, as well as 
specifi c activities with the gay community to actively promote community involvement. Approaches have been developed to leverage the 
power of social networks and mass media to support changes in social norms. This combination of strategies is expected to promote healthy 
behaviour outcomes and contribute to the ultimate elimination of stigma and discrimination in the long term.
Fig. 6.1 Estimated HIV prevalence by key population, Mexico, 2008–2009
2 4 6 8 10 12 14 16
Women who have sex with men 0.2%
Prevalence (%)
Direct comparisons between HIV prevalence may not be appropriate because of differences in sampling methods and populations surveyed.
Men who do not have sex with men 0.5%
Clients of sex workers 0.6%
Prison inmates 1.0%
Female sex workers 2.0%
People who inject drugs 5.0%
Men who have sex with men 11.0%
Male sex workers 15.0%
0
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Promoting 
consistent 
condom usea 
Individual- 
and 
community- 
level 
interventions
Prevention 
interventions 
in sex venues
Social 
marketing 
campaigns
Internet-
based 
intervention
HIV 
testing and 
counselling
HIV 
treatment 
and care
Sexually 
transmitted 
infection 
management,b 
including 
screening for 
asymptomatic 
gonorrhoea, 
chlamydia 
and syphilis
Hepatitis B 
vaccination
Comprehensive 
package of 
interventions 
for men who 
have sex with 
men who inject 
drugs
Total number of 
countries reporting 113 110 110 111 109 113 113 109 109 107
Number of 
countries reporting 
this intervention 
79 70 55 48 33 84 80 60 23 15
East, South and South-East Asia 
Yes 20 20 12 14 8 24 22 21 7 2
No 6 6 14 12 18 2 4 5 19 24
Europe and Central Asia  
Yes 16 14 13 9 12 17 17 11 7 5
No 3 4 4 9 5 2 2 6 10 11
Latin America and the Caribbean
Yes 20 15 18 14 7 19 19 13 4 3
No 1 4 3 7 14 2 2 8 17 17
North Africa and the Middle East
Yes 7 7 4 3 3 8 8 4 2 2
No 4 4 6 7 7 3 3 6 8 8
Sub-Saharan Africa
Yes 16 14 8 8 3 16 16 11 3 3
No 20 22 28 28 32 20 20 24 32 32
a This indicator may underestimate the availability of condom programmes, since it may not include non-targeted programming from non-public providers.
b  Includes screening for asymptomatic Neisseria gonorrhoeae infection, Chlamydia trachomatis infection and syphilis.
Table 6.4 Number of low- and middle-income countries (of 149 countries surveyed) reporting the availability of interventions for HIV 
prevention, treatment and care among men who have sex with men
6.2.3 Sex workers
A total of 113 low- and middle-income countries 
reported information on the existence of programmes 
and policies engaging sex workers1  (Table 6.5). Similar 
to men who have sex with men, the most commonly 
available targeted intervention was HIV testing and 
counselling, reported by 101 of the 113 countries. HIV 
treatment and care were available in 100 countries 
and symptomatic treatment of sexually transmitted 
infections in 94 countries. The least commonly reported 
intervention was access to a package of interventions 
for sex workers who also inject drugs.
Regional variation was considerable. In East, South 
and South-East Asia, all reporting countries indicated 
making available targeted services for HIV testing and 
counselling, HIV treatment and care and treatment 
of symptomatic sexually transmitted infections. In 
contrast, availability was substantially more limited in 
1 Most data refer to female sex workers.
North Africa and the Middle East, where at least one 
quarter of the reporting countries indicating having no 
targeted interventions for sex workers.
Despite the availability of interventions for STI 
management among sex workers, syphilis prevalence 
remains high in several regions of the world (Box 6.4). 
The reported prevalence of active syphilis  was over 15% 
in countries such as Argentina, Guinea-Bissau, Mongolia, 
Nicaragua, and Papua New Guinea (Annex 1).
Sex workers are also often subject to the effects of 
harmful legislation and human rights violations, which 
include coercion, stigma, poor access to information and 
prevention services and frequent exposure to violence. 
Structural interventions, including decriminalizing 
sex work and involving sex workers in planning and 
implementing interventions, are necessary to reduce 
social vulnerability and improve the access to and 
uptake of essential HIV interventions.
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Targeted condom 
programminga 
HIV testing and 
counselling
HIV treatment 
and care
Treating 
symptomatic 
sexually 
transmitted 
infections
Treating 
asymptomatic 
sexually 
transmitted 
infections
Periodic 
presumptive 
treatment 
of sexually 
transmitted 
infectionsb
Access to a 
package for 
people who inject 
drugs
Empowerment of 
sex workersc
Total number of 
countries reporting 113 113 112 109 109 109 109 109
Number of 
countries reporting 
this intervention 
95 101 100 94 64 34 16 74
East, South and South-East Asia 
Yes 24 26 25 26 19 10 4 20
No 2 0 0 0 7 16 22 5
Europe and Central Asia  
Yes 15 17 18 13 9 4 4 8
No 4 2 1 4 7 10 12 7
Latin America and the Caribbean
Yes 19 20 19 18 12 6 2 16
No 2 1 2 3 9 15 17 5
North Africa and the Middle East
Yes 7 8 8 6 4 1 2 3
No 4 3 3 4 6 9 8 7
Sub-Saharan Africa
Yes 30 30 30 31 20 13 4 27
No 6 6 6 4 16 22 31 8
a This indicator may underestimate the availability of condom programmes, since it may not include non-targeted programming from non-public providers.
b Or syndromic management of sexually transmitted infections in accordance with recent guidelines (13).
c Participation in planning and implementation of HIV and sexually transmitted infection prevention and care activities.
Table 6.5 Number of low- and middle-income countries (of 149 countries surveyed) reporting the availability of interventions for the 
prevention, treatment and care of HIV among sex workers
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Box 6.4 
Preventing and managing sexually transmitted infections among sex workers and men who have sex with men1
Among 149 low- and middle-income countries surveyed in 2010, 40 (27%) submitted data on the percentage of sex workers with active syphilis 
and 31 (21%) on the percentage of men who have sex with men with active syphilis. The reporting level was similar in 2008 (Table 6.6).2 
The overall median percentage of sex workers with active syphilis among reporting countries was 3.8% in 2010. Active syphilis was highest 
among sex workers in Latin America and the Caribbean, at 5.1%, and lowest in sub-Saharan Africa, at 2.4%.
The overall median percentage of men who have sex with men with active syphilis among reporting countries, at 6.4% in 2010, was slightly 
higher than among sex workers. Latin America and the Caribbean had the highest reported positivity, reaching 13.1%, and East, South and 
South–East Asia the lowest, with 5.0%. Annex 1 provides detailed country data on indicators related to sexually transmitted infections for 2010.
Trends cannot yet be assessed over time because limited longitudinal data are available across a comparable sample. However, as the breadth 
and robustness of monitoring and evaluation systems improve and more countries contribute data, more and higher-quality information on 
services and interventions related to sexually transmitted infections for these populations is expected to become available.
1 Chapter 7 discusses three indicators addressing sexually transmitted infections among antenatal care attendees.
2 “Active” syphilis was defi ned in this context as a positive result on both treponemal and non-treponemal tests.
Sex workers Men who have sex with men
Region
Number of 
countries 
reporting in 
2008 
Median 
positivity of 
active syphilis 
in 2008
Number of 
countries 
reporting in 
2010 
Median 
positivity of 
active syphilis 
in 2010
Number of 
countries 
reporting in 
2008
Median 
positivity of 
active syphilis 
in 2008
Number of 
countries 
reporting in 
2010
Median 
positivity of 
active syphilis 
in 2010
East, South and 
South-East Asia
13 2.7% 14 2.9% 11 3.3% 12 5.0%
Europe and Central 
Asia
8 13.2% 3 a 8 3.8% 3 a
Latin America and 
the Caribbean
8 7.7% 11 5.1% 7 7.8% 12 13.1%
North Africa and 
the Middle East
4 a 2 a 2 a 1 a
Sub-Saharan Africa 9 7.1% 10 2.4% 3 a 3 a
Global total 42 6.9% 40 3.8% 31 4.1% 31 6.4%
a Regional medians are not calculated if fewer than fi ve countries provided data.
Table 6.6 Median positivity of active syphilis among sex workers and men who have sex with men in 149 countries 
surveyed, 2008 and 2010
6.3 Knowledge of serostatus among key 
populations at higher risk of HIV 
infection
As the gateway to other HIV services, improving 
knowledge of serostatus among populations at higher 
risk of HIV infection is essential in implementing 
comprehensive HIV responses and identifying inequity 
in the access to HIV services.
Table 6.7 summarizes data reported by countries on the 
uptake of testing and counselling by people who inject 
drugs, men who have sex with men and sex workers. 
Substantially more countries were able to report on 
testing coverage among sex workers than among men 
who have sex with men or people who inject drugs. In 
addition, although coverage of HIV testing remained 
generally low across populations and regions, it was 
relatively higher among sex workers than among men 
who have sex with men and people who inject drugs.
Globally, 52 countries reported data on HIV testing and 
counselling among sex workers versus 45 in 2008. The 
median proportion of sex workers who knew their status 
from a recent HIV test was 49%, with considerable 
country variability. Knowledge of serostatus among 
sex workers reached a median of 60% in sub-Saharan 
Africa (16 countries, range 0–95%) and 59% in Latin 
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America and the Caribbean (10 countries, range 18–
75%), and 35% in East, South and South-East Asia (17 
countries, range 14–98%).
Forty-one countries provided data on the uptake of HIV 
testing and counselling among men who have sex with 
men. Overall, median coverage was 32% and highest 
in Latin America and the Caribbean, at 32% (range 
7–63%), followed by Europe and Central Asia at 31% 
(range 4–60%). In a group of 26 reporting countries, 
a median of only 23% of people who inject drugs had 
received an HIV test in the past 12 months and knew 
the results. Europe and Central Asia had the highest 
median coverage of testing and counselling among 
people who inject drugs, with 26%, followed by East, 
South and South–East Asia, with 21%.
Establishing clear regional or global time trends in 
scaling up HIV testing and counselling across countries 
is challenging because the sample sizes of available 
surveys are generally small, and many may not 
adequately refl ect rapid changes that may take place 
over a short period of time. Nevertheless, the overall 
direction of change can be gauged by comparing data 
reported by countries that have conducted more than 
one survey from 2006 to 2010 (Table 6.8).
People who inject drugs Men who have sex with men Sex workers
Overall median 23% 32% 49%
Total number of countries reporting  (n =) 26 41 52
East, South and South-East Asia 
Median 21% 27% 35%
n =  11 14 17
Europe and Central Asia  
Median 26% 31% 42%
n =  9 11  8
Latin America and the Caribbean  
Median … 32% 59%
n = 2 11 10
North Africa and the Middle East 
Median … … …
n = 2 1 2
Sub-Saharan Africa
Median … … 60%
n = 2 4 15
a Annexes 3A.1, 3A.2 and 3A.3 provide detailed country data. Country data may have been generated through surveys that are not nationally representative, and some survey results may 
overestimate the proportion of people accessing services. For instance, where reported coverage is close to 100%, they may represent people enrolled in treatment services or other 
settings where an HIV test is required to access the service.
Table 6.7 Percentage of selected key populations at higher risk of HIV infection who received an HIV test in the last 12 
months and who know the results, 2008–2010a
2006–2008 2009–2010
People who inject drugs 
Median 23% 25%
n = 13
Men who have sex with men  
Median 30% 35%
n = 16
Sex workers  
Median 39% 52%
n = 23
a Annexes 3A.1, 3A.2 and 3A.3 provide detailed country data. Country data may have 
been generated through surveys that are not nationally representative, and some 
survey results may overestimate the proportion of people accessing services. For 
instance, where reported coverage is close to 100%, they may represent people 
enrolled in treatment services or other settings where an HIV test is required to 
access the service.
n = Number of countries reporting
Table 6.8 Median percentage of selected key populations 
at higher risk of HIV infection who received an HIV test in 
the last 12 months and who know the results, 2006–2008 
and 2009–2010
Available fi gures suggest that the median uptake of 
HIV testing and counselling has increased among 
sex workers between 2006–2008 and 2009–2010, 
from 39% to 52% among 23 reporting countries, with 
notable regional improvements in reported proportions 
observed in sub-Saharan Africa, from 49% (range 34–
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71%) to 60% (range 38–89%); East, South and South-
East Asia, from 19% (range 5–68%) to 33% (range 
14–98%); and in Europe and Central Asia, where the 
median proportion of sex workers who reported receiving 
a recent HIV test and learned their results increased from 
45% (range 31–68%) to 59% (range 23–59%).
Longitudinal data on men who have sex with men and 
people who inject drugs are more limited and show 
that the median uptake of HIV testing and counselling 
in the past 12 months grew more modestly among 
men who have sex with men between 2006–2008 and 
2009–2010, from 30% to 35% (16 reporting countries), 
and among people who inject drugs from 23% to 25% 
(13 reporting countries). Such low levels underscore the 
need for greater investment to monitor access to and 
increase the uptake of HIV testing and counselling by 
these population groups.
6.4 Treatment and care for key populations 
at higher risk of HIV infection
Despite improving epidemiological surveillance, limited 
disaggregated data are available globally on access to 
antiretroviral therapy by sex workers, men who have sex 
with men and people who inject drugs. Nevertheless, 
progress has been made in Europe and Central Asia 
towards consistently collecting fi gures on antiretroviral 
therapy uptake by mode of transmission, including 
through injecting drug use.
This is especially noteworthy given the key role of 
injecting drug use in the region’s epidemiological 
dynamics and scientifi c evidence that indicates that 
providing antiretroviral therapy to this population has 
individual and population-wide health benefi ts (16). 
Such data are also important to identify gaps in service 
coverage and to design policies to ensure equitable 
access to HIV treatment. Using HIV surveillance (case 
reporting) fi gures and data from antiretroviral therapy 
programmes, the WHO Regional Offi ce for Europe has 
also assessed the extent to which people who inject 
drugs in the region have access to antiretroviral therapy 
and how these patterns have changed over time.
Data collected through standardized annual reporting 
between 2002 and 2010 show that uneven progress 
has been made towards ensuring that people who 
inject drugs have access to antiretroviral therapy 
in the region’s low- and middle-income countries. 
Comparing the proportion of HIV cases caused by 
injecting drug use with the corresponding proportion 
of people receiving antiretroviral therapy who inject 
drugs, in 2002, 71% of the reported people living with 
HIV acquired HIV infection through injecting drug use, 
whereas only 20% of those receiving antiretroviral 
therapy were people who injected drugs.1 In 2005 and 
2006, among 21 and 23 countries with available data, 
people who injected drugs represented 77% of reported 
cases and 26% of antiretroviral therapy recipients, 
a proportion that declined to 22% in 2010 among 
19 reporting countries.
Although no trends can be statistically ascertained 
due to incomparable samples (notably missing data 
from the Russian Federation in 2002 and 2010), these 
data suggest that most of the people who acquire 
HIV infection in reporting countries are people who 
inject drugs and that, despite this, their treatment 
needs remain considerably underserved (Table 6.9). 
These fi ndings are corroborated by recent research that 
shows that in fi ve countries – China, Malaysia, Russian 
Federation, Ukraine and Viet Nam – people who inject 
drugs comprised 67% of the cumulative people living 
with HIV in 2008 but only 25% of those receiving 
antiretroviral therapy (17).
1 Comprehensive estimates of antiretroviral therapy needs for people who 
inject drugs are not available.
2002 2005 2006 2010a
Number of reporting countries among 26 low- 
and middle-income countries surveyed 
17 21 23 19
HIV cases among people who inject drugs 
(% among cumulative reported HIV cases with a 
known transmission route)
46 052
(71%)
221 849
(77%)
249 982
(77%)
185 565
(62%)
People who inject drugs receiving antiretroviral 
therapy (% among the total reported people 
receiving antiretroviral therapy with a known 
route of transmission)
130
(20%)
4 670
(26%)
5 275
(26%)
7 646
(22%)
a 2009 HIV case-reporting data.
Table 6.9 Proportion of people who inject drugs receiving 
antiretroviral therapy in low- and middle-income countries 
in Europe and Central Asia, 2002–2010
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KEY FINDINGS7
National political commitments to expand HIV prevention, treatment, care and support services for women and 
children intensifi ed in 2010. The global plan to eliminate new HIV infections among children and improve the health 
of mothers set ambitious targets for 2015, including reducing the number of children newly infected with HIV by 
90%, reducing the number of women dying from HIV-associated causes during pregnancy, delivery and postpartum 
by 50% and reducing the mother-to-child transmission of HIV to less than 5%.
In 2010, 35% of pregnant women in low- and middle-income countries received HIV testing and counselling, up 
from 26% in 2009. In sub-Saharan Africa, the region with the highest number of pregnant women living with HIV, 
coverage increased from 35% to 42%, with especially high rates of increase in countries in eastern and southern 
Africa (from 52% to 61%).
In 2010, the coverage of pregnant women receiving the most effective regimens for preventing mother-to-child 
transmission (excluding single-dose nevirapine) is an estimated 48% [44–54%].
Among the 22 priority countries for eliminating mother-to-child transmission, 5 reached the 2001 UNGASS goal of 
providing antiretroviral medicine (excluding single-dose nevirapine) for preventing mother-to-child transmission to 
80% of pregnant women living with HIV in need: Botswana, Lesotho, Namibia, South Africa and Swaziland.
Among the estimated 1.49 million infants born to mothers living with HIV, 42% [38-48%] received antiretroviral 
medicine to prevent HIV transmission from their mothers, up from 32% [29–36%] in 2009.
The coverage of HIV interventions for infants and children is improving but remains low. Among 65 reporting countries, 
only 28% [24–30%] of infants born to mothers living with HIV received an HIV test within the fi rst two months of life. 
Only 23% [19–24%] of HIV-exposed children in 87 reporting countries received co-trimoxazole prophylaxis within 
two months of birth in 2010. The number of children receiving antiretroviral therapy increased from an estimated 
354 600 in 2009 to 456 000 in 2010, but the coverage for the estimated 2 020 000 [1 800 000–2 300 000] children 
in need is only 23% [20–25%], much lower than the 51% [48–54%] coverage of antiretroviral therapy among adults.
Scaling up HIV services for women 
and children: towards eliminating mother-
to-child transmission and improving maternal 
and child health in the context of HIV
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A global consensus emerged during the past year on 
the need for and feasibility of substantially reducing 
the number of children newly infected with HIV and 
improving the health of mothers and children to 
accelerate progress towards achieving the related 
Millennium Development Goals,1 including Millennium 
Development Goal 6 on HIV/AIDS. The updated 2010 
WHO guidelines on antiretroviral medicine to treat 
pregnant women and prevent HIV infection among 
infants (1), combined with a renewed commitment 
to delivering comprehensive services for preventing 
mother-to-child transmission, defi ne approaches to 
considerably reducing the rates of HIV transmission, 
making eliminating mother-to-child transmission an 
achievable goal even in resource-limited settings.2 
In June 2010, under the leadership of the Executive 
Directors of UNICEF and UNAIDS and the Director-
General of WHO, United Nations agencies and key 
global partners committed to work towards eliminating 
the mother-to-child transmission of HIV by 2015. The 
world leaders gathered at the United Nations General 
Assembly High-level Meeting on AIDS in June 2011 
further endorsed this goal by adopting the Political 
Declaration on HIV/AIDS (3).
7.1 Global Plan towards the elimination of 
new HIV infections among children by 
2015 and keeping their mothers alive
At the United Nations General Assembly High-level 
Meeting on AIDS in June 2011, the United Nations 
Secretary-General launched the Global Plan towards 
the elimination of new HIV infections among children by 
2015 and keeping their mothers alive (4), which lays out 
key actions needed at both the global and country level 
to expedite progress toward these goals.3 The Global 
1 Millennium Development Goal 4: Reduce child mortality (with a target 
of reducing the mortality rate among children younger than fi ve years by 
two thirds between 2009 and 2015); Millennium Development Goal 5: 
Improve maternal health (with targets of reducing by three quarters the 
maternal mortality ratio and achieving universal access to reproductive 
health by 2015).
2 A technical consultation convened by WHO and partners in Geneva in 
November 2010 defi ned elimination of mother-to-child transmission as 
“achieving less than a 5% transmission rate of HIV from mother to child 
at the population level and a 90% reduction of infections among young 
children by 2015, from a 2009 baseline” (2).
3 A high-level Global Task Team, co-chaired by the UNAIDS Executive 
Director and the United States Global AIDS Coordinator, was 
established to support the development of a global plan to structure 
partner engagement towards eliminating the mother-to-child 
transmission of HIV. The Global Task Team comprises 25 countries and 
30 civil society organizations, private sector organizations, networks of 
people living with HIV and international organizations.
Box 7.1
The 22 priority countries for eliminating mother-to-
child transmission
Angola
Botswana
Burundi
Cameroon
Chad
Côte d’Ivoire
Democratic Republic of the Congo
Ethiopia
Ghana
India
Kenya
Lesotho
Malawi
Mozambique
Namibia
Nigeria
South Africa
Swaziland
Uganda
United Republic of Tanzania
Zambia
Zimbabwe
Box 7.2 
The Global Plan’s country implementation actions 
towards eliminating new HIV infections among 
children and keeping their mothers alive: 10-point 
plan
1 Conduct a strategic assessment of key barriers.
2 Develop or revise nationally owned plans and cost them.
3 Assess the available resources and develop a strategy to 
address unmet needs.
4 Implement and create demand for a comprehensive, 
integrated package of HIV prevention and treatment 
interventions and services.
5 Strengthen synergies and integration fi t to context 
between HIV prevention and treatment and related 
health services to improve maternal and child health 
outcomes.
6 Enhance the supply and utilization of human resources 
for health.
7 Evaluate and improve access to essential medicines and 
diagnostics and strengthen supply chain operations.
8 Strengthen community involvement and communication.
9 Better coordinate technical support to enhance service 
delivery.
0 Improve outcomes assessment, data quality, and impact 
assessment.
Source: Global Plan towards the elimination of new HIV infections among children 
by 2015 and keeping their mothers alive (4).
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Plan (4) recognizes the need to better integrate HIV 
interventions with broader maternal, newborn and child 
health programmes to expand coverage, ensure the 
sustainability of service delivery and ultimately improve 
the survival of mothers and children in countries with a 
high burden of HIV. Within the Global Plan, 22 countries 
(India and 21 countries in sub-Saharan Africa), which 
account for nearly 90% of pregnant women living 
with HIV, have been identifi ed as priority countries for 
intensifi ed support (Boxes 7.1 and 7.2) (5).
7.1.2 Regional initiatives towards eliminating 
new HIV infections among children
Regional initiatives have been launched to galvanize 
efforts and accelerate progress towards achieving the 
goals set out in the Global Plan (Box 7.3). Regional plans 
have already been released in the European Region (6,7), 
Region of the Americas (8) and Asia-Pacifi c regions (9) 
and are currently being developed in the African Region 
(Box 7.3). Each initiative recognizes the unique regional 
epidemic and challenges that need to be addressed to 
eliminate new HIV infections among children. Some 
have also been integrated with initiatives for eliminating 
congenital syphilis (Box 7.7).
7.1.3 Tracking the progress of the Global Plan
Accountability and shared responsibility for results 
at the community, country, regional, and global levels 
are central components of the Global Plan (4), which 
incorporates the four prongs of the comprehensive 
approach recommended by the United Nations to 
reduce the mother-to-child transmission of HIV (13):
1. primary prevention of HIV infection among women 
of childbearing age;
2. preventing unintended pregnancies among women 
living with HIV;
3. preventing HIV transmission from pregnant women 
living with HIV to their infants; and
4. providing appropriate treatment, care and support to 
mothers living with HIV and their children and families.
The Global Plan (4) includes 10 ambitious targets for 
2015 to monitor progress on its objectives (Fig. 7.1).
This report provides the global baseline fi gures that 
will be used to monitor progress towards the Global 
Plan targets (Annex 7 provides data on the 22 priority 
countries). Updates against these baseline numbers 
will be provided annually (Boxes 7.4 and 7.5).
Box 7.3
Regional initiatives towards eliminating new HIV infections among children
Region Main features of each regional initiative
Europe • The Strategic Framework for the Prevention of HIV Infections in Infants in Europe (6) set targets to prevent 
children from acquiring HIV infections, with high-level political commitment.
• The regional plan (6) supports universal coverage of HIV testing during pregnancy and promotes access to 
interventions for preventing mother-to-child transmission for people who inject drugs.
• The fi rst regional progress report towards eliminating mother-to-child transmission was published in January 2011 
(10).
• The European Action Plan for HIV/AIDS 2012–2015 (7) aims to reduce vertical transmission to less than 2% among 
children who are not breastfeeding populations and to less than 5% among children who are breastfeeding by 
2015.
Americas • A dual initiative to eliminate congenital syphilis and mother-to-child transmission of HIV was adopted in 2009 
(11).
• A regional monitoring strategy was published in 2010 (8).
• The fi rst progress report is scheduled to be released soon (12).
Asia-Pacifi c • A dual elimination initiative was launched in August 2011: Elimination of new paediatric HIV infections and 
congenital syphilis in Asia-Pacifi c 2011–2015: conceptual framework and monitoring and evaluation guide (9).
• The regional plan supports a common systematic approach to dual elimination and outlines a strategy that HIV, 
sexually transmitted infection and maternal, newborn and child health programmes in the region can adapt to 
develop country-specifi c operational plans.
Africa • This region has the highest burden of HIV.
• A strategic regional framework towards the elimination of new HIV infections among children and keeping 
mothers alive was reviewed in October 2011, and the regional plan for coordinated agency responses to support 
the implementation of the strategic framework was fi nalized.
• The regional plan for eastern and southern Africa will be launched in December 2011.
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Prong 1 Target
Reduce HIV incidence in 
women 15-49 by 50%.
Prong 2 Target
Reduce unmet need for 
family planning among 
women to zero (MDG goal).
Prong 3 Target
Reduce mother-to-child 
transmission of HIV to 5%.
90% of mothers receive 
perinatal antiretroviral 
therapy or prophylaxis.
90% of breastfeeding 
infant-mother pairs receive 
antiretroviral therapy or 
prophylaxis.
Prong 4 Target
Provide 90% of pregnant 
women in need of 
antiretroviral therapy for their 
own health with life-long 
antiretroviral therapy.
TARGETS AND INDICATORS
Overall Targets
1. REDUCE THE NUMBER OF 
NEW HIV INFECTIONS AMONG 
CHILDREN BY 90%.
2. REDUCE THE NUMBER OF 
HIV-ASSOCIATED DEATHS 
AMONG WOMEN DURING 
PREGNANCY, DELIVERY AND 
PUERPERIUM BY 50%.
Provide antiretroviral 
therapy for all HIV infected 
children.
Reduce under 5 deaths 
due to HIV by > 50%
Fig. 7.1 Monitoring framework of the Global Plan
Source: Countdown to zero: Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive 2011–2015 (4).
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Box 7.4
Global Plan indicators, baselines and targets
Table 7.1 summarizes the main indicators included in the Global Plan (4), along with their 2009 baseline values, 2015 targets and progress 
in 2010 for low- and middle- income countries. 
Areas to monitor 2009 2010 2015 target 
Number of women living with HIV delivering 1 490 000a 1 490 000 743 000b
Overall target: 
Number of new paediatric HIV infections 430 000 390 000 <43 000
Overall target: 
HIV-associated deaths among women during pregnancy, delivery and puerperium 42 000c Not available 21 000
Prong 1 target: 
New HIV infections in women aged 15-49 1 070 000
a 1 050 000 535 000
Prong 2 target: 
Unmet family planning need among women 15–49 years old 11%
d Not available 0
Prong 3, target 3.1:
Mother-to-child HIV transmission rate 29%
a 26% <5%
Prong 3, target 3.2: 
Maternal antiretroviral (prophylaxis and therapy) coverage
48%e
(including single-
dose nevirapine)
48%f
(excluding single-
dose nevirapine)
90%
Prong 3, target 3.3: 
Antiretroviral coverage among breastfeeding women Not available
g Not available 90%
Prong 4 target: 
Antiretroviral therapy coverage among eligible pregnant women living with HIV Not available 34% 90%
Child target: 
Deaths due to HIV among children under 5 years 162 000
h Not available <81 000
Child target: 
Coverage of antiretroviral therapy among children 21% 23% 100%
a Current estimates for 2009,UNAIDS.
b A 50% reduction in the number of deliveries among pregnant women living with HIV along with a reduction from 27% to 5% in mother-to-child transmission will result in a 90% 
reduction in the number of children newly infected. This is not an offi cial target.
c 2008 value (14).
d 2009 estimate for low- and middle-income countries (15,16). The baseline is 25% for sub-Saharan Africa.
e The coverage data include provision of only single-dose nevirapine, which is no longer recommended by WHO (17).
f The coverage data include only the most effi cient regimens as recommended by WHO (excluding single-dose nevirapine).
g Comprehensive data are not yet available because the provision of antiretroviral medicine during the breastfeeding period became an international recommendation in 2010.
h Source: World health statistics 2011 (18).
Table 7.1 Monitoring the Global Plan: main indicators, 2009 baseline fi gures, 2015 targets and progress made in 2010 
in low- and middle-income countries
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7.2 Preventing HIV infection among women 
of reproductive age
Preventing women of reproductive age from acquiring 
HIV infection is critical to achieving the two high-
level targets of the Global Plan: reducing the number 
of children newly infected with HIV by 90% and 
reducing the number of mothers dying from AIDS-
related causes by 50%.
The Global Plan also establishes a 50% reduction 
in the number of women 15–49 years old acquiring 
HIV infection by 2015 as the main target for Prong 1. 
Achieving this target requires converging robust and 
focused combination prevention strategies. Ensuring 
that women remain HIV-negative will also improve 
the survival of mothers. Globally, HIV is a major 
cause of death among women of childbearing age and 
contributes signifi cantly to mothers dying (20).
In 2010, an estimated 1 490 000 [1 300 000–
1 600 000] women living with HIV were pregnant. 
This number has remained relatively stable since 2005. 
Although the global number of people newly infected 
with HIV has declined, in sub-Saharan Africa, the 
region with the largest number of pregnant women 
living with HIV, the estimated number of pregnant 
women living with HIV was 1 400 000 [1 300 000–
1 600 000] in 2005 and declined slightly to 1 360 000 
[1 200 000–1 500 000] in 2010. In several priority 
countries for preventing mother-to-child transmission, 
the incidence of HIV infection among adults fell by 
50% or more between 2001 and 2009, including in 
Botswana, Zimbabwe, Côte d’Ivoire and Namibia (21).
Young women have an especially high risk of acquiring 
HIV infection. In 2010, about 3.2 million women 15–
24 years old were living with HIV, including more 
than 1.1 million living in South Africa and Nigeria in 
2009. Evidence shows that the prevalence of HIV 
infection among young women in sub-Saharan Africa is 
disproportionately higher than among young men. The 
discrepancy is most stark in sub-Saharan Africa where, 
in 2010, 71% of the people 15–24 years old living with 
HIV were women (22) (see Chapter 2). Eliminating new 
HIV infections among children requires ensuring that 
HIV prevention services reach this population and keep 
adolescent girls HIV-negative.
Box 7.5
Reaching the goal of reducing the number of children newly infected with HIV by 90% requires concerted action on all 
four prongs
Fig. 7.2 shows the estimated number of children who acquired HIV infection from mother-to-child transmission between 2000 and 2009. 
The Global Plan (4) target is to reduce the number of children acquiring HIV infection by 90%, from 429 000 in 2009 (the baseline) to 
43 000 in 2015.
Mathematical modelling shows that eliminating mother-to-child transmission requires simultaneously implementing all four prongs of the 
United Nations comprehensive approach to preventing mother-to-child transmission (19).
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7.2.1 Strategies for primary prevention of HIV 
infection among women of reproductive age
Programmes to prevent the mother-to-child 
transmission of HIV, delivered in the context of 
maternal, newborn and child health services, represent 
an important entry point to provide information on HIV 
prevention to women of reproductive age. Provider-
initiated testing and counselling and testing and 
counselling for couples delivered through programmes 
for preventing mother-to-child transmission contribute 
significantly to primary prevention by increasing 
knowledge of HIV status in the general population of 
women of reproductive age and, increasingly, among 
male partners (23). Based on the evidence of high rates 
of HIV seroconversion during pregnancy and the early 
postpartum period (24), HIV prevention counselling 
for HIV-negative pregnant women in early pregnancy 
is particularly important. Other evidence-informed 
HIV prevention interventions include: social and 
behaviour change communication; abstinence from 
sex and injecting drug use; condom use; medical male 
circumcision; harm reduction; and the emerging area 
of antiretroviral therapy (22).
Ensuring comprehensive, correct knowledge about 
how to prevent HIV transmission is a critical fi rst step 
towards reducing the number of people acquiring 
HIV infection. In sub-Saharan Africa, the region that 
accounted for 74% of the people 15–24 years old 
acquiring HIV infection globally in 2010, only 26% (22) of 
young women had comprehensive, correct knowledge 
about HIV prevention versus 33% of young men. Within 
sub-Saharan Africa, the proportion is higher in eastern 
and southern Africa (34%) and lower in western and 
central Africa (20%).
Although comprehensive knowledge about HIV 
prevention is still generally low throughout the region, 
several priority countries for preventing mother-to-
child transmission have made important progress 
towards improving this among women 15–24 years old. 
Improvements have been observed in Mozambique, 
from 20% (2003) to 36% (2009); in Kenya, from 34% 
(2003) to 48% (2008–2009); and in Lesotho, from 
26% (2004) to 39% (2009) (25). Fewer young women 
have comprehensive knowledge of HIV prevention in 
Asia (17% in South Asia and 24% in East Asia and the 
Pacifi c) than in sub-Saharan Africa.
HIV testing
Antenatal care is a critical opportunity for both 
pregnant women and their partners to receive HIV 
testing and counselling. This is particularly important 
in sub-Saharan Africa, where about half the people 
living with HIV are in a long-term sexual relationship 
with an HIV-negative partner (26). Couples testing and 
counselling in settings for preventing mother-to-child 
transmission is an important strategy for reaching male 
partners with HIV testing and counselling, helping HIV-
negative women and men remain negative and reducing 
the risk of transmission in serodiscordant couples. 
Couples testing and counselling may also improve 
Box 7.6
Involving male partners is central to Rwanda’s strategy for eliminating the mother-to-child transmission of HIV
By embracing a family-centred approach to comprehensive services 
for preventing mother-to-child transmission, Rwanda has been able to 
substantially improve the participation of male partners in preventing 
mother-to-child transmission as part of a gender-sensitive transformation 
of its health system. National strategies encouraging male partners to 
participate in HIV counselling and testing in antenatal care services have 
been supported by high-level political commitment and are bearing fruit. In 
2010, 81% of pregnant women who were tested for HIV through the national 
programme for preventing mother-to-child transmission had male partners 
who also tested for HIV within the past 12 months, many of whom were 
tested with their partner as part of antenatal care (Fig. 7.3).
It is also essential to consider how HIV testing strategies in antenatal care 
services can best address the needs of young people who, although sexually 
active, are often not in stable relationships. Data on antenatal care are 
currently not disaggregated by age in many countries, thereby limiting the 
ability to determine the proportions of young people accessing HIV testing 
and counselling in antenatal care services.
Fig. 7.3 HIV testing and counselling of male partners 
during antenatal care, Rwanda, 2003–2010
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adherence to antiretroviral therapy and to interventions 
for preventing mother-to-child transmission (see 
Chapter 4) (27).
Though couples testing in antenatal care is often 
encouraged, uptake among male partners is still 
generally limited; among 37 countries providing data 
on the uptake of HIV testing and counselling among 
male partners of women attending antenatal care, 
20 countries reported uptake levels of less than 5%, 
although it reached 81% in Rwanda (Box 7.6).
Select primary prevention methods
Condom use among women 15–24 years old who had 
more than one sexual partner in the past year has 
increased in some countries with high HIV prevalence 
(Fig. 7.4). However, the rates of condom use among 
young people are still generally low across regions, 
with young men reporting higher rates of condom use 
than young women.
New studies published in 2010 and 2011 (Table 3.4) 
have added two important new tools to the array 
of effective prevention technologies. Antiretroviral 
therapy has been shown to greatly reduce the risk of 
HIV transmission, and topical and oral antiretroviral 
pre-exposure prophylaxis, including an antiretroviral-
based microbicide for women, can lower the risk of 
acquiring HIV among HIV-negative individuals. These 
methods (see Chapter 3) are expected to be able to 
considerably strengthen the primary prevention of HIV 
infection among women of reproductive age and can 
help further reduce the number of these women who 
are newly infected with HIV.
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Fig. 7.4 Percentage of people 15–24 years old who had more than one sexual partner in the past 12 months reporting the use 
of a condom during their last sexual intercourse, by selected countries that had trend data for men and women in the same 
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Sources: MEASURE DHS: all surveys by country [web site] (25). Demographic and Health Surveys: Côte d’Ivoire 1998–1999; Kenya, 2003 and 2008–2009; Lesotho, 2004 and 2009; Malawi, 
2000; Swaziland, 2006–2007. AIDS Indicator Surveys: Côte d’Ivoire, 2005.
Multiple Cluster Indicator Survey [web site] (28). Multiple Cluster Indicator Surveys: Malawi, 2006; Swaziland, 2010.
a The data for women in Swaziland from the 2006–2007 Demographic and Health Survey (25) are based on small denominators (typically 25–49 unweighted cases).
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Box 7.7
Towards eliminating congenital syphilis
Untreated syphilis in pregnancy leads to adverse outcomes among more than half the women with active disease, including early fetal loss, 
stillbirth, prematurity, low birth weight, neonatal and infant death and congenital disease among newborn babies. Similarly to HIV, syphilis 
in pregnancy is usually sexually transmitted, and testing for syphilis early in pregnancy and immediately treating women found to be positive 
are effective and cost-effective interventions even in low-prevalence settings (29). Testing pregnant women and their partners for syphilis 
is also an important measure to support the primary prevention of HIV infection, as active syphilis can increase the risk of transmitting and 
acquiring HIV (30,31). New rapid syphilis testing technology now enables syphilis and HIV testing to be offered jointly through an integrated 
approach in nearly any antenatal care setting.
WHO, UNICEF, UNFPA, UNAIDS and other partners support the global initiative to eliminate congenital syphilis. The Americas and the Asia-
Pacifi c region and several countries have developed integrated initiatives to eliminate the mother-to-child transmission of both HIV and 
syphilis, given their common target groups and service delivery platforms (8,9).
According to the most recent (2008) estimates, about 1.9 million pregnant women had active syphilis. Assuming moderate coverage of syphilis 
testing and treatment in pregnancy, in 2008 there were an estimated 300 000 stillbirths or early fetal losses, 140 000 neonatal deaths and 
380 000 infants that were preterm, of low birth weight or had congenital disease associated with syphilis (8).
In 2010, 63 low- and middle-income countries reported on the proportion of women attending antenatal care tested for syphilis at the fi rst 
visit. In this subgroup, 17 low- and middle-income countries reported having achieved the global target of testing at least 90% of women 
attending antenatal care at the fi rst visit for syphilis (1) (Belize, Chile, Cuba, Fiji, Gabon, Grenada, Guyana, Kiribati, Malaysia, Mauritius, 
Namibia, Oman, Samoa, Seychelles, Sri Lanka, Uruguay and Venezuela (Bolivarian Republic of)). Overall global median testing coverage did 
not improve from 2008 to 2010 (Table 7.2). Nevertheless, median testing coverage improved in Latin America and the Caribbean (from 73% 
in 2008 to 80% in 2010) and in East, South and South-East Asia (from 52% to 78%). In 27 reporting countries from sub-Saharan Africa, 
a median of only 59% of pregnant women were tested for syphilis. Eight low- and middle-income countries reported not offering routine 
syphilis screening in antenatal care in 2010.
% of women attending antenatal care tested for 
syphilis at the fi rst visit
% of women attending antenatal care seropositive 
for syphilis
2008 2010 2008 2010
Region
Number 
reportingb Median (%)
Number 
reportingb Median (%)
Number 
reportingb Median (%)
Number 
reportingb Median (%)
East, South and South-
East Asia
7 52% 12 78% 14 0.5% 16 0.5%
Eastern Europe and 
Central Asia
9 100% c c 9 0.3% 2 a
Latin America and the 
Caribbean
14 73% 20 80% 14 0.9% 20 1.3%
North Africa and the Middle 
East
2 a 4 a 5 0.0% 3 a
Sub-Saharan Africa 19 64% 27 59% 30 2.3% 34 1.6%
Total 51 78% 63 68% 72 1.3% 75 1.3%
a Regional values are not calculated when fewer than 5 countries reported.
b Number of low- and middle-income countries requested to report: 149.
c This indicator was not included in universal access reporting for Eastern Europe and Central Asia in 2010.
Table 7.2 Number of low- and middle-income countries reporting and median proportion of women attending 
antenatal care tested for syphilis at the fi rst visit and seropositive for syphilis, 2008 and 2010a
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7.3  Preventing unintended pregnancies 
among women living with HIV
Globally, an estimated 80 million (38%) of the 211 
million pregnancies each year are unintended (32). 
According to World contraceptive use 2011 (15), the level 
of unmet family planning need among the 1.18 billion 
women 15–49 years old is an estimated 11% globally.1 
Among the 128 million women (married or in a union) 
15–49 years old in sub-Saharan Africa, the estimated 
unmet need for family planning is more than twice as 
high, at 25%.
Unintended pregnancies have important harmful 
effects on the survival and well-being of both women 
and their children. A lower total fertility rate through 
increased contraceptive use has been shown to reduce 
by up to 15% the number of mothers dying than would 
have occurred with no fertility decline (33). In addition, 
the benefi ts of family planning include increased family 
1 “Unmet need for family planning” refers to the number of women 
who are fecund and sexually active but are not using any method of 
contraception and report not wanting any more children or wanting to 
delay the birth of their next child.
savings and productivity, better prospects for education 
and employment and improvement in the status of 
women (15). Current contraception levels prevent 
188 million unintended pregnancies, which results in 
112 million fewer abortions, 1.1 million fewer newborns 
dying and 150 000 fewer mothers dying (34,35).
One of the targets of the Millennium Development 
Goals, agreed by all United Nations Member States, is 
to achieve, by 2015, universal access to reproductive 
health, including family planning (36). To accelerate 
progress towards this goal, the Global Plan (4) also 
aims to reduce the unmet need for family planning to 
zero by 2015 (37). In this context, the United Nations 
Secretary-General’s Global Strategy for Women’s and 
Children’s Health and the HANDtoHAND campaign 
will target 100 million new people for accepting family 
planning by 2015 (38).
Women living with HIV who know their HIV-positive 
status need sexual and reproductive health services 
to make informed decisions about their future 
reproductive life, including when to seek support and 
services to prevent unintended pregnancies. The use 
In 2010, 75 (of 149) low- and middle-income countries surveyed provided data on the prevalence of syphilis among antenatal care attendees; 
the global median was 1.3% for 2010, with a high of 1.6% in sub-Saharan Africa. Country and regional variability was high: the Central African 
Republic, Equatorial Guinea, Liberia, Madagascar, Mozambique, Papua New Guinea, the Solomon Islands, Swaziland and Zambia all reported 
antenatal care syphilis prevalence rates above 5% in 2010 (Fig. 7.5 and Annex 1).
Percentage (%)
<0.5 (28 countries)
(9 countries)
(34 countries)
.0 (9 countries)
Data not available
Not applicable
0.5–0.9
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Fig. 7.5 Syphilis seropositivity of women attending antenatal care reported by countries in 2010
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of modern contraceptive methods is a cost-effective 
means of preventing transmission because of any 
unintended pregnancy and to promote healthy birth 
spacing (39–42).
Fewer unintended pregnancies among women living 
with HIV mean fewer infants born to them, resulting 
in fewer infants exposed to HIV and potentially living 
with HIV (42,43). Modelling has demonstrated that 
the mother-to-child transmission of HIV cannot be 
eliminated without reducing unintended pregnancies 
among women living with HIV (19). However, limited 
data are available on the access to and uptake of family 
planning services among women living with HIV at the 
population level (Box 7.9); most data focus on the family 
planning practices among women of reproductive age 
without disaggregating based on serostatus.
Addressing unmet family planning needs is essential 
for all women, regardless of their serostatus. As such, 
services should not exclusively focus on women living 
with HIV. Nevertheless, in some countries people 
living with HIV have greater unmet need. In Uganda, a 
recently published survey (47) found signifi cantly greater 
unmet need for family planning among people living 
with HIV than among HIV-negative people (75% versus 
34%). In other countries, women living with HIV have 
lower unmet need than HIV-negative women (Box 7.8).
Unintended pregnancy among women living with 
HIV may elevate the risk of both mother-to-child 
transmission and the abandonment of infants, especially 
among marginalized women (such as people who 
inject drugs and illegal migrants) who may not access 
antenatal care, HIV services (such as antiretroviral 
therapy or services for preventing mother-to-child 
transmission) or access to safe abortion. Unintended 
pregnancy rates are likely to be high among people 
who inject drugs, who have low rates of effective 
contraception use. 
A study of postnatal women living with HIV in Ukraine 
(48,49) highlighted the unmet need for contraception 
among women living with HIV in this setting: 23% 
had not planned their most recent pregnancy, 20% 
were not currently using any family planning method 
(although some of these women reported not being 
sexually active at the time) and a further 20% were using 
Box 7.8
Family planning needs among women living with HIV
Recent household surveys that collect data on HIV status and fertility preferences enable the unmet need for family planning among women 
living with HIV to be estimated. The unmet family planning need among women living with HIV is compared with unmet need among other 
women, using data from six recent surveys (Kenya, Lesotho, Malawi, Swaziland, Zambia and Zimbabwe) that included questions on both HIV 
testing and fertility preferences (44–47). Data analysis from these surveys was limited to women who reported knowing their HIV status, 
since they are more likely to adapt their fertility preferences based on this knowledge.
Unmet need is lower for women living with HIV than 
for HIV-negative women in 5 of the 6 countries. In 
Zambia, the difference was statistically signifi cant. 
(Table 7.3).
Overall, the unmet need for family planning in the 
general population in these countries has been stable 
in recent years. The only countries in which unmet need 
has declined among the general population are Lesotho 
and Malawi, and in both countries, the unmet need is 
lower among women living with HIV who reported 
knowing their status. For the women living with HIV, 
special efforts should be made to ensure they have the 
resources to meet their fertility preferences.
Country and 
year of survey
Unmet need 
among women 
living with HIV
Unmet need 
among 
HIV-negative 
women 
Change in unmet need over 
time among all women
Kenya 2008 21% 21% 25% (2003) to 26% (2008)
Lesotho 2009 16% 18% 31% (2004) to 23% (2009)
Malawi 2010 18% 21% 28% (2004) to 26% (2010)
Swaziland 2007 12% 14% No comparison available
Zambia 2007a 14% 20% 27% (2002) to 27% (2007)
Zimbabwe 2006 14% 8% 13% (1999) to 12% (2006)
Sources: UNAIDS calculations of data from Demographic and Health Surveys (MEASURE DHS: all surveys 
by country [web site] (25)) and Millennium Development Goals indicators [web site] (36).
a The difference between women living with HIV and HIV-negative women is statistically signifi cant.
Table 7.3 Unmet need for family planning by HIV serostatus based on 
data from Demographic and Health Surveys in six countries
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non-effective methods (such as coitus interruptus). 
Further, the most important factor associated with lack 
of postnatal contraception was affordability, despite the 
national policy of providing contraception free of charge.
Moreover, many women living with HIV still do not 
know their HIV status (Box 7.9). Since many people 
who inject drugs have a large gap in information 
about their HIV status, addressing the broader 
problem of many unintended pregnancies requires 
better monitoring and providing key interventions 
to all women. The desired outcome is to eliminate 
unintended pregnancies, including among women living 
with HIV. Family planning, delivered as part of universal 
access to reproductive health, is a key intervention in 
this regard (20).
A strategic framework has been fi nalized in support of 
the Global Plan to strengthen policies and programming 
for prong 1 – the primary prevention of HIV among 
women of reproductive age, emphasizing pregnant 
and breastfeeding women – and prong 2 – preventing 
unintended pregnancies among women living with 
HIV. Although the framework focuses predominantly 
on the health sector, it supports the integration of 
sexual and reproductive health and HIV services 
(especially maternal, newborn and child health, family 
planning and HIV treatment) and a robust human 
rights–based platform for providing services. Concerted 
action on both prongs is essential to improve the health 
of mothers and children and to eliminate new HIV 
infections among children.
Box 7.9
Knowledge of HIV status among pregnant women 
living with HIV
In 2011, 12 of the 22 priority countries for preventing mother-to-
child transmission reported data on pregnant women known to 
be living with HIV at the fi rst antenatal care visit. About 23% 
of pregnant women attending antenatal care were reported to 
have known their HIV-positive status before their fi rst antenatal 
care visit, and 77% were found to be HIV-positive at the visit. 
In some countries, 40% or more of pregnant women living 
with HIV attending antenatal care knew their status before the 
fi rst antenatal care visit, including in Botswana (61%), Namibia 
(49%), Swaziland (46%) and Lesotho (40%).
7.4 Preventing the vertical transmission 
of HIV and improving the health of 
pregnant women living with HIV
7.4.1 HIV testing and counselling among 
pregnant women
High-quality and timely HIV testing and counselling are 
essential to identify pregnant women living with HIV 
who can benefi t from HIV care and from interventions 
to reduce the risk of transmitting HIV from mother to 
child (Fig. 7.6).
In 2010, an estimated 35% of the estimated 123 million 
pregnant women in low- and middle-income countries 
received an HIV test, up from 26% in 2009, 21% in 
2008 and 8% in 2005. The percentage increased 
in almost all regions, growing around 10 percentage 
points or more between 2009 and 2010 in eastern 
and southern Africa (52% to 61%) and East, South and 
South-East Asia (18% to 30%). Although progress has 
been signifi cant in almost all regions, nearly two thirds 
of pregnant women still do not know their HIV status, 
including many pregnant women living with HIV who 
could benefi t from further health interventions such as 
lifelong care for HIV and interventions to reduce the 
mother-to-child transmission of HIV.
Of the 43 170 000 pregnant women estimated to have 
received an HIV test in low- and middle-income countries 
in 2010, 1 006 000 (2.3%) were reported to be living 
with HIV. This represents 68% of the estimated total 
of 1.49 million pregnant women living with HIV needing 
antiretroviral medicine to prevent the mother-to-child 
transmission of HIV. Although effort must be focused on 
identifying the remaining one third still unaware of their 
HIV status, ensuring that all pregnant women identifi ed 
as living with HIV receive effective interventions for 
preventing mother-to-child transmission and links 
to HIV care and treatment is also critical. Additional 
important objectives include providing effective services 
at decentralized primary care settings, reaching women 
who do not access antenatal care and achieving universal 
coverage of testing and counselling in low-level and 
concentrated epidemics.
In some settings, the coverage of antenatal care is 
still low, and increasing access to antenatal care may 
be an effective way to expand the coverage of HIV 
testing and counselling among pregnant women living 
with HIV. In settings in which women do not access 
antenatal care or are not tested in antenatal care, 
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testing at labour and delivery is recommended as a 
second opportunity to identify women living with HIV 
and offer at least part of the package of interventions 
for preventing mother-to-child transmission. In 
countries and settings in which almost all pregnant 
women attend antenatal care, provider-initiated 
testing and counselling has helped increase the 
number of pregnant women receiving an HIV test 
and knowing the result (Box 7.10) (see Chapter 4).
Eliminating the mother-to-child transmission of HIV 
requires identifying nearly all pregnant women living 
with HIV. In 2010, the estimated coverage of HIV 
testing and counselling among pregnant women 
exceeded 50% in 13 of the 22 priority countries for 
eliminating mother-to-child transmission (section 7.1). 
The coverage of HIV testing and counselling among 
pregnant women in Botswana, South Africa, Zambia 
and Zimbabwe was estimated to exceed 90% in 2010. 
However, in Chad, the Democratic Republic of the 
Congo and Nigeria, less than 20% of the estimated 
number of pregnant women living with HIV received 
HIV testing and counselling (Table 7.4).
Box 7.10
Promoting provider-initiated testing and counselling for pregnant women
Systematic HIV testing and counselling during pregnancy involves provider-initiated testing and counselling performed as early as possible 
to allow pregnant women to benefi t from prevention, treatment and care and access to interventions to reduce transmission to their infants. 
In generalized epidemics, pregnant women testing HIV negative in the fi rst or second trimester should be retested in the third trimester. 
For women who present during labour without having accessed antenatal care, HIV testing is recommended to all women of unknown 
status or as soon as possible after delivery. If an HIV test has not previously been done, HIV testing should be recommended to women in 
the postpartum period. In generalized epidemics, women who test HIV negative in the fi rst or second trimester who have not had a repeat 
test during the third trimester or during labour should be recommended to retest immediately after delivery or as soon as possible in the 
postpartum period (51), preferably early to benefi t from HIV-related services for themselves and their infant, including counselling on and 
support for infant feeding and diagnosis for the infant.
As of December 2010, 98 of 119 responding countries reported having policies or guidelines on provider-initiated testing and counselling 
for pregnant women.1 However, even in countries with almost universal antenatal care coverage and a national policy of provider-initiated 
testing and counselling among all pregnant women, not all pregnant women are tested, and intensifi ed efforts are needed to close the gap 
between policy and practice.
1 In seven countries from Eastern Europe and Central Asia, provider-initiated testing and counselling for pregnant women was reported as mandatory. Provider-initiated testing and 
counselling as defi ned by WHO and UNAIDS is neither mandatory nor compulsory; pregnant women should receive counselling so they can give informed consent for an HIV test, 
thereby appreciating the signifi cance of test results for themselves and their family.
Fig. 7.6 Estimated percentage of pregnant women who received an HIV test in the past 12 months in low- and middle-income countries by 
region, 2005 and 2008–2010
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7.4.2 Antiretroviral medicine to prevent the 
mother-to-child transmission of HIV
The 2010 WHO guidelines on the use of antiretroviral 
drugs for treating pregnant women and preventing HIV 
infection in infants (1) are based on two key approaches: 
(1) lifelong antiretroviral therapy for the pregnant 
women who need treatment for their own health, 
which is also safe and highly effective in reducing 
mother-to-child transmission; and (2) new options 
for antiretroviral prophylaxis to prevent mother-to-
child transmission during pregnancy, delivery and 
breastfeeding for those who do not require treatment.
7.4.2.1 Assessing the eligibility of pregnant 
women living with HIV to receive 
antiretroviral therapy for their own 
health
Pregnant women living with HIV should be clinically 
assessed (including CD4 testing) to determine whether 
they are eligible for antiretroviral therapy. As with 
all adults living with HIV, initiation of antiretroviral 
therapy is now recommended for all pregnant women 
living with HIV with CD4 counts at or below 350 cells 
per mm3, regardless of WHO clinical staging, and for 
all pregnant women in WHO clinical stage 3 or 4, 
regardless of CD4 cell count. Initiating antiretroviral 
therapy among women eligible for treatment, before 
or during pregnancy, will help improve the mother’s 
health and prevent mother-to-child transmission during 
the perinatal period and while breastfeeding. Giving 
the mother antiretroviral therapy is also the most 
effective way of reducing mother-to-child transmission. 
The introduction of point-of-care CD4 testing is a 
promising new approach that would help expand access 
to assessment of immune status.
In 2010, among 99 low- and middle-income countries 
reporting data (representing 81% of the estimated 
number of pregnant women living with HIV), an 
estimated 45% of pregnant women who were known 
to be living with HIV were assessed for their eligibility 
to receive antiretroviral therapy (either through clinical 
staging or CD4 cell count), versus 51% in 2009 and 
34% in 2008. About 30% were assessed through CD4 
count, versus 37% in 2009 and 24% reported in 2008.
Surprisingly, reported data showed a decrease in the 
percentage of women living with HIV assessed for 
eligibility for antiretroviral therapy. The causes for this 
should be investigated further as this may also be an 
artefact of reporting. In 2010, the number of women 
attending antenatal care already knowing that they 
were living with HIV was 11% higher than in 2009. 
When a pregnant women is already aware that she is 
living with HIV at her fi rst antenatal clinic visit and is 
receiving HIV care in a different facility, some clinics 
may not record information on whether she has already 
been clinically assessed.
The gap between the number of pregnant women 
living with HIV who are aware of their serostatus and 
the number who are actually assessed for eligibility for 
antiretroviral therapy leads to missed opportunities to 
maximize health benefi ts for mothers and minimize the 
risk of transmitting HIV to their infants.
In 2010, an estimated 571 000 pregnant women living 
with HIV (38% of the pregnant women living with 
HIV needing antiretroviral medicine for preventing 
mother-to-child transmission) had CD4 counts at or 
below 350 cells per mm3 and were thus eligible for 
antiretroviral therapy (based on modelled estimates). 
Among pregnant women who needed antiretroviral 
Percentage of pregnant 
women tested for HIV
Country 2005 2010
Angola 1% 32%
Botswana 92% >95%
Burundi 2% 39%
Cameroon 17% 41%
Chad Not available 7%
Côte d’Ivoire 6% 59%
Democratic Republic of the Congo 3% 11%
Ethiopia 2% 26%
Ghana 4% 68%
India 2% 23%
Kenya 31% 83%
Lesotho 9% 57%
Malawi 10% 66%
Mozambique 12% 87%
Namibia 46% 86%
Nigeria 1% 14%
South Africa 47% >95%
Swaziland 39% 83%
Uganda 18% 63%
United Republic of Tanzania 14% 86%
Zambia 14% 94%
Zimbabwe 29% 90%
Table 7.4 Estimated percentage of pregnant women tested 
for HIV in the 22 priority countries for eliminating mother-
to-child transmission, 2005 and 2010
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therapy, 35% (197 000) received it. In most of the 
22 priority countries for eliminating mother-to-child 
transmission, less than 50% of the estimated number 
of pregnant women eligible for antiretroviral therapy 
received it in 2010 (see Annex 7).
7.4.2.2 Coverage of antiretroviral prophylaxis 
to prevent the mother-to-child 
transmission of HIV
For pregnant women living with HIV who are not eligible 
for treatment, WHO recommends two efficacious 
antiretroviral regimen options for prophylaxis to reduce 
transmission during the perinatal period and while 
breastfeeding. For the fi rst time, antiretroviral medicine 
to either the mother or the infant is recommended 
throughout the breastfeeding period, in settings where 
breastfeeding is the safest option for feeding the infant.
For option A, the mother takes zidovudine during the 
antenatal period, starting from as early as 14 weeks of 
pregnancy. A single dose of nevirapine and lamivudine 
is added during labour, and zidovudine and lamivudine 
are continued for seven days after delivery as a “tail” to 
decrease the risk of nevirapine resistance. If the mother 
breastfeeds, the baby will receive nevirapine syrup from 
birth until one week after all exposure to breast-milk 
has ended. If the mother is giving the baby replacement 
feeding, he or she will only get either nevirapine or 
zidovudine from birth until 4–6 weeks of age.
For option B, the mother takes a prophylaxis regimen 
consisting of three antiretroviral medicines during 
pregnancy, labour and after delivery until one week 
after all exposure to breast-milk has ended. Infants 
born to mothers on option B receive either nevirapine or 
zidovudine from birth until 4–6 weeks of age, regardless 
of their feeding method. WHO recommends four 
possible triple antiretroviral prophylaxis regimens for 
option B, with the choice of regimen to be made at the 
country level.
Importantly, a single dose of nevirapine is no longer 
recommended as a standard practice (Box 7.11).
One hundred and one (101) countries, representing 
98% of the pregnant women living with HIV in low- and 
middle-income countries receiving any antiretroviral 
medicines for preventing mother to child transmission, 
reported disaggregated data on antiretroviral regimens.
The estimated coverage of most effective antiretroviral 
regimens for preventing the mother-to-child 
Box 7.11
Phasing out single-dose nevirapine for preventing mother-to-child transmission
Single-dose nevirapine given to mothers during labour and to the infant at birth was one of the original short-course antiretroviral interventions, 
after it was shown to reduce the peripartum risk of HIV transmission to the infant by nearly 50% (50). This regimen was one of the least 
expensive and easiest to administer, and many early programmes for preventing mother-to-child transmission adopted it, especially in sub-
Saharan Africa, soon after 2000. However, since more effective regimens were developed and became increasingly available, WHO guidelines 
on antiretroviral medicine for preventing the mother-to-child transmission of HIV progressively recommended shifting away from single-dose 
nevirapine towards more effective alternatives.
Beginning with the 2006 revision, single-dose nevirapine has not been recommended as a standard intervention for preventing mother-to-child 
transmission. This decision refl ects evidence demonstrating that single-dose nevirapine does not protect against antenatal transmission or 
postpartum transmission during breastfeeding, and the risk of developing drug resistance is high in the mother and (if infected) the infant. 
The most recent 2010 guidelines on preventing mother-to-child transmission (1) now recommend more effective antiretroviral regimens for 
the mother or infant during breastfeeding.
Although single-dose nevirapine is no longer recommended as the primary regimen for preventing mother-to-child transmission in any country, 
some countries have only recently changed their guidelines to recommend more effective regimens (such as India and Zimbabwe), and single-
dose nevirapine is still being used in some situations, with 33 countries reporting that women received only single-dose nevirapine in 2010.
Data on interventions for preventing mother-to-child transmission, including information on country policies and estimates on the 
disaggregated use of various regimens for preventing mother-to-child transmission, are crucial to track progress towards providing more 
effective regimens and fully phasing out single-dose nevirapine and to identify where programme and policy issues involving single-dose 
nevirapine still need to be addressed. WHO, UNAIDS and UNICEF strongly discourage the use of single-dose nevirapine as an intervention for 
preventing mother-to-child transmission, and many partner agencies are working with countries to assist in rapidly phasing out single-dose 
nevirapine. Progress towards fully phasing out single-dose nevirapine must be accelerated to safeguard the safety and health of babies and 
their mothers and to eliminate mother-to-child transmission by 2015.
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Fig 7.7 Coverage of antiretroviral medicine for preventing mother-to-child transmission: most effective regimens and single-dose 
nevirapine, low- and middle-income countries, by region, 2010a
z  Most effective regimens    z  Single-dose nevirapine
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a Single-dose nevirapine is no longer recommended by WHO 
Table 7.5 Estimated number of women living with HIV receiving the most effective antiretroviral regimens for preventing 
mother-to-child transmission and coverages with most effective regimens and with single dose nevirapine, low- and middle-
income countries, by geographical region, 2010a
Geographical region
Number of pregnant women 
living with HIV receiving the 
most effective antiretroviral 
regimens (excluding 
single-dose nevirapine) for 
preventing mother-to-child 
transmission
Estimated number of 
pregnant women living with 
HIV who need antiretroviral 
medicine for preventing 
mother-to-child transmission
Estimated coverage with the 
most effective regimens, as 
recommended by WHO
Estimated coverage with 
single-dose nevirapine 
only (regimen no longer 
recommended by WHO)
Sub-Saharan Africa 674 000 1 360 000 [1 200 000–1 500 000] 50% [45–56%] 10%
Eastern and southern 
Africa 600 700
940 000 
[840 000–1 000 000] 64% [57–71%] 13%
Western and central 
Africa 73 300
410 000 
[360 000–470 000] 18% [15–20%] 3%
Latin America and the 
Caribbean 15 000
25 600 
[17 000–33 000] 59% [46–90%] 2%
Latin America 11 700 18 300 [11 000–25 000] 64% [47–>95%] 2%
Caribbean 3 300 7 300 [5 900–9 000] 46% [37–57%] 3%
East, South and South-
East Asia 12 200
73 800 
[53 000–95 000] 16% [13–23%] 16%
Europe and Central Asia 14 700 18 600 [15 000–22 000] 79% [65–94%] 9%
North Africa and the 
Middle East 600
14 200 
[9 900–19 000] 4% [3–6%] 3%
All low- and middle-
income countries 716 500
1 490 000 
[1 300 000–1 600 000] 48% [44–54%] 11%
Note: Some numbers do not add up because of rounding.
a Annex 6 provides country-specifi c data.
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transmission of HIV in low- and middle-income 
countries was 48% [44–54%] in 2010. In addition, 
11% pregnant women, more than 150 000, received 
single dose nevirapine, a regimen which is no longer 
recommended by WHO (Fig. 7.7 and table 7.5). The 
proportion trend analysis is limited as estimated 
coverage from previous years included single dose 
nevirapine (14% [13-16%] in 2005; 48% [43–54%] 
in 2008). 
Progress on the coverage of antiretroviral medicine for 
preventing mother-to-child transmission at the national 
level can mask signifi cant inequality within countries. 
For example, in Ukraine, the use of antiretroviral 
medicine for preventing mother-to-child transmission 
among people who inject drugs and other people, 
respectively, was: none 12% versus 5%; single-dose 
nevirapine only 27% versus 9%; zidovudine and single-
dose nevirapine 45% versus 68%; and antiretroviral 
therapy 16% versus 18% (52). 
The 2001 Declaration of Commitment on HIV/AIDS 
set a target of 80% coverage of antiretroviral medicine 
Box 7.12
Antiretroviral regimens
Data from the 101 countries reporting disaggregated data show 
that the proportion of pregnant women living with HIV receiving 
only single-dose nevirapine decreased substantially between 
2007 and 2010 (Fig. 7.8).
Fig 7.8 Percentage distribution of various regimens 
provided to pregnant women who have received 
antiretroviral drugs to prevent mother-to-child 
transmission in low- and middle-income countries, 
2007, 2009 and 2010
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Box 7.13
Monitoring progress on providing antiretroviral 
medicine to prevent the mother-to-child 
transmission of HIV
Providing antiretroviral medicine to pregnant women living 
with HIV is a key intervention of programmes for preventing the 
mother-to-child transmission of HIV. However, at the national 
and global levels, accurately monitoring the number of women 
receiving antiretroviral medicine and the type of regimens 
received is challenging.
Women needing lifelong antiretroviral therapy may not access 
antiretroviral therapy at the same place where antiretroviral 
prophylaxis is provided, which can result in not including all 
relevant data on preventing mother-to-child transmission 
or double-counting when data from different sources are 
aggregated. When antiretroviral medicine is provided to the 
same woman or mother–child pair across various service delivery 
points (for example, at facilities providing antenatal care, labour 
and delivery services, child health services or HIV care and 
treatment services), data points may be double counted.
Data recording forms may not be able to collect the various 
types of regimens received, especially when antiretroviral 
guidelines may have recently been revised or if reporting to 
the subnational or national levels on the types of regimens 
delivered is not required, making it impossible to categorize 
the regimen provided, especially if a mix of regimens is being 
provided within a country. Thus, some countries may not have 
monitoring systems that allow the coverage of antiretroviral 
medicine for preventing mother-to-child transmission to be 
accurately recorded and reported.
In addition to improving existing monitoring mechanisms for 
adequately monitoring the provision of antiretroviral medicine 
for preventing mother-to-child transmission, the provision of 
antiretroviral medicine now needs to be monitored during the 
breastfeeding period, in accordance with the 2010 guidelines 
on antiretroviral medicine for preventing mother-to-child 
transmission (1). More work is needed at the country level, and 
as part of global reporting mechanisms, to standardize reporting 
of the types of regimens received by mother–baby pairs.
to reduce mother-to-child transmission by 2010. The 
target has nearly been achieved in Eastern Europe and 
Central Asia (with a coverage with the most effi cient 
regimens) of 79%. In Eastern and southern Africa, the 
sub-region with the highest number of pregnant women 
living with HIV has achieved 64% coverage (Fig. 7.7 and 
Table 7.7). But, in addition, 13% of women only received 
a single dose of nevirapine instead of the most effective 
regimens recommended by WHO. Coverage remained 
low in western and central Africa (18%) and North Africa 
and the Middle East (4%) and in Asia (16%), where most 
women continue to receive only single-dose nevirapine. 
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Only 12 countries reached the 80% coverage target 
(Table 7.6) with effective regimens among the 
estimated number of pregnant women living with HIV 
in need.1
Among the 22 priority countries for eliminating mother-
to-child transmission, 5 (Botswana, Lesotho, Namibia, 
South Africa and Swaziland) exceeded 80% coverage 
in accordance with the latest international standards 
(Table 7.7). Several countries still have low coverage 
levels, and intensified efforts are needed to improve 
access to effective interventions. 
The Global Plan (4) aims to increase the coverage of the 
most efficacious antiretroviral regimens for preventing 
1 Among countries with at least 100 pregnant women estimated to need 
antiretroviral medicine for preventing mother-to-child transmission.
Region
Number of 
countriesa Countries
Sub-Saharan 
Africab
5
Botswana, Lesotho, Namibia, South 
Africa and Swaziland 
Latin America 
and the 
Caribbean
4
Argentina, Brazil, Ecuador and 
Honduras
Eastern Europe 
and Central Asia
3 Belarus, Romania and Ukraine
a Countries with at least 100 pregnant women estimated to need antiretroviral 
medicine for preventing mother-to-child transmission. 
b  The 5 countries in this region are among the 22 priority countries for eliminating 
mother-to-child transmission.
Table 7.6 Low- and middle-income countries achieving 
the UNGASS target of coverage with effective regimens 
of antiretroviral medicine for preventing mother-to-child 
transmission (≥80%)
mother-to-child transmission to 90% by 2015, as 80% 
coverage (the UNGASS coverage target established 
in 2001) is insufficient to make substantial progress 
towards eliminating new HIV infections among 
children (19). 
C
Number of pregnant women 
living with HIV receiving 
most effective regimens to 
reduce the risk of mother-to- 
child transmission of HIV
Coverage with 
most effective 
regimens Range
Number of pregnant women 
living with HIV receiving 
single-dose nevirapine to 
reduce the risk of mother-to- 
child transmission of HIVa
Angola 3 125 20% [15–28%] 0b
Botswana 14 641 >95% [>95–>95%] 0
Burundi 2 617 36% [32–49%] 0
Cameroon 15 720 53% [43–65%] 1 244
Chad 1 000 7% [5–9%]  0
Côte d’Ivoire 11 561 66% [54–79%]  0
Democratic Republic of the Congo 307 1% [<1–1%] 3 064
Ethiopia 7 844 …c 0b
Ghana 5 845 48% [40–57%] 0b
India 0d …c …c 10 878
Kenya 41 378 43% [37–49%] 24 554e
Lesotho 12 370 89% [77–>95%] 0
Malawi 17 729 …c [23–31%] 11 960
Mozambique 52 222 52% [44–62%] 17 658
Namibia 7 790 >95% [79–>95%] 600
Nigeria 19 733 9% [7–10%] 6 505e
South Africa 250 072 >95% [85–>95%] 0
Swaziland 9 273 >95% [88–>95%] 0
Uganda 39 566 42% [36–51%] 21 596
United Republic of Tanzania 58 161 59% [52–68%] 22 897
Zambia 59 602 75% [67–85%] 10 048
Zimbabwe 21 044 46% [40–52%] 18 738
a Regimen not recommended by WHO.
b In Angola, Ethiopia and Ghana most regimens provided were not specified (100%, 86% and 100% respectively) and provision of single-dose nevirapine could therefore not be 
validated.
c No coverage can be presented, or only a range, as the estimated number of pregnant women living with HIV in need of antiretroviral medicine is currently being reviewed and 
will be adjusted, as appropriate, based on ongoing data collection and analysis.
d In 2010, India was still providing single-dose nevirapine but the country is currently updating its national guidelines.
e The single-dose nevirapine value has been readjusted: as the country also reported a number of women receiving an unspecified antiretroviral medicine, this has been 
proportionally added to the other reported regimens.
Table 7.7 Estimated antiretroviral coverage for preventing mother-to-child transmission in the 22 priority countries for 
eliminating mother-to-child transmission
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Fig. 7.9 depicts the 25 countries with the largest estimated 
number of pregnant women needing interventions 
for preventing mother-to-child transmission and their 
contribution to the global gap to reach 90% coverage 
of antiretroviral medicine for pregnant women living 
with HIV. The global gap is the difference between the 
current number of pregnant women in need who have 
access to antiretroviral medicine (with the most effective 
regimens) for preventing mother-to-child transmission 
and the estimated number who must be reached to 
achieve the 90% coverage goal. As Fig. 7.9 shows, four 
countries – Nigeria, the Democratic Republic of the 
Congo, Uganda and Malawi – accounted for nearly 50% 
of the gap in 2010.
7.4.3 Antiretroviral prophylaxis for infants born 
to mothers living with HIV
All infants born to mothers living with HIV should 
receive antiretroviral prophylaxis (1). This includes not 
just the short postpartum prophylaxis for 4–6 weeks 
recommended for all HIV-exposed infants, regardless 
of the regimen used for preventing mother-to-child 
transmission or of breastfeeding, but also extended 
antiretroviral therapy or other antiretroviral medicine 
for the mother or infant during breastfeeding. However, 
because of loss to follow-up, too few HIV-exposed 
infants receive the prophylaxis that they need to protect 
them from acquiring HIV infection.
Current reporting on prophylaxis for infants, at 
least through 2010, refl ects immediate postpartum 
prophylaxis for infants. Although the coverage of 
antiretroviral prophylaxis among infants was still less 
than the coverage among mothers in 2010, the reported 
coverage among infants increased between 2009 and 
2010 from 32% [29–36%] to 42% [38–48%] of the 
estimated 1.49 million infants born to mothers living 
with HIV. Despite this increase, the gap between 
infants’ and mothers’ uptake of antiretroviral medicine 
is still substantial, suggesting problems with providing 
the postpartum prophylaxis to the infant, reporting on 
infant prophylaxis or early loss to follow-up of mother–
infant pairs (Fig. 7.10). The coverage of antiretroviral 
prophylaxis among infants varies between regions 
and subregions, with Eastern Europe and Central Asia 
attaining the highest coverage in 2010, at 75% [63–
91%], and coverage remaining lowest and relatively 
stagnant during the past year in western and central 
Africa at 14% [12–16%] (Fig. 7.11). In sub-Saharan 
Africa, coverage increased from 32% [28–36%] in 
2009 to 43% [38–48%] in 2010. This increase was 
mostly driven by eastern and southern Africa, where 
coverage increased from 41% [36–45%] in 2009 to 
55% [50–62%] in 2010. In Latin America and the 
Caribbean and South-East Asia, coverage remained 
about the same, at 55% [43–84%] and 32% [25–45%] 
in 2010 respectively.
Nigeria (29%)
Uganda (7%)
Democratic Republic 
of the Congo (7%)
Mozambique (6%)
Kenya (6%)
Other low- and middle-
income countries (10%)
a These countries  include Angola, Botswana, 
Burkina Faso, Cameroon, Central African 
Republic, Chad, Côte d’Ivoire, Ghana, 
Lesotho, Russian Federation, Rwanda, South 
Africa, Sudan, Swaziland, United Republic of 
Tanzania, Zambia, Zimbabwe.
United Republic of 
Tanzania (5%)
Countries among the 25 
highest-burden countries 
estimated to contribute 
less than 2% to the global 
gapa (13%)
India (6%)
Fig. 7.9 Countries with the largest contribution to the global gap in reaching 90% of pregnant women living with HIV in need 
with antiretroviral medicine for preventing mother-to-child transmission, 2010
Ethiopia (2%)
Zimbabwe (3%)
Malawi (6%)
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The bar indicates the uncertainty range around the estimate.
Fig 7.11 Percentage of infants born to pregnant women living with HIV who received antiretroviral prophylaxis for preventing mother-to-child 
transmission, 2005, 2009 and 2010
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Fig 7.10 Percentage of pregnant women living with HIV and their infants who received antiretroviral medicine for 
preventing mother-to-child transmission, low- and middle-income countries, 2005–2010
z  Pregnant women living with HIV receiving antiretroviral medicine for preventing mother-to-child transmissiona
z  Infants born to women living with HIV receiving antiretroviral medicine for preventing mother-to-child transmissionb
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a Coverage in 2010 cannot be compared with previous years as it does not include single-dose nevirapine which is no longer recommended by WHO. 
b This includes only the initial (4-6 weeks) prophylaxis for infants. 
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7.5 Treatment, care and support for 
children
A child can still acquire HIV even if a mother and 
her infant receive interventions for preventing the 
mother-to-child transmission of HIV. Early initiation of 
antiretroviral therapy will improve the health of children 
living with HIV and reduce morbidity and mortality 
(54). Although HIV care and treatment services for 
children exposed to and living with HIV are expanding 
in resource-limited settings, they are still inadequate. 
There is still a major gap in coverage of antiretroviral 
therapy for children versus adults. Of the 2.02 million 
[1 800 000–2 300 000) children estimated to need 
antiretroviral therapy in 2010, only 23% [20–25%] had 
access versus 51% of adults [48–54%] (see Chapter 5).
7.5.1 Infant diagnosis
Early diagnosis of HIV infection is critical to ensure 
optimal treatment outcomes for children. If diagnosed 
early and provided with appropriate treatment, infants 
and children living with HIV can survive to adolescence 
and adulthood. Although progress has been made in 
early diagnosis of infants, many children living with 
HIV still go undiagnosed. Without diagnosis and 
effective treatment, one third of infants living with HIV 
die before the age of one year and almost half during 
their second year of life.
Children born to mothers living with HIV have been 
exposed to HIV but may not be HIV-positive. WHO’s 
2010 guidelines on antiretroviral therapy for HIV 
infection among infants and children (55) recommend 
that HIV-exposed infants be tested by 4–6 weeks 
of age using polymerase chain reaction (PCR). It is 
important for HIV-exposed infants to be tested early 
so that, if they are diagnosed as HIV-positive, they can 
immediately start antiretroviral therapy, regardless of 
clinical or immune status (56), to improve chances of 
survival. A second confi rmatory HIV test should be 
done, but this should not delay starting antiretroviral 
therapy (56,57).
Signifi cant progress has been made in scaling up the 
coverage of early infant diagnosis in 2010. In 65 low- 
and middle-income countries providing data (up from 
54 countries in 2009), 28% [24–30%] of infants were 
reported to have been tested for HIV within the fi rst 
Box 7.14
Implementing new recommendations on HIV and infant feeding and monitoring progress
Since the WHO 2010 guidelines on HIV and infant feeding (53) were published, many countries, especially those in sub-Saharan Africa, have 
revised their national recommendations on infant-feeding practices by mothers living with HIV. At the end of December 2010, 93 (76%) of 123 
responding low- and middle-income countries had decided to adopt and implement protocols to provide antiretroviral drugs after delivery.
WHO recommends two equally effective options (A and B: see section 7.4.2.2) to reduce transmission during the perinatal period and while 
breastfeeding.
Countries have varied in their choice of strategy for antiretroviral medicine for preventing HIV infection through breastfeeding. National 
authorities in Eastern Europe and Central Asia and South-East Asia have reviewed practices and recommendations.
Despite protocols that aim to increase the coverage of antiretroviral medicine and enable mothers living with HIV to breastfeed with a 
signifi cantly diminished risk, adequately implementing these recommendations remains a major challenge. Very little information is available 
on antiretroviral medicine used during breastfeeding.
Routine health information systems have only recently begun to collect data on feeding practices of mothers living with HIV. Such data are 
essential to monitor progress on implementation in countries. The limited national-level data on infant-feeding practices related to exclusive 
breastfeeding in children younger than six months old suggest considerable variability in uptake, with levels ranging from 3% to 88% in the 
general population of the 22 priority countries for eliminating mother-to-child transmission.
Population-based surveys have generally not disaggregated infant-feeding practices by the mother’s HIV status because the sample sizes 
of HIV-exposed infants are small in surveys. However, several countries, including Lesotho, South Africa and Zambia, have started or plan to 
prospectively collect data about infant-feeding practices when infants are immunized at about three months of age. As of 2012, countries 
are expected to be able to report more extensively on infant-feeding practices (such as exclusive breastfeeding, replacement feeding and 
mixed feeding) of HIV-exposed infants attending child clinics for DPT3 immunization and on the coverage of antiretroviral medicine among 
the HIV-exposed infants who are breastfeeding.
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two months of birth, versus 6% [5–7%] in 2009. This 
increase results in part from including data in 2010 from 
nine priority countries for eliminating mother-to-child 
transmission that did not report on this indicator in 2009.
Among the 22 priority countries for eliminating mother-
to-child transmission, several have exceeded 50% 
coverage of virological HIV testing. The coverage of 
virological testing of HIV-exposed children at two 
months of age reached 78% in Lesotho and 68% in 
South Africa in 2010. Kenya (64%), Namibia (62%), 
Swaziland (54%) and Botswana (53%) have also 
made considerable gains in this area. In other priority 
countries, greater efforts are needed to scale up early 
infant diagnosis to ensure that children living with HIV 
can initiate treatment as soon as possible. Priority 
actions include building technical competencies, 
developing laboratory capacity, strengthening systems 
for transporting blood specimens and results, improving 
cross-service referrals and expanding the routine offer 
of testing to more sites where mothers and children 
access care, especially in generalized epidemic settings.
In addition, reducing the rate of loss to follow-up among 
HIV-exposed infants in the postnatal period is essential. 
Many infants, even when tested, do not receive their 
results or are not given antiretroviral therapy following 
an HIV-positive diagnosis. Investment must be made 
to improve data collection and service delivery along 
the continuum of care so that children who test 
positive are enrolled in treatment in a timely manner. 
It is also necessary to better understand and address 
the challenges faced by mothers in accessing health 
services for their infants as well as for themselves.
7.5.2 Co-trimoxazole prophylaxis for HIV-
exposed children
An essential component of the care and treatment 
package for children living with HIV is providing 
co-trimoxazole prophylaxis, a highly efficacious, 
affordable, cost-effective and widely available 
antibiotic that has been shown to signifi cantly reduce 
morbidity and mortality among infants and children 
who are living with or exposed to HIV. The use of 
co-trimoxazole prophylaxis increases the chances of 
survival of infants living with HIV until antiretroviral 
therapy can be initiated. This is especially important in 
resource-limited settings, where access to interventions 
for preventing mother-to-child transmission and to 
antiretroviral therapy is still insuffi cient. The 2006 
WHO guidelines recommend that all HIV-exposed 
children born to mothers living with HIV start co-
trimoxazole prophylaxis between four and six weeks 
of age and continue until breastfeeding has terminated 
and HIV serostatus is known to be negative (58).
In 2010, 87 countries provided information on the 
number of infants born to pregnant women living with 
HIV who initiated co-trimoxazole prophylaxis by two 
months of age, up from 72 countries in 2009. Even 
though several countries have established policies to 
support access to co-trimoxazole prophylaxis for infants 
and children, only 23% [19–24%] of HIV-exposed 
infants in reporting low- and middle-income countries 
received co-trimoxazole in 2010; nevertheless, this was 
a substantial increase compared with 13% [11–14%] in 
2009. The expansion in coverage was predominantly 
driven by progress made in countries from eastern and 
southern Africa, where coverage increased from 16% 
[15–18%] in 2009 to 31% [28–35%] in 2010. Coverage 
Box 7.15
Key priorities for scaling up antiretroviral therapy for children
The Paediatric Care and Treatment Working Group of the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant 
Women, Mothers and Children recently published recommendations for accelerating the scaling up of antiretroviral therapy for children (59). 
Key actions include the following.
• Set high national targets for HIV testing and treatment of children.
• Expand access to early infant diagnosis of HIV.
• Increase retention in HIV programmes for children.
• Rationalize formularies for children and provide access to optimal drugs.
• Implement task-shifting of antiretroviral therapy for children.
• Address the special needs of adolescents living with HIV.
Source: Paediatric advocacy tool kit for improved paediatric HIV diagnosis, care and treatment in high prevalence countries and regions (59).
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in Latin America and the Caribbean also improved from 
15% [13–25%] in 2009 to 25% [21–42%] in 2010, 
with a larger number of countries reporting. Coverage 
among the 22 priority countries for eliminating mother-
to-child transmission was 21% [18–25%] in 2010.
Expanding access to co-trimoxazole prophylaxis 
requires a set of interrelated interventions, including 
developing stronger links between HIV testing and 
treatment and establishing mechanisms to identify 
and follow up HIV-exposed infants at and after birth. 
In addition, health workers must be trained to consider 
HIV infection in infants at birth and at all clinic or health 
facility encounters, and delivery must be decentralized 
to the lowest appropriate, feasible and effective level 
of the health care system. A consistent supply of co-
trimoxazole must be available, and monitoring and 
evaluation systems need to be strengthened to support 
the provision of co-trimoxazole prophylaxis to children 
living with or exposed to HIV (58).
7.5.3 Antiretroviral therapy for children
Although the best strategy for preventing children 
from acquiring HIV infection and dying from AIDS-
related causes is expanding effective programmes 
for preventing mother-to-child transmission, many 
HIV-related deaths among children living with HIV 
could be avoided by providing early HIV diagnosis and 
timely provision of care and treatment. To maximize 
the survival and well-being of children living with HIV, 
WHO released updated treatment guidelines in 2010 
(56), which include signifi cant changes to the criteria for 
children initiating antiretroviral therapy (see Box 7.15).
Box 7.16
Improvements in estimating the number of children living with HIV who need antiretroviral therapy
The Spectrum software package is used to estimate the number of children living with HIV; the same estimate is used to identify the number 
of children who need antiretroviral therapy. These estimates require assumptions about fertility among women living with HIV, the effi cacy of 
various prophylaxis regimens to prevent mother-to-child transmission, the timing of progression between different CD4 levels and children’s 
survival rates (depending, for example, on how and at what age they became infected). Based on a review of the literature and the latest 
available evidence, several important changes have been made to those assumptions in the past two years.
New evidence shows that the timing of infection among children is important. Survival curves now refl ect, respectively, the different survival 
rates for children living with HIV depending on when they acquired infection – either in utero, during birth or during breastfeeding (at 0–6 
months, 6–12 months or 12–14 months). The revised survival curves indicate longer life expectancy than those previously in use, thereby 
increasing the number of children living with HIV who need treatment (see Chapter 2).
In addition, the Spectrum program now has different survival times for adults of different ages, which has resulted in a larger proportion of 
women with HIV who are in the most fertile age groups compared with the estimates produced in previous years. Spectrum now also enables 
more detailed data on programmes for preventing mother-to-child transmission to be incorporated, including the various types of regimens 
mothers are using during pregnancy and during breastfeeding. The basic methods regarding the estimate of the number of women needing 
antiretroviral medicine have not changed. The regimen-specifi c probabilities of HIV transmission have been updated based on current evidence 
from research studies and trials on preventing mother-to-child transmission. These transmission probabilities are based on a woman’s CD4 
level, making estimates of the rate of mother-to-child transmission more accurate. The transmission probabilities during breastfeeding are 
also improved, refl ecting the CD4 level of the mother. Finally, the model incorporates the very high probability of transmission if a woman 
becomes infected while she is pregnant or breastfeeding.
The modelling process has also incorporated the new eligibility criteria for initiating antiretroviral therapy among children, in accordance 
with the revised WHO treatment guidelines for infants and children (56). The change in age-specifi c eligibility criteria, from younger than 
12 months of age to younger than 24 months of age, took effect in 2010.
The new set of estimates, based on improved data on the distribution of regimens and of infant feeding practices, combined with the above 
changes in methods has resulted in a larger number of children newly infected than in previous estimates despite increases in reported 
coverage of interventions for preventing mother-to-child transmission. Past reported estimates probably underreported the number of children 
newly infected. This, combined with longer survival of children who acquire HIV infection through breastfeeding, has resulted in increases in 
the number of children newly infected with HIV, more children living with HIV and therefore more children who need antiretroviral therapy. 
The estimated number of children who needed antiretroviral therapy in 2009 has been revised based on these new assumptions and has 
increased from 1 270 000 (as published in previous reports) to 1 670 000. For 2010, the number of children who need antiretroviral therapy 
is an estimated 2 020 000. The large difference between 2009 and 2010 is explained by the change in age-specifi c eligibility criterion. These 
increases in the estimates of the number of children who need antiretroviral therapy are affecting the estimated coverage of antiretroviral 
therapy among children. To assess trends over time, the coverage rates for 2009 and 2005 published in the 2011 report should not be 
compared with the coverage fi gures published in previous annual progress reports.
162     GLOBAL HIV/AIDS RESPONSE – Epidemic update and health sector progress towards Universal Access – Progress Report 2011
Data reported by low- and middle-income countries 
show that, as of December 2010, about 456 000 
children younger than 15 years who need antiretroviral 
therapy were receiving it, a 29% rise from a year 
earlier (354 600 in 2009) and a six-fold increase 
since 2005 (75 000) (Fig 7.12 and Table 7.8). These 
children represent an estimated 23% [20–25%] of the 
estimated 2.02 million children who need antiretroviral 
therapy. In 2009, coverage was estimated at 21% 
[19–24%]. At the end of 2010, eleven countries had 
reached at least 80% coverage of antiretroviral therapy 
for children, including two countries with generalized 
Table 7.8 Reported number of children 0–14 years old living with HIV receiving antiretroviral therapy, children needing 
antiretroviral therapy and estimated coverage in low- and middle-income countries according to region, December 2010a
Geographical region
Reported number of children (0–14 
years old) living with HIV receiving 
antiretroviral therapy, 
December 2010
Estimated number of children living 
with HIV needing antiretroviral 
therapy, 2010 
[range]a
Antiretroviral therapy coverage 
among children living with HIV, 
December 2010 
[range]b
Sub-Saharan Africa 387 500 1 840 000 [1 600 000–2 100 000] 21% [19–24%]
Eastern and southern Africa 337 200 1 290 000 [1 100 000–1 400 000] 26% [23–29%]
Western and central Africa 50 200 550 000 [480 000–630 000] 9% [8–11%]
Latin America and the Caribbean 16 300 41 400 [34 000–50 000] 39% [32–48%]
Latin America 13 600  30 600 [25 000–38 000] 44% [36–55%]
Caribbean 2 700  10 800 [8 700–13 000] 25% [21–31%]
East, South and South-East Asia 43 800  113 000 [84 000–140 000] 39% [30–52%]
Europe and Central Asia 7 500  11 400 [10 000–13 000] 65% [55–71%]
North Africa and the Middle East  840 18 500 [12 000–25 000] 5% [3–7%]
All low- and middle-income 
countries 456 000
2 020 000
 [1 800 000–2 300 000] 23% [20–25%]
Note: some numbers do not add up because of rounding.
a For an explanation of the methods used, see the explanatory notes to Annex 9.
b The coverage estimate is based on the estimated unrounded number of children receiving and needing antiretroviral therapy.
The bar indicates the uncertainty range around the estimate.
Note: the data have been retroactively calculated according to the revised methods (see Box 7.16).
Fig. 7.12 Percentage of children living with HIV receiving antiretroviral therapy in low- and middle-income countries, 2005, 2009 and 2010
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Botswana 88%
20 40 60 800 100
Democratic Republic of the Congo 8%
Thailand 69%
Rwanda 45%
South Africa 36%
Zambia 26%
Kenya 21%
Zimbabwe 32%
Lesotho 22%
Uganda 16%
United Republic of Tanzania 18%
Burkina Faso 10%
Côte d’Ivoire 12%
Mozambique 19%
Angola 10%
Ghana 13%
Burundi 13%
Cameroon 11%
Nigeria 7%
Chad 5%
Sudan 2%
Note: some numbers do not add up because of rounding.
a Ethiopia and Malawi are estimated to belong to the list of 25 countries with the highest need for antiretroviral therapy among children living with HIV, but no coverage can be provided at 
this stage as their need estimates are currently being reviewed.
Fig. 7.13 Percentage of children living with HIV receiving antiretroviral therapy in 25 countries with a high burden of HIV in 2010a
India 35%
Central African Repulblic 7%
Percentage (%)
Countriesa
Percentage point difference between the 
antiretroviral therapy coverage 
of adults and children, 2010
Estimated antiretroviral 
therapy coverage among 
children, December 2010
Estimated antiretroviral 
therapy coverage among 
adults, December 2010
Zambia 58 26% 84%
Kenya 53 21% 74%
Guinea 52 14% 66%
Rwanda 51 45% 96%
Burkina Faso 50 10% 60%
Venezuela, Bolivarian Republic of 50 12% 62%
Chad 44 5% 49%
Benin 43 23% 66%
Togo 42 16% 58%
Lesotho 41 22% 63%
Uganda 40 16% 56%
Haiti 38 19% 57%
Mali 37 16% 53%
Zimbabwe 33 32% 65%
Cameroon 32 11% 43%
Côte d'Ivoire 30 12% 42%
Angola 29 10% 39%
United Republic of Tanzania 29 18% 47%
Niger 29 6% 35%
Congo 27 21% 48%
Ghana 27 13% 40%
Burundi 26 13% 39%
Mozambique 25 19% 44%
Cambodia 25 71% 96%
a Countries are classifi ed by decreasing order of difference between adult and child coverage.
Table 7.9 Low- and middle-income countries with more than 5000 children who need antiretroviral therapy with a 
difference between the antiretroviral therapy coverage among children and adults of at least 25 percentage points
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epidemics (Botswana and Namibia) and nine countries 
(Belarus, Chile, Ecuador, Guyana, Jamaica, Mexico, 
Paraguay, Uruguay and Uzbekistan) with concentrated 
or low-level epidemics.1 Five countries – Nigeria (with 
an estimated unmet need of 262 000 for antiretroviral 
therapy for children), South Africa (196 000), Kenya 
(133 000), Uganda (102 000) and United Republic 
of Tanzania (91 000) – accounted for about 50% of 
the unmet need for antiretroviral therapy for children 
in 2010.
Regionally, between 2009 and 2010, the coverage of 
antiretroviral therapy for children increased substantially 
only in Europe and Central Asia, from 56% [47–60%] 
to 65% [55–71%]. Coverage in sub-Saharan Africa, 
the region with the highest burden of children in need, 
remained stable at 21% [19–24%] in 2010 versus 20% 
[17–22%] in 2009. Eastern and southern Africa had 
the highest number of children receiving antiretroviral 
therapy, at 337 000, or 26% [23–29%] of those 
estimated to be in need, up from 255 000, or 23% 
[21–26%], in 2009. The coverage of antiretroviral 
therapy for children in western and central Africa was 
considerably lower. Although the number of children 
receiving antiretroviral therapy increased from 41 000 in 
2009 to 50 000 in 2010, coverage dropped slightly from 
10% [8–11%] in 2009 to 9% [8–11%] in 2010 (Table 7.8).
Coverage was also steady in East, South and South-East 
Asia at 39% [30–52%] in 2010, although the number 
of children receiving antiretroviral therapy increased 
from 36 400 in 2009 to 43 800 in 2010. In North 
Africa and the Middle East, coverage remained similar 
at 5% [3–7%]. Coverage fell in Latin America and 
the Caribbean, from 45% [38–55%] in 2009 to 39% 
[32–48%] in 2010.
In the group of 25 high-burden countries accounting 
for an estimated 91% of the children who need 
antiretroviral therapy (Fig. 7.13), Botswana (88%) and 
Thailand (69%) had the highest levels of coverage. 
Chad (5%) and Sudan (2%) had the lowest levels of 
coverage among these countries.
Although progress is being made, less than 25% of 
children who needed antiretroviral therapy in low- 
and middle-income countries received it in 2010, 
versus 50% coverage among adults, and this gap was 
even wider in some countries (Table 7.9). In 2010, 24 
countries with more than 5000 children who needed 
1 Countries with less than 100 children needing antiretroviral therapy are 
excluded.
antiretroviral therapy had a difference between the 
antiretroviral therapy coverage levels of adults and 
children of at least 25 percentage points. Implementing 
adequate policies and interventions to ensure that 
the treatment needs of children are adequately met 
is essential.
7.6 Measuring the impact towards 
eliminating mother-to-child 
transmission
The Global Plan (4) seeks to reduce the number of 
children newly infected with HIV by 90% by 2015 
(compared with 2009), reduce the number of women 
dying from HIV-related cause among during pregnancy, 
delivery and postnatally by 50% and cut the mother-to-
child transmission of HIV to less than 5%. Adequately 
measuring progress towards these objectives is an 
essential part of the Plan’s success.
The partners involved in the Global Plan have developed 
a guide summarizing fi ve key approaches to assess the 
impact of preventing mother-to-child transmission:2 
(1) mathematical modelling; (2) prospective or 
retrospective cohort studies of mother–infant pairs; 
(3) assessing the HIV exposure and infection status of 
infants from the general population in immunization 
settings; (4) population-based surveys; and 
(5) assessing infection status through early infant 
diagnosis programmes. The approaches include 
methods to overcome loss to follow-up, which has 
been hampering efforts to evaluate preventing mother-
to-child transmission for the past decade.3
South Africa has recently fi nalized the fi rst part of the 
national impact evaluation of the national programme 
for preventing mother-to-child transmission. It 
administered a questionnaire and collected dried 
blood spot samples through a cross-sectional survey 
of children attending immunization clinics around the 
age of 4–8 weeks. Antibody tests were performed to 
2 In addition to WHO, the United States Centers for Disease Control 
and Prevention and UNICEF, the Clinton Health Access Initiative, the 
International Center for AIDS Care and Treatment Programs, the Offi ce 
of the United States Global AIDS Coordinator, UNAIDS and the United 
States Agency for International Development have contributed to the 
guide thus far.
3 The fi ve approaches were presented at a special Measuring PMTCT 
Impact satellite session at the International AIDS Conference in Rome in 
July 2011, and fi ve countries (Kenya, Mozambique, Swaziland, Rwanda 
and South Africa) shared their experiences in planning or implementing 
national evaluations of the impact of programmes for preventing the 
mother-to-child transmission of HIV (60).
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identify children who had been exposed to HIV, and 
PCR tests were then performed on antibody-positive 
dried blood spot samples to detect HIV infection 
in the child. The preliminary results from the study 
showed that 31% of infants were born to a mother 
living with HIV; these percentages of HIV seropositivity 
among mothers were higher than data from women 
attending antenatal care, suggesting there may be 
some seroconversion of mothers during pregnancy. The 
estimated national rate of mother-to-child transmission 
among infants 4–8 weeks old was 3.5% [2.9–4.1%], 
with regional variation, demonstrating that low levels 
of peripartum transmission can be achieved. Adding 
the postnatal transmission from breastfeeding (late 
transmission) results in an estimated fi nal mother-to-
child-transmission rate of 12–18% in 2010.
This approach to measuring impact may be particularly 
useful in countries with a high prevalence of HIV 
infection and high immunization coverage rates, 
since it enables the assessment of outcomes of a 
nationally representative sample of children attending 
immunization visits. However, although it measures 
progress in interventions for preventing mother-to-child 
transmission delivered during pregnancy and delivery, 
it does not capture breastfeeding transmission, which 
is an important source of transmission in primarily 
breastfeeding populations. It also misses children living 
with HIV who have already died by the age of 4–8 weeks. 
A follow-up study to assess fi nal transmission is being 
planned in South Africa.
Although studies evaluating the impact of programmes 
for preventing mother-to-child transmission by directly 
collecting outcome data are planned or are underway in 
several countries, the results will not be available until 
2013. As such, although the mathematical modelling 
of mother-to-child transmission and the number of 
children acquiring HIV infection has limitations, it 
remains the only way to systematically assess impact 
across many countries and regions and globally.
Based on current models that include the distribution 
of antiretroviral regimens, mother-to-child transmission 
is estimated to have declined in low- and middle-
income countries from 35% in 2001 to 26% in 2010. 
In sub-Saharan Africa, the corresponding estimated 
transmission rates were similar to the global rate in 
all years. The estimated numbers of children acquiring 
HIV infection in low- and middle-income countries 
were 536 000 in 2000, 535 000 in 2005, 430 000 
in 2009 and 390 000 in 2010. Providing antiretroviral 
prophylaxis to pregnant women living with HIV has 
enabled more than 350 000 children to avoid acquiring 
HIV infection since 1995 (see Box 2.9). Annex 7 reports 
on the number of children newly infected with HIV in 
the 22 priority countries in 2009 and 2010.
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T
he achievements of the global HIV response 
over the last 10 years have been extraordinary. 
The incidence of HIV infection declined by 
more than 25% between 2001 and 2009 in 
33 countries, and the HIV prevalence among young 
pregnant women attending antenatal clinics has 
declined by 25% or more in 7 countries (1). At the end 
of 2010, more than 6.6 million people were receiving 
antiretroviral therapy in low- and middle-income 
countries, a 16-fold increase from the approximately 
400 000 people recorded in December 2003. Forty-
eight low- and middle-income countries now provide 
antiretroviral therapy to more than 50% of adults in 
need, including 10 countries with universal access, 
and about 50% of pregnant women received the most 
effective regimens to prevent the mother-to-child 
transmission of HIV in 2010. As a result of these efforts, 
the annual number of AIDS-related deaths worldwide 
has fallen from the peak of 2.2 million recorded in 2005 
to an estimated 1.8 million in 2010.
Although much has been accomplished since the 2001 
United Nations General Assembly Special Session 
on HIV/AIDS, the launch of the “3 by 5” initiative 
in December 2003 and the adoption of the 2006 
Political Declaration on HIV/AIDS, this report also 
draws attention to the multiple challenges that must 
be tackled before universal access to HIV prevention, 
treatment, care and support becomes a global reality. 
An estimated 2.7 million [2 400 000–2 900 000] 
people were newly infected with HIV in 2010, including 
390 000 [340 000–450 000] children, bringing the 
total number of people living with HIV to 34 million 
[31 600 000–35 200 000]. The coverage, quality 
and accessibility of many interventions, especially 
among populations at higher risk for HIV infection, are 
still insuffi cient. Most people living with HIV remain 
unaware of their serostatus, and late initiation of 
antiretroviral therapy is still common in many contexts. 
Retention levels across the cascade of interventions, 
from HIV testing to treatment and care, are inadequate, 
and many people identifi ed as HIV positive are lost to 
follow-up.
A time of opportunities
Nevertheless, the global HIV response has seldom 
been better positioned to address these challenges. 
The year 2011 has brought new political momentum, 
and important scientific breakthroughs have been 
announced. The recent United Nations General 
Assembly High Level Meeting on AIDS (2) has 
regalvanized partners, and its fi nal Declaration fully 
recognizes the central role of universal access to HIV 
prevention, treatment, care and support services in 
achieving the full range of the Millennium Development 
Goals. It provides a clear framework to deliver on 
ambitious, yet feasible, time-bound goals by 2015, 
including reducing sexual transmission by 50%, cutting 
in half the number of people living with HIV dying 
from TB and providing antiretroviral therapy to at 
least 15 million people who need it. The international 
community has also developed and endorsed a detailed, 
action-oriented global plan to support the elimination 
of the mother-to-child transmission of HIV and improve 
maternal health by 2015 (3).
New scientific evidence and innovation have also 
expanded the toolkit of interventions for delivering on 
these goals. The old divisions between treatment and 
prevention have been torn down. The landmark HPTN 
052 study (Box 3.6) has now clearly demonstrated 
that antiretroviral therapy can dramatically reduce 
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HIV transmission. Various studies have similarly 
demonstrated the effi cacy of pre-exposure prophylaxis 
in reducing the risk of acquiring HIV infection, including 
among men who have sex with men.
Such breakthroughs have also brought new impetus to 
vaccine research and development, and the scientifi c 
community is actively engaged in designing approaches 
that may lead to an eventual cure. Essential as this is, 
however, the importance of innovation goes well beyond 
scientifi c discoveries. It is also vital to improve and bring 
to scale existing technologies while designing new 
approaches that can best leverage available resources 
and optimize outcomes.
Innovation and effi ciency: the unfi nished 
agenda
An optimized global HIV response driven by more 
effi cient and innovative approaches lies at the core 
of the WHO global health sector strategy on HIV/
AIDS 2011–2015 (4) and the new investment framework 
proposed by UNAIDS and partners. By promoting 
the scaling up of six core programmatic activities, 
according to relevant population needs, investing in 
critical social and programmatic enablers and seeking 
synergy with other development sectors, more focused 
investment can result in more than 12 million fewer 
people infected with HIV and 7.4 million fewer deaths 
by 2020 as compared to the baseline. Realizing greater 
effi ciency and impact by developing and scaling up new 
modalities of service delivery is also central to the fi ve 
pillars of the Treatment 2.0 initiative.
Although investing available resources more effectively 
is essential, fully implementing this optimized approach 
requires a further US$ 7 to 9 billion annually, in addition 
to the US$ 15 billion currently available, to expand the 
coverage of key interventions. The resources available 
globally to fund the HIV response declined in 2010 
despite growing evidence of effectiveness and impact. 
HIV programmes must be fully funded not only to 
sustain current achievements but also to ensure that 
interventions reach the scale and intensity needed to 
maximize their population-level benefi t.
After almost a decade of extraordinary efforts and 
results, it has become increasingly clear that achieving 
universal access to HIV prevention, treatment, care 
and support requires changing both the demand 
for and supply of services. More must be done to 
stimulate users to seek out services and ensure they 
can access them, and systems must be adapted and 
strengthened to provide timely, affordable and high-
quality interventions.
Reach and retain
In many contexts, current accomplishments refl ect 
coverage of the most accessible segments of the 
population, mostly more highly educated city residents 
with comparatively greater monetary resources in 
closer proximity to health systems (5–7). Greater efforts 
and novel strategies are needed to extend service 
provision to harder-to-reach populations, including 
poorer rural communities and key populations at higher 
risk of HIV infection and transmission, such as men who 
have sex with men, transgender people, sex workers, 
people who inject drugs, migrants and prisoners.
More data have become available on the burden of 
the epidemic among these populations, including in 
countries with generalized epidemics in sub-Saharan 
Africa (see Chapter 1). However, the responses have 
lagged considerably behind. For instance, in Eastern 
Europe and Central Asia, people who inject drugs, one 
of the most severely affected key populations, continue 
to be less likely to have access to antiretroviral therapy 
than people who acquired HIV through other routes of 
transmission (see section 6.4). Moreover, key populations 
at higher risk of HIV infection continue to face high 
levels of stigma, criminalization and harassment, thus 
impairing their ability and willingness to seek life-saving 
prevention, treatment, care and support. Gender-based 
violence also remains a major source of inequity in 
health services. Addressing these situations requires 
considerably stronger human rights frameworks so that 
these populations can be adequately protected and can 
freely access, without fear of persecution or reprisal, 
services tailored to their needs.
Greater attention is also needed to ensure that people 
who are aware of their serostatus are adequately 
followed up so that they can enrol in care or receive 
antiretroviral therapy. For instance, many pregnant 
women, even when found to be living with HIV and 
provided with antiretroviral drugs to prevent the vertical 
transmission of HIV, are not retained in care for their 
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own health. Lack of follow-up also negatively affects 
their babies, who fail to receive early diagnosis and, if 
found to be living with HIV, provided with the necessary 
treatment. Retention therefore needs to be improved 
throughout the cascade of interventions by developing 
more robust linkage systems and by identifying and 
addressing key barriers. Several countries have made 
progress in developing systems to measuring and 
reducing patient attrition (Box 5.6).
Adapting services to meet clients’ needs
The experiences of countries that have successfully 
achieved universal access for some programme 
components, such as Rwanda, clearly demonstrate 
the importance of bringing services closer to 
communities (Box 5.10). Transport and opportunity 
costs can powerfully deter seeking out health care 
and associated commodities, which is especially 
important given the lifelong nature of antiretroviral 
therapy. Decentralizing high-quality services to the 
lowest feasible level of the health system can facilitate 
early diagnosis and retention in care and may ensure 
that non-urban and often poorer segments of the 
population can reach services (8).
System structures and pathways must be streamlined 
and coordinated so that navigating them becomes less 
burdensome and time-consuming to users. Multiple 
appointments, scheduled for different days and at 
different services, discourage people from attending 
and being followed up. Moreover, a client-centred 
approach requires recognizing that individuals often 
reach health systems with multiple needs that 
extend beyond those related to HIV. For instance, 
a woman may need family planning for herself and 
vaccination for her children in addition to antiretroviral 
drugs. Nevertheless, patient needs are still too often 
perceived and addressed in isolation, and many missed 
opportunities result in profound detrimental effects on 
general health outcomes.
Closer collaboration and integration must be developed 
among services, including those for maternal and child 
health, harm reduction, sexual and reproductive health 
and managing TB, other sexually transmitted infections 
and viral hepatitis. Organizational arrangements must 
consider the local context, including epidemiological 
profiles. They may cover a broad spectrum, from 
strengthening referral systems to establishing one-stop 
clinics that can offer multiple interventions by the same 
clinical team. Greater coordination between HIV and 
noncommunicable disease programmes is also vital to 
expand the coverage of interventions that can address 
a host of other critical conditions, including those 
associated with ageing, poor nutrition and sanitation 
and mental disorders.
Preparing systems for reaching and 
sustaining universal access
As HIV programmes continue to be scaled up, health 
systems must be prepared to provide care to more 
people, at an earlier stage of HIV infection and for a 
longer period of time. In settings facing severe shortages 
of health care workers, enhanced task-shifting strategies 
need to be designed and implemented to tackle 
enrolment bottlenecks and ensure the sustainability 
of programmes. Health workers need to be adequately 
prepared and supported to address the needs of 
increasing numbers of people who require lifelong 
care. In Malawi, local programmes have pioneered 
innovative approaches (see Box 5.6) with remarkable 
results. Procurement and supply management systems 
must also be improved and expanded, as stock-outs of 
antiretroviral drugs are still common in more than one 
third of reporting low- and middle-income countries 
(see section 5.3.6). This is especially important as new 
medicines and interventions become available, such 
as point-of-care diagnostics, and are incorporated into 
health care supply chains.
Governance systems must be further strengthened 
to ensure inclusive, transparent and accountable 
leadership. In this respect, communities of people 
living with or affected by HIV must be fully engaged in 
designing, implementing and evaluating national HIV 
responses. Their continued activism is fundamental in 
catalysing and sustaining political momentum.
Although emergency approaches were instrumental 
in building or strengthening HIV programmes for 
rapid scale-up in most countries, their transition 
to sustainable models of service delivery must be 
accelerated. This entails addressing three key issues. 
First, the capacity of governments, communities 
and civil society organizations to take leadership of 
national responses must be reinforced. In addition, 
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HIV responses need to be clearly linked with other 
national social and economic goals and frameworks 
so that programmes address the epidemic within their 
broader health and development contexts. Lastly, as life 
expectancy increases and HIV management evolves 
towards a model of chronic-disease care, greater 
attention needs to be focused on monitoring the quality 
of the services provided, as this strongly infl uences 
long-term adherence, retention in care and outcomes.
The challenges towards universal access are 
considerable, but so are the technical resources, 
political support and commitment of all partners 
involved in the global HIV response. Additional focused 
investment and building on current achievements 
and applying the lessons learned from implementing 
programmes can enable the effi ciency, quality and 
coverage of interventions to be increased and ultimately 
make universal access to large-scale, high-quality HIV 
prevention, treatment, care and support a reality.
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Annex 1 Reported proportion of women attending antenatal care tested for syphilis at the fi rst visit, women attending 
antenatal care seropositive for syphilis, sex workers seropositive for active syphilis,  men who have sex with men 
seropositive for active syphilis, as reported by low- and middle-income countries in 2010a
Country
% of women 
attending 
antenatal care 
tested for 
syphilis at the 
fi rst visit Year
% of women 
attending 
antenatal care 
seropositive for 
syphilis Year
% of sex workers 
seropositive for 
active syphilis Year
% of men who 
have sex with 
men seropositive 
for active syphilis Year
Number of countries reporting 63 75 40 31
Afghanistan … … … … 8.7% 2010 17.0% 2010
Argentina 84.4% 2010 1.3% 2010 22.4% 2008 20.5% 2008
Bangladesh … … 0.6% 2008 4.2% 2007 1.0% 2007
Belize 90.4% 2010 1.4% 2010 … … … …
Bhutan … … 1.0% 2006 … … … …
Botswana … … 1.3% 2009 … … … …
Brazil 75.1% 2006 … 2.5% 2009 13.4% 2009
Burkina Faso 0.9% 2009 1.4% 2009 … … … …
Cambodia … … 0.4% 2010 2.3% 2005 0.9% 2005
Cameroon … … 0.6% 2009 … … … …
Central African Republic 71.9% 2010 10.0% 2010 … … … …
Chile 100% 2010 0.2% 2010 6.3% 2010 … …
China … … 0.4% 2010 2.9% 2010 8.4% 2010
Colombia 85.4% 2005 0.6% 2010 … … 3.3% 2010
Comoros 0.0% 2010 0.0% NR 0.5% 2010 … …
Costa Rica 85.0% 2009 1.4% 2009 12.9% 2009 13.7% 2009
Côte d’Ivoire … … 0.2% 2008 … … … …
Cuba 100% 2010 0.0% 2010 … … … …
Democratic Republic of the Congo 2.1% 2009 3.3% 2009 … … … …
Djibouti 63.3% 2009 0.2% 2009 … … … …
Dominican Republic … … 0.5% 2010 5.1% 2010 7.0% 2010
Ecuador 67.8% 2009 0.1% NR … … 6.5% NR
El Salvador 63.6% 2009 0.5% 2009 2.7% 2008 6.2% 2008
Equatorial Guinea 35.8% NR 14.0% NR … … … …
Eritrea 0.0% 2010 … … … … … …
Ethiopia … … 2.2% 2007 … … … …
Fiji 100% NR 2.8% NR … … 26.5% NR
Gabon 95.0% 2010 1.0% 2010 2.1% 2010 … …
Ghana 9.0% 2010 3.4% 2010 … … … …
Grenada 100% NR 3.7% NR … … … …
Guatemala 13.5% 2010 4.2% 2010 4.8% 2010 16.7% 2010
Guinea-Bissau … … 1.1% 2009 19.6% 2010 2.0% 2010
Guyana 100% 2010 0.2% NR … … … …
Haiti 68.4% 2010 4.7% 2010 … … … …
Honduras 41.5% 2010 1.5% NR 1.5% NR 12.9% NR
Hungary … … … … … … 4.4% NR
India 65.4% 2010 0.3% 2010 … … … …
Indonesia … … … … 6.1% 2009 8.0% 2009
Iran (Islamic Republic of) 0.0% NR … … … … … …
Iraq 27.3% 2010 0.0% 2010 … … … …
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Country
% of women 
attending 
antenatal care 
tested for 
syphilis at the 
fi rst visit Year
% of women 
attending 
antenatal care 
seropositive for 
syphilis Year
% of sex workers 
seropositive for 
active syphilis Year
% of men who 
have sex with 
men seropositive 
for active syphilis Year
Jamaica 73.1% 2010 1.6% 2010 1.2% 2008 15.0% 2007
Jordan 0.0% NR … … … … … …
Kenya 58.8% 2010 1.8% 2010 0.8% 2010 0.9% 2010
Kiribati 100% 2010 … … … … …
Lao People’s Democratic Republic … … … … 0.6% 2008 … …
Lesotho 66.9% 2010 1.6% 2010 … … … …
Liberia 10.9% 2010 13.6% 2010 … … … …
Madagascar 84.7% 2010 6.0% 2010 12.2% 2007 … …
Malawi … … 1.1% 2007 … … … …
Malaysia 98.7% 2010 0.1% 2010 … … … …
Maldives 41.7% 2010 0.0% 2010 … … … …
Mali … … 2.4% 2009 0.0% 2009 … …
Mauritius 100% 2010 0.1% 2010 4.4% 2010 5.8% 2010
Mongolia 82.9% 2010 2.2% 2010 18.3% 2009 5.4% 2009
Morocco … … 0.6% 2010 9.4% 2010 16.8% 2010
Mozambique 66.7% 2010 5.7% NR … … … …
Myanmar 8.1% NR 0.7% 2010 … … … …
Namibia 93.8% 2010 1.7% 2010 … … … …
Nepal … … … … 1.0% 2008 1.5% 2009
Nicaragua 60.0% 2010 0.5% 2010 5.3% 2010 6.4% 2010
Niger … … … 2.3% 2010 … …
Nigeria … … 1.5% 2005 … … … …
Oman 99.4% 2010 … … … … … …
Papua New Guinea … … 7.0% 2010 21.1% 2010 … …
Paraguay 52.7% 2010 4.5% 2010 14.6% NR 18.8% NR
Peru 72.1% 2010 0.3% 2010 … … … …
Philippines … … 0.2% 2010 1.3% 2009 2.1% 2009
Republic of Moldova … … 0.4% 2010 8.9% 2010 12.1% 2010
Rwanda 75.2% 2010 1.5% 2010 … … … …
Samoa 100% NR 2.3% NR … … … …
Sao Tome and Principe 89.2% 2010 0.4% 2010 … … … …
Seychelles 100% NR 0.0% NR … … … …
Sierra Leone 0.0% 2010 1.4% 2010 … … … …
Slovakia … … 0.1% 2010 … … … …
Solomon Islands 72.8% 2010 6.7% 2010 … … … …
Somalia 8.5% 2010 1.3% 2010 3.4% 2008 … …
South Africa 74.5% 2010 2.2% 2010 … … … …
Sri Lanka 98.0% NR 0.0% NR 3.0% 2009 4.7% 2009
Sudan 3.3% 2010 2.2% 2009–
2010
… … … …
Swaziland 34.8% 2009 8.3% 2010 … … … …
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…  Data not available or not applicable.
NR Data not reported.
a The data should be interpreted with caution, since the data may not be nationally representative and the methods varied among countries.
Country
% of women 
attending 
antenatal care 
tested for 
syphilis at the 
fi rst visit Year
% of women 
attending 
antenatal care 
seropositive for 
syphilis Year
% of sex workers 
seropositive for 
active syphilis Year
% of men who 
have sex with 
men seropositive 
for active syphilis Year
Tajikistan … … … … 11.5% 2010 … …
Thailand … … 0.1% 2010 0.6% 2010 … …
Timor-Leste 0.0% NR … … 8.8% 2010 5.3% 2010
Togo 4.6% 2010 1.2% 2010 … … … …
Turkey … … … … 2.9% 2010 … …
Ukraine … … … … 4.4% 2009 1.9% 2009
United Republic of Tanzania 78.1% 2007–
2008
2.8% 2007–
2008
2.5% 2010 … …
Uruguay 94.6% 2009 1.3% 2009 … … … …
Venezuela (Bolivarian Republic of) 96.1% NR 1.9% NR … … … …
Viet Nam … … … … 1.6% 2009 1.1% 2009
Zambia 43.3% 2010 5.3% 2010 … … … …
Zimbabwe 56.1% 2010 4.3% 2010 … … … …
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Annex 2 Reported number of facilities with HIV testing and counselling and number of people older than 15 years who received HIV testing 
and counselling, low- and middle-income countries, 2009–2010
Low- and middle-income countriesa
Testing and 
counselling facilities, 
2009
Testing and 
counselling facilities, 
2010
Number of people aged 15 years and older 
who received HIV testing and counselling, 
2009b
Number of people aged 15 years and 
older who received HIV testing and 
counselling, 2010b
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Afghanistan 25 0.2 11 0.1  8 001 0.6 Jan. 09–Dec. 09  22 844 1.6 Jan. 10–Dec. 10
Albania … … 18 1.1 … …  2 896 1.7 Oct. 09–Sept. 10
Algeria … … 59 0.3 … …  53 736 2.6 Jan. 10–Dec. 10
Angola 285 3.3 270 3.1 … …  442 200 51.6 Jan. 10–Dec. 10
Argentina  7 856 38.7  7 856 38.4 … … … …
Armenia 150 9.2 150 9.3  70 955 43.7 Jan. 09–Dec. 09  71 316 44.4 Jan. 10–Dec. 10
Azerbaijan … … … … … …  361 574 66.6 Jan. 10–Dec. 10
Bangladesh 105 0.1 105 0.1  26 369 0.3 Jan. 09–Dec. 09  33 190 0.4 Jan. 10–Dec. 10
Belarus  1 070 20.9  1 070 21.4 … …  816 234 163.3 Jan. 10–Dec. 10
Belize 43 26.3 66 39.6  23 802 145.5 Jan. 09–Dec. 09  27 305 163.9 Jan. 10–Dec. 10
Benin 126 3 416 10  280 982 67 Jan. 09–Dec. 09  318 389 76.9 Oct 09–Sept. 10
Bhutan 34 8.8 … … … …  8 915 21.7 Jan. 10–Dec. 10
Bolivia (Plurinational State of) 250 5.1 305 6.1  210 021 42.5 Jan. 09–Dec. 09  260 641 52.2 Jan. 10–Dec. 10
Bosnia and Herzegovina 40 2.1 41 2.1  20 369 10.5 Jan. 09–Dec. 09  19 897 10.3 Jan. 10–Dec. 10
Botswana 666 62.7 865 79.2  330 159 d 311 Jan. 09–Dec. 09  353 430 323.6 Jan. 10–Dec. 10
Brazil  3 579 3.4  3 579 3.4 … … 16 768 609 157.3 Jan. 10–Dec. 10
Bulgaria … … … … … … … …
Burkina Faso  1 267 17.4  1 531 19.9  602 961 82.6 Jan. 09–Dec. 09  565 311 73.4 Jan. 10–Dec. 10
Burundi 319 7.4 399 9.2  281 959 65.6 Jan. 09–Dec. 09  373 895 85.8 Jan. 10–Dec. 10
Cambodia 233 2.9 246 3.2  622 127 77.2 Jan. 09–Dec. 09  762 774 98.5 Jan. 10–Dec. 10
Cameroon  2 025 21.4  2 067 21.6  450 022 47.6 Jan. 09–Dec. 09  648 019 67.7 Jan. 10–Dec. 10
Cape Verde 205 76.5 … …  25 075 93.5 Jan. 09–Dec. 09 … …
Central African Republic 105 4.9 112 5.3  136 202 64.2 Jan. 09–Dec. 09  118 045 55.6 Jan. 10–Dec. 10
Chad 72 1.4 77 1.5  66 191 13.1 Jan. 09–Dec. 09  57 878 11.4 Jan. 10–Dec. 10
Chile 844 9.3  1 897 20.7  560 147 61.5 Jan. 09–Dec. 09  427 011 46.6 Jan. 10–Dec. 10
China  7 335 1  9 475 1.3 … … … …
Colombia … … … … … …  772 116 31 Jan. 10–Dec. 10
Comoros 14 4 15 4.3  3 281 9.4 Jan. 09–Dec. 09  4 428 12.6 Jan. 10–Dec. 10
Congo 103 5.7 118 6  82 332 45.8 Jan. 09–Dec. 09  89 546 45.5 Jan. 10–Dec. 10
Cook Islands … … … … … … … …
Costa Rica  1 106 43.3  1 166 44.7 … … … …
Côte d’Ivoire 550 5.5 636 6.8  727 290 72.5 Jan. 09–Dec. 09  791 424 84.6 Jan. 10–Dec. 10
Croatia 10 0.5 10 0.5  1 643 0.8 Jan. 09–Dec. 09  2 866 1.4 Jan. 10–Dec. 10
Cuba 378 6.2 378 6.2 1 888 065 310.7 Jan. 09–Dec. 09 … …
Democratic People’s Republic of Korea … … … … … … … …
Democratic Republic of the Congo 538 1.8 655 2.2  392 491 17.7 Jan. 09–Oct. 09  599 895 20.2 Jan. 10–Dec. 10
Djibouti 28 6.1 … …  14 154 31.1 Jan. 09–Dec. 09  9 936 21.2 Jan. 10–Dec. 10
Dominica 60 172.1 52 146.7  4 402 126.3 Jan. 09–Dec. 09 … …
Dominican Republic 150 2.8 150 2.9  259 110 49.1 Jan. 09–Dec. 09  209 125 40.5 Jan. 10–Dec. 10
Ecuador  1 263 18  2 406 31.5  403 263 57.3 Jan. 09–Dec. 09  415 770 54.5 Jan. 10–Dec. 10
Egypt … … 127 0.3 … …  14 185 0.3 Jan. 10–Dec. 10
El Salvador 489 15.7 658 20.5  362 628 116.6 Jan. 09–Dec. 09 … …
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Low- and middle-income countriesa
Testing and 
counselling facilities, 
2009
Testing and 
counselling facilities, 
2010
Number of people aged 15 years and older 
who received HIV testing and counselling, 
2009b
Number of people aged 15 years and 
older who received HIV testing and 
counselling, 2010b
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Equatorial Guinea 80 24.6 … …  24 256 74.6 Jan. 09–Dec. 09  24 075 70.2 Jan. 10–Dec. 10
Eritrea … … 173 6.6  132 829 52.2 Jan. 09–Dec. 09  127 202 48.2 Jan. 10–Dec. 10
Ethiopia  1 823 4.7  2 243 5.6 6 630 647 172.3 Jan. 09–Dec. 09 9 407 180 235.6 Jan. 10–Dec. 10
Fiji 31 7 26 5.6  27 865 63.3 Jan. 09–Dec. 09  17 182 37.1 Jan. 10–Dec. 10
Gabon 119 15.8 119 15.3  33 550 44.5 Jan. 09–Dec. 09  48 348 62.2 Jan. 10–Dec. 10
Gambia 34 4.2 35 4.2  47 549 66 Jan. 09–Oct. 09  58 326 70.1 Jan. 10–Dec. 10
Georgia … … 334 15 … …  70 615 31.8 Jan. 10–Dec. 10
Ghana 808 6.7  1 059 8.7 1 253 312 104.4 Jan. 09–Dec. 09 1 063 085 87.3 Jan. 10–Dec. 10
Grenada 38 65.9 48 83.1 … …  3 293 57 Jan. 10–Dec. 10
Guatemala 230 3.5 258 3.8  243 644 37.3 Jan. 09–Dec. 09  216 139 32 Jan. 10–Dec. 10
Guinea 83 1.8 83 1.8  74 090 15.8 Jan. 09–Dec. 09  166 576 35.8 Jan. 10–Dec. 10
Guinea-Bissau 62 8.4 62 8.6  24 871 33.8 Jan. 09–Dec. 09  73 476 102.2 Jan. 10–Dec. 10
Guyana 168 42.7 206 52.2  99 837 e 253.8 Jan. 09–Dec. 09  106 484 270 Jan. 10–Dec. 10
Haiti 167 3.3 170 3.3  681 002 132.8 Jan. 09–Dec. 09  504 827 98.8 Jan. 10–Dec. 10
Honduras 700 18.5 743 19.1  199 006 52.5 Jan. 09–Dec. 09  265 541 68.2 Jan. 10–Dec. 10
Hungary 144 3 144 3  99 538 20.6 Jan. 09–Dec. 09 … …
India  5 089 0.8  7 657 1.2 13 494 372 21.2 Jan. 09–Dec. 09 14 125 701 21.6 Jan. 10–Dec. 10
Indonesia 565 0.4 388 0.3  170 791 f 1.3 Jan. 09–Dec. 09  189 729 1.4 Jan. 10–Dec. 10
Iran (Islamic Republic of) … … 476 1 … …  52 802 1.2 Oct. 09–Sept. 10
Iraq … … 33 0.2 … …  3 780 0.3 Jan. 10–Dec. 10
Jamaica 343 24.3 338 23.9 … … … …
Jordan 12 0.3 12 0.4 271 0.1 Jan. 09–Dec. 09 134 0 Jan. 10–Dec. 10
Kazakhstan  3 801 43.9  5 330 60.6 1 498 858 173.1 Jan. 09–Dec. 09 1 938 180 220.3 Jan. 10–Dec. 10
Kenya  4 115 21.3  4 438 22.5 4 433 557 230 Jan. 09–Dec. 09 5 738 282 290.8 Jan. 10–Dec. 10
Kiribati 9 17 12 23.2  5 957 112.7 Jan. 09–Dec. 09  1 714 33.1 Jan. 10–Dec. 10
Kyrgyzstan 25 0.8 … …  172 106 56.9 Jan. 09–Dec. 09 … …
Lao People’s Democratic Republic 110 3.4 146 4.4  40 962 12.7 Jan. 09–Dec. 09  33 683 10.2 Jan. 10–Dec. 10
Latvia  4 743 416.2 … … … … … …
Lebanon 19 0.8 21 0.9 … … … …
Lesotho 239 23.8 216 19.4  251 242 250.6 Jan. 09–Dec. 09  235 295 211 Jan. 10–Dec. 10
Liberia 114 6.1 176 9.3  80 295 43 Jan. 09–Dec. 09  170 341 90.3 Jan. 10–Dec. 10
Libya … … … … … … … …
Lithuania 758 45.2 … … … … … …
Madagascar 816 8.8  1 642 16.9  324 809 35 Jan. 09–Dec. 09  192 813 19.9 Jan. 10–Dec. 10
Malawi 728 10.7 772 11.6 1 449 645 213.7 Jan. 09–Dec. 09 1 726 762 258.4 Jan. 10–Dec. 10
Malaysia  7 627 51.3  7 552 50.4  662 062 44.6 Jan. 09–Dec. 09  903 011 60.2 Jan. 10–Dec. 10
Maldives 8 4.3 8 4.2  4 285 22.9 Jan. 09–Dec. 09  6 185 32.6 Jan. 10–Dec. 10
Mali  1 091 17.6  1 182 17  255 835 41.3 Jan. 09–Dec. 09  239 115 34.3 Jan. 10–Dec. 10
Marshall Islands 2 6 … … … … … …
Mauritania … … … …  9 498 5.7 Jan. 09–Dec. 09  7 738 4.4 Jan. 10–Dec. 10
Mauritius 193 27.1 222 30.6  33 744 47.4 Jan. 09–Dec. 09  44 769 61.6 Jan. 10–Dec. 10
Mexico  2 784 4.7  14 260 23.5 … … … …
Micronesia (Federated States of) … … … … … … … …
Mongolia 57 3.5 61 3.7  9 015 5.5 Jan. 09–Dec. 09  77 768 47.4 Jan. 10–Dec. 10
Montenegro 8 2.6 8 2.6 738 2.4 Jan. 09–Dec. 09 780 2.5 Jan. 10–Dec. 10
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Low- and middle-income countriesa
Testing and 
counselling facilities, 
2009
Testing and 
counselling facilities, 
2010
Number of people aged 15 years and older 
who received HIV testing and counselling, 
2009b
Number of people aged 15 years and 
older who received HIV testing and 
counselling, 2010b
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Morocco … … 103 0.6 … …  49 060 2.8 Jan. 10–Dec. 10
Mozambique 356 3.4  1 274 11.9 1 201 942 114.4 Jan. 09–Dec. 09 1 139 166 106.3 Jan. 10–Dec. 10
Myanmar 350 1.2 470 1.7  270 301 9.6 Jan. 09–Dec. 09  365 677 13.4 Jan. 10–Dec. 10
Namibia 264 23.4 381 32.1  249 011 221 Jan. 09–Dec. 09  136 305 114.8 Jan. 10–Dec. 10
Nauru … … … … … … … …
Nepal 179 1.2 227 1.5  125 400 8.3 Jan. 09–Dec. 09  198 045 12.9 Jan. 10–Dec. 10
Nicaragua 862 28.6  1 079 35.3  205 233 68.1 Jan. 09–Dec. 09  175 000 57.3 Jan. 10–Dec. 10
Niger 321 5 546 8.3  358 071 55.6 Jan. 09–Dec. 09  425 696 64.8 Jan. 10–Dec. 10
Nigeria  1 074 1.5  1 046 1.4 2 570 386 35.1 Jan. 09–Dec. 09 2 287 805 30.9 Jan. 10–Dec. 10
Niue … … … … … … … …
Oman 61 3.7 227 12.8  605 755 368 Jan. 09–Dec. 09  757 709 428 Jan. 10–Dec. 10
Pakistan 13 0 14 0  11 439 0.1 Jan. 09–Dec. 09 … …
Palau … … … … … … … …
Panama 123 6.7 … …  60 798 33.3 Jan. 09–Dec. 09 … …
Papua New Guinea 177 5.2 266 7.7  159 005 46.9 Jan. 09–Dec. 09  136 643 39.5 Jan. 10–Dec. 10
Paraguay 143 4.4 285 8.6  159 607 49 Jan. 09–Dec. 09  82 477 24.8 Jan. 10–Dec. 10
Peru  5 096 32.6  7 902 50.8 … …  989 547 63.7 Jan. 10–Dec. 10
Philippines 82 0.2 91 0.2  10 110 0.2 Jan. 09–Dec. 09  13 287 0.3 Jan. 10–Dec. 10
Poland  2 645 13.7 … …  25 452 1.3 Jan. 09–Dec. 09 … …
Republic of Moldova 56 2.9 67 3.5  86 558 45.1 Jan. 09–Dec. 09  101 541 53.8 Jan. 10–Dec. 10
Romania 120 1.1 120 1.1  280 510 25.8 Jan. 09–Dec. 09  291 915 26.7 Jan. 10–Dec. 10
Russian Federation … … … … … … … …
Rwanda 395 8 434 8.5 1 932 420 393.8 Jan. 09–Dec. 09 2 407 073 469.2 Jan. 10–Dec. 10
Saint Kitts and Nevis … … … … … … … …
Saint Lucia 39 40.3 … …  1 629 16.8 Jan. 09–Dec. 09 … …
Saint Vincent and the Grenadines 40 66.6 … …  6 416 106.9 Jan. 09–Dec. 09 … …
Samoa … … 9 10.3 … … 589 6.7 Jan. 10–Dec. 10
Sao Tome and Principe 41 51.1 38 46.4  13 212 164.8 Jan. 09–Dec. 09  14 689 179.3 Jan. 10–Dec. 10
Senegal 532 8.8 … …  352 197 58.3 Jan. 09–Dec. 09 … …
Serbia 52 1.1 56 1.2  53 399 11 Jan. 09–Dec. 09  51 727 10.7 Jan. 10–Dec. 10
Seychelles 27 58.3 26 53.7  10 808 233.4 Jan. 09–Dec. 09  10 867 224.6 Jan. 10–Dec. 10
Sierra Leone 416 15.2 511 18.1  281 218 102.7 Jan. 09–Dec. 09  232 452 82.4 Jan. 10–Dec. 10
Slovakia … …  3 902 134.2 … …  128 563 44.2 Jan. 10–Dec. 10
Solomon Islands … … 25 9.3 … …  1 020 g 3.8 Jan. 10–Dec. 10
Somalia 19 0.5 42 1  10 057 h 2.4 Jan. 09–Dec. 09  16 588 3.9 Jan. 10–Dec. 10
South Africa  4 326 15.8  4 552 16.7 6 989 312 256.1 Jan. 09–Dec. 09 6 553 952 240.1 Jan. 10–Dec. 10
Sri Lanka 47 0.4 96 0.9 … …  16 767 1.5 Jan. 10–Dec. 10
Sudan 210 i 1 281 i 1.3  103 373 i 4.9 Jan. 09–Dec. 09  108 803 5.1 Jan. 10–Dec. 10
Suriname 59 21.2 67 23.9  19 276 69.3 Jan. 09–Dec. 09 … …
Swaziland 170 28.5 198 32.6  149 755 251.3 Jan. 09–Dec. 09  148 072 243.7 Jan. 10–Dec. 10
Syrian Arab Republic … … 23 0.2 … …  3 022 0.3 Jan. 10–Dec. 10
Tajikistan 231 6.3 235 6.5  285 831 78.5 Jan. 09–Dec. 09  278 738 77.6 Jan. 10–Dec. 10
Thailand  1 014 2.7  1 316 3.5 1 099 657 29.3 Jan. 09–Dec. 09 1 164 656 31.1 Jan. 10–Dec. 10
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Low- and middle-income countriesa
Testing and 
counselling facilities, 
2009
Testing and 
counselling facilities, 
2010
Number of people aged 15 years and older 
who received HIV testing and counselling, 
2009b
Number of people aged 15 years and 
older who received HIV testing and 
counselling, 2010b
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
number
Estimated 
number per 
100 000 
adult 
population
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
Reported 
numberc
Estimated 
number per 
100 000 
adult 
population Reporting period
The former Yugoslav Republic of 
Macedonia
14 1.3 24 2.2 … … … …
Timor-Leste … … 17 3.5 … …  1 241 2.5 Jan. 10–Dec. 10
Togo 225 6.9 377 12.5  166 887 51.1 Jan. 09–Dec. 09  200 190 66.5 Jan. 10–Dec. 10
Tonga … … 10 20 … …  6 402 128.1 Jan. 10–Dec. 10
Tunisia  2 430 40.9 261 4.4  13 915 2.3 Jan. 09–Dec. 09  12 000 2 Jan. 10–Dec. 10
Turkey  1 362 3.3  1 362 3.4 … … … … Jan. 10–Dec. 10
Turkmenistan … … … … … … … …
Tuvalu … … … … … … … …
Uganda  1 215 8.5  1 904 13 2 363 468 j 165.1 Oct. 08–Sept. 09 2 654 683 181 Jan. 10–Dec. 10
Ukraine  2 002 8.5  1 880 8.1 … … 3 247 002 140.5 Jan. 10–Dec. 10
United Republic of Tanzania  2 134 10.6  2 193 10.7 1 970 324 98.3 Jan. 09–Dec. 09 2 115 827 103.1 Jan. 10–Dec. 10
Uruguay … … 190 11.7 … … … …
Uzbekistan  5 153 32.9  5 153 33.1 1 250 185 79.8 Jan. 09–Dec. 09 1 482 014 95.2 Jan. 10–Dec. 10
Vanuatu … … … … … … … …
Venezuela (Bolivarian Republic of) 103 0.7 … … … … … …
Viet Nam 479 1 676 1.3  777 256 15.5 Jan. 09–Dec. 09 1 132 374 22 Jan. 10–Dec. 10
Yemen 20 0.2 14 0.1  7 525 0.7 Jan. 09–Dec. 09  10 933 1 Jan. 10–Dec. 10
Zambia  1 563 27  1 689 28.7 1 582 621 273.9 Jan. 09–Dec. 09 1 318 975 224.1 Jan. 10–Dec. 10
Zimbabwe  1 560 25  1 218 19.2 1 142 052 182.9 Jan. 09–Dec. 09 1 612 388 254.8 Jan. 10–Dec. 10
a See the country classifi cation by income, level of the epidemic and geographical, UNAIDS, UNICEF and WHO regions.
b This number should include all people aged 15 years and older who received HIV testing and counselling through any method or setting, including voluntary counselling and testing and antenatal care settings. Not all 
countries are able to report data from all settings.
c Some countries reported voluntary counselling and testing and antenatal care testing data separately; these data are combined here. 
d Does not include data from all voluntary counselling and testing networks, and routine health sector testing may include signifi cant repeat testing.
e Includes all people younger than 15 years who were tested.
f Only partial reporting available.
g Only data from Honiara is currently collated and available.
h Only 80% reporting available.
i Separate reports were received from Sudan for 2009 and 2010: testing and counselling facilities; northern Sudan, 132 (2009) and 189 (2010); southern Sudan, 78 (2009) and 92 (2010); number of people who received 
testing and counselling: northern Sudan, 52 770 (2009) and 49 966 (2010); southern Sudan, 50 502 (2009) and 58 837 (2010).
j Includes all people older than four years who were tested.
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Country
Percentage of people 
who inject drugs who 
received an HIV test in 
the past 12 months and 
who know the results Numerator Denominator Year
Number of countries reporting 26
Overall median 23%
Sub-Saharan Africa (n = 2) 
Mauritius 45% 228 511 2009
Nigeria 31% 480 1 545 2010
Median ...
Latin America and the Caribbean (n = 2) 
Brazil 13% 234 1 802 2010
Paraguay 12% 34 283 2007–2008
Median  ...
East, South and South-East Asia (n = 11) 
Afghanistan 5% 1 033 20 000 2009
China 41% 24 265 59 878 2010
Indonesia 20% 138 681 2009
Iran (Islamic Republic of) 25% 631 2 530 2010
Malaysia 33% 208 630 2009
Myanmar 27% 248 908 2007–2008
Nepal 21% 64 300 2009
Pakistan 12% 352 2 979 2008
Philippines 1% 14 959 2009
Thailand 89% 356 399 2010
Viet Nam 18% 544 3 036 2009
Median  21%
Europe and Central Asia (n = 9) 
Albania 17% 33 200 2008
Armenia 20% 55 270 2010–2011
Georgiab 6% 64 1 127 2008–2009b 
Kazakhstan 61% 3 014 4 950 2010
Republic of Moldova 48% 153 326 2009–2010
Romania 19% 85 450 2009
Serbia 33% 121 371 2010
Tajikistan 27% 453 1 657 2009
Ukraine 26% 1 667 6 460 2009
Median 26%
North Africa and the Middle East (n = 2) 
Lebanon 66% 72 109 2008
Tunisia 21% 148 711 2009
Median ...
a Country data may have been generated through surveys that are not nationally representative, and some survey results may overestimate the proportion of people accessing services. For 
instance, where reported coverage is close to 100%, they may represent people enrolled in treatment services or other settings where an HIV test is required to access the service.
b Butami (2008) and Tbilisi (2009).
Annex 3A.1 Percentage of people who inject drugs who received an HIV test in the past 12 months and who know the results, 
2010a
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Country
Percentage of men who 
have sex with men who 
received an HIV test in 
the last 12 months and 
who know the results Numerator Denominator Year
Number of countries reporting 41
Overall median 32%
Sub-Saharan Africa (n = 4) 
Burkina Faso 36% 133 373 2010
Mauritius 39% 140 362 2010
Nigeria 31% 486 1 545 2010
Togo 53% 335 630 2010
Median ...
Latin America and the Caribbean (n = 11) 
Brazil 13% 243 1 829 2010
Chile 25% 118 471 2008–2009
Colombia 23% 571 2 494 2010
Costa Rica 63% 189 300 2009
Cuba 32% 81 517 251 529 2009
Dominican Republic 7% 115 1 565 2010
Guatemalab 38% 688 400 1 793 613 2010
Nicaragua 51% 488 948 2009
Panama 51% 293 575 2009
Paraguay 34% 173 506 2007-2008
Uruguay 26% 81 309 2010
Median 32%
East, South and South-East Asia (n = 14) 
Bangladesh 9% 42 457 2010
Cambodia 51% 519 1 026 2010
China 49% 16 389 33 386 2010
Indonesia 16% 98 599 2009
Lao People's Democratic Republic 22% 66 300 2010
Malaysia 41% 212 517 2009
Mongolia 78% 149 192 2009
Myanmar 48% 262 550 2009
Nepal 41% 163 400 2009
Philippines 7% 296 4 367 2011
Thailand 17% 339 1 966 2010
Timor-Leste 33% 98 300 2010
Tonga 2% 2 100 2008
Viet Nam 19% 301 1 578 2009
Median 27%
Europe and Central Asia (n = 11) 
Albania 45% 89 198 2008
Armenia 46% 124 270 2010–2011
Azerbaijan 10% 46 454 2010
Croatia 4% 4 103 2010
Georgia 26% 72 278 2010
Kazakhstan 60% 566 943 2010
Latvia 25% 180 734 2010
Republic of Moldova 12% 34 188 2009–2010
Romania 31% 718 2 328 2010
Serbia 34% 94 280 2010
Ukraine 43% 997 2 300 2009
Median 31%
North Africa and the Middle East (n = 1) 
Tunisia 18% 214 1178 2009
a Country data may have been generated through surveys that are not nationally representative, and some survey results may overestimate the proportion of people accessing services. For 
instance, where reported coverage is close to 100%, they may represent people enrolled in treatment services or other settings where an HIV test is required to access the service. 
b The fi gures were extrapolated to the entire population of the country.
Annex 3A.2 Percentage of men who have sex with men who received an HIV test in the past 12 months and who know the 
result, 2010a
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Country
Percentage of sex 
workers who received 
an HIV test in the last 
12 months and who 
knows the results Numerator Denominator Year
Number of countries reporting 52
Overall median 49%
Sub-Saharan Africa (n = 15) 
Angola 35% 651 1 848 2008
Burkina Faso 83% 845 1 019 2010
Burundi 66% 382 576 2008
Chadb 38% 389 1 023 2010
Gabon 64% 385 601 2010
Gambia 83% 251 301 2010
Madagascar 60% 991 1 663 2008
Mali 71% 665 938 2009
Mauritius 42% 126 299 2010
Niger 45% 399 893 2008
Nigeria 60% 2 668 4 459 2010
Rwanda 89% 1 143 1 291 2010
Somalia 0% 0 237 2008
Togo 58% 278 476 2010
United Republic of Tanzania 95% 511 537 2010
Median 60%
Latin America and the Caribbean (n = 10) 
Argentina 62% 257 415 2008
Brazil 18% 442 2 523 2009
Cuba 35% 28 837 82 838 2009
Dominican Republic 67% 913 1 367 2010
Guatemala 73% 44 428 60 533 2010
Jamaica 75% 207 277 2008
Nicaragua 55% 458 830 2010
Paraguay 52% 401 770 2007–2008
Suriname 63% 162 259 2009
Uruguay 26% 81 313 2010
Median 59%
East, South and South-East Asia (n = 17) 
Bangladesh 38% 177 471 2010
Cambodia 98% 104 106 2010
China 34% 67 295 197 146 2010
Indonesia 25% 1 102 4 325 2009
Iran (Islamic Republic of) 28% 248 888 2010
Lao People's Democratic Republic 33% 297 912 2009
Malaysia 21% 215 1 003 2009
Mongolia 52% 438 835 2009
Myanmar 71% 394 554 2007–2008
Nepal 32% 161 500 2008
Pakistan 14% 606 4 446 2008
Papua New Guinea 46% 275 593 2010
Philippines 19% 1 711 9 206 2009
Sri Lanka 44% 481 1 094 2007-2008
Thailand 37% 1 531 4 121 2010
Timor-Leste 66% 120 181 2010
Viet Nam 35% 1 842 5 295 2009
Median 35%
Annex 3A.3 Percentage of sex workers who received an HIV test in the past 12 months and who know the results, 2010a
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Europe and Central Asia (n = 8) 
Armenia 25% 62 250 2010–2011
Georgia 26% 72 280 2008–2009
Kazakhstan 80% 1 798 2 259 2010
Republic of Moldova 23% 84 298 2009–2010
Romania 27% 89 335 2010
Serbia 59% 147 250 2010
Tajikistan 56% 451 812 2009
Ukraine 59% 1 929 3 284 2009
Median 42%
North Africa and the Middle East (n = 2) 
Lebanon 71% 107 150 2008
Tunisia 14% 56 397 2009
Median ...
a Country data may have been generated through surveys that are not nationally representative, and some survey results may overestimate the proportion of people accessing services. For 
instance, where reported coverage is close to 100%, they may represent people enrolled in treatment services or other settings where an HIV test is required to access the service.
b Female sex workers.
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Country 2006–2008 2009–2010
Number of countries reporting 13 13
Overall median 23% 25%
Sub-Saharan Africa (n = 1) 
Nigeria 23% 31%
East, South and South-East Asia (n = 6) 
China 42% 41%
Indonesia 36% 20%
Iran (Islamic Republic of) 23% 25%
Nepal 21% 21%
Philippines 4% 1%
Viet Nam 11% 18%
Median 22% 21%
Europe and Central Asia (n = 6) 
Georgiab 9% 6%
Kazakhstan 52% 61%
Republic of Moldova 34% 48%
Romania 19% 19%
Serbia 33% 33%
Ukraine 29% 26%
Median 31% 29%
a Country data may have been generated through surveys that are not nationally representative, and some survey 
results may overestimate the proportion of people accessing services. For instance, where reported coverage is close 
to 100%, they may represent people enrolled in treatment services or other settings where an HIV test is required to 
access the service. 
b The available surveys are from 2006 and 2008.
Annex 3B.1 Percentage of people who inject drugs who received an HIV test in 
the past 12 months and who know the results, 2006–2008 and 2009–2010a 
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Country 2006–2008 2009–2010
Number of countries reporting 16 16
Overall median 30% 35%
Sub-Saharan Africa (n = 2) 
Burkina Faso 28% 36%
Nigeria 30% 31%
Latin America and the Caribbean (n = 1) 
Brazil 24% 13%
East, South and South-East Asia (n = 9) 
Bangladesh 3% 9%
Cambodia 57% 51%
China 30% 49%
Indonesia 32% 16%
Lao People's Democratic Republic 5% 22%
Mongolia 81% 78%
Nepal 30% 41%
Philippines 16% 7%
Viet Nam 16% 19%
Median 30% 22%
Europe and Central Asia (n = 4) 
Kazakhstan 44% 60%
Serbia 31% 34%
The former Yugoslav Republic of Macedonia 56% 98%
Ukraine 26% 43%
Median ... ...
a Country data may have been generated through surveys that are not nationally representative, and some survey 
results may overestimate the proportion of people accessing services. For instance, where reported coverage is close 
to 100%, they may represent people enrolled in treatment services or other settings where an HIV test is required to 
access the service. 
Annex 3B.2 Percentage of men who have sex with men who received an HIV test 
in the past 12 months and who know the results, 2006–2008 and 2009–2010a 
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Country 2006–2008 2009–2010
Number of countries reporting 23 23
Overall median 39% 52%
Sub-Saharan Africa (n = 7) 
Burundib 71% 66%
Chad 34% 38%
Gabon 54% 64%
Madagascarc 49% 60%
Nigeria 39% 60%
Rwanda 65% 89%
Togo 40% 58%
Median 49% 60%
Latin America and the Caribbean (n = 1) 
Dominican Republic 95% 67%
East, South and South-East Asia (n = 10) 
Bangladesh 5% 38%
Cambodia 68% 98%
China 36% 34%
Indonesia 31% 25%
Iran (Islamic Republic of) 20% 28%
Lao People's Democratic Republic 18% 33%
Mongolia 53% 52%
Pakistan 8% 14%
Philippines 12% 19%
Viet Nam 15% 35%
Median 19% 33%
Europe and Central Asia (n = 4) 
Georgiac 33% 26%
Kazakhstan 68% 80%
Republic of Moldova 31% 23%
Serbia 45% 59%
Ukraine 46% 59%
Median 45% 59%
a Country data may have been generated through surveys that are not nationally representative, and some survey 
results may overestimate the proportion of people accessing services. For instance, where reported coverage is close 
to 100%, they may represent people enrolled in treatment services or other settings where an HIV test is required to 
access the service.   
b The available surveys are from 2007 and 2008.
c The available surveys are from 2006 and 2008.
Annex 3B.3 Percentage of sex workers who received an HIV test in the past 
12 months and who know the results, 2006–2008 and 2009–2010a 
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Low- and middle-income 
countriesa
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2009b,c
Month and 
year of 
report
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2010b,c
Month and 
year of 
report
Estimated number of people needing 
antiretroviral therapy based on 2010 WHO 
guidelines, 2010b,d
Estimated 
antiretroviral therapy 
coverage based on 
2010 WHO guidelines, 
2010 [range]b,eEstimate Low estimate High estimate
Afghanistan   19 f Dec. 09   46 Dec. 10  1 600 <1 000  5 400 3% [1-6%]
Albania   114 Dec. 09   145 Dec. 10 … …
Algeria  1 526 Dec. 09  2 012 Dec. 10  6 200  4 700  8 100 32% [25-43%]
Angola  20 640 Dec. 09  27 931 Dec. 10  86 000  65 000  110 000 33% [25-43%]
Argentina  42 815 Dec. 09  43 313 Dec. 10  55 000  49 000  63 000 79% [68-89%]
Armenia   179 Dec. 09   250 Dec. 10 <1 000 <1 000  1 800 30% [14-49%]
Azerbaijan   238 Dec. 09   435 Dec. 10  1 400  1 000  1 800 32% [24-43%]
Bangladesh   353 Dec. 09   465 Dec. 10  1 400  1 000  1 800 33% [26-46%]
Belarus  1 776 Dec. 09  2 614 Dec. 10  5 100  3 500  7 900 51% [33-75%]
Belize   855 Dec. 09  1 053 Dec. 10  2 000  1 700  2 300 53% [47-60%]
Benin  15 401 Dec. 09  18 230 Dec. 10  31 000  28 000  35 000 58% [52-65%]
Bhutan …   57 Dec. 10 <500 <200 <500 27% [20-45%]
Bolivia (Plurinational State of)  1 115 Dec. 09  1 283 Dec. 10  6 500  3 400  12 000 20% [10-37%]
Bosnia and Herzegovina   38 Dec. 09   48 Dec. 10 … …
Botswana  145 190 Dec. 09  161 219 Dec. 10  170 000  170 000  180 000 93% [89->95%]
Brazil  185 982 f Dec. 09  201 279 Dec. 10  290 000  270 000  310 000 70% [65-75%]
Bulgaria   327 Dec. 09 …  1 400  1 100  1 800 24% [19-30%]
Burkina Faso  26 448 Dec. 09  31 543 Dec. 10  64 000  57 000  72 000 49% [44-55%]
Burundi  17 661 Dec. 09  22 735 Dec. 10  68 000  57 000  73 000 34% [31-40%]
Cambodia  37 315 Dec. 09  42 799 Dec. 10  46 000  33 000  63 000 92% [68->95%]
Cameroon  76 228 Dec. 09  89 455 Dec. 10  230 000  210 000  270 000 38% [34-43%]
Cape Verde   611 Dec. 09 …  1 400  1 000  1 900 43% [32-61%]
Central African Republic  14 474 Dec. 09  15 287 Dec. 10  64 000  58 000  72 000 24% [21-27%]
Chad  32 288 Dec. 09  32 288 Dec. 10  83 000  71 000  97 000 39% [33-46%]
Chile  12 762 Dec. 09  12 789 Dec. 10  15 000  8 700  25 000 88% [52->95%]
China  65 481 Dec. 09  86 122 Dec. 10  270 000  230 000  330 000 32% [26-37%]
Colombia  16 302 Dec. 09  29 803 Dec. 10  88 000  67 000  120 000 34% [26-45%]
Comoros   12 Dec. 09   17 Dec. 10 <100 <100 <100 >95% [35->95%]
Congo  7 998 Dec. 09  14 830 Dec. 10  35 000  30 000  41 000 42% [36-49%]
Cook Islands …   0 Dec. 10 … …
Costa Rica  3 064 Dec. 09  3 265 Dec. 10  5 100  4 300  5 800 65% [57-76%]
Côte d'Ivoire  72 011 Dec. 09  75 237 Sept. 10  200 000  180 000  220 000 37% [34-41%]
Croatia   441 Dec. 09   510 Dec. 10 <1 000 <500 <1 000 89% [70->95%]
Cuba  5 034 Dec. 09  5 587 Dec. 10  5 900  4 900  7 200 95% [78->95%]
Democratic People's Republic of 
Korea
… … <1 000 <500 <1 000 …
Democratic Republic of the Congo  34 967 Dec. 09  43 878 Dec. 10  300 000  270 000  340 000 14% [13-16%]
Djibouti   913 Dec. 09  1 008 Dec. 10  5 700  4 600  7 800 18% [13-22%]
Dominica   38 Dec. 09   41 Dec. 10 … …
Dominican Republic  13 785 Dec. 09  17 082 Dec. 10  24 000  21 000  28 000 72% [62-82%]
Ecuador  5 538 Dec. 09  8 977 Dec. 10  14 000  9 900  20 000 63% [45-91%]
Egypt   359 Dec. 09   525 Dec. 10  5 100  2 500  13 000 10% [4-21%]
El Salvador … f  5 843 Dec. 10  9 900  7 100  16 000 59% [36-82%]
Equatorial Guinea  1 645 Dec. 09  2 432 Dec. 10  9 900  6 600  14 000 24% [18-37%]
Eritrea  4 955 Dec. 09  5 387 Dec. 10  13 000  7 900  23 000 42% [23-68%]
Annex 4 People of all ages receiving and needing antiretroviral therapy and coverage percentages, 2009 and 2010
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Low- and middle-income 
countriesa
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2009b,c
Month and 
year of 
report
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2010b,c
Month and 
year of 
report
Estimated number of people needing 
antiretroviral therapy based on 2010 WHO 
guidelines, 2010b,d
Estimated 
antiretroviral therapy 
coverage based on 
2010 WHO guidelines, 
2010 [range]b,eEstimate Low estimate High estimate
Ethiopia  176 632 Dec. 09  222 723 Dec. 10 … h ... 
Fiji   52 Nov. 09   58 Dec. 10 <200 <200 <500 33% [24-43%]
Gabon  9 976 Dec. 09  11 488 Dec. 10  22 000  15 000  31 000 53% [38-75%]
Gambia   921 Sept. 09  1 869 Dec. 10  5 400  2 400  11 000 35% [17-78%]
Georgia   655 Dec. 09   830 Dec. 10  1 300 <1 000  4 100 65% [20->95%]
Ghana  30 265 Dec. 09  40 575 Dec. 10  110 000  100 000  130 000 35% [31-40%]
Grenada   54 Dec. 09   61 Dec. 10 … …
Guatemala  10 362 Dec. 09  12 053 Dec. 10  23 000  14 000  52 000 53% [23-89%]
Guinea  14 999 Dec. 09  20 430 Dec. 10  36 000  31 000  43 000 57% [47-67%]
Guinea-Bissau  2 764 Dec. 09  3 632 Dec. 10  7 600  6 200  9 300 48% [39-59%]
Guyana  2 832 Dec. 09  3 059 Dec. 10  3 600  2 800  5 200 84% [59->95%]
Haiti  26 007 Dec. 09  29 180 Dec. 10  57 000  50 000  65 000 51% [45-58%]
Honduras  7 075 Dec. 09  7 718 Dec. 10  15 000  12 000  20 000 51% [39-65%]
Hungary   547 Dec. 09   630 Dec. 10  1 700  1 300  2 100 38% [30-48%]
India  320 074 Dec. 09  424 802 Dec. 10 … h 1 100 000 1 400 000 ... [30-38%]
Indonesia  15 442 Nov. 09  19 572 Dec. 10  82 000  55 000  120 000 24% [17-35%]
Iran (Islamic Republic of)  1 486 Jan. 10  1 800 Sept. 10  26 000  23 000  30 000 7% [6-8%]
Iraq …   5 Dec. 10 … …
Jamaica  7 244 Dec. 09  8 016 Dec. 10  14 000  12 000  17 000 57% [46-69%]
Jordan   63 Dec. 09   83 Dec. 10 … …
Kazakhstan  1 035 Jan. 10  1 336 Dec. 10  4 400  3 900  5 100 30% [26-35%]
Kenya  336 980 Dec. 09  432 621 Dec. 10  710 000  650 000  770 000 61% [56-66%]
Kiribati …   6 Dec. 10 … …
Kyrgyzstan   231 Jan. 10   548 Dec. 10  4 600  2 700  7 800 12% [7-21%]
Lao People's Democratic Republic  1 345 Dec. 09  1 690 Dec. 10  3 300  2 300  5 100 51% [33-73%]
Latvia   439 Dec. 09   508 Dec. 10  2 800  2 200  3 500 18% [14-23%]
Lebanon   354 Dec. 09   412 Dec. 10  1 100 <1 000  1 600 37% [25-55%]
Lesotho  61 736 Dec. 09  76 487 g Dec. 10  130 000  130 000  140 000 57% [53-60%]
Liberia  2 970 Dec. 09  4 412 Dec. 10  16 000  14 000  19 000 27% [23-32%]
Libya … … … …
Lithuania   145 Dec. 09 … <1 000 <500 <1 000 27% [21-34%]
Madagascar   214 Dec. 09   248 Dec. 10  19 000  14 000  25 000 1% [1-2%]
Malawi  198 846 Dec. 09  250 987 Dec. 10 … h  440 000  510 000 ... [49-57%]
Malaysia  9 962 Mar. 10  13 918 Dec. 10  38 000  31 000  51 000 36% [27-44%]
Maldives   3 Dec. 09   2 Dec. 10 <100 <100 <100 14% [11-17%]
Mali  21 100 Dec. 09  24 778 Dec. 10  53 000  45 000  63 000 46% [39-56%]
Marshall Islands   4 Dec. 09   6 Dec. 10 … …
Mauritania  1 401 Dec. 09  1 669 Dec. 10  7 600  5 100  12 000 22% [14-33%]
Mauritius   652 Dec. 09   646 Dec. 10  4 100  3 500  4 800 16% [14-18%]
Mexico  60 911 Dec. 09  64 487 Dec. 10  83 000  57 000  110 000 78% [59->95%]
Micronesia (Federated States of)   5 Dec. 09   5 Dec. 10 … …
Mongolia   9 Dec. 09   28 Dec. 10 <200 <100 <200 26% [19-39%]
Montenegro   31 Mar. 10   40 Dec. 10 … …
Morocco  2 647 Dec. 09  3 200 Dec. 10  11 000  8 200  17 000 30% [19-39%]
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Low- and middle-income 
countriesa
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2009b,c
Month and 
year of 
report
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2010b,c
Month and 
year of 
report
Estimated number of people needing 
antiretroviral therapy based on 2010 WHO 
guidelines, 2010b,d
Estimated 
antiretroviral therapy 
coverage based on 
2010 WHO guidelines, 
2010 [range]b,eEstimate Low estimate High estimate
Mozambique  170 198 Dec. 09  218 991 Dec. 10  550 000  480 000  610 000 40% [36-46%]
Myanmar  21 138 Dec. 09  29 825 Dec. 10  120 000  110 000  140 000 24% [21-27%]
Namibia  70 498 Sept. 09  88 717 Dec. 10  98 000  84 000  110 000 90% [78->95%]
Nauru …   0 Dec. 10 … …
Nepal  3 226 Jul. 09  4 867 Dec. 10  27 000  19 000  45 000 18% [11-26%]
Nicaragua  1 063 Dec. 09  1 286 Dec. 10  1 100 <500  2 900 >95% [45->95%]
Niger  6 445 Dec. 09  7 812 Dec. 10  27 000  24 000  30 000 29% [26-33%]
Nigeria  302 973 Dec. 09  359 181 Dec. 10 1 400 000 1 300 000 1 500 000 26% [24-28%]
Niue …   0 Dec. 10 … …
Oman   486 Dec. 09   469 Dec. 10  1 100 <1 000  1 400 44% [33-54%]
Pakistan  1 320 Dec. 09  1 892 Dec. 10  22 000  14 000  50 000 9% [4-13%]
Palau   3 Dec. 09   3 Dec. 10 … …
Panama  4 463 Dec. 09  4 888 Dec. 10  13 000  9 100  22 000 36% [22-54%]
Papua New Guinea  6 751 Dec. 09  7 555 Dec. 10  14 000  12 000  17 000 54% [43-65%]
Paraguay  2 073 Dec. 09  2 962 Nov. 10  4 500  2 600  7 700 66% [38->95%]
Peru  14 780 Dec. 09 …  26 000  18 000  36 000 57% [41-84%]
Philippines   750 Dec. 09  1 274 Dec. 10  2 500  1 500  3 400 51% [38-83%]
Poland  4 329 Dec. 09  4 897 Dec. 10  14 000  11 000  20 000 34% [25-44%]
Republic of Moldova   984 Dec. 09  1 237 Dec. 10  4 900  4 200  5 800 25% [21-30%]
Romania  7 244 Dec. 09  7 276 Dec. 10  11 000  9 400  12 000 69% [60-77%]
Russian Federation  75 900 Dec. 09  79 430 Dec. 10 … h  270 000  380 000 ... [21-29%]
Rwanda  76 726 Dec. 09  91 984 Dec. 10  100 000  96 000  120 000 88% [76->95%]
Saint Kitts and Nevis … … … …
Saint Lucia   124 Dec. 09 … … …
Saint Vincent and the Grenadines   162 Dec. 09 … … …
Samoa …   13 Dec. 10 … …
Sao Tome and Principe   169 Dec. 09   196 Dec. 10 <1 000 <500 <1 000 34% [25-46%]
Senegal  12 249 Dec. 09 …  25 000  19 000  31 000 50% [39-64%]
Serbia   790 Dec. 09   915 Dec. 10  2 700  2 000  3 500 34% [26-45%]
Seychelles   139 Dec. 09   156 Dec. 10 … …
Sierra Leone  3 660 Dec. 09  5 552 Dec. 10  18 000  15 000  21 000 31% [27-38%]
Slovakia …   118 Dec. 10 <200 <200 <200 81% [63->95%]
Solomon Islands   4 Dec. 09   7 Dec. 10 … …
Somalia   578 Dec. 09   878 Dec. 10  25 000  18 000  33 000 3% [3-5%]
South Africa  971 556 Oct. 09 1 389 865 Dec. 10 2 500 000 2 400 000 2 700 000 55% [52-58%]
Sri Lanka   207 Dec. 09   256 Dec. 10  1 000 <1 000  1 300 25% [19-34%]
Sudan  3 825 Dec. 09  4 345 Dec. 10  93 000  60 000  140 000 5% [3-7%]
Suriname   996 Jul. 09  1 106 Dec. 10  2 500  1 700  3 700 45% [30-64%]
Swaziland  47 241 Dec. 09  59 802 Dec. 10  83 000  79 000  89 000 72% [67-76%]
Syrian Arab Republic   99 Dec. 09   110 Dec. 10 … …
Tajikistan   322 Dec. 09   504 Dec. 10  3 200  1 900  5 800 16% [9-27%]
Thailand  216 118 Sept. 09  236 808 Sept. 10  350 000  280 000  430 000 67% [55-85%]
The former Yugoslav Republic of 
Macedonia
  24 Dec. 09   36 Dec. 10 … …
Timor-Leste   31 Dec. 09   39 Dec. 10 … …
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Low- and middle-income 
countriesa
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2009b,c
Month and 
year of 
report
Reported 
number of 
people receiving 
antiretroviral 
therapy, 2010b,c
Month and 
year of 
report
Estimated number of people needing 
antiretroviral therapy based on 2010 WHO 
guidelines, 2010b,d
Estimated 
antiretroviral therapy 
coverage based on 
2010 WHO guidelines, 
2010 [range]b,eEstimate Low estimate High estimate
Togo  16 710 Dec. 09  24 635 Dec. 10  49 000  44 000  56 000 50% [44-56%]
Tonga …   0 Dec. 10 … …
Tunisia   412 Dec. 09   412 Dec. 10  4 000  1 700  13 000 10% [3-24%]
Turkey  1 000 Dec. 09  1 000 Dec. 10  1 800  1 400  2 200 56% [45-72%]
Turkmenistan … … … …
Tuvalu   1 Dec. 09   0 Dec. 10 … …
Uganda  200 413 Sept. 09  248 222 Sept. 10  530 000  490 000  580 000 47% [43-51%]
Ukraine  15 871 Dec. 09  22 697 Dec. 10  170 000  140 000  220 000 13% [11-16%]
United Republic of Tanzania  199 413 Dec. 09  258 069 Dec. 10  610 000  570 000  660 000 42% [39-46%]
Uruguay  2 510 Dec. 09  3 124 Dec. 10  4 400  2 900  9 900 71% [32->95%]
Uzbekistan  1 753 Dec. 09  2 479 Dec. 10  8 900  5 300  15 000 28% [16-47%]
Vanuatu   2 Dec. 09   2 Dec. 10 … …
Venezuela (Bolivarian Republic of)  32 302 Dec. 09  37 827 Dec. 10  67 000  55 000  80 000 57% [47-69%]
Viet Nam  37 995 Dec. 09  49 492 Dec. 10  96 000  81 000  110 000 52% [43-61%]
Yemen   274 Dec. 09   531 Dec. 10 … …
Zambia  283 863 Dec. 09  344 407 Dec. 10  480 000  450 000  510 000 72% [67-77%]
Zimbabwe  218 589 Feb. 10  326 241 Dec. 10  560 000  520 000  600 000 59% [54-62%]
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High-income countriesa
Reported 
number of 
people 
receiving 
antiretroviral 
therapy, 
2005–2009
Month and 
year of 
report
Reported 
number 
of people 
receiving 
antiretroviral 
therapy, 
2010
Month and 
year of 
report
Andorra   27 Dec. 09 …
Antigua and Barbuda   98 Dec. 09   153 Dec. 10
Australia  9 933 Dec. 07  11 120 Dec. 10
Austria  1 800 Sept. 09  3 163 Dec. 10
Bahamas  1 506 Dec. 09 …
Bahrain … …
Barbados   804 Dec. 09   847 Dec. 10
Belgium  8 690 Dec. 09 …
Brunei Darussalam …   17 Dec. 10
Canada  27 000 Dec. 08 …
Cyprus   187 Dec. 09   198 Dec. 10
Czech Republic   706 Oct. 09   760 Dec. 10
Denmark  3 000 Oct. 09  3 000 Dec. 10
Estonia  1 263 Dec. 09  1 793 Dec. 10
Finland   450 Aug. 06 …
France  79 680 Dec. 08  93 090 Dec. 10
Germany  42 900 Dec. 09 …
Greece  4 236 Dec. 08  5 114 Dec. 10
Iceland   100 j <05 …
Ireland  1 600 Dec. 05 …
Israel  2 876 Dec. 08  2 745 Jun. 10
Italy  95 000 Dec. 08 …
… Data not available or not applicable.
a See the country classifi cation by income, level of the epidemic and geographical, UNAIDS, UNICEF and WHO regions (Annex 10).
b Annex 5 provides antiretroviral therapy data by age and sex.
c Private sector data have been included in the total number of people on treatment, when available:
Country 2010
Argentina  13 429
Bangladesh   465
Botswana  13 610
Burundi  11 533
Cambodia  3 603
Congo   299
Djibouti   28
Eritrea   601
Ethiopia  6 500
Gabon   475
Gambia   946
Guinea-Bissau  1 566
Guyana   907
India  35 000
Liberia  1 999
Namibia  2 760
Niger   516
Pakistan   434
Papua New Guinea   676
Rwanda  1 316
Sierra Leone   340
Swaziland  11 001
Togo   456
United Republic of Tanzania   35
Uruguay  1 100
Zambia  9 696
d The needs estimates are based on the methods described in the explanatory notes and in Box 5.9.
e The coverage estimates are based on the estimated unrounded numbers of people receiving antiretroviral therapy and the estimated unrounded need for antiretroviral therapy (based on UNAIDS/WHO methods).  
The ranges in coverage estimates are based on plausibility bounds in the denominator: that is, low and high estimates of need. 
f Updated 2009 value. See last year’s annex (http://www.who.int/entity/hiv/data/tuapr2010_annex3.xls).
g Since it only refl ects 90% of the data received from facilities, this number is underreported.
h Estimates of the number of people needing antiretroviral therapy are currently being reviewed and will be adjusted, as appropriate, based on ongoing data collection and analysis. Some countries have therefore 
requested that only a range be published or no needs estimate at all.
i Two separate reports were received for 2010 from Sudan: northern Sudan, 2122; southern Sudan, 2223. The fi gures refl ect the situation as of 2010 before the declaration of independence of South Sudan.
j <05 indicates that data exist but no update has been received since December 2004. These data should be interpreted cautiously, as they may refl ect the situation in early 2004 or even 2003.
High-income countriesa
Reported 
number of 
people 
receiving 
antiretroviral 
therapy, 
2005–2009
Month and 
year of 
report
Reported 
number 
of people 
receiving 
antiretroviral 
therapy, 
2010
Month and 
year of 
report
Japan   94 Mar. 09 …
Kuwait 131 Dec. 09 …
Luxembourg   434 Dec. 09 …
Malta   100 Dec. 09   119 Dec. 10
Monaco   45 Dec. 05 …
Netherlands  7 919 Apr. 07  11 780 Dec. 10
New Zealand 1 204 Jun. 09 1 348 Dec. 10
Norway   900 Dec. 05 …
Portugal  18 107 Dec. 09 …
Qatar 70 Jan. 09 …
Republic of Korea … …
San Marino … …
Saudi Arabia   865 Dec. 08 …
Singapore … …
Slovenia   157 Jul. 07 …
Spain  79 500 Dec. 09  85 700 Dec. 10
Sweden  4 185 Dec. 09 ...
Switzerland … …
Trinidad and Tobago  2 639 Dec. 09  1 485 Dec. 10
United Arab Emirates   121 Dec. 09 …
United Kingdom  50 292 f Dec. 09 …
United States of America  268 000 j <05 …
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Countries
Overall target Overall target Prong 1 target Prong 2 target
Number of women living with HIV 
delivering
New child infections due to mother-to-
child transmission
HIV-associated 
deaths to women 
during pregnancy, 
delivery and 
puerperium
HIV incidence in women 
15–49 years old (%)
Percentage of women 
15-49 with unmet 
need for family 
planning
2009 2010 2009 2010 2008 2010 2009 2010 2009 Year
Angola  15 000 [11 000–20 000]
 16 000 
[11 000–21 000]
 5 200 
[3 600–7 200]
 5 200 
[3 500–7 100] 330 …
0.25% 
[0.17-0.36%]
0.24% 
[0.15-0.34%] …
Botswana  13 000 [12 000–15 000]
 13 000 
[12 000–15 000]
<1 000 
[<500–1 100]
<500 
[<500–<1 000]  140 …
1.46% 
[1.22-1.78%]
1.31% 
[1.09-1.59%] …
Burundi  7 500 [5 900–8 400]
 7 300 
[5 400–8 200]
 2 500 
[1 800–2 800]
 2 000 
[1 400–2 400]  240 …
0.21% 
[0.08-0.22%]
0.19% 
[0.08-0.21%] 29.0% 2002
Cameroon  30 000 [25 000–37 000]
 30 000 
[24 000–37 000]
 8 800 
[6 900–11 000]
 6 800 
[4 900–9 200] 1 200 …
0.45%
[0.34–0.68%]
0.43%
[0.32–0.61%] 20.2% 2004
Chad  14 000 [11 000–18 000]
 14 000 
[11 000–19 000]
 4 800 
[3 700–6 200]
 4 700 
[3 500–6 200]  530 …
0.32%
[0.21–0.54%]
0.30%
[0.19–0.52%] 20.7% 2004
Côte d’Ivoire  19 000 [16 000–23 000]
 18 000 
[15 000–21 000]
 5 600 
[4 400–7 100]
 4 800 
[3 700–6 200] 1 000 …
0.20%
[0.15–0.27%]
0.19%
[0.15–0.25%] …
Democratic Republic 
of the Congo
 50 000 
[41 000–61 000]
 50 000 
[41 000–61 000]
 19 000 
[15 000–23 000]
 18 000 
[15 000–23 000]  990 …
0.23%
[0.15–0.34%]
0.23%
[0.15–0.34%] 24.4% 2007
Ethiopia …b …b …b …b 1 800 … …b …b 33.8% 2005
Ghana  13 000 [11 000–15 000]
 12 000 
[10 000–15 000]
 4 200 
[3 500–5 100]
 3 700 
[3 000–4 600]  500 …
0.12%
[0.09–0.15%]
0.11%
[0.08–0.15%] 35.3% 2008
India …
b 
[23 000–65 000]
…b 
[22 000–61 000]
…b 
[7 900–23 000]
…b 
[7 300–21 000] 2 500 …
…b 
[0.01-0.02%]
…b
[0.01–0.02%] 12.8% 2006
Kenya  87 000 [75 000–100 000]
 87 000 
[75 000–100 000]
 23 000 
[18 000–27 000]
 19 000 
[15 000–23 000] 2 200 …
0.67%
[0.58–0.79%]
0.62%
[0.53–0.75%] 25.6% 2009
Lesotho  14 000 [12 000–16 000]
 14 000 
[12 000–16 000]
 3 900 
[3 400–4 600]
 3 700 
[3 100–4 400]  370 …
3.15%
[2.68–3.79%]
2.80%
[2.41–3.42%] 31.0% 2005
Malawi …
b 
[59 000–79 000]
…b 
[57 000–76 000]
…b 
[19 000–26 000]
…b 
[16 000–24 000] 1 900 …
…b
[0.57–0.81%]
…b
[0.50–0.71%] 27.6% 2004
Mozambique  99 000 [84 000–120 000]
 100 000 
[85 000–120 000]
 30 000 
[24 000–36 000]
 32 000 
[26 000–38 000] 2 500 …
1.33%
[1.10–1.54%]
1.28%
[1.06–1.50%] 18.4% 2004
Namibia  8 200 [6 100–10 000]
 8 000 
[6 000–9 900]
 1 500 
[1 000–2 100]
 1 100 
[<1 000–1 600]  100 …
0.98% 
[0.58 -1.52%]
0.94%
[0.55–1.48%] 20.6% 2007
Nigeria  220 000 [190 000–250 000]
 230 000 
[200 000–260 000]
 72 000 
[63 000–84 000]
 75 000 
[65 000–86 000] 4 900 …
0.53%
[0.44–0.61%]
0.53%
[0.43–0.62%] 20.2% 2008
South Africa  270 000 [240 000–300 000]
 260 000 
[230 000–290 000]
 61 000 
[52 000–72 000]
 48 000 
[42 000–58 000] 3 800 …
1.77%
[1.64–1.96%]
1.70%
[1.58–1.88%] 13.8% 2004
Swaziland  9 300 [8 300–11 000]
 9 100 
[8 100–10 000]
 1 700 
[1 400–2 200]
 1 300 
[1 100–1 700]  230 …
3.29%
[2.77–4.00%]
3.13%
[2.59–3.81%] 24.0% 2007
Uganda  89 000 [75 000–110 000]
 94 000 
[77 000–110 000]
 28 000 
[22 000–33 000]
 28 000 
[22 000–34 000] 3 000 …
0.97%
[0.70–1.26%]
0.88%
[0.64–1.12%] 40.6% 2006
United Republic of 
Tanzania
 97 000 
[85 000–110 000]
 98 000 
[85 000–110 000]
 29 000 
[24 000–34 000]
 24 000 
[20 000–29 000] 3 100 …
0.70%
[0.62–0.78%]
0.68%
[0.59–0.76%] 21.8% 2005
Zambia  79 000 [70 000–87 000]
 79 000 
[70 000–88 000]
 20 000 
[17 000–23 000]
 16 000 
[13 000–19 000] 1 900 …
1.07%
[0.80–1.30%]
0.97%
[0.71–1.19%] 26.5% 2007
Zimbabwe  49 000 [43 000–56 000]
 46 000 
[41 000–53 000]
 15 000 
[12 000–17 000]
 11 000 
[9 500–14 000] 3 200 …
1.27%
[0.95–1.64%]
1.12%
[0.83–1.46%] 12.8% 2006
Sources: Spectrum Spectrum Trends in Maternal 
Mortality 1990 to 2008.  
Estimates developed by 
WHO, UNICEF, UNFPA, 
and The World Bank
Spectrum UNStats MDG database
Annex 7 Progress in 22 priority countries on key indicators for the Global Plan for eliminating mother-to-child transmission
… Data not available or not applicable.
a Distribution of HIV-related deaths based on 2008 estimates (published in World health statistics 2011); envelope of  deaths among children younger than fi ve years, 2010 estimates (published by the United Nations 
Inter-agency Group for Child Mortality Estimation in 2011: http://www.childmortality.org).
b At the request of the country, no value can be presented, or only a range, as the estimates are currently being reviewed and will be adjusted, as appropriate, based on ongoing data collection and analysis.
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Countries
Overall target Overall target Prong 1 target Prong 2 target
Countries
Prong 3 target 3.1 Prong 3 target 3.2 Prong 3 target 3.3 Prong 4 target Child  target
Number of women living with HIV 
delivering
New child infections due to mother-to-
child transmission
HIV-associated 
deaths to women 
during pregnancy, 
delivery and 
puerperium
HIV incidence in women 
15–49 years old (%)
Percentage of women 
15-49 with unmet 
need for family 
planning
Mother-to-child 
transmission rate (%)
Coverage of maternal 
antiretroviral 
medicine 
(prophylaxis and 
therapy) (%)
Percentage of infants 
born to HIV-infected 
women provided 
with antiretrovirals 
(either mother of 
infant) to reduce 
the risk of HIV 
transmission during 
the breastfeeding 
period
Percentage of eligible 
pregnant women 
provided with 
antiretroviral therapy
Percentage of 
under-five deaths due 
to HIVa
Coverage of 
antiretroviral therapy 
among children 
younger than 
15 years old (%)
2009 2010 2009 2010 2008 2010 2009 2010 2009 Year 2009 2010
Coverage excluding 
single-dose 
nevirapine 2010 2009/2010 2009 2010 2009 2010 2009 2010
Angola  15 000 [11 000–20 000]
 16 000 
[11 000–21 000]
 5 200 
[3 600–7 200]
 5 200 
[3 500–7 100] 330 …
0.25% 
[0.17-0.36%]
0.24% 
[0.15-0.34%] … Angola
34%
[18–64%]
33%
[17–63%]
20%
[15–28%] … … … 1.9% …
11%
[8–14%]
10%
[7–14%]
Botswana  13 000 [12 000–15 000]
 13 000 
[12 000–15 000]
<1 000 
[<500–1 100]
<500 
[<500–<1 000]  140 …
1.46% 
[1.22-1.78%]
1.31% 
[1.09-1.59%] … Botswana
5%
[3–9%]
3%
[2–6%]
>95%
[>95–>95%] … …
67%
[63–71%] 16.6% …
87%
[77–>95%]
88%
[79–>95%]
Burundi  7 500 [5 900–8 400]
 7 300 
[5 400–8 200]
 2 500 
[1 800–2 800]
 2 000 
[1 400–2 400]  240 …
0.21% 
[0.08-0.22%]
0.19% 
[0.08-0.21%] 29.0% 2002 Burundi
33%
[22–48%]
28%
[17–44%]
36%
[32–49%] … … … 5.5% …
13%
[12–16%]
13%
[11–16%]
Cameroon  30 000 [25 000–37 000]
 30 000 
[24 000–37 000]
 8 800 
[6 900–11 000]
 6 800 
[4 900–9 200] 1 200 …
0.45%
[0.34–0.68%]
0.43%
[0.32–0.61%] 20.2% 2004 Cameroon
29%
[19–44%]
23%
[13–38%]
53%
[43–65%] … …
21%
[19–23%] 5.0% …
10%
[9–12%]
11%
[9–13%]
Chad  14 000 [11 000–18 000]
 14 000 
[11 000–19 000]
 4 800 
[3 700–6 200]
 4 700 
[3 500–6 200]  530 …
0.32%
[0.21–0.54%]
0.30%
[0.19–0.52%] 20.7% 2004 Chad
34%
[21–56%]
33%
[19–57%]
7%
[5–9%] … …
9%
[7–12%] 2.7% …
5%
[4–6%]
5%
[4–6%]
Côte d’Ivoire  19 000 [16 000–23 000]
 18 000 
[15 000–21 000]
 5 600 
[4 400–7 100]
 4 800 
[3 700–6 200] 1 000 …
0.20%
[0.15–0.27%]
0.19%
[0.15–0.25%] … Côte d’Ivoire
30%
[19–44%]
27%
[17–42%]
66%
[54–79%] … …
27%
[23–32%] 4.4% …
14%
[12–17%]
12%
[11–15%]
Democratic Republic 
of the Congo
 50 000 
[41 000–61 000]
 50 000 
[41 000–61 000]
 19 000 
[15 000–23 000]
 18 000 
[15 000–23 000]  990 …
0.23%
[0.15–0.34%]
0.23%
[0.15–0.34%] 24.4% 2007
Democratic Republic 
of the Congo
37%
[25–56%]
37%
[25–56%]
1%
[<1–1%] … … … 1.1% …
7%
[7–8%]
8%
[8–8%]
Ethiopia …b …b …b …b 1 800 … …b …b 33.8% 2005 Ethiopia …b …b …b … … … 2.1% … …b …b
Ghana  13 000 [11 000–15 000]
 12 000 
[10 000–15 000]
 4 200 
[3 500–5 100]
 3 700 
[3 000–4 600]  500 …
0.12%
[0.09–0.15%]
0.11%
[0.08–0.15%] 35.3% 2008 Ghana
33%
[23–48%]
30%
[20–44%]
48%
[40–57%] … … … 4.1% …
10%
[8–12%]
13%
[11–16%]
India …
b 
[23 000–65 000]
…b 
[22 000–61 000]
…b 
[7 900–23 000]
…b 
[7 300–21 000] 2 500 …
…b 
[0.01-0.02%]
…b
[0.01–0.02%] 12.8% 2006 India
…b
[12–100%]
…b
[12–97%] …                                     … … … 0.5% …
…b
[24–59%]
…b
[24–59%]
Kenya  87 000 [75 000–100 000]
 87 000 
[75 000–100 000]
 23 000 
[18 000–27 000]
 19 000 
[15 000–23 000] 2 200 …
0.67%
[0.58–0.79%]
0.62%
[0.53–0.75%] 25.6% 2009 Kenya
26%
[19–36%]
21%
[15–31%]
43%
[37–49%] … …
47%
[43–51%] 8.9% …
18%
[16–21%]
21%
[18–25%]
Lesotho  14 000 [12 000–16 000]
 14 000 
[12 000–16 000]
 3 900 
[3 400–4 600]
 3 700 
[3 100–4 400]  370 …
3.15%
[2.68–3.79%]
2.80%
[2.41–3.42%] 31.0% 2005  Lesotho
28%
[21–37%]
26%
[19–35%]
89%
[77–>95%] … …
47%
[43–51%] 30.7% …
19%
[17–22%]
22%
[20–25%]
Malawi …
b 
[59 000–79 000]
…b 
[57 000–76 000]
…b 
[19 000–26 000]
…b 
[16 000–24 000] 1 900 …
…b
[0.57–0.81%]
…b
[0.50–0.71%] 27.6% 2004 Malawi
…b
[24–45%]
…b
[22–42%]
…b
[23–31%] … …
…b
[23–29%] 13.3% …
…b
[18–23%]
…b
[19–24%]
Mozambique  99 000 [84 000–120 000]
 100 000 
[85 000–120 000]
 30 000 
[24 000–36 000]
 32 000 
[26 000–38 000] 2 500 …
1.33%
[1.10–1.54%]
1.28%
[1.06–1.50%] 18.4% 2004 Mozambique
29%
[20–43%]
31%
[22–44%]
52%
[44–62%] … …
17%
[15–20%] 10.5% …
11%
[10–14%]
19%
[16–23%]
Namibia  8 200 [6 100–10 000]
 8 000 
[6 000–9 900]
 1 500 
[1 000–2 100]
 1 100 
[<1 000–1 600]  100 …
0.98% 
[0.58 -1.52%]
0.94%
[0.55–1.48%] 20.6% 2007 Namibia
18%
[10–34%]
14%
[8–27%]
>95%
[85–>95%] … …
54%
[46–62%] 19.5% …
85%
[70–
>95%]
87%
[74–>95%]
Nigeria  220 000 [190 000–250 000]
 230 000 
[200 000–260 000]
 72 000 
[63 000–84 000]
 75 000 
[65 000–86 000] 4 900 …
0.53%
[0.44–0.61%]
0.53%
[0.43–0.62%] 20.2% 2008 Nigeria
33%
[25–43%]
33%
[25–43%]
9%
[7–10%] … …
8%
[7–9%] 4.1% …
8%
[7–10%]
7%
[6–8%]
South Africa  270 000 [240 000–300 000]
 260 000 
[230 000–290 000]
 61 000 
[52 000–72 000]
 48 000 
[42 000–58 000] 3 800 …
1.77%
[1.64–1.96%]
1.70%
[1.58–1.88%] 13.8% 2004 South Africa
23%
[18–31%]
18%
[14–25%]
>95%
[85–>95%] … …
>95%
[84–
>95%]
34.8% … 36%[32–40%]
36%
[32–40%]
Swaziland  9 300 [8 300–11 000]
 9 100 
[8 100–10 000]
 1 700 
[1 400–2 200]
 1 300 
[1 100–1 700]  230 …
3.29%
[2.77–4.00%]
3.13%
[2.59–3.81%] 24.0% 2007 Swaziland
19%
[13–26%]
14%
[11–21%]
>95%
[88–>95%] … …
53%
[50–56%] 29.5% …
56%
[49–63%]
55%
[48–61%]
Uganda  89 000 [75 000–110 000]
 94 000 
[77 000–110 000]
 28 000 
[22 000–33 000]
 28 000 
[22 000–34 000] 3 000 …
0.97%
[0.70–1.26%]
0.88%
[0.64–1.12%] 40.6% 2006 Uganda
31%
[21–44%]
30%
[20–44%]
42%
[36–51%] … …
32%
[27–37%] 6.2% …
14%
[12–16%]
16%
[14–19%]
United Republic of 
Tanzania
 97 000 
[85 000–110 000]
 98 000 
[85 000–110 000]
 29 000 
[24 000–34 000]
 24 000 
[20 000–29 000] 3 100 …
0.70%
[0.62–0.78%]
0.68%
[0.59–0.76%] 21.8% 2005
United Republic of 
Tanzania
30%
[22–40%]
25%
[17–34%]
59%
[52–68%] … …
30%
[27–33%] 5.6% …
11%
[10–13%]
18%
[16–21%]
Zambia  79 000 [70 000–87 000]
 79 000 
[70 000–88 000]
 20 000 
[17 000–23 000]
 16 000 
[13 000–19 000] 1 900 …
1.07%
[0.80–1.30%]
0.97%
[0.71–1.19%] 26.5% 2007 Zambia
25%
[19–33%]
20%
[15–27%]
75%
[67–85%] … …
44%
[40–47%] 11.7% …
27%
[24–30%]
26%
[23–30%]
Zimbabwe  49 000 [43 000–56 000]
 46 000 
[41 000–53 000]
 15 000 
[12 000–17 000]
 11 000 
[9 500–14 000] 3 200 …
1.27%
[0.95–1.64%]
1.12%
[0.83–1.46%] 12.8% 2006 Zimbabwe
30%
[22–40%]
25%
[18–34%]
46%
[40–52%] … …
23%
[21–26%] 24.7% …
25%
[22–29%]
32%
[28–35%]
Sources: Spectrum Spectrum Trends in Maternal 
Mortality 1990 to 2008.  
Estimates developed by 
WHO, UNICEF, UNFPA, 
and The World Bank
Spectrum UNStats MDG database Sources: Spectrum UA reports, Spectrum UA (N/A this yr) UA reports, Spectrum CEIWG
(2008 estimates)
UA reports, Spectrum
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General country information 
#1  Number of administrative units in the country
#2  Number of health facilities
A Testing and counselling 
#A1 Number of health facilities that provide HIV testing and counselling services
#A2 Number of women and men aged 15 and older who received HIV testing and counselling (T&C) in the last 12 months and 
know their results
#A3 Percentage of women and men aged 15–49 who received an HIV test in the last 12 months and who know their results
#A4 Percentage of most-at-risk populations (MARPs) who received an HIV test in the last 12 months and who know their results
B Prevention in health care settings 
#B1 Percentage of health care facilities where all therapeutic injections are given with new, disposable, single use injection 
equipment
#B2 Number of health facilities with post-exposure prophylaxis (PEP) services available on site
C Prevention of sexual transmission of HIV and prevention of transmission through injecting drug use 
#C1 Estimated number of injecting drug users (IDUs)
#C2 Number of needle and syringe programme (NSP) sites
#C3 Number of people on opioid substitution therapy (OST)
#C4 Number of syringes/needles distributed by needle and syringe programmes (NSP)
#C5a Percentage of injecting drug users (IDUs) reporting the use of sterile injecting equipment the last time they injected
#C5b Percentage of injecting drug users (IDUs) reporting the use of a condom the last time they had sexual intercourse
#C5c Percentage of female and male sex workers (SWs) reporting the use of a condom with their most recent client
#C5d Percentage of men reporting the use of a condom the last time they had anal sex with a male partner
#C6a Percentage of injecting drug users (IDUs) who are HIV-infected
#C6b Percentage of sex workers (SWs) who are HIV-infected
#C6c Percentage of men who have sex with men (MSM) who are HIV-infected
D Care
#D1 Percentage of adults and children enrolled in HIV care and eligible for cotrimoxazole (CTX) prophylaxis (according to national 
guidelines) currently receiving CTX prophylaxis
E HIV/TB
#E1 Percentage of health-care facilities providing ART services for people living with HIV with demonstrable infection control 
practices that include TB control
#E2 Percentage of estimated HIV-positive incident TB cases that received treatment for TB and HIV
#E3 Percentage of adults and children newly enrolled in HIV care starting isoniazid preventive therapy (IPT)
#E4 Percentage of adults and children enrolled in HIV care who had TB status assessed and recorded during their last visit 
F Sexually transmitted infections
#F1 Percentage of women accessing antenatal care (ANC) services who were tested for syphilis at fi rst ANC visit
#F2 Percentage of antenatal care attendees who were positive for syphilis
#F3 Percentage of antenal care attendees positive for syphilis who received treatment
#F4 Percentage of sex workers with active syphilis
#F5 Percentage of men who have sex with men (MSM) with active syphilis
Annex 11 List of indicators in the WHO, UNICEF and UNAIDS annual reporting form for monitoring the health sector response to HIV/AIDS, 2011
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G Antiretroviral therapy (ART)
#G1 Number of health facilities that offer antiretroviral therapy (ART)
#G2a Percentage eligible adults and children currently receiving antiretroviral therapy
#G2b Number of eligible adults and children who newly enrolled on antiretroviral therapy during the reporting period (2010)
#G3a Percentage of adults and children with HIV still alive and known to be on treatment 12 months after initiation of antiretroviral 
therapy among those who initiated in 2009
#G3b Percentage of adults and children with HIV still alive and known to be on treatment 24 months after initiation of antiretroviral 
therapy among those who initiated in 2008
#G3e Percentage of adults and children with HIV still alive and known to be on treatment 60 months after initiation of antiretroviral 
therapy among those who initiated in 2005
H Health systems
#H1 Percentage of health facilities dispensing antiretrovirals (ARVs) that have experienced a stock-out of at least one required 
ARV in the last 12 months
#H2 Percentage of facilities providing ART using CD4 monitoring in line with national guidelines/policies, on site or through referral
I Women and children
#I1 Number of pregnant women attending ANC at least once during the reporting period
#I2a Number of health facilities providing ANC services
#I2c Number of health facilities providing ANC services that also provide HIV testing and counselling for pregnant women
#I2d Number of health facilities providing ANC services that offer both HIV testing and antiretroviral drugs for the prevention of 
mother-to-child transmission on site
#I2b Number of health facilities providing ANC services that also provide CD4 testing on site, or have a system for collecting and 
transporting blood samples for CD4 testing for HIV-infected pregnant women
#I3 Number of health facilities that offer paediatric ART
#I4 Percentage of health facilities that provide virological testing services (e.g. PCR) for diagnosis of HIV in infants on site or from 
dried blood spots (DBS)
#I5 Percentage of pregnant women who were tested for HIV and received their results – during pregnancy, during labour and 
delivery, and during the post-partum period (<72 hours), including those with previously known HIV status
#I6 Percentage of pregnant women attending antenatal care whose male partner was tested for HIV
#I7 Percentage of HIV-infected pregnant women assessed for ART eligibility through either clinical staging or CD4 testing
#I8 Percentage of HIV-infected pregnant women who received antiretroviral drugs to reduce the risk of mother-to-child 
transmission (MTCT)
#I9 Percentage of infants born to HIV-infected women receiving antiretroviral prophylaxis for prevention of mother-to-child 
transmission (PMTCT)
#I10 Percentage of infants born to HIV-infected women started on cotrimoxazole (CTX) prophylaxis within two months of birth
#I11 Percentage of infants born to HIV-infected women receiving a virological test for HIV within two months of birth
#I12 Distribution of feeding practices (exclusive breastfeeding, replacement feeding, mixed feeding/other) for infants born to 
HIV-infected women at DTP3 visit
#I13 Percentage of HIV-infected children aged 0–14 years who are currently receiving ART
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Explanatory notes
Data collection and validation 
Annex 1 presents country data on sexually transmitted infections.
Annex 2 presents country data on health facilities providing HIV testing and counselling services and uptake of testing and counselling 
among adults.
Annex 3 presents country survey data on HIV testing and counselling among key populations at higher risk of HIV infection and 
transmission.
Annexes 4 and 5 present country data related to antiretroviral therapy.
Annex 6 presents country data on interventions related to preventing the mother-to-child transmission of HIV and interventions 
targeting children.
Annex 7 presents key indicators for the 22 priority countries for the Global Plan towards the elimination of new HIV infections among 
children by 2015 and keeping their mothers alive.
Annex 8 presents breakdowns, according to WHO and UNICEF regions, of key epidemiological indicators.
Annex 9 presents breakdowns, according to WHO and UNICEF regions, of key indicators on antiretroviral therapy coverage and 
coverage of antiretroviral medicine for preventing mother-to-child transmission.
Annex 10 lists countries with epidemic and economic classifi cations.
Annex 11 lists the indicators collected from countries for this report.
WHO, UNICEF and UNAIDS collected the data presented in these annexes through the annual reporting tool for monitoring the health 
sector response to HIV/AIDS (1). The reporting tool was sent to countries in January 2011. To facilitate collaboration at the country 
level, the country offi ces of WHO, UNICEF and UNAIDS worked jointly with national counterparts and partner agencies to collate and 
validate data in a single collaborative consultation process. The countries sent the data to the regional offi ces and to WHO and UNICEF 
headquarters between March and April 2011.
In addition, an international data reconciliation meeting was organized in June 2011 to review and cross-validate data reported to 
WHO, UNICEF, the UNAIDS Secretariat, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States President’s 
Emergency Plan for AIDS Relief. When discrepancies were identifi ed between data reported to the different organizations, follow-up 
letters were sent to UNAIDS, UNICEF and WHO country offi ces to liaise with national authorities to seek clarifi cation and resolve 
the discrepancies.
Explanatory notes for Annex 1
Percentage of women attending antenatal care tested for syphilis at the fi rst visit
The coverage of syphilis testing among women attending antenatal care for the fi rst time is generally derived from national programme 
records. Data from sentinel surveys were included in the 2011 report only they were considered representative of the national 
programme. Data are presented for 61 reporting low- and middle-income countries. The data should be interpreted with caution, 
especially as the reported denominator does not always represent the majority of women attending antenatal care.
Percentage of women attending antenatal care seropositive for syphilis
Data on the prevalence of syphilis among women attending antenatal care can be reported from national programme records, 
sentinel surveillance or other special studies. For purposes of this indicator, seropositivity was defi ned as having either a positive 
treponemal or a non-treponemal test result. Data are presented for 75 reporting low- and middle-income countries. The data should 
be interpreted with caution, since the type of test used to determine seropositivity varied by country.
Active syphilis seroprevalence among sex workers
Data on the seroprevalence of active syphilis among sex workers can be obtained from sentinel surveillance or special surveys. 
Because of the frequency of previous syphilis infections, this indicator defi ned active syphilis as being positive on both a treponemal 
and non-treponemal test. Data are presented for 40 reporting low- and middle-income countries. The data should be interpreted 
with caution, since the type of test used to determine seropositivity varied by country.
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Active syphilis seroprevalence among men who have sex with men
Data on the seroprevalence of active syphilis among men who have sex with men can be obtained from sentinel surveillance or 
special surveys. Because of the frequency of previous syphilis infections, this indicator defi ned active syphilis as being positive on 
both a treponemal and non-treponemal test. Data are presented for 31 low- and middle-income reporting countries. The data should 
be interpreted with caution, since the type of test used to determine seropositivity varied by country.
Explanatory notes for Annex 2
Annex 2 presents country data on the scaling up of HIV testing and counselling services for 2009–2010 and provides country-specifi c 
data on the availability of HIV testing and counselling services in health facilities at the national level for adults in 118 (2009) and 
119 (2010) low- and middle-income countries.
It also provides country-specifi c data on the uptake of HIV testing and counselling for adults in 110 low-and middle-income countries.
Number of health facilities with HIV testing and counselling services
The number of health facilities with HIV testing and counselling services is based on data summarized at the national or subnational 
level as reported by countries. Aggregated data should include facilities providing services in the private and nongovernmental 
organization sectors and voluntary testing and counselling sites but this is not always possible in some countries. A total of 119 
countries reported data in 2010.
Number of people 15 years and older who received HIV testing and counselling and know the results
The number of adults who received HIV testing and counselling in the past 12 months and know the results is collected from routine 
reports from all service points, which includes voluntary counselling and testing sites, clinics, hospitals and nongovernmental 
organization outreach points. Data are compiled at the district or local level and fi nally at the national level. A total of 110 countries 
reported data in 2010. These data are not corrected for the fraction of people who have been tested more than once in the year.
Explanatory notes for Annex 3
Annex 3 presents data on access to testing and counselling services for key populations at higher risk of HIV infection.
Annex 3a–c reports on the coverage of testing and counselling services respectively for people who inject drugs (26 countries), men 
who have sex with men (41 countries) and sex workers (52 countries). The data reported by countries come from surveys among 
specifi c populations between 2008 and 2010. When the sample is less than 100, the data are not reported.
Annex 3d–e reports on the coverage of testing and counseling services respectively for people who inject drugs (14 countries), men 
who have sex with men (16 countries) and sex workers (23 countries) for countries who have reported more than one survey in the 
considered population between 2006 and 2010. The results of data collected between 2006 and 2008 are presented separately 
from those collected between 2009 and 2010.
The data should be interpreted with caution, since they may have been generated through surveys that are not nationally 
representative. Some survey results may overestimate the proportion of people accessing services.
Explanatory notes for Annexes 4 and 5
Annexes 4 and 5 present country data on access to antiretroviral therapy.
Annex 4 provides country-specifi c data on access to antiretroviral therapy at the national level for all age groups in 149 low-and 
middle-income countries, of which 138 countries reported data for 2010. Data from the private sector have been provided as footnotes.
In addition, the report presents the most recent available data from high-income countries.
Number of people receiving antiretroviral therapy
The reported data on people currently receiving antiretroviral therapy, both in low- and middle-income countries and in high-income 
countries, were compiled from the most recent reports from health ministries or from other reliable sources in the countries, such 
as bilateral partners, foundations and nongovernmental agencies that are major providers of treatment services. WHO, UNAIDS 
and UNICEF work with countries to obtain as many facility-specifi c data as possible on the numbers of people receiving treatment
Of the 149 low-and middle-income countries, 133 countries provided data on access to antiretroviral therapy in December 2010. 
These accounted for 91% of the people receiving treatment by the end of 2010. For fi ve countries, including Thailand and Uganda, 
data are available for September or November 2010. Together, these 138 countries represent more than 99% of the total estimated 
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number of people receiving antiretroviral therapy at the end of 2010 in low-and middle-income countries. Only 11 relatively small 
countries did not report for 2010.
Estimating the number of people receiving antiretroviral therapy involves some uncertainty for countries that have not yet established 
regular reporting systems that can capture accurate data on people who initiate treatment for the fi rst time, people who discontinue 
treatment, people who are lost to follow-up and people who die.
Uncertainty may also arise because of the diffi culty in measuring the extent of treatment provided in the for-profi t and not-for-profi t 
private sector. Some people receive treatment through nongovernmental organizations and/or private clinics that do not report 
through offi cial channels in some countries. Private companies may have programmes to support the provision of antiretroviral 
therapy to workers with advanced HIV disease but do not report the data related to these programmes to the public health authorities 
in some cases.
Estimating treatment need and coverage
Standard methods were used for estimating the size and course of the HIV epidemic, number of people living with HIV, new infections, 
mortality attributable to AIDS and treatment need (2,3). Treatment need is estimated using statistical modelling methods that include 
all people who meet the criteria for initiating treatment, whether or not these people know their HIV status and their eligibility for 
antiretroviral therapy (Box 5.9).
The estimates of antiretroviral therapy coverage presented in Annex 4 were calculated by dividing the number of people receiving 
antiretroviral therapy at the end of 2010 by the estimated number of people who need treatment in 2010. Ranges around the 
levels of coverage are based on the uncertainty ranges around the estimates of need (4). Some countries have developed their own 
methods for estimating treatment need, which could differ from the estimates derived using UNAIDS/WHO methods. To analyse 
and compare antiretroviral therapy coverage across countries, the report uses standardized estimates of treatment need using 
UNAIDS/WHO methods.
Annex 5 provides data on access to antiretroviral therapy disaggregated by sex and by age (adults – 15 years and older; children – 
younger than 15 years) for low- and middle-income countries. Disaggregated data on the number of children and adults receiving 
antiretroviral therapy are available for 136 countries. Overall, 128 countries provided breakdowns by age group for 2010. Data 
disaggregated by sex were available for 131 countries, of which 115 reported for 2010. Annex 5 reports also on estimated treatment 
need and coverage of antiretroviral therapy for children younger than 15 years by country in 2010.
The treatment needs of children are estimated using standard UNAIDS/WHO methods, including uncertainty ranges (see Box 7.16).
The 2010 WHO treatment guidelines (3) recommend that all children younger than 24 months living with HIV be provided with 
antiretroviral therapy regardless of CD4 counts.
The estimates of antiretroviral therapy coverage for children presented in Annex 5 were calculated by dividing the number of children 
receiving antiretroviral therapy at the end of 2010 by the estimated number of children who need treatment in 2010 (based on 
UNAIDS/WHO methods). Ranges around the levels of coverage are based on the uncertainty ranges around the estimates of need (4).
The need estimates of some countries are currently being reviewed, and these countries therefore expressed a preference that 
their estimates not be published (or only a range), but their estimates are nevertheless used to estimate the regional estimates and 
coverage.
Explanatory notes for Annex 6
Prevention of mother-to-child transmission
Annex 6 provides data on the indicators collected through the WHO, UNICEF and UNAIDS annual reporting form for monitoring 
the health sector response to HIV/AIDS (1).
Number of pregnant women living with HIV receiving antiretroviral medicine for preventing mother-to-child 
transmission
The number of pregnant women living with HIV receiving antiretroviral medicine for preventing mother-to-child transmission is 
based on national programme data aggregated from facilities or other service delivery sites and as reported by countries.
A total of 136 countries reported data for 2010. These 136 countries accounted for nearly all (99.7%) of the estimated 1.49 million 
pregnant women living with HIV in low- and middle-income countries. Among these countries, 101 countries, representing 98% of 
the pregnant women in low- and middle-income countries that reported receiving any antiretroviral medicine, provided disaggregated 
data on antiretroviral regimens in 2010. The reported number of pregnant women includes only the most effective regimens as 
recommended by WHO (antiretroviral therapy and combination regimens) and excludes single-dose nevirapine (see Box 7.11). In 
some countries, comprehensive disaggregated data on antiretroviral regimens are not available. In these cases, the distribution 
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of regimens was applied to the uncategorized portion of antiretroviral regimen in the country to estimate the number of pregnant 
women receiving the most effective regimen (excluding single-dose nevirapine).
Estimating the number of pregnant women living with HIV who need antiretroviral medicine for preventing mother-to-
child transmission
The number of pregnant women living with HIV who need antiretroviral medicine for preventing mother-to-child transmission 
is estimated using standardized statistical modelling based on UNAIDS/WHO methods that consider various epidemic and 
demographic parameters and the national programme coverage of antiretroviral therapy in the country, such as the HIV prevalence 
among women of reproductive age and the effect of HIV on fertility and antiretroviral therapy coverage (2). These statistical modelling 
procedures are used to derive a comprehensive population-based estimate of the total number of pregnant women living with HIV 
who need antiretroviral medicine for preventing mother-to-child transmission in the country. Regular scientifi c updates have been 
provided on these tools (5).
Similar to the estimates of antiretroviral therapy need presented in Annex 4, Annex 6 presents uncertainty ranges around the 
estimated population needing antiretroviral medicine to prevent the mother-to-child transmission of HIV and, accordingly, the 
coverage of pregnant women living with HIV receiving antiretroviral medicine for preventing mother-to-child transmission. The need 
estimates of some countries are currently being reviewed, and these countries therefore expressed a preference that their estimates 
not be published (or only a range), but their estimates are nevertheless used to estimate the regional needs and coverage.
Coverage of pregnant women living with HIV receiving antiretroviral medicine for preventing mother-to-child 
transmission
The coverage of antiretroviral medicine for preventing the mother-to-child transmission of HIV is calculated by dividing the number 
of pregnant women living with HIV who received the most effective antiretroviral regimens (excluding single dose nevirapine) for 
preventing mother-to-child transmission of HIV in 2010 by the estimated number of pregnant women living with HIV who need 
antiretroviral medicine for preventing mother-to-child transmission in the country.
The ranges around the levels of coverage are based on the uncertainty ranges around the estimates of need. Point estimates and 
ranges are given for countries with a generalized epidemic, whereas only ranges are given for countries with a concentrated epidemic.
In addition, Annex 6 also presents data on the following indicators:
• the number and percentage of pregnant women tested for HIV;
• the number and percentage of infants born to women living with HIV receiving antiretroviral medicine for preventing mother-to-
child transmission;
• the number and percentage of infants born to women living with HIV receiving co-trimoxazole prophylaxis within two months of 
birth; and
• the number and percentage of infants born to women living with HIV receiving a virological test by two months of birth.
Explanatory notes for Annex 7
Annex 7 presents data on key indicators for the 22 focus countries of the Global Plan towards the elimination of new HIV infections 
among children by 2015 and keeping their mothers alive (6). The indicators are those identifi ed in the framework for monitoring the 
Global Plan.
Among these indicators, the following are modelled, using the Spectrum UNAIDS/WHO software (see Box 2.4):
• number of women living with HIV delivering (2009 and 2010)
• new paediatric HIV infections (2009 and 2010)
• HIV incidence in women 15–49 years old (2009 and 2010)
• mother-to-child transmission rate (2009 and 2010).
Others are coverage indicators, using country-reported data for the numerators and estimated needs using spectrum software for 
the denominator:
• coverage of maternal antiretroviral medicine (prophylaxis and antiretroviral therapy) without single-dose nevirapine, 2010;
• antiretroviral therapy coverage among pregnant women; and
• antiretroviral therapy coverage among children.
Three other denominators are collected from other sources:
• HIV-associated maternal deaths (2008) (7);
• Percentage of Under fi ve deaths due to HIV (2008) from World health statistics 2011 (8); and
• the unmet need for family planning from World health statistics 2011 (8).
For the last indicator, coverage of antiretroviral medicine during breastfeeding, no data are currently available. WHO, UNICEF and 
UNAIDS will support countries for collecting this information.
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Explanatory notes for Annex 10
Classifi cation by income
Unless stated otherwise, all data analysis in this report is based on data from 149 countries classifi ed as low- and middle income 
by the World Bank as of July 2007 (9).
Economies are classifi ed as low, middle or high income according to the gross national income per capita, calculated using the World 
Bank Atlas method (to reduce the effect of exchange-rate fl uctuation). The groups are: low income, US$ 905 or less; lower-middle 
income, US$ 906 to US$ 3595; upper-middle income, US$ 3896–US$ 11 115; and high income, US$ 11 116 or more.
Classifi cation by HIV epidemic level
HIV epidemics are categorized as low level, concentrated and generalized based on the following principles and numerical proxies.
Low level
Principle. Although HIV infection may have existed for many years, it has never spread to signifi cant levels in any subpopulation. 
Recorded infection is largely confi ned to individuals with high-risk behaviour, such as sex workers, people who inject drugs and men 
who have sex with men. This epidemic state suggests that networks of risk are rather diffuse (with low levels of partner exchange 
or sharing of drug-injecting equipment) or that the virus has been introduced very recently.
Concentrated
Principle. HIV has spread rapidly in a defi ned subpopulation but is not well established in the general population. This epidemic state 
suggests active networks of risk within the subpopulation. The future course of the epidemic is determined by the frequency and 
nature of links between highly infected subpopulations and the general population.
Generalized
Principle. In generalized epidemics, HIV is fi rmly established in the general population. Although populations at higher risk may 
continue to contribute disproportionately to the transmission of HIV, sexual networking in the general population is suffi cient to 
sustain an epidemic independent of populations at higher risk of infection and transmission.
Classifi cation by geographical region
This report presents data on 149 low- and middle-income countries by geographical region.1 The geographical regions are based on 
UNAIDS regions, with one difference: Somalia is classifi ed as being in sub-Saharan Africa in the geographical regions but classifi ed as 
being in the Middle East and North Africa in the UNAIDS regions.2 East, South and South-East Asia combines two UNAIDS regions, 
as does Latin America and the Caribbean as well as Eastern Europe and Central Asia. The 149 countries are therefore categorized as 
follows: sub-Saharan Africa (n = 46); Latin America and the Caribbean (n = 29); East, South and South-East Asia (n = 20); Europe 
and Central Asia (n = 26); and North Africa and the Middle East (n = 14). In Oceania (n = 14), only Fiji and Papua New Guinea have 
estimated needs. For this report, the values for Oceania are included in East, South and South-East Asia.
For the period of data collection, WHO had 193 Member States grouped in six regions, and 149 WHO of these were low-and middle-
income countries: WHO African Region (n = 46); WHO Region of the Americas (n = 29); WHO Eastern Mediterranean Region (n 
= 16); WHO European Region (n = 26); WHO South-East Asia Region (n = 11); and WHO Western Pacifi c Region (n = 21). Annex 
4 lists the remaining 44 high-income countries in the second section.
UNICEF groups the 149 low- and middle-income countries into seven regions: Eastern and Southern Africa (n = 22); West and 
Central Africa (n = 24); East Asia and the Pacifi c (n = 26); Latin America and the Caribbean (n = 29); South Asia (n = 8); North 
Africa and the Middle East (n = 14); and Central and Eastern Europe and the Commonwealth of Independent States (n = 21). Five 
middle-income countries are classifi ed as being industrialized.
1 With South Sudan becoming independent on 9 July 2011, the number of United Nations and WHO Member States is now 194, and 150 of these are low- and middle-income 
countries. The data collected for this report apply to the period before South Sudan became independent.
2 UNAIDS brings together the efforts and resources of 10 United Nations System organizations in the response to HIV. The 10 UNAIDS Cosponsors are:
• Offi ce of the United Nations High Commissioner for Refugees (UNHCR);
• United Nations Children’s Fund (UNICEF);
• World Food Programme (WFP);
• United Nations Development Programme (UNDP);
• United Nations Population Fund (UNFPA);
• United Nations Offi ce on Drugs and Crime (UNODC);
• International Labour Organization (ILO);
• United Nations Educational, Scientifi c and Cultural Organization (UNESCO);
• World Health Organization (WHO); and
• World Bank.
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